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Abstract 
 
Sialic acids are prevalent in many organisms and facilitate a range of cellular processes in both 
bacteria and mammals. N-Acetylneuraminic acid (NANA) is the most common naturally occurring 
sialic acid and plays a key role in the pathogenesis of a select number of neuroinvasive bacteria such 
as Neisseria meningitidis. These pathogens coat themselves with polysialic acids, mimicking the 
exterior surface of mammalian cells and consequentially concealing the bacteria from the host’s 
immune system. NANA is synthesised in prokaryotes via a condensation reaction between 
phosphoenolpyruvate (PEP) and N-acetylmannosamine (ManNAc). This reaction is catalysed by the 
domain swapped, homodimeric enzyme, N-acetylneuraminic acid synthase (NANAS).  NANAS 
comprises two distinct domains; an N-terminal catalytic (β/α)8 barrel linked to a C-terminal 
antifreeze protein-like (AFPL) domain. The AFPL domain contributes a highly conserved arginine 
(Arg314) into the active site of the opposing monomer chain. 
Chapter 2 of this thesis details the examination of Arg314 in N. meningitidis NANAS (NmeNANAS) 
through mutagenesis and a combination of kinetic and structural analyses. Using isothermal titration 
calorimetry and molecular modelling, Arg314 is found to be essential to the catalytic function of 
NmeNANAS. The delocalised, positively charged guanidinium functionality of Arg314 steers the sugar 
substrate ManNAc into a suitable position for reaction with PEP. 
Chapter 3 details an investigation into the role of the AFPL domain by characterising a truncated 
variant of NmeNANAS. The results from this chapter demonstrate that the AFPL domain plays a 
critical role in both the catalytic function and quaternary structure stability of NmeNANAS.  
Molecular dynamics simulations and amino acid substitutions expose a complex hydrogen bonding 
relay, which links the roles of the catalytic and AFPL domains across subunit boundaries.    
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The work in Chapter 4 of this thesis examines the evolutionary relationships within the bacterial 
sialic acid synthase (SAS) family. An alignment of bacterial sequences identifies four distinct enzyme 
clades denoted as NANASs, legionaminic acid synthases (LegSs), pseudaminic acid synthases (PseSs) 
and a fourth clade with unknown catalytic activity termed Type IV SASs. The NANAS, LegS and PseS 
paralogues from Campylobacter jejuni as well as the Type IV SAS from Chlorobium tepidum were 
analysed to compare the relationships between these enzymes. Structural analysis techniques such 
as molecular modelling, substrate docking, small-angle X-ray scattering (SAXS) and analytical 
ultracentrifugation (AUC) were used to identify key similarities and differences between the four SAS 
homologues. 
Chapter 5 of this thesis outlines the structural and kinetic analyses of the SAS from Streptococcus 
suis. The kinetic parameters of SsuSAS were successfully obtained, revealing NANAS activity even 
though the enzyme was identified to be more closely related to members of the LegS clade. A crystal 
structure of SsuSAS was also obtained at a resolution of 2.30 Å. Docking analyses using the crystal 
structure of SsuSAS revealed favourable binding poses for the substrate of Leg biosynthesis, 
indicating that SsuSAS may have LegS activity.   
Chapter 6 details the cloning of two chimeric constructs. The catalytic and AFPL domains of 
NmeNANAS and Homo sapiens N-acetylneuraminic-9-phosphate synthase (NANA-9-PS) were 
interchanged in an effort to switch the activity of the two SAS enzymes. The NmeNANAS catalytic 
domain (Nme/Hsa) chimera was solubly expressed, however, the HsaNANA-9-PS catalytic domain 
(Hsa/Nme) chimera was not. Although soluble, the Nme/Hsa chimera was not active as either a 
NANAS or NANA-9-PS. The Nme/Hsa chimera was found to have a destabilised quaternary state 
through AUC analysis, which is the likely cause of activity loss.  
Chapter 7 discusses and interprets the results outlined in Chapters 2 to 6 and outlines the future 
prospects of the work begun in this thesis.   
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1.1 Sialic acids 
 
The sialic acids are a structurally diverse family of nine-carbon sugars which contain an α-keto 
acid functionality (1). Sialic acids are derivatives of neuraminic acid, which has an amino group at 
position C-5 and a carboxylate group at C-1 (Figure 1.1). The carboxylate group of neuraminic acid 
confers a negative charge under physiological conditions, making the compound a strong organic 
acid with a pKa of 2.2 (2). 
 
 
 
 
 
 
Figure 1.1 The structure of neuraminic acid. 
 
The unmodified sialic acid, neuraminic acid does not occur naturally (2). The most common sialic 
acid in nature is N-acetylneuraminic acid (NANA), in which the C-5 amino group of neuraminic acid is 
acetylated (Figure 1.2). Whilst NANA is not ubiquitous in nature it is found in almost all vestiges of 
life, from mammals to bacteria (1). NANA is so prevalent in nature, it is often synonymous with the 
term sialic acid (3-6). NANA is also a precursor for the production of many pharmaceutical drugs 
including Zanamivir, a neuraminidase inhibitor which has been used to treat and prevent the 
infection of influenza virus strains H5N1 and H1N1 (7).  
 
 
 
 
 
 
 
Figure 1.2 The structure of N-acetylneuraminic acid. 
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Other common naturally occurring sialic acids include N-glycolylneuraminic acid (NGNA), in which 
the C-5 amino group of neuraminic acid is glycolylated and 2-keto-3-deoxy-nonulosonic acid (KDN), 
in which the C-5 amino group of neuraminic acid is replaced with a hydroxyl (Figure 1.3). NGNA is 
common in many animal species, however, it is not naturally present in humans due to an 
irreversible mutation to the gene responsible for its biosynthesis (8). NGNA is produced in the 
cytosol via NANA, where the N-acetyl functional group is oxidised to produce an N-glycolyl group (9).  
The presence of NGNA in humans has only been noted in association with particular types of cancer 
(10). KDN is not present in many members of the animal kingdom however it is common among 
lower vertebrates (11, 12). KDN is also found in bacteria and in many types of glycoconjugates such 
as glycoproteins, glycolipids and capsular polysaccharides (12).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.3 The structures of N-glycolylneuraminic acid and 2-keto-3-deoxy-nonulosonic acid. 
 
There are over fifty sialic acid molecules currently described (1). Whilst NANA, NGNA and KDN are 
the most frequently observed natural sialic acids, several alternate derivatives of neuraminic acid 
have been identified (2). Displayed in Figure 1.4 are common modifications to the neuraminic acid 
structure. The most frequent modification of neuraminic acid is esterification or O-acetylation of the 
hydroxyl groups, mainly at positions C-7, C-8 and C-9 although esterification at C4 is also known (13). 
Sialic acid can also contain multiple substitutions such as in N-7, 8, 9-tri-O-acetyl-N-acetylneuraminic 
acid and N-7, 8, 9-tri-O-acetyl-N-glycolylneuraminic acid (2). 
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Figure 1.4 The family of naturally occurring sialic acids. Displayed in centre is the sialic acid template 
architecture. Figure is modified from Schauer (2004) (1). 
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1.2 Sialic acids in nature 
 
1.2.1 Plants 
The diversity of structure and functional group modifications enable the sialic acids to facilitate a 
vast range of cellular tasks. Whilst sialic acids are abundantly present in the animal kingdom, they 
have also been observed in select bacterial species and protozoa (1). Sialic acids have also been 
observed in pathogenic fungi (14), however, their existence in the plant kingdom is currently a topic 
of much debate (15-18).  
Evidence supporting the existence of sialic acids in plant materials includes their reported 
quantification in several species (18), whilst contrary experimental analyses suggest that the levels 
of sialic acids present in plants are infinitesimal and within the range of extraneous contamination 
(17).  The results from the latter investigation suggest that due to the small amounts of the 
compound measured, it is not possible to unequivocally demonstrate that plants synthesise sialic 
acids.   
Interestingly, putative gene homologues of animal sialyltransferases and cytidine 
monophosphate (CMP)-NANA transporters have been detected in several plant genomes (15, 16). 
Sialyltransferases catalyse the transfer of CMP-NANA (an activated form of NANA) to the glycan 
moiety of glycoconjugates (19), whilst CMP-sialic acid transporters are typically localised in the 
membranes of the Golgi apparatus and provide sialyltransferases with appropriate substrate (20).   
Although a NANA metabolic pathway could not be elucidated, the putative CMP-NANA transporter-
like protein in rice was observed to exhibit CMP-NANA transporter activity (16). 
  
1.2.2 Fungi 
The existence of NANA in fungi was first demonstrated in the yeast-like cells of Sporothrix 
schenckii (21) . Following its discovery in fungi, NANA has been observed in several species including 
Ascocalix abietina (22), Cryptococcus neoformans (23), Fonsecaea pedrosoi (24) and Paracoccidioides 
brasiliensis (25).  Presently, NANA is the only known sialic acid observed in fungi and has only been 
noted in pathogenic species (26).  
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Although the metabolism and role of sialic acids in fungi are currently unknown, the 
incorporation of NANA in the cell surface of A. abietina has been shown to improve fungal resistance 
to unfavourable environmental conditions (22). Sialic acids on the cell surface of fungi are proposed 
to be involved with interfacial interactions (26). Electrostatic forces are known to mediate cell 
adhesion processes and surface electronegativity plays a vital role in fungal attachment to host cells 
(24). Given the strongly acidic carboxylate group of NANA (pKa = 2.6), a NANA rich surface would 
provide a net negative charge under physiological conditions that would facilitate cell adhesion to 
positively charged substances (26). 
 
1.2.3 Insects 
Sialic acids were long thought to be non-existent in lower animals and insects until NANA was 
detected in Drosophila melanogaster (fruit-fly) (27). NANA polysaccharide was observed in the 
ventral nervous system and brain ganglia of D. melanogaster larvae. The presence of poly-NANA was 
only noted during a short period, 14-18 hours into development (27). Interestingly, NANA has not 
been observed in the adult form of D. melanogaster (28).  Conclusive evidence for the existence of a 
sialic acid biosynthetic pathway in D. melanogaster was given upon the characterisation of an N-
acetylneuraminic-9-phosphate synthase (NANA-9-PS) and CMP-NANA synthetase, analogous to the 
mammalian and bacterial versions of the enzymes respectively. (29, 30). 
Currently, several examples indicating the presence of sialic acids in insects have been 
documented. Similar to D. melanogaster, the existence of NANA was described during the 
developmental stages of Galleria mellonella (greater wax moth) (31). NANA was noted to be present 
in the testes of G. mellonella with the highest quantities observed during the early pupal stages. 
Another example of developmental expression of NANA is in Manduca sexta (tobacco hornworm), 
where NANA was determined to be present in the inducible immune glycoprotein, scolexin (32). 
Scolexin is involved in a coagulation response to intruding bacteria (33). Insect glycoproteins 
typically terminate with either mannose or N-acetylglucosamine (29), however, sialylated glycans 
were observed in Danaus plexippus (the monarch butterfly) (34). NANA was also detected in 
glycoprotein isolated from the larvae of Bombyx mori (silk worm) (35).  
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1.2.4 Mammals 
Whilst sialic acids are fairly scarce in lower animals, they are prolific in members of the animal 
kingdom from echinoderms up to higher organisms such as mammals (36).  In mammals, NANA is 
incorporated as the terminal residue of cell surface glycoconjugates and plays an essential biological 
role in cell signalling, recognition and adhesion events (2, 37). Depicted in Figure 1.5 is a 
diagrammatic representation of a mammalian cell surface with sialylated glycoproteins. 
 
 
 
 
 
 
 
 
 
Figure 1.5 A diagrammatic representation of a mammalian cell membrane. Modified from Figure 2.6 of 
Medical microbiology, 4th edition (38) 
 
Sialic acids are a frequent component of the oligosaccharide chains of mucins, glycoproteins and 
glycolipids. In mammals, the sialic acid NANA is incorporated in gangliosides (Figure 1.6) and plays a 
crucial role in brain development and in the normal functioning of cell membranes (39). Gangliosides 
have been shown to play an essential role in the transmission and storage of information (40). 
Increased NANA concentration in brain gangliosides has been associated with enhanced neuritic 
growth and has a protective effect against glutamate toxicity, where abnormally high levels of 
glutamate can lead to nerve cell damage and necrosis (41). Whilst the highest concentration of 
NANA is observed in brain gangliosides, it is also present in several extraneural tissues and body 
fluids such as saliva and milk (40, 42, 43).  
 
Glycoprotein 
NANA 
Phospholipid 
Polysaccharide 
Cytoplasm 
Extracellular  
fluid 
8 
 
 
 
 
 
 
 
Figure 1.6 Structure of the sialoganglioside GM3 as an example of a glycoconjugate molecule (44). N-
acetylneuraminic acid (NANA) is highlighted in red. 
 
The concentration of NANA in brain gangliosides is increased in species that are higher on the 
phylogenetic scale (40). The mean concentration of NANA in the human brain was determined to be 
approximately 900 µg/g of ganglioside, with approximately 500 µg/g and 250 µg/g of ganglioside in 
rat and pig respectively (40).  
The neural cell adhesion molecule is a heavily sialylated glycoprotein which is present in 
mammals and is involved in intercellular adhesion, synaptic plasticity as well as cognition and 
memory (45, 46). Gene knockout studies in mice revealed that sialylation of the neural cell adhesion 
molecule is essential to foetal development (46). The removal of enzymes that were required for the 
biosynthesis of NANA in mice resulted in early embryonic lethality (46). Furthermore, NANA is an 
important dietary supplement present in mammalian breast milk that is proposed to aid the rapid 
development of the infant brain (45).  
As previously mentioned, NANA plays an important role in cell recognition. Sialic acid binding 
lectins known as siglecs interact with the specific substituents of NANA such as the carboxylate, N-
acetyl and C-6 hydroxyl functionalities (47).  Sialoadhesin is a particular form of siglec which is 
involved in the mediation of leukocyte-endothelial cell interactions in mammalian inflammatory and 
immune responses (48, 49). Sialoadhesin exists in macrophages and predominately binds 
neutrophils, but can also bind monocytes, natural killer cells, B cells and a subset of cytotoxic T cells 
by interacting with NANA molecules in the ligands on their surfaces (49). 
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NGNA is abundant in the glycoconjugates of most mammalian species, however, it is not present 
in healthy human tissue due to a deletion in the gene of the enzyme essential to its biosynthesis (9, 
10). The paradoxical existence of NGNA in certain human tumour cells is attributed to NGNA 
absorption from dietary sources and subsequent metabolic incorporation into specific cell types (10, 
50). Although the precise involvement of NGNA is unknown, one current hypothesis is that chronic 
inflammation related to the reaction between antigens and latent anti-NGNA antibodies might 
facilitate carcinogenesis (50). The net surface charge of sialic acid glycoconjugates on tumour cells 
produces electronegative repulsion between other cells. This results in loss of cell adhesion to the 
tumour mass and subsequently aids proliferation (51, 52). 
Mucins are high molecular weight glycoproteins produced by mucosal epithelia (43). The peptide 
backbone of mucins is extensively glycosylated and a high proportion of the glycoconjugates 
terminate with NANA (43). The negative charge of NANA at physiological pH modulates bacterial and 
viral adhesion, however, some bacteria and viruses have evolved to colonise the mucosal niche (43, 
53). 
Neuraminidases are a class of glycosidic hydrolase enzymes which cleave the glycosidic linkages 
of NANA (54, 55), and are found in a range of organisms including mammals (56). The 
neuraminidases of certain viruses are of particular biological interest due to their role in viral 
pathogenicity. In particular, the viral neuraminidase of the influenza virus has been extensively 
researched (54, 55, 57).  Viral neuraminidases hydrolyse the terminal NANA residues from host cell 
receptors and assist the mobility of virus particles via respiratory tract mucins to a target cell (57).  
Viral neuraminidases also aid in the elution of viral progeny from within an infected cell by 
preventing the aggregation of viral particles. Since NANA is the substrate for viral neuraminidases, 
several frontline drugs such as Zanamivir (Relenza™) are structural analogues of NANA (Figure 1.7) 
(57).  
 
 
 
Figure 1.7 Structures of NANA and Zanamivir (Relenza™). Structural features such as the N-acetyl, 
carboxylate and glycerol functional groups are analogous to NANA (57).  
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1.2.5 Bacteria 
Although sialic acids are typically absent in prokaryotes (5), several Gram-negative, pathogenic 
bacteria biosynthesise and integrate NANA into their cell surface, imitating the exterior of 
mammalian cells (3). This cell-surface mimicry enables pathogens such as Neisseria meningitidis, 
Haemophilus influenza and Escherichia coli K1, which are involved in bacterial meningitis as well as 
Campylobacter jejuni, which is involved in gastroenteritis, to evade the host immune response (58-
60). Depicted in Figure 1.8, is a diagrammatic representation of a Gram-negative, bacterial cell wall 
with sialylated lipopolysaccharide.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.8 A diagrammatic representation of a Gram-negative bacterial cell wall. Modified from Figure 
2.6 of Medical microbiology, 4th edition (38). 
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The sialic acid KDN is also present in several bacterial species (12). Bacterial KDN was first 
reported in the capsular polysaccharide of the Gram-negative Klebsiella ozaenae, a pathogenic 
bacterium which causes respiratory disease in humans (61). KDN has also been reported in the cell 
wall polysaccharides of Sinorhizobium fredii, which is involved in nitrogen fixation in certain legumes 
and Pseudomonas corrugate, the causative agent of tomato pith necrosis (12).  
Depicted in Figure 1.9 are pseudaminic acid (Pse) and legionaminic acid (Leg), two notable 
nonulosonates which are commonly referred to as bacterial sialic acids in the literature (13). Leg has 
the same absolute configuration as NANA (Figure 1.2), however, Leg has a second N-acetyl 
functionality at position C-7 and does not contain a hydroxyl group at C-9. Pse is a diastereoisomer 
of Leg with inverted stereochemistry at positions C-5, C-7 and C-8. Pse and Leg are bacteria specific 
compounds and at this time have not been observed in any other form of life (13).  
 
 
 
 
 
Figure 1.9 The structures of pseudaminic and legionaminic acid. 
 
Glycosylation with Pse is an essential modification to the flagellar proteins in both Helicobacter 
pylori and C. jejuni (62-64). Flagella are complex locomotive components which are present in 
certain bacterial species and function by quickly rotating thin microfilaments in a reversible motion 
which directionally propel the microorganism (65). Sialylation of flagellin, the major glycoprotein 
component of flagella, is vital to its function (66). H. pylori and C. jejuni are pathogens of the 
gastrointestinal tract and their motility is vital to their pathogenesis (63, 64).  
Several derivatives of Pse also occur naturally (Figure 1.10). 5-Acetamido-7-acetamidino-3,5,7,9-
tetradeoxy-L-glycero-α-L-manno-nonulosonic acid (Pse5Am5Ac) and 5-acetamidino-7-acetamido-
3,5,7,9-tetradeoxy-L-glycero-α-L-manno-nonulosonic acid (Pse5Ac7Am) have each been isolated 
from the flagellin proteins of C. jejuni (67). 
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Figure 1.10 Structures of Pse and derivatives 5-acetamido-7-acetamidino-3,5,7,9-tetradeoxy-L-glycero-α-
L-manno-nonulosonic acid (Pse5Am5Ac) and 5-acetamidino-7-acetamido-3,5,7,9-tetradeoxy-L-glycero-α-
L-manno-nonulosonic acid (Pse5Ac7Am). 
 
Leg is named for its presence and antigenic role in the lipopolysaccharide of Legionella 
pneumophila (68). L. pneumophila is the causative pathogen of Legionnaire’s disease, an often fatal 
pneumonia which was first observed in an outbreak at an American Legion convention in 1976 (69, 
70). Similar to Pse, Leg has been observed as a component of flagellar glycans in both C. jejuni and 
Campylobacter coli (71, 72).  
N-Methylacetimidoyl derivatives of Leg; 5-acetamidino-7-acetamido-3,5,7,9,-tetradeoxy-D-
glycero-D-galacto-nonulosonic acid (Leg5Am7Ac) and 5-E/Z-N-(N-methylacetimidoyl)-7-acetamidino-
3,5,7,9-tetradeoxy-D-glycero-D-galacto-nonulosonic acid (Leg5AmNMe7Ac), have also been 
identified in C. coli (Figure 1.11) (71). Both Leg and  a novel derivative of Leg, 7-acetamido-5-(N-
methyl-glutam-4-yl)-amino-3,5,7,9-tetradeoxy-D-glycero-D-galacto-nonulosonic acid 
(Leg5GluNMe7Ac), have also been found in the glycosides of flagellin from Clostridium botulinum 
(73). C. botulinum is a spore-forming, Gram-positive anaerobe which produces the potent paralytic 
toxin botulinum neurotoxin which is responsible for food-borne botulism (73).  
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Figure 1.11 Structures of Leg and derivatives 5-acetamidino-7-acetamido-3,5,7,9,-tetradeoxy-D-glycero-
D-galacto-nonulosonic acid (Leg5Am7Ac), 5-E/Z-N-(N-methylacetimidoyl)-7-acetamidino-3,5,7,9-
tetradeoxy-D-glycero-D-galacto-nonulosonic acid (Leg5AmNMe7Ac) and 7-acetamido-5-(N-methyl-
glutam-4-yl)-amino-3,5,7,9-tetradeoxy-D-glycero-D-galacto-nonulosonic acid (Leg5GluNMe7Ac). 
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1.3 Neisseria meningitidis 
 
1.3.1 Organism 
N. meningitidis is a Gram-negative diplococcus bacterium and an exclusive pathogen of humans 
(74). It is frequently observed to colonise the human nasopharynx and oropharynx, however, the 
bacteria has also been noted to colonise the oral mucosa, rectum and urogenital tract (74). N. 
meningitidis has substantial genetic variation, with 13 different serogroups currently identified 
which are categorised by differentiation of capsular polysaccharide structures (75). The genetic 
plasticity and phenotypic diversity observed in N. meningitidis is speculated to be a result of 
recurrent interspecies recombination and horizontal gene transfer (76). 
 
1.3.2 Bacterial meningitis 
N. meningitidis is the leading causative agent of bacterial meningitis in the world and infection 
can also result in pneumonia and septicaemia (77-79). Meningitis is characterised by fever, 
headache, stiff neck, nausea, vomiting, photophobia, and altered consciousness (80). The annual 
number of deaths caused by invasive diseases in 2012 was reported to be 1.2 million, with 135, 000 
deaths related to meningococcal disease (79). Displayed in Figure 1.12, Sub-Saharan Africa contains 
a region where bacterial meningitis infection is particularly rampant and has consequentially been 
dubbed the meningitis belt (78). In this particular region, the majority of meningococcal outbreaks 
are caused by serotype A (78). Conversely, in the developed world meningitis infection is primarily 
caused by serotype B (74). Meningococcal disease primarily impacts children and the fatality rate 
can be up to twenty times that of the adult population (74).  
 
 
 
 
 
 
 
Figure 1.12 The Sub-Sahara African meningitis belt (red). This region is accountable for 65% of annual 
meningococcal incidences in Africa. Infections are primarily caused by serotype A followed by serotype 
W-135, C and X. Figure modified from Stephens et al (2007) (81). 
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As mentioned in the previous Section, N. meningitidis is most commonly observed in the human 
nasopharynx and oropharynx. N. meningitidis cells are thus transmitted via direct contact with nasal 
or oral secretions during activities such as coughing, sneezing or kissing (74). The virulence of N. 
meningitidis is associated with the components of the organism’s outer membrane, specifically the 
capsular polysaccharide and lipo-oligosaccharide (82).  
Colonisation by meningococci is initiated by adhesion to epithelial surfaces, which is 
subsequently followed by invasion of a target cell (83). Once internalised, the pathogen induces 
cytotoxicity of the host cell, which is mediated by tumour necrosis factor-α (83). N. meningitidis is 
capable of traversing the mucosal barrier and entering the host’s blood stream which results in 
septicaemia. The pathogen is also capable of traversing the blood-brain barrier which is most often 
fatal (83).  
The persistence of the meningitis bacterium in the host is a vital factor in its pathogenicity. N. 
meninigitidis is capable of evading the host immune response through sialylation of its 
lipopolysaccharide (59). Sialylation of the meningococcal lipopolysaccharide has been observed to 
inhibit phagocytosis (82). 
As previously mentioned, there are 13 known serogroups of N. meningitidis, however the 
majority of infectious cases are resultant from the A, B, C, X, Y and W-135 serogroups (79). 
Vaccinations against serotypes A, C, W-135, and Y are currently available, whilst vaccination for 
serotype B is presently under development (75). Treatment of bacterial meningitis infections are 
typically through the use of antibiotics (84, 85). Cefalosporin-based antibiotics such as cefotaxime or 
cetriaxone are typically used, however, chloramphenicol (either alone or in combination with 
ampicillin) is known to be equally effective (85). The appearance of antibiotic resistance in N. 
meningitidis is of considerable concern. Meningitis strains with resistance to penicillin have been 
reported in Spain and resistance to chloramphenicol has also been observed in south-east Asia (74). 
Alarmingly, a recent study has shown that strain W-135 is particularly resistant to several different 
families of antibiotics (86). Given the evolutionary capacity of N. meningitidis and the emergence of 
drug-resistant strains, the development of novel therapeutics is of increased importance in the fight 
against meningococcal infection.  
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1.4 Campylobacter jejuni 
 
1.4.1 Organism 
C. jejuni is a motile, curved, Gram-negative bacterium (87). C. jejuni is microaerophilic and shows 
optimal growth in an atmosphere containing approximately 10 % CO2 and only 5 % O2 (87). The 
bacteria has a particularly narrow temperature growth range from a minimum of 30 °C to a maximal 
temperature of approximately 46 °C (87). C. jejuni produces the sialic acids NANA, Pse and Leg (88-
90). Gene knockout studies in C. jejuni identified the necessity of both Pse and Leg in the natural 
functioning of flagella (88). In particular, C. jejuni strains without the ability to produce Pse were 
non-motile. Conversely, the absence of NANA biosynthesis did not affect motility (88). 
 
1.4.2 Pathogenesis 
C. jejuni is a food-borne pathogen of humans and is the main causative agent of gastroenteritis, 
although it can also cause septicaemia and meningitis as well as the neuropathological Guillain–
Barré and Miller Fisher syndromes (87, 91, 92). C. jejuni infection is characterised by profuse and 
often bloody diarrhoea as well as acute abdominal pain and fever. Campylobacters are the principal 
source of bacterial diarrhoea worldwide (91). A reported 82% of people admitted to hospital under 
the diagnosis of food poisoning in the UK suffered from a campylobacter infection (93). 
C. jejuni is primarily observed to colonise the intestinal tract of chickens, turkeys and ducks 
however, it has been noted in several wild and domestic animal species (92). The bacterium is 
zoonotic and able to cross between species (91). Human infection typically arises from consumption 
of uncooked food and contact with animal wastes. Many of the symptoms caused by C. jejuni 
virulence arise from inflammatory permeation of neutrophils, whilst villi atrophy and ulceration of 
the mucosal epithelium result from cytotoxicity of C. jejuni (87). Uncomplicated cases of C. jejuni 
infection are rarely treated with antibiotics, however, an augmented microbial resistance to certain 
drug types has been increasingly reported (94).  
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1.5 NANA biosynthesis 
 
1.5.1 Bacteria 
As previously mentioned, NANA is the most abundant sialic acid in nature (1). The 
biosynthetic pathway of NANA in bacteria and mammals is well documented and each of the 
enzymes involved have been elucidated (5).  The route for enzymatic synthesis of NANA differs 
between bacterial and mammalian species (95, 96). Depicted in Figure 1.13 is the bacterial 
NANA biosynthetic pathway.     
 
 
 
 
 
 
 
 
 
Figure 1.13 The biosynthetic pathway of CMP-NANA in bacteria. Figure modified from Tanner et al 
(2005) (5).  
 
The first step in the biosynthesis of NANA is the formation of N-acetylmannosamine (ManNAc) 
from UDP linked N-acetylglucosamine (UDP-GlcNAc) (97). UDP-GlcNAc is an indirect by-product of 
glycolysis (98). The formation of ManNAc is catalysed by a hydrolysing UDP-GlcNAc 2-epimerase (99, 
100). UDP-GlcNAc 2-epimerase catalyses an inversion at the C-2 stereocentre and hydrolyses the 
glycosidic phosphate bond to liberate free UDP and N-acetylmannosamine (97). The reaction 
catalysed by the hydrolysing epimerase is irreversible and thus the enzyme is not classified as a true 
epimerase (5).   
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An evolutionarily related non-hydrolysing form of UDP-GlcNAc 2-epimerase enzyme exists in 
bacteria, however, it is not involved in NANA biosynthesis (101, 102). Instead the non-hydrolysing 
UDP-GlcNAc 2-epimerase synthesises UDP-activated ManNAc, which is itself incorporated into the 
lipopolysaccharide (102). Unlike its hydrolysing counterpart, the non-hydrolysing UDP-GlcNAc 2-
epimerase catalyses a reversible reaction (99). 
The penultimate step in the bacterial biosynthetic pathway is an aldol-like condensation reaction 
between phosphoenol pyruvate (PEP) and ManNAc, catalysed by N-acetyl-neuraminic acid synthase 
(NANAS) (103). Bacterial enzymes with NANAS activity have been characterised from N. meningitidis 
(104), C. jejuni (90), E. coli (95) and Streptococcus agalactiae (105). The final bacterial reaction 
involves the formation of activated CMP-NANA from NANA and CTP (Figure 1.13). This reaction is 
catalysed by CMP-NANA synthetase (106). CMP-NANA is the substrate of sialyltransferase enzymes 
which catalyse the incorporation of NANA into cell surface glycoconjugates (107). Interestingly, the 
utilisation of CMP activated NANA is biologically unusual, as the majority of activated 
monosaccharides identified employ UDP or GDP linked pathways (4). Also of note, several bacterial 
species are known to utilise NANA as an alternative catabolic energy source (59, 107). 
 
1.5.2 Mammals 
Displayed in Figure 1.14, the CMP-NANA biosynthetic route of mammals is noticeably different to 
that of bacteria. Whilst the first enzymatic reaction still involves the generation of ManNAc from 
UDP-GlcNAc, the second step in the mammalian pathway is not the direct formation of NANA (108). 
Instead, NANA is synthesised via two phosphorylated intermediates; N-acetylmannosamine-6-
phosphate (ManNAc-6-P) and N-acetylneuraminic acid-9-phosphate (NANA-9-P) (5, 96).  
 
 
 
 
 
 
Figure 1.14 The biosynthetic pathway of CMP-NANA in mammals. Enzymatic reactions that are not 
present in the bacterial pathway are highlighted in red. Figure modified from Tanner et al (2005) (5).  
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The first and second reactions in the mammalian biosynthetic pathway are catalysed by a 
bifunctional enzyme with both UDP-GlcNAc 2-epimerase and ManNAc kinase activity (109, 110). The 
mammalian UDP-GlcNAc 2-epimerase/ManNAc kinase is able to convert UDP-GlcNAc to ManNAc in a 
similar reaction to that observed in the bacterial hydrolysing orthologue (110). Unlike the bacterial 
UDP-GlcNAc 2-epimerase, the mammalian enzyme possesses ManNAc kinase activity and is capable 
of condensing ATP and ManNAc to produce ManNAc-6-P and free pyrophosphate (Figure 1.14).  
The third enzymatic step is analogous to that of the bacterial NANAS enzyme (103). Instead of 
condensing ManNAc and PEP, however, the mammalian orthologue condenses ManNAc-6-P and PEP 
to produce NANA-9-P (103). Depicted in Figure 1.14, NANA-9-P is subsequently dephosphorylated by 
NANA-9-P phosphatase to produce NANA and inorganic phosphate (5). Similar to the bacterial 
pathway, the final reaction in mammals is the formation of activated NANA via CMP-NANA 
synthetase (111).  
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1.6 NANA synthase 
 
1.6.1 Enzyme structure 
The structure of NmeNANAS is the only defined crystal structure of a NANAS enzyme currently 
available (112, 113). NmeNANAS has been crystallised with Mn2+, PEP and a reduced form of 
ManNAc (rManNAc) bound in the active site (112), and has also been crystallised with an analogue 
of the reaction intermediate (113). NmeNANAS was elucidated as a domain swapped homodimer 
(Figure 1.15). Each monomer comprises of an N-terminal catalytic (β/α)8 barrel with an extended 
linker region to a C-terminal antifreeze protein-like (AFPL) domain. The N-terminal catalytic domain 
contributes the majority of the active site residues, whilst a functionally essential arginine residue is 
provided by the AFPL domain of the opposing monomer (112, 114).  
 
 
 
 
 
 
 
Figure 1.15 NmeNANAS dimer with Chain A coloured grey and Chain B coloured by domain. The catalytic 
domain of chain B is shown in purple (residues Q2-G271), linker domain in orange (residues G272-F290) 
and AFPL domain (residues A291-E349) in blue. rManNAc is coloured green, PEP pink, Mn2+ yellow. 
NmeNANAS PDB coordinates 1XUZ (112). 
 
The AFPL domain is a unique extension which is only observed in sialic acid synthases (SASs), the 
family of enzymes of which NANAS belongs to (112, 115). Interestingly, several putative SAS 
enzymes lack sequence corresponding to the AFPL domain. The AFPL domain is named due to its 
structural homology to Type III antifreeze proteins which are commonly found in fish (112), and 
inhibit the formation of ice through thermal hysteresis (116).  Whilst a complete structure of a 
NANA-9-PS enzyme is unavailable, the AFPL domain of the NANA-9-PS from H. sapiens has been 
elucidated by NMR (115). Displayed in Figure 1.16, the structure of the HsaNANA-9-PS AFPL domain 
is similar to that of the NmeNANAS enzyme (RMSD = 0.40).  
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Figure 1.16 Alignment of NmeNANAS AFPL domain (purple) with HsaNANA-9-PS AFPL domain (green). 
N-terminal residues are coloured blue and C-terminal residues are coloured red. NmeNANAS AFPL 
domain structure generated from crystallographic coordinates 1XUZ (112) and HsaNANA-9-PS AFPL 
domain from coordinates 1WVO (115). 
The existence of the antifreeze protein fold in bacteria and mammals has raised speculation into 
the genesis of this unique conformation (115, 117). Previous genetic analyses have suggested that 
the origins of both the mammalian NANA-9-PS and Type III antifreeze proteins share evolutionary 
roots with an ancestral SAS (115, 117). This is evidenced by sequence and structural analyses of 
several Type III antifreeze protein and AFPL domain sequences, which suggest that the Type III 
antifreeze proteins are more closely related to the mammalian AFPL domains than the bacterial 
AFPL domains (115). Furthermore, several of the key residues in the ice binding motif of Type III 
antifreeze proteins are observed in the peptide sequence of the human AFPL domain (approximately 
40% sequence identity) (115). It has been inferred from this that the mammalian AFPL domain is an 
evolutionary precursor of the Type III antifreeze protein (115). 
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1.6.2 Catalytic site 
Displayed in Figure 1.17 is the active site architecture of NmeNANAS with Mn2+, PEP and 
rManNAc bound (112). As previously mentioned, the majority of the catalytic residues in NmeNANAS 
are contributed by the N-terminal domain. A single Phe288 residue is contributed by the linker 
region and a highly conserved Arg314 is contributed by the AFPL domain. Phe288 forms a part of the 
hydrophobic pocket for the ManNAc binding site, whilst Arg314 directly interacts with the N-acetyl 
carbonyl of rManNAc in NmeNANAS 1XUZ. Phe288 is present in select members of the bacterial SAS 
family whilst Arg314 is completely conserved in bacterial SAS enzymes which contain sequence 
pertaining to an AFPL domain. Additionally, Arg314 is not present in the sequences of mammalian 
NANA-9-PS AFPL domains (115).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.17 NmeNANAS active site. Residues contributed by the catalytic domain are in grey, linker in 
orange and AFPL domain in blue. ManNAc is coloured green, PEP pink, Mn2+ yellow and waters are in red. 
H-bonds are depicted with black dashes and dipolar bonds with red dashes (PDB code (1XUZ) (112)). 
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In addition to Arg314, the fully conserved catalytic domain residues Asp247, Gln55 and Tyr186 
each interact with rManNAc (Figure 1.17). Asn74, which is contributed by the β2-α2 loop of the 
catalytic domain, interacts with the C-6 hydroxyl of ManNAc. Asn74 is fully conserved in NANAS 
enzymes but is not present in other members of the SAS family.  
As depicted in Figure 1.17, Ser132, Ser154 and Ser213 form H-bonds to the phosphate group of 
PEP. Each of the serine residues are fully conserved in bacterial SASs and mammalian NANA-9-PSs. 
Asn184 also interacts with the phosphate of PEP, however, it is not completely conserved in the SAS 
family. The conserved residues Lys53 and Lys129 of the catalytic domain interact with the 
carboxylate group of PEP (Figure 1.17). The reactive group of Thr110 is proximal to the PEP 
carboxylate but is not within hydrogen bonding range in NmeNANAS 1XUZ. The positioning of 
Thr110 is consistent amongst available NmeNANAS structures (112-114). Additionally, Thr110 is 
conserved as either a threonine or a serine in the SAS family.  
The active site Mn2+ ion has octahedral geometry and forms interactions with the imidazole side-
chains of His215 and His236 (Figure 1.18). His215 and His236 are fully conserved in both mammalian 
and bacterial SASs, indicating that metal dependence is an essential evolutionary trait. A water 
molecule and the O2P of PEP complete the ligand sites of the equatorial plane whilst the axial 
positions of the metal ion are occupied by a second water molecule and O1 of rManNAc. The 
positioning of the C-1 hydroxyl group from rManNAc suggests that the carbonyl group of the non-
reduced sugar substrate would be in an ideal location for electrophilic activation by the metal ion 
(112).  
 
 
 
 
 
 
Figure 1.18 NmeNANAS metal coordination. Residues contributed by the enzyme are in grey. ManNAc is 
coloured green, PEP pink, Mn2+ yellow and waters are in red. Metal-ligand interactions are depicted with 
with red dashes (PDB code (1XUZ) (112)). 
His215 
His236 
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1.6.3 Catalytic mechanism 
As previously mentioned, NANAS catalyses the formation of NANA via an aldol-like condensation 
reaction between ManNAc and PEP (104). NANAS is a metalloenzyme and requires a divalent metal 
ion for catalysis (112). Mn2+ has been established as the most activating metal ion for catalysis in 
both NmeNANAS and CjeNANAS followed by Co2+ (90, 104). Whilst ManNAc exists primarily in a ring-
closed, pyranose form in solution, it is also in equilibrium with its open chain form. It is the open 
chain form that is reacted with PEP by NANAS as evidenced by ligand bound crystal structures of 
NmeNANAS (112, 113).  Displayed in Figure 1.19 are two proposed mechanisms for the reaction 
catalysed by NANAS arising from nucleophilic attack by PEP. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.19 Two potential mechanisms for the reaction catalysed by NANAS enzymes. (A) A C-O bond 
cleavage mechanism via an oxocarbenium ion and tetrahedral intermediates. (B) A P-O bond cleavage 
mechanism via an enolate nucleophile. Figure modified from Tanner (2005) (5). 
 
 
 
A 
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The first mechanism is a C-O bond cleavage reaction (Figure 1.19A). This is initiated by attack of 
the ManNAc carbonyl at C-1 by electrons from the double bond of PEP. The result of the nucleophilic 
attack from PEP is the formation of an oxocarbenium ion intermediate which is then readily attacked 
by water to yield a tetrahedral intermediate. The formation of the tetrahedral intermediate is also 
possible through a concerted mechanism that is not depicted. Once produced, the tetrahedral 
intermediate is resolved by the elimination of phosphate, affording free NANA and inorganic 
phosphate (5). 
The second possible mechanism is a P-O bond cleavage reaction (Figure 1.19B). This reaction 
mechanism is initiated by the formation of an enolate nucleophile derived from PEP. The 
phosphorous group of PEP is attacked by water yielding an enolate form of pyruvate and inorganic 
phosphorous. The resultant enolate attacks the carbonyl of ManNAc at C-1 to produce NANA (5). 
Mechanistic studies with isotopic labelling of PEP were used to distinguish which of the 
aforementioned mechanisms occurs in NANAS (112). An 18O incorporated into the phosphate O, 
bridging C-2 and P in PEP was used to determine whether the C-O bond or P-O bond is cleaved 
during the enzyme catalysed reaction. For the mechanism where the C-O bond is cleaved, the 18O 
label is retained in the inorganic phosphate by-product (Figure 1.19A). Conversely, in the P-O bond 
cleavage mechanism, the 18O label is incorporated into NANA (Figure 1.19B).  
The 18O labelling experiment was carried out using NmeNANAS, and isotopic labelling of reaction 
products were monitored using 31P NMR spectroscopy (112). An upfield shift of resonance resulting 
from a P-18O bond was observed in the isolated products (112).  This indicated that the 18O label was 
incorporated into the inorganic phosphate and not NANA, revealing that the reaction catalysed by 
NANAS proceeds via a C-O bond cleavage mechanism. Furthermore, this mechanism implies that 
either a water or a hydroxyl group acts as a nucleophile on C-2 of PEP. 
 The stereospecificity of the nucleophilic attack by PEP has also been examined in previous 
studies with CjeNANAS (90). PEP can theoretically attack either the si or re face of the C-1 aldehyde 
group of ManNAc (Figure 1.19A). To determine the facial selectivity of the NANAS enzyme, the 
products from the reaction of ManNAc with Z and E isomers of mono-deuterated PEP were analysed 
using 1H NMR. Depicted in Figure 1.20, the enzymatic reaction utilising Z-[3-2H]-PEP produced (3S)-3-
deutero-NANA with 2H at the equatorial position, whereas the reaction with E-[3-2H]-PEP produced 
(3R)-3-deutero-NANA with 2H at the axial position (90).  
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Figure 1.20 Facial selectivity of the reaction catalysed by NANAS enzymes. (A) Reaction of ManNAc with 
Z-[3-2H]-PEP to produce (3S)-3-deutero-NANA. (B) Reaction of ManNAc with Z-[3-2H]-PEP to produce 
(3S)-3-deutero-NANA. Figure modified from Tanner (2005) (5). 
 
Similar experiments were undertaken using isomers of mono-fluorinated PEP. CjeNANAS was 
assayed with ManNAc and either E-[3-F]-PEP or Z-[3-F]-PEP, and the products were analysed using 
19F NMR spectroscopy (90).  The enzyme did not accept E-[3-F]-PEP as a substrate whilst the reaction 
with Z-[3-F]-PEP produced (3S)-3-fluoro-NANA. The results from both analyses indicate that the 
facial selectivity of the reaction catalysed by NANAS is for the si face of PEP with the si face of the C1 
carbonyl of ManNAc (90). 
 
A 
B 
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Further evidence for the si-facial selectivity of NANAS was afforded by the elucidation of an 
NmeNANAS crystal structure with a bound tetrahedral analogue (113). A structural mimic of the 
tetrahedral intermediate was synthesised and determined to inhibit catalysis by NmeNANAS (Ki of 
3.1 ± 0.1 µM) (113). Displayed in Figure 1.21, the tetrahedral analogue bears a hydrogen instead of a 
hydroxyl at the C-2 stereocentre.  
 
 
 
 
 
 
 
Figure 1.21 Structures of the tetrahedral intermediate for the NANAS reaction and the inhibitor based on 
its structure.  
 
NANAS activity was analysed using two diastereoisomers of the intermediate mimic, with either 
(2R) or (2S) configuration at the C-2 tetrahedral centre. Whilst the two diastereoisomers could not 
be completely isolated, it was successfully demonstrated that the (2R) configuration accounted for 
the majority of the inhibition observed (113). Furthermore, a 1.75 Å resolution crystal structure of 
NmeNANAS was elucidated with (2R)-inhibitor bound in the active site even though the crystals 
were soaked in a 4.5:1 mixture of (2S)-inhibitor:(2R)-inhibitor (Figure 1.22) (113).    
The preference for the (2R)-inhibitor observed in the NmeNANAS 2WQP crystal structure and 
improved inhibition values compared to the (2S)-inhibitor, likely indicates that the natural 
tetrahedral intermediate would share (2R) geometry. The (2R)-configuration indicates that the 
reaction mechanism occurs via a si face attack to the oxocarbenium ion intermediate. The structure 
may also imply that the metal ion plays a dual catalytic role; activating the aldehyde of ManNAc and 
acting as a source of nucleophilic, activated water for attack of the oxocarbenium ion intermediate 
(Figure 1.19A) (113).  
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Figure 1.22 NmeNANAS active site with tetrahedral intermediate mimic bound. Residues contributed by 
the catalytic domain are in grey, linker in orange and AFPL domain in blue. Tetrahedral intermediate 
mimic is in purple, Mn2+ yellow and waters are in red. Polar contacts are depicted with black dashes and 
dipolar bonds with red dashes (PDB code (2WQP) (113)). 
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1.7 Evolutionary relationships 
 
1.7.1 PEP aldolases 
The C-O bond cleavage mechanism employed by the NANAS enzyme is unusual and very few PEP 
utilising enzymes are known to react in this manner (5). Enzymes which have similar catalytic 
mechanisms include 5-enolpyruvylshikimate-3-phosphate synthase (EPSPS), UDP-N-
acetylglucosamine enolpyruvyl transferase (MurA), 2-keto-3-deoxy-D-arabino-heptulosonate 
synthase (DAH7PS) and 2-keto-3-deoxy-D-manno-octulosonate synthase (KDO8PS) (118-121). The 
aforementioned enzymes are divided into two categories, enolpyruvyl transferases (EPSPS and 
MurA) and PEP aldolases (DAH7PS, KDO8PS and NANAS) (122). Enolpyruvyl transferases catalyse an 
addition-elimination reaction where a pyruvyl moiety from PEP is transferred to an acceptor alcohol 
(120, 121). In comparison, PEP aldolases catalyse an aldol-like addition of PEP to an aldehyde (118, 
119).  
The catalytic mechanism of both DAH7PS and KDO8PS are extensively documented in the 
literature (118, 123, 124). DAH7PS and KDO8PS each catalyse aldol-like reactions combining PEP 
with D-erythrose 4-phosphate (E4P) or D-arabinose 5-phosphate (A5P) respectively, to produce the 
corresponding sugar phosphate products (Figure 1.23). Due to the similarity in mechanisms 
employed, it has been previously proposed that the contemporary families of PEP aldolases evolved 
from a common ancestral enzyme (122). Although DAH7PS and KDO8PS have low sequence 
similarity to NANAS enzymes (< 10% identity) (113), each share a similar (β/α)8 barrel catalytic 
domain fold (124, 125). A notable difference is that in both DAH7PS and KDO8PS enzymes, the PEP 
molecule attacks the re face of the aldehyde. As previously discussed in Section 1.6.3, in NANAS it is 
the si face of the aldehyde that is attacked (5).  
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Figure 1.23 Reactions catalysed by the PEP aldolase super-family of enzymes. The reactions of DAH7PS, 
KDO8PS and NANAS enzymes are depicted with PEP highlighted in red.   
 
1.7.2 DAH7PS 
DAH7PS catalyses an aldol-like condensation between PEP and E4P to produce DAH7P. DAH7PS 
catalyses the first reaction of the shikimate pathway, the metabolic route by which chorismate is 
formed (Figure 1.24) (126). Chorismate is an important metabolite from which the aromatic amino 
acids, folate and vitamin K are generated (127). The shikimate pathway is present in plants and 
microorganisms but is absent in higher life forms (126). Enzymes from this pathway are therefore 
potential targets for the development of antimicrobials and herbicides. Since the reaction catalysed 
by DAH7PS is the first committed step in a branched enzymatic pathway, it is a key metabolic control 
point and is highly regulated (127).  
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Figure 1.24 The shikimate pathway.  The first reaction is catalysed by DAH7PS. Multiple enzymatic steps 
convert DAH7P to chorismate, which is the branch point of the aromatic amino acid, folate and vitamin K 
biosynthetic routes.  
 
DAH7PS enzymes contain a core, catalytic (β/α)8 barrel yet are structurally diverse due to a 
variety of extra-domain decorations. These barrel extensions enable feedback regulation of the 
enzyme (127). DAH7PSs are classed as Iα, Iβ or II based on the nature of the additions (125, 128). 
Similar to NANAS enzymes, DAH7PS require a divalent metal ion for catalysis (129). As previously 
mentioned, NANAS has a low sequence identity to DAH7PS enzymes. Correlatively, the metal 
binding scaffolds of NANAS and DAH7PS are disparate.   
 
1.7.3 KDO8PS 
KDO8PS condenses PEP and A5P to form KDO8P (Figure 1.23), which is a metabolic precursor of 
3-deoxy-D-manno-octulosonate (KDO); an essential component of the lipopolysaccharides of Gram-
negative bacteria (130). Gene knock-out studies have indicated that KDO8PS performs an essential 
function for bacterial homeostasis, and that loss of KDO8PS function can arrest cell growth (131, 
132). KDO8PS is thus a potential drug target against Gram-negative, pathogenic bacteria (128). 
KDO8PS enzymes are closely related to DAH7PSs, however, unlike DAH7PS and NANAS they have 
variable metal dependence (113). Several KDO8PS enzymes do not require metal ions for their 
catalytic function (133). Additionally, whilst KDO8PS, DAH7PS and NANAS share a common (β/α)8 
barrel scaffold, KDO8PS enzymes do not possess extra barrel decorations (130).  
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1.7.4 Sialic acid synthase family 
Whilst it was originally believed that the NANAS enzyme was evolutionarily similar to DAH7PS 
and KDO8PS (122), more recent investigations have indicated that this relationship is quite distant 
(113, 134). NANAS belongs to a family of SAS enzymes which include pseudaminic acid synthase 
(PseS) and legionaminic acid synthase (LegS) (89, 135). Displayed in Figure 1.25, LegS catalyses an 
aldol-like condensation reaction between PEP and 2,4-diacetamido-2,4,6-trideoxymannose to form 
Leg, whilst PseS reacts PEP with 2,4-diacetamido-2,4,6-trideoxyaltrose to form Pse. Genes encoding 
NANAS, LegS and PseS are present in the C. jejuni genome, making it an excellent model for studying 
the relationships between these three homologous enzymes (64).  
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.25 Reactions catalysed by the SAS family of enzymes. The reactions of NANAS, PseS and LegS 
and enzymes are depicted with PEP highlighted in red.   
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1.7.5 CMP-Leg biosynthesis 
The biosynthetic pathways of Leg and Pse are very similar to that described for NANA in Section 
1.5.1. A 30 kb locus has been previously identified in L. pneumophila that contains many of the 
necessary genes for Leg biosynthesis (136). Within this locus there are homologues of each of the 
final three enzymes involved in CMP-NANA biosynthesis (68, 135). As shown in Figure 1.26, the first 
of these enzymes is a nucleoside diphosphate (NDP)-sugar hydrolase/2-epimerase that catalyses 
both an inversion of configuration at C-2 and a hydrolysis of the glycosidic-NDP linkage, converting 
NDP-2,4-diacetamido-2,4,6-trideoxy-glucopyranose into 2,4-diacetamido-2,4,6-trideoxymannose 
and free NDP. The second enzyme is LegS which, as previously mentioned, condenses PEP and 2,4-
diacetamido-2,4,6-trideoxymannose to form Leg and free, inorganic phosphate. The final enzyme in 
the CMP-Leg biosynthetic pathway is CMP-Leg synthetase which activates Leg as a CMP derivative. 
 
Figure 1.26 The final three enzymatic reactions of the CMP-Leg biosynthetic pathway. The substituent 
NDP can be either uracil (UDP) or guanine (GDP) (68, 135).  
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LegS enzymes have been previously characterised from both L. pneumophila (135) and C. jejuni 
(68). As reported by Glaze et al (2008), LpnLegS was characterised as a maltose binding (MalE) fusion 
protein as there was significant difficulty in producing soluble enzyme (68). LpnLegS-MalE was found 
to catalyse the condensation reaction between PEP and 2,4-diacetamido-2,4,6-trideoxymannose 
through NMR analysis but had a very poor specific activity of 4.4 x 10-3 µmol min-1. It was postulated 
that the low specific activity ascertained for LpnLegS was not an accurate representation of the in 
vivo parameter due to the MalE modification. Furthermore, it was revealed by [2-18O]PEP that LegS 
catalysed its reaction through C-O bond cleavage similar to the mechanism previously shown for 
NANAS (112). 
The CMP-Leg pathway from C. jejuni was elucidated by Shoenhofen et al (2009) (135). It was 
proven by NMR that CjeLegS was able to condense PEP with 2,4-diacetamido-2,4,6-trideoxymannose 
to form Leg. Shoenhofen et al (2009) proposed that the biosynthetic route for CMP-Leg synthesis 
occurred via GDP-linked sugars as opposed to UDP-linked sugars, contrary to what had been 
previously reported for both NANA and Pse biosynthesis (5, 63). It was reasoned that the use of 
GDP-linked sugars enabled differentiation of the Leg biosynthetic pathway from other UDP-linked 
pathways such as those involving UDP-2,4-diacetamido-2,4,6-trideoxy-glucopyranose (involved in N-
linked protein glycosylation). In comparison, UDP-linked sugars were used in the previously 
mentioned study by Glaze et al (2008), where UDP-2,4-diacetamido-2,4,6-trideoxyglucopyranose 
was shown to be utilised by the Leg biosynthetic sugar hydrolase/2-epimerase (68). It is unclear from 
these reports whether UDP or GDP linked precursors are preferred by the enzymes of the CMP-Leg 
biosynthetic pathway and it is likely that either may be utilised.  
 
1.7.6 CMP-Pseudaminic acid biosynthesis 
The CMP-Pse pathway has been elucidated in both H. pylori (63) and C. jejuni  (137, 138). The 
final three enzymes involved in CMP-Pse biosynthesis are shown in Figure 1.27. The first enzyme 
shown is a UDP-sugar hydrolase that catalyses a hydrolysis of the glycosidic-UDP linkage, converting 
UDP-2,4-diacetamido-2,4,6-trideoxyaltrose into 2,4-diacetamido-2,4,6-trideoxyaltrose. This reaction 
differs from the analogous step in Leg and NANA biosynthesis, where the corresponding sugar 
hydrolases have an additional epimerase functionality that inverts the stereochemistry at position C-
2. In Pse biosynthesis, C-2 stereochemistry is retained during this step. The crystal structure of the 
pseudaminic UDP-sugar hydrolase has been elucidated from C. jejuni (137). 
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The second enzyme depicted is PseS which condenses PEP and 2,4-diacetamido-2,4,6-
trideoxyaltrose to form Pse and free, inorganic phosphate. CjePseS has been previously 
characterised using a continuous coupled phosphate assay with purine nucleotide phosphorylase 
and product formation was confirmed by both 1H and 31P NMR (89). Using the coupled assay, 
CjePseS was determined to have a kcat = 0.65 ± 0.01 s
-1, Km (PEP) = 6.5 µM and Km (2,4-diacetamido-
2,4,6-trideoxyaltrose) = 9.5 ± 0.7 µM (89). The most activating metal for CjePseS was determined to 
be Co2+ followed by Mn2+. Similar to NANAS and LegS, [2-18O] PEP was used to confirm that PseS 
catalysed Pse synthesis via C-O bond cleavage. The final enzymatic step in the CMP-Pse biosynthetic 
pathway is catalysed by a CMP-synthetase which activates Pse. 
 
Figure 1.27 The final three enzymatic reactions of the CMP-pseudaminic acid biosynthetic pathway.  
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1.8 Research objectives 
 
Sialic acids play important roles in many biological processes such as cell signalling, recognition 
and adhesion (2, 37). They are also involved in the pathogenesis of several invasive species (59), thus 
the enzymes involved in their synthesis are of substantial therapeutic interest. SASs are critical in the 
generation of sialic acids, and understanding their catalytic function is of significant importance to 
the development of novel antimicrobials. Current knowledge of SAS catalysis is limited to the 
reaction mechanism, and minimal investigation has been made into the role of specific catalytic site 
residues. Furthermore, the role of the unique AFPL domain has not been examined beyond its 
contribution of residue Arg314.   
The evolutionary relationships within the SAS family are also poorly understood, with several SAS 
enzymes misannotated in online databases. In general, this thesis aims to further develop the 
current understanding of SAS evolutionary relationships and improve existing knowledge of the 
catalytic mechanism by investigation of key residues as well as the unique SAS AFPL domain.  
The specific research objectives for this thesis are as follows: 
 Characterisation of wild-type NmeNANAS using an uncoupled, continuous assay. 
 Investigation of the catalytic function of NmeNANAS Arg314 through site-directed 
mutagenesis. 
 To develop an understanding of the role of the AFPL domain in catalysis through the 
generation of an AFPL domain truncation variant. 
 To use bioinformatic analysis to explore the evolutionary relationships within the SAS 
family and to identify key residues and sequences that may confer substrate 
selectivity. 
 Characterisation and comparison of NANAS, LegS and PseS from C. jejuni to gain 
further insight into the relationships between these enzymes. 
 Characterisation of the putative SAS enzyme from Chlorobium tepidum which does 
not natively express an AFPL domain, and developing an understanding of its 
evolutionary relationship to other members of the SAS family.   
 Determining substrate selectivity of the SASs using an assortment of ManNAc 
analogues.  
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 Characterisation of the putative SAS enzyme from Streptococcus suis in an effort to 
observe substrate plasticity.  
 Elucidation of additional SAS enzyme structures, to further study the evolutionary 
variation of the active site architecture.  
 Generation of two AFPL domain chimeras combining the NANAS enzyme from N. 
meningitidis and NANA-9-PS from Homo sapiens in an effort to interchange substrate 
selectivity.  
 
Since NmeNANAS is the most thoroughly investigated and the only SAS from which a complete 
structure is elucidated, it was used as a basis and point of comparison for much of the work outlined 
in this thesis (5, 103, 104, 112, 113). The SAS enzymes from C. jejuni were used to compare 
evolutionary relationships between NANAS, LegS and PseS, as a C. jejuni paralogue from each clade 
has been previously identified (64). The putative SAS enzyme from C. tepidum was selected to 
investigate a naturally truncated SAS. Substrate plasticity has been observed in Streptococcus 
agalactiae NANAS (105) and thus to compare this phenomenon, the SAS from S. suis (which has the 
highest sequence identity to SagNANAS) was isolated.  
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Chapter 2 
Investigating the role of Arg314 in 
NmeNANAS 
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2.1 Background 
 
 
2.1.1 Structure of N-acetylneuraminic acid synthase 
The structure of N. meningitidis NANAS (NmeNANAS), has been previously elucidated in the 
presence of Mn2+, PEP and a reduced form of ManNAc (Figure 2.1), and has also been crystallised in 
the presence of a tetrahedral intermediate mimic (112, 113).  Both structures have revealed that 
NmeNANAS is a domain swapped homodimer, with each subunit comprising of two structurally 
distinct domains joined by a linker region. The N-terminal domain of NmeNANAS is a (β/α)8 barrel 
fold and contributes the majority of the residues comprising the catalytic site. The C-terminal 
domain comprises 58 amino acid residues and strongly resembles the fold of fish Type III antifreeze 
proteins (103, 117).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1 (A) NmeNANAS dimer with one monomer coloured grey and the second coloured by domain. 
The catalytic domain is shown in purple, linker domain in orange and anti-freeze protein like (AFPL) 
domain in blue. Crystallographic coordinates 1XUZ (112). 
 
The antifreeze protein like (AFPL) domain caps the catalytic domain of the opposing monomer, 
donating one key residue (Arg314), directly into the active site (Figure 2.2).  Arg314 is positioned to 
form a hydrogen bond with the acetyl group oxygen of rManNAc and is thus proposed to interact 
with the congruent functionality of the natural substrate.  Residue Arg314 is also highly conserved in 
bacterial SASs. The importance of Arg314 has been previously implicated in Streptococcus agalactiae 
NANAS where treatment of the enzyme with the Arg modifying reagent phenylglyoxal was found to 
inhibit catalytic activity (105). 
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Figure 2.2 Close up of active site. Residues contributed by the catalytic domain are shown in grey and 
residues from linker in orange and AFPL domain in blue. ManNAc is coloured green, PEP pink, Mn2+ 
yellow and waters are shown in red. H-bonds are depicted with black dashes and dipolar bonds with red 
dashes (PDB code (1XUZ) (112)). 
  
2.1.2 Goals of this research 
NmeNANAS is the most thoroughly investigated member of the SAS family (5, 104, 112, 113). 
NmeNANAS is also the only wild-type SAS with a complete crystal structure available (112, 113). The 
current knowledge on this enzyme makes NmeNANAS an excellent starting point and model for 
mechanistic studies and evolutionary comparisons to other SASs. The work done in this chapter aims 
to build upon previous studies and to develop a point of reference for comparisons made in later 
chapters.  
Currently very little is known about the role of the AFPL domain other than its contribution of 
Arg314. The work outlined in this chapter aims to investigate the role of Arg314 in the catalytic 
mechanism of NmeNANAS. 
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2.2 Cloning, expression and purification of 
NmeNANAS  
 
2.2.1 Cloning   
The gene encoding NANAS from N. meningitidis serotype B strain MC58 (neuB) was amplified 
from genomic DNA using the nested PCR method outlined in Section 8.3.2. Gene specific nested 
primers were designed incorporating generic extensions for further rounds of nested PCR (Table 
8.5). Following successful amplification as determined by agarose gel electrophoresis, the product 
from the first round of nested PCR was purified. Purified first round product was extended using 
generic gateway primers, which incorporated a sequence encoding an N-terminal TEV protease 
cleavage site (Table 8.5).  
Successful amplification was determined by agarose gel electrophoresis and the product from the 
second round of nested PCR was also purified. Cloning and sub-cloning of neuB was achieved 
through the use of the gateway system as outlined in Section 8.3. The linear product from second 
round nested-PCR was cloned into the donor vector pDONR-221. Ligated product was subsequently 
transformed into E. coli One Shot® TOP10 cells (Invitrogen) as outlined in Section 8.3.10. Plasmid 
from a selected transformant was purified and neuB was successfully sequence verified in the donor 
vector. The neuB gene was sub-cloned into the destination vector pDEST-17, which encodes an N-
terminal His-tag.  
 
2.2.2 Expression and purification 
The neuB gene was transformed into three different expression cell lines to optimise the yield of 
soluble protein. The neuB gene was transformed into E. coli BL21 (DE3) Star cells, E. coli Rosetta™ 2 
(DE3) cells and E.coli Bl21 (DE3) pBB540/pBB542 (Chaperone 3) cells. In order to compare induced 
against non-induced samples, two cultures of each cell line were grown overnight in LB, with one 
induced by IPTG and the other not. The best yield of soluble protein was attained using Chaperone 3 
cells as analysed by SDS PAGE. NmeNANAS was thus expressed and purified from this cell line.  
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NmeNANAS was expressed and purified using the method outlined in Section 8.4. Cell pellets 
were resuspended in buffer and lysed via sonication. The resulting lysate was clarified by 
centrifugation to separate out the cell debris. Soluble protein was filtered and run through an IMAC 
column to purify the His-tagged protein. After the first round of IMAC purification, protein was 
desalted and treated with TEV protease to remove the His-tag and then run through a second IMAC 
column to separate the tag and TEV protease (which itself has a non-cleavable His-tag) from the 
target protein. SEC was used as a final, polishing step and fractions were subsequently pooled, 
concentrated, flash-frozen and stored at -80 °C. Samples of purified enzyme were analysed by SDS 
PAGE (Figure 2.3). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.3 SDS-PAGE gel of NmeNANAS wild-type purification. Lane M contains marker with molecular 
weights defined. Lane 1 contains insoluble lysate, Lane 2 soluble lysate, Lane 3 first IMAC flow-through, 
Lane 4 first IMAC bound protein (His-tagged NmeNANAS) and Lane 5 purified NmeNANAS after TEV 
protease treatment, second IMAC and SEC.  
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2.3 Characterisation of NmeNANAS 
 
2.3.1 Michaelis-Menten kinetics 
Previously, two different assays have been described for determining the kinetic parameters of 
NmeNANAS. The first of these is a stopped assay, and the second is a continuous assay where 
NANAS activity is coupled with NANA lyase, the latter of which breaks down NANA into ManNAc and 
pyruvate, which is spectrophotometrically monitored (6, 112). NANA lyase catalyses a reversible 
reaction which breaks down NANA into pyruvate and ManNAc (139, 140). The spectroscopic assay 
used for kinetic analysis of NmeNANAS in this thesis is continuous, and directly monitors the loss of 
PEP. This assay has been previously described for activity assays of other PEP aldolases such as 
DAH7PS and KDO8PS (123, 124). 
The kinetic parameters of wild-type NmeNANAS were determined using the assay described in 
Section 8.5.1.  Cuvettes containing 50 mM BTP (pH 8), 1 mM MnCl2, PEP (varied) and ManNAc 
(varied) were incubated for 10 min at 25 °C. The enzymatic reaction was initiated by the addition of 
purified enzyme. Michaelis-Menten steady-state approximations were utilised to determine kinetic 
parameters (Figure 2.4).    
 
  
 
 
 
 
 
 
 
 
 
Figure 2.4 Michaelis-Menten curves for NmeNANAS wild-type with ManNAc and PEP. (A) NmeNANAS 
PEP Km curve and (B) NmeNANAS ManNAc Km curve. Data points are shown in black and a line of best fit 
in red. A double reciprocal plot is displayed as an inset for each graph.  
 
A B 
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The Km of ManNAc for NmeNANAS was calculated to be 2.9 ± 0.2 mM and the Km of PEP for 
NmeNANAS was calculated to be 28 ± 3 µM. The previously determined values for the Km of ManNAc 
and PEP were 6.25 mM and 42 µM respectively (104). The kinetic assay used for the previously 
reported value was a stopped assay with thiobarbituric acid. The differences in values attained in 
previous studies are likely a result of variation in methodology and conditions used for analysis. The 
kcat for the reaction was calculated to be 3.1 ± 0.1 s
-1 with the literature value determined as 0.9 s-1 
(103).  
 
2.3.2 Mass spectrometry 
The molecular mass of His6-tagged NmeNANAS was analysed using mass spectrometry. A 
theoretical mass of 41,977 Da was calculated for NmeNANAS from the peptide sequence using 
ProtParam (141). The experimental mass determined by mass spectrometry was 41,977 Da which 
was identical to the aforementioned calculated mass.  
 
2.3.3 Circular dichroism 
CD spectroscopy was used to assess the secondary structure profile of NmeNANAS (Figure 2.5). 
The K2D3 server (142) was used to estimate the secondary structure composition from CD spectra. 
Shown in Table 2.1, estimated secondary structure is compared to values derived from the crystal 
structure of NmeNANAS (PDB code: 1XUZ). 
 
 
 
 
 
Figure 2.5 CD spectra for NmeNANAS wild-type (red). 
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Table 2.1 Predictions of secondary structure composition for NmeNANAS wild-type calculated from CD 
data using K2D3 server (142). Secondary structure composition of NmeNANAS structure calculated from 
crystallographic coordinates 1XUZ. 
 
The results from CD reveal that the NmeNANAS enzyme is folded in solution (Figure 2.5). 
Depicted in Table 2.1, the secondary structure composition estimated from the CD data of wild-type 
NmeNANAS is comparable to the levels of α-helix and β-sheet calculated using the crystal structure 
NmeNANAS 1XUZ (112). The results from CD thus indicate that the solution structure of NmeNANAS 
has similar secondary structure elements to the previously elucidated crystal structure.  
 
2.3.4 Thermal stability 
Differential scanning fluorimetry (DSF) was used to assess the melting temperature of 
NmeNANAS wild-type. The method used for DSF analysis is outlined in Section 8.5.3. DSF employs a 
dye which increases in fluorescence when it is bound to hydrophobic protein residues. The number 
of previously internalised hydrophobic residues available for binding increases as a protein 
denatures. By steadily raising the temperature of a protein’s environment and monitoring the 
fluorescence, the denaturation temperature can be measured as the point of greatest increase in 
fluorescence. Enzymes used for DSF were treated with 10 mM EDTA prior to SEC to ensure removal 
of trace metals. The melting point of metal-free (apoenzyme) NmeNANAS was determined to be 43 
± 0.5 °C.  
 
 
 
 
 
 NmeNANAS 
(CD)   
NmeNANAS  
(structure) 
α-helix 59.9 % 50.3 % 
β-sheet 12.3 % 15.5 % 
other 27.8 % 34.2 % 
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2.4 Cloning, expression and purification of  
NmeArg314 variants 
 
2.4.1 Site-directed Mutagenesis   
In order to assess the role of Arg314 in NmeNANAS, two variants of the protein were generated. In 
the first, Arg314 was substituted for Lys in order to diminish the hydrogen bonding capability of the 
side-chain, but preserve some of the functionality of the wild-type protein. For the second variant, 
Arg314 was substituted for Ala, removing the hydrogen bonding capability of the side-chain at this 
residue completely.  
The NmeNANAS wild-type pDEST-17 vector described in Section 2.2.1 was used as a template to 
generate NmeR314A and NmeR314K. DNA sequence encoding an N-terminal TEV protease cleavage 
site and N-terminal His-tag were incorporated from the template. The methods used for PCR 
amplification are outlined in Section 8.3.2, and primer sequences are displayed in Table 8.6. 
 
2.4.2 Expression and purification 
The pDEST-17 plasmids bearing the variant genes for NmeR314A and NmeR314K (outlined in 
Section 2.4.1) were transformed into Chaperone 3 cells to optimise the yield of soluble protein. 
NmeR314A and NmeR314K were each expressed and purified using a similar method to that outlined 
for NmeNANAS wild-type in Section 8.4. Purified enzymes were concentrated, flash-frozen and 
stored at -80 °C. Samples of purified enzyme were analysed by SDS PAGE (Figure 2.6). 
 
 
 
 
 
 
47 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.6 SDS-PAGE gel of purified NmeNANAS wild-type, NmeR314A and NmeR314K. Lane M contains 
marker with molecular weights defined. Lane 1 contains purified NmeNANAS wild-type, Lane 2 
NmeR314A and Lane 3 NmeR314K. 
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2.5 Kinetic analysis of NmeArg314 variants 
 
2.5.1 Michaelis-Menten kinetics 
To determine the kinetic parameters of the NmeNANAS Arg314 variants, the consumption of PEP 
was monitored using the assay described in Section 8.5.1. NmeR314K was found to be kinetically 
active however NmeR314A was inactive and no loss of PEP was observed even with excess 
concentrations of enzyme. Michaelis-Menten steady-state approximations were utilised to 
determine kinetic parameters of NmeR314K (Figure 2.7). Kinetic parameters were compared to the 
values ascertained for NmeNANAS wild-type (Table 2.2).  
 
  
 
 
 
 
 
 
 
 
Figure 2.7 Michaelis-Menten curves for NmeR314K with ManNAc and PEP. (A) NmeR314K PEP Km curve 
and (B) NmeR314K ManNAc Km curve. Data points are shown in black and a line of best fit in red. A double 
reciprocal plot is displayed as an inset for each graph. Assays were carried out in 50 mM BTP at pH 7.5 
with 1 mM MnCl2, PEP (varied) and ManNAc (varied) at 25 °C. Reactions were initiated by the addition of 
5 µL of purified enzyme at a stock concentration of 2.5 – 3.5 mg/mL. Michaelis-Menten steady-state 
approximations were utilised to determine kinetic parameters with nonlinear fitting in GraFit (Erathicus 
Software). To determine apparent Km (PEP), ManNAc concentration was held at 30 mM, and the 
concentration of PEP varied. To determine apparent Km (ManNAc), PEP was kept constant at 1 mM, and 
ManNAc concentration was varied. 
 
 
 
A B 
49 
 
 
 
 
Table 2.2 Kinetic parameters for wild-type NmeNANAS, NmeR314K and NmeR314A. Values with - 
indicates kcat of enzyme is less than 0.004 s-1.  
 
Although NmeR314K is catalytically active, an approximately seven-fold reduction in the specificity 
constant with respect to wild-type NmeNANAS was observed (Table 2.2).  This change arises from 
both a reduction in the kcat (approximately two-fold) and an elevation in the Km (ManNAc) for 
NmeR314K in comparison to wild-type NmeNANAS. In contrast, Km (PEP) values of the NmeR314K 
variant and wild-type NmeNANAS are quite similar, indicating that the PEP site is unaffected by the 
mutation of arginine for lysine. No loss of PEP was observed with NmeR314A even with a 10-fold 
increased addition of enzyme, indicating that this variant was unable to catalyse the aldol 
condensation between PEP and ManNAc.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 Wild-type  
NmeNANAS 
R314K  
NmeNANAS 
R314A 
NmeNANAS 
kcat (s
-1) 3.1 ± 0.1 1.7 ± 0.1 - 
Km PEP (µM) 28 ± 3 32 ± 3 - 
Km ManNAc (mM) 2.9 ± 0.2 10.5 ± 0.1 - 
kcat/Km  ManNAc (s
-1/M) 1068 ± 108 162 ± 11 - 
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2.6 Binding studies of NmeNANAS wild-type 
and NmeArg314 variants 
 
2.6.1 Isothermal titration calorimetry 
In order to identify the causes for the loss of activity of the R314A variant of NmeNANAS, binding 
studies were undertaken using isothermal titration calorimetry (ITC). ITC was used to determine the 
dissociation constants (Kd) for NmeNANAS wild-type, NmeR314K and NmeR314A with respect to 
Mn2+, PEP and rManNAc (Table 2.3). The Raw experimental binding curves and one-site model fitted 
ITC data for Mn2+ and PEP and rManNAc are displayed in Figure 2.8. The methods used for ITC 
analysis are described in Section 8.5.4.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2.3 ITC derived binding constants for wild-type NmeNANAS, NmeR314K and NmeR314A.  
 
 
 
 
 
 
 
 
 
 Wild-type R314K R314A 
Kd Mn
2+ (µM) 10.6 ± 0.5 13.5 ± 0.4 4.8 ± 0.1 
Kd PEP (µM) 219 ± 11 406 ± 12 382 ± 26 
Kd rManNAc (µM) 201 ± 16 206 ± 18 377 ± 26 
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Figure 2.8 Enthalpy changes measured by isothermal titration calorimetry. (A-C) Mn2+ binding to metal-free 
NmeNANAS wild-type, NmeR314K, and NmeR314A respectively. (D-F) PEP binding to metal-bound 
NmeNANAS wild-type, NmeR314K, and NmeR314A respectively, (G-I) rManNAc binding to PEP/metal-bound 
NmeNANAS wild-type, NmeR314K and NmeR314A respectively. To determine Kd(Mn), 5 mM MnCl2 was titrated 
into 70 µM enzyme. To determine Kd (PEP), 50 mM PEP was titrated into 40 µM enzyme containing a 
background concentration of 1 mM MnCl2. To determine Kd (rManNAc), 10 mM rManNAc was titrated into 100 - 
200 µM enzyme containing a background concentration of 1 mM MnCl2 and 1 mM PEP. 
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To determine the Kd values for metal with NmeNANAS wild-type, NmeR314K and NmeR314A, Mn
2+ 
was titrated into metal-free enzyme. Mn2+ was chosen to investigate metal binding, as it has been 
previously established as the most activating metal (103, 104).  The titration of Mn2+ into metal-free 
enzyme revealed similar affinity of these three enzymes for this metal ion. This is unsurprising given 
that the mutations made are not proximal to the metal binding site.  Titration of PEP into metal-
bound enzymes revealed that the Kd values of PEP with respect to NmeR314K and NmeR314A were 
almost two-fold greater than those determined for the wild-type enzyme. This correlates with the 
observations in Section 2.3.1 where the Km (PEP) values of NmeR314K and wild-type NmeNANAS are 
noted to be similar, and indicates that the PEP site is also unaffected by mutation. Interestingly, it 
was noted that the binding of PEP into NmeNANAS wild-type, NmeR314K and NmeR314A was 
endothermic and hence a large favorable entropy must be associated with PEP binding (Figure 4D-F).  
Titration of ManNAc into PEP-free and metal-bound wild-type or variant enzymes did not result in 
any observable heat changes.  However, measurable heat changes were observed when rManNAc 
was titrated into the metal-bound enzymes with saturating levels of PEP present. Evidence for the 
binding of rManNAc was not observed in the absence of PEP, demonstrating that a functional 
binding site for the aldehydic substrate requires PEP to be bound to the protein. The dissociation 
constants for rManNAc with wild-type NmeNANAS and NmeR314K in the presence of metal and PEP 
were found to be similar, however, for the NmeR314A variant, the Kd for rManNAc was significantly 
greater. 
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2.7 Structural analysis of NmeNANAS wild-
type and NmeArg314 variants 
 
2.7.1 Mass spectrometry 
The masses of each of the NmeNANAS Arg314 variants were analysed using mass spectrometry. 
The experimental masses determined for both NmeR314K and NmeR314A were almost identical to 
those calculated from the respective peptide sequences using ProtParam (141). NmeR314K was 
observed to have a mass of 41,950 Da and had an expected mass of 41,949 Da, whilst NmeR314A 
was observed to have a mass of 41,890 Da and had an expected mass of 41,892 Da. 
 
2.7.2 Thermal stability 
DSF was used to assess the melting temperatures of the NmeNANAS Arg314 variants. The 
method used for DSF analysis is outlined in Section 8.5.3. Enzymes used for DSF were treated with 
10 mM EDTA prior to SEC to ensure removal of trace metals. The melting points for apoenzyme 
NmeR314K and NmeR314A were 43 ± 0.5 °C, identical to that determined for wild-type NmeNANAS 
(Section 2.3.4). The results from DSF indicate that the thermal stability of the variant proteins have 
not been significantly altered through mutagenesis.   
 
2.7.3 Circular dichroism 
CD was used to assess and compare the secondary structure of the NmeNANAS Arg314 variants 
with wild-type NmeNANAS. Displayed in Figure 2.9, the CD profiles for both of the NmeNANAS 
Arg314 variants are almost identical to the profile for NmeNANAS wild-type. Furthermore, the 
secondary structure ratios determined from the variant CD data using the K2D3 server (142), were 
identical to the values obtained for wild-type NmeNANAS (Section 2.3.3). The results from CD 
indicate that the secondary structure of the variants is unlikely to have been significantly affected by 
any of the mutations made.    
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Figure 2.9 CD spectra for NmeNANAS wild-type (red), NmeR314A (green) and NmeR314K (purple).  
 
2.7.4 Crystallisation 
Purified NmeR314K and NmeR314A were crystallised using a modified condition previously 
identified for wild-type NmeNANAS (112, 113). Orthorhombic crystals of NmeR314K and NmeR314A 
(between 0.4 and 0.5 mm in size) were formed using the hanging drop crystallisation technique in 
the presence of 1.7 - 1.9 M malate and 10 mM MnCl2 at pH 6.2 (Figure 2.10). Data sets were 
collected at the Australian Synchrotron using the MX2 beamline.  
 
 
 
 
 
 
 
 
 
 
Figure 2.10 Image of orthorhombic NmeNANAS R314K and R314A crystals viewed through a Leica light 
microscope.  
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2.7.5 Structures of NmeR314A and NmeR314K 
Crystal structures of NmeR314K and NmeR314A were successfully solved to resolutions of 2.15 
and 1.75 Å respectively (Table 2.4). The overall folds for both NmeNANAS variants were found to be 
very similar to that of the malate-bound wild-type structure (PDB code 1XUU) with RMS deviations 
for the monomer of the malate-bound wild-type protein compared to the monomers of NmeR314K 
and NmeR314A, calculated as 0.165 Å (315 to 315 atoms) and 0.183 Å (319 to 319 atoms) 
respectively. The space group and unit cell dimensions are also retained (112). 
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 NmeR314K NmeR314A 
A. Data collection   
Crystal system; space group P21212 P21212 
Unit cell parameters (Å) 
a, b, c, α, β, γ 
58.23, 76.05, 77.67, 
90.00, 90.00, 90.00 
58.00, 75.80, 77.52, 
90.00, 90.00, 90.00 
Resolution range (outer shell) (Å) 38.00-2.15 (2.2-2.15) 27.16-1.75 (1.8-1.75) 
Measurements 261,329 481,122 
Unique reflections 19,392 35,205 
Redundancy 13.5 13.7 
Completeness (outer shell) (%) 100.0 (100.0) 100.0 (99.9) 
I/σ(outer shell) (I) 15.9 (7.3) 21.7 (5.2) 
Rmerge (outer shell) 0.137 (0.405) 0.106 (0.508) 
Wilson B-value (Å
2
) 13.706 10.119 
   
B. Refinement   
Resolution (Å) 2.15 1.75 
Rcryst 0.1739 0.1613 
Rfree 0.2423 0.1972 
Chain length 351 351 
Observed number of residues 351 351 
Water molecules 193 359 
Other 2 3 
Mean B (Å
2
)   
 Protein 23.0 17.2 
 Water 22.9 23.1 
 Other 29.4 16.9 
r.m.s.d. from target values   
 Bond lengths (Å) 0.0139 0.0072 
 Bond angles (°) 1.370 1.110 
 Dihedral angles (°) 5.690 5.449 
Ramachandran   
 Most favored (%) 97.8 98.0 
 Allowed (%) 2.2 2.0 
 Generously allowed (%) 0 0 
 Disallowed (%) 0 0 
PDB entry 4IPJ 4IPI 
 
 
Table 2.4 Crystal parameters, data collection and refinement statistics for crystal structure of NmeR314K 
and NmeR314A.  
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As aforementioned, crystals were formed in high concentrations of malic acid (1.7 - 1.9 M), and 
as a result bound malate was observed in the active sites of both NmeR314K and NmeR314A. Malate 
binding was also observed in crystals of wild-type enzyme, and soaking with high concentrations of 
substrate was required to displace malic acid (112). Crystals of both variant proteins were soaked for 
24 hours with 2 M sodium phosphate (pH 6.2), 10 mM MnCl2, 10 mM PEP, and 10 mM rManNAc, 
however, this treatment resulted in significant physical deterioration of the crystals. Additionally, a 
variety of crystallisation conditions and soaking conditions were screened to try to obtain crystals of 
the mutants in the presence of substrates PEP and ManNAc (or rManNAc). Unfortunately no 
additional crystallisation conditions that yielded crystals of diffraction quality were found.  
Most active site residues in the variant structures are in identical positions to that for the 
previously elucidated wild-type structures with either malate or substrates bound (PDB codes 1XUU 
and IXUZ respectively). In both variant structures the backbone conformation at the site of mutation 
is retained and changes in density pertaining to the mutated residue are clearly apparent (Figure 
2.11).  
 
Figure 2.11 Electron density Maps of (A) NmeR314K and (B) NmeR314A showing the mutation at 
residue 314. The electron density map (2Fo-Fc) is displayed at a σ level of 1.0 in blue and the difference 
density map (Fo-Fc) is displayed at a σ level of 3.5 in green and red.  
 
In the substrate-bound wild-type structure, the hydroxyl group of Tyr186 is positioned closer to 
the active site Mn2+ ion (hydroxyl is 2.8 Å away from Mn2+) whereas in the malate-bound wild-type 
structure Tyr186 is slightly displaced (hydroxyl is 4.5 Å away from Mn2+). Partial occupancy of both 
conformations for this residue is observed in the structures of R314K and R314A NmeNANAS (Figure 
2.12). 
A B 
Ala314 
Lys314 
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Figure 2.12 (A) Stereo view of active-site structure of malate-bound NmeNANAS wild-type (PDB code 
1XUU), residues shown in orange. (B) Active-site structure of R314K NANAS, residues shown in purple. 
(C) Active-site structure of R314A NANAS, residues shown in yellow. Malate is shown in green and Mn2+ 
in blue. Hydrogen bonds to malate with distances between 2.0-3.4 Å are displayed with black dashed lines 
and metal-ligand interactions are displayed with red dashed lines. Note: the side-chain of Gln55 in the 
two mutant structures is flipped compared to that of the wild-type structure. This particular 
conformation was modelled in the mutant structures as it allows for more reasonable hydrogen bonds 
with surrounding residues. 
A 
B 
C 
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Malate bound in the active site of R314A is observed in two alternative conformations in both 
enzyme variants. One of these conformations is similar to that observed in the malate bound wild-
type NANAS (Figure 2.12). There is also a slight change in positioning of Mn2+ (1.0 Å towards Tyr186) 
for the malate bound structures (including the wild-type structure 1XUU) when compared to the 
substrate bound wild-type structure (1XUZ), which presumably arises due to the presence of 
different ligands in the active site. One possible consequence of the substitution of Arg314 for Ala 
could be the loss of the ability of the protein to exclude water molecules from the active site. A 
comparison between the wild-type, R314K and R314A NmeNANAS crystal structures around the site 
of mutation indicates that R314A NmeNANAS does not bind additional water molecules in the region 
where Arg314 side-chain is missing (Figure 2.13). 
 
 
 
 
 
 
 
Figure 2.13 Water molecules surrounding the side-chains of residue 314. Crystal structure of the wild-
type NmeNANAS is shown in orange (PDB code 1XUU), R314K NmeNANAS is purple and R314A 
NmeNANAS is shown in yellow. 
 
 
 
 
 
Ala314 
Lys314 
Arg314 
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2.7.6 Substrate docking in NmeR314A and NmeR314K 
As discussed in Section 2.7.5, substrate-bound structures of NmeR314K and NmeR314A were 
unable to be obtained. In order to determine the possible substrate interactions leading to 
diminished activity in NmeR314K and loss of activity in NmeR314A, docking studies using the malate-
bound structures of NmeR314K (PDB code 4IPJ) and NmeR314A (PDB code 4IPI) were undertaken. 
Docking experiments and the following analyses were carried out by Dr Wanting Jiao. 
In the crystal structure of wild-type NmeNANAS (PDB code 1XUZ), the substrate analogue 
rManNAc is bound in the active site (Figure 2.2) (112). The C1 hydroxyl group of rManNAc that 
corresponds to the aldehyde of ManNAc is held in position by hydrogen bonds to Tyr186, His236 and 
a water molecule. The hydroxyl groups on the carbon chain of rManNAc pick up hydrogen bonds 
with residues Asp247, Gln55, and Asn74. The side-chain of Arg314 mainly interacts with the N-acetyl 
group of rManNAc. Molecular modelling studies were conducted to investigate the effect of R314K 
and R314A mutations on the binding mode of the substrate ManNAc.  
ManNAc was first modelled into the wild-type active site to confirm that the correct binding pose 
for this substrate was reproduced in the docking calculation. The modelling study produced a total of 
10 possible low energy binding poses for ManNAc in the wild-type enzyme; all of the 10 poses 
predicted similar positioning of the N-acetyl group of ManNAc as that observed for rManNAc in the 
crystal structure, i.e. with the N-acetyl group interacting with Arg314 (Figure 2.14).  
 
 
 
 
 
 
Figure 2.14 Ensembles of conformations of ManNAc in wild-type NmeNANAS. NmeNANAS receptors 
predicted by docking calculations using crystallographic coordinates 1XUZ. Catalytic residues are in green 
and ManNAc is in grey. 
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The distance between the N-acetyl carbonyl carbon atoms in the crystal structure and those in the 
output poses ranges from 0.15 to 0.55 Å (Table 2.5). Each of the output poses was compared to the 
observed binding mode of the ManNAc analogue, rManNAc, and RMS deviations were measured 
(Table 2.6).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2.5 Distances between the N-acetyl carbonyl carbon atoms in the crystal structure and those in the 
modelled poses. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2.6 Table of RMS deviations between output poses from modelling calculations and the observed 
binding pose in the crystals structure. 
 
 
 
Pose number Wild-type (Å) R314K (Å) R314A (Å) 
1 0.32 0.17 0.14 
2 0.20 0.24 0.85 
3 0.15 0.24 0.42 
4 0.25 0.43 1.32 
5 0.30 0.24  
6 0.25 0.42  
7 0.24 0.27  
8 0.25   
9 0.55   
10 0.47   
 
 
Pose number Wild-type (Å) R314K (Å) R314A (Å) 
1 3.781 3.786 3.787 
2 3.780 3.852 3.803 
3 3.786 3.851 3.778 
4 3.761 3.775 3.853 
5 3.815 3.852  
6 3.849 3.777  
7 3.836 3.835  
8 3.839   
9 3.762   
10 3.799   
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The output pose in the wild-type enzyme with the smallest measured RMS deviation closely 
resembles the binding pose of rManNAc observed in the crystal structure (Figure 2.15A, Figure 
2.16A), with identical interactions between the substrate and the active site residues predicted. The 
aldehyde group of ManNAc in this pose is placed with a distance of 3.2 Å between the aldehyde 
carbon and PEP C3; and a distance of 2.7 Å between the aldehyde oxygen and the active site metal 
ion.  The aldehyde group of ManNAc can thus coordinate to the metal ion for activation.  
 
 
 
 
 
 
 
 
 
Figure 2.15 Modelled pose of ManNAc in (A) NmeNANAS wild-type, (B) NmeR314K, and (C) NmeR314A 
enzymes, superimposed with the binding position of rManNAc in the crystal structure (PDB 1XUZ). 
Modelled poses are in cyan whilst binding pose of rManNAc is coloured yellow. 
 
 
 
 
 
 
 
 
 
 
A B 
C 
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Figure 2.16 Docking poses of ManNAc in to the enzyme of (A) NmeNANAS wild-type, (B) NmeR314K, and 
(C) NmeR314A, superimposed with the binding poses of PEP and rManNAc from the crystal structure, 
which are displayed with yellow carbon atoms (PDB code 1XUZ). Docked ManNAc is in cyan and catalytic 
residues are in green. Polar interactions are depicted with yellow dashes.  
 
The Bürgi–Dunitz angle of nucleophilic attack of PEP to the aldehyde was measured to be 94.0˚ in 
the 1XUZ crystal structure with rManNAc, which is slightly lower than the normal range of 100°-110° 
for Bürgi–Dunitz angles. This possibly arises from the presence of the tetrahedral center of rManNAc 
in the crystal structure. The Bürgi–Dunitz angle in the modelled pose of ManNAc with the smallest 
RMS deviation was measured to be 96.8°, (the range of Bürgi–Dunitz angles measured from all 
output poses is provided in Table 2.7). Therefore, the aldehyde group of ManNAc in this pose is held 
and positioned favorably for reaction to proceed. 
 
A B 
C 
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Table 2.7 Table of Bürgi–Dunitz angles for output poses from modelling calculations. 
 
 
Modelling of ManNAc into the NmeR314K variant produced 7 possible low energy binding poses 
for ManNAc in NmeR314K, and all of the 7 poses predicted similar positioning of the N-acetyl group 
as that observed in the crystal structure (Figure 2.17). The distance between the N-acetyl carbonyl 
carbon atoms in the crystal structure and those in the output poses ranges from 0.17 to 0.43 Å 
(Table 2.5). Following the same procedure as for the wild-type system, the output poses of ManNAc 
in R314K NmeNANAS were compared with the observed binding mode of rManNAc in the crystal 
structure and the RMS deviations were measured (Table 2.6).  
 
 
 
 
 
 
 
 
 
 
 
Figure 2.17 Ensembles of conformations of ManNAc in NmeR314K. NmeR314K receptors predicted by 
docking calculations using crystallographic coordinates 4IPJ. Catalytic residues are in green and ManNAc 
is in grey. 
 
 
Pose number Wild-type (°) R314K (°) R314A (°) 
1 97.8 98.6 98.7 
2 100.4 105.9 74.3 
3 98.3 105.9 88.1 
4 96.8 97.4 102.8 
5 68.5 105.9  
6 105.6 97.5  
7 88.6 111.7  
8 101.2   
9 85.7   
10 85.1   
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The output pose of ManNAc in NmeR314K with the smallest RMS deviation is still quite similar to 
that of rManNAc in the crystal structure (Figure 2.15B, Figure 2.16B), with all hydroxyl groups 
adopting the same positions as observed in NmeNANAS 1XUZ. The position of the N-acetyl group is 
shifted slightly away from Lys314, due to loss of the hydrogen bond caused by the Arg to Lys 
substitution. However, the aldehyde of ManNAc in the NmeR314K enzyme is still positioned similarly 
to that of the best pose in the wild-type enzyme, with a distance between the aldehyde carbon and 
PEP C3 of 3.2 Å, and a distance between the aldehyde oxygen and the active site metal ion of 2.7 Å. 
The Bürgi–Dunitz angle in this pose is measured to be 97.4˚. Therefore, even with slight 
displacement of the N-acetyl group of ManNAc in NmeR314K, the position of the ManNAc molecule 
(especially that of the aldehyde group) is not significantly affected, so that reaction may still proceed 
for the R314K variant. 
The modelling of ManNAc into NmeR314A produced 4 poses (Figure 2.18). Although all 4 poses 
predicted that the N-acetyl groups of ManNAc occupied the same binding site, due to the loss of 
Arg314 side-chain, the N-acetyl groups show a more diverse range of positions compared to the 
NmeNANAS wild-type and NmeR314K variant systems (Figures 2.14 and 2.17 respectively).  
 
 
 
 
 
 
 
Figure 2.18 Ensembles of conformations of ManNAc in NmeR314A. NmeR314A receptors predicted by 
docking calculations using crystallographic coordinates 4IPI. Catalytic residues are in green and ManNAc 
is in grey. 
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The distance between the N-acetyl carbonyl carbon atoms in the crystal structure and those in the 
output poses ranges from 0.14 to 1.32 Å, in comparison to the ranges of 0.15-0.55 Å for NmeNANAS 
wild-type and 0.17-0.43 Å for NmeR314K (Table 2.5). The output poses were compared to the 
crystallographically observed binding pose (Table 2.6), and the pose in NmeR314A with the smallest 
RMS deviation appears to be very different to the poses found in wild-type NmeNANAS and 
NmeR314K enzymes (Figure 2.15C, Figure 2.16C), with hydroxyl groups on C3, C4 and C5 of ManNAc 
being placed in different positions to that observed in the crystal structure. 
The R314A mutation also results in some displacement of the N-acetyl and aldehyde groups of 
ManNAc in the model. Specifically, the distance between the aldehyde carbon of ManNAc and PEP 
C3 is slightly increased (3.3 Å compared to 3.2 Å for NmeNANAS wild-type and NmeR314K systems), 
and the distance between the aldehyde oxygen and the active site metal ion was found to be 
similarly larger (2.8 Å compared to 2.7 Å in NmeNANAS wild-type and NmeR314K). The largest 
difference between the modelled pose in NmeR314A and that of the wild-type and NmeR314K 
systems is in the Bürgi–Dunitz angle, which is unfavourably reduced to 88.2˚(compared to 96.8˚ and 
97.4˚ in wild-type and NmeR314K systems respectively). This observed difference in angle size is 
caused by the changes in conformation of ManNAc in NmeR314A (Table 2.7). It can be inferred that 
when the side-chain functionality of Arg314 is removed through mutagenesis, the enzyme has a 
diminished ability to correctly position the ManNAc aldehyde group and the reaction is unable to 
proceed.   
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2.8 Summary of results 
Wild-type NmeNANAS was successfully amplified from N. meningitidis genomic DNA and cloned 
into a His-tag expression vector. NmeNANAS was expressed and purified by metal affinity and size 
exclusion chromatography. NmeNANAS was successfully characterised using a continuous kinetic 
assay previously described for DAH7PS and KDO8PS enzymes (123, 124). The molecular mass of 
NmeNANAS was verified using mass spectrometry and the enzyme was determined to be folded in 
solution using CD. The melting temperature of apoenzyme NmeNANAS was measured at 43 ± 0.5 °C. 
In order to assess the role of residue Arg314, variant enzymes NmeR314K and NmeR314A were 
generated using site-directed mutagenesis. Both NmeR314K and NmeR314A were determined to be 
soluble and had similar CD and thermal melting profiles to wild-type NmeNANAS. NmeR314K was 
determined to have diminished catalytic activity whilst NmeR314A had no detectable activity at all.  
Structures of both NmeR314K and NmeR314A were obtained using similar conditions to those 
previously used for wild-type NmeNANAS (112, 113).  The structures of both variants contained 
malate in the active site due to high concentrations of the compound being present in the 
crystallisation conditions. Substrate bound structures were unable to be obtained even with ligand 
soaking and co-crystallisation. 
In order to uncover the reason for loss of activity in NmeR314A, substrate binding studies were 
undertaken. Using ITC, each of the variants were determined to have similar binding affinities for 
both Mn2+ and PEP when compared with wild-type NmeNANAS. Interestingly, binding of ManNAc 
could not be observed with either NmeNANAS wild-type, NmeR314K or NmeR314A. Binding could be 
observed with rManNAc only in the presence of PEP and Mn2+, indicating that PEP is required for 
ManNAc binding. Under these conditions, NmeR314A was found to bind rManNAc with a similar ITC 
profile to both NmeNANAS wild-type and NmeR314K.  
ManNAc docking studies using the aforementioned crystal structures of NmeR314K and 
NmeR314A were carried out by Dr Wanting Jiao in an effort to determine the reasoning for 
diminished activity in NmeR314K and loss of activity in NmeR314A. The results from modelling 
revealed that NmeR314K was able to bind ManNAc in a similar fashion to the wild-type enzyme 
whereas NmeR314A was not. Several unreactive poses were observed in the docking analysis of 
NmeR314A with the angle of the aldehyde substrate relative to PEP being inappropriate for 
nucleophilic attack. It was thus revealed that the role of Arg314 in NmeNANAS is to steer the 
aldehyde substrate into a reactive position.  
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2.9 Discussion 
The primary aim of the work described in this chapter was to develop an understanding of the 
role played by residue Arg314 in the catalytic mechanism of NmeNANAS. To achieve this goal, wild-
type NmeNANAS and the variant enzymes NmeR314K and NmeR314A were successfully constructed, 
expressed and purified for structural and functional comparisons. Kinetic characterisation using a 
continuous assay revealed that NmeR314K had diminished catalytic activity when compared against 
wild-type NmeNANAS, whilst NmeR314A was found to be completely inactive. Crystal structures of 
both NmeR314K and NmeR314A were obtained with malate bound in the active sites. 
Interestingly, the binding of ManNAc to NmeNANAS could not be observed by ITC, whilst binding 
of rManNAc could only be observed in the presence of PEP. This indicated that endothermic PEP 
liganding might pre-organise the binding site of ManNAc in NmeNANAS. The results obtained from 
ITC indicated that each of the variant enzymes was able to bind Mn2+, PEP and rManNAc even 
though NmeR314A was inactive. ManNAc docking carried out by Dr Wanting Jiao revealed that 
ManNAc binding in NmeR314K was similar to that of wild-type NmeNANAS, however, modelling of 
ManNAc in NmeR314A predicted revealed several unreactive poses. In particular, the angle of the 
aldehyde substrate relative to PEP was not suitable for the nucleophilic reaction to occur. The 
combined results from kinetics, ITC and molecular modelling suggested that the primary role of 
Arg314 was not in binding of ManNAc but in steering the sugar substrate into a reactive position.   
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Chapter 3 
Investigating the role of the 
antifreeze protein like domain from 
NmeNANAS 
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3.1 Background 
 
3.1.1 Multimeric proteins 
Multimeric proteins are ubiquitous in nature, and oligomerisation is widely believed to be 
evolutionarily favourable (143). Oligomerisation has many structural and functional advantages. 
Multimeric proteins can have enhanced stability and can often regulate accessibility and control 
reactivity and specificity of enzyme active sites (144, 145). Domain swapping is a specific case of 
oligomer assembly in which two or more polypeptide chains exchange units (144). There are many in 
vivo examples of domain swapped proteins where the interchange of domains is essential to 
function (146-148). The prevalence of multimeric proteins in nature makes understanding their 
evolutionary selection and function an invaluable focus of proteomics. 
 
3.1.2 NmeNANAS structure and AFPL domain 
The enzyme responsible for the biosynthesis of NANA is a domain swapped homodimer. The 
structure of NmeNANAS has been elucidated in the presence of Mn2+, PEP and a reduced form of 
ManNAc  (rManNAc), and has also been crystallised in the presence of a tetrahedral intermediate 
mimic (112, 113). The dimeric structure of NmeNANAS is displayed in Figure 3.1A.  Each monomer 
consists of a core catalytic, (βα)8 barrel domain with a short linker extension to an AFPL domain. The 
AFPL domain is exclusive to the SAS family and is named for its high structural similarity to type III 
antifreeze proteins from fish (103, 117). The structure of this domain has also been elucidated by 
NMR from the closely related human enzyme NANA-9PS (117). Other members of the SAS family 
share high sequence homology and are also likely to contain this domain. 
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Figure 3.1 (A) NmeNANAS dimer with one monomer coloured grey and the second coloured by domain. 
The catalytic domain is shown in purple, linker domain in orange and anti-freeze protein like (AFPL) 
domain in blue. (B) Close up of active site. Residues contributed by the catalytic domain are in grey, linker 
in orange and AFPL domain in blue. ManNAc is coloured green, PEP pink, Mn2+ yellow and waters are 
shown in red. H-bonds are depicted with black dashes and dipolar bonds with red dashes (PDB code 
(1XUZ) (112)). 
 
The AFPL domain caps the (βα)8 barrel domain of the opposing monomer and contributes an 
essential arginine into the catalytic site (Figure 3.1) (112, 113). Arg314 is fully conserved in AFPL 
domains from bacterial SASs but is not present in the AFPL domain of mammalian NANA-9-PS. 
Depicted in Figure 3.1B, the guanidinium functionality of Arg314 interacts with the carbonyl oxygen 
of the N-acetyl group from rManNAc. Arg314 of NmeNANAS has been determined to play an 
important role in steering ManNAc into an appropriate orientation for catalysing its reaction with 
PEP (Chapter 2) (114). While the role of Arg314 has been elucidated, the full purpose of the AFPL 
domain has not yet been uncovered.  
A 
B 
Phe288 
Arg314 
His215 
His236 
Lys53 
Thr110 
Lys129 
Ser213 
Ser132 
Ser154 
Asn184 
Tyr186 
Asp247 
Asn74 
Gln55 
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SASs are closely related to both DAH7PS and KDO8PS (122). DAH7PS and KDO8PS catalyse 
analogous aldol-like condensation reactions between PEP and either E4P or A5P (124, 149). Each of 
these three PEP-utilizing aldolases shares many similarities. They each employ similar reaction 
chemistry (112), each adopt a (β/α)8 barrel catalytic domain and they are all considered to share a 
common evolutionary ancestor (122). The notable difference is that the AFPL domain is both 
mechanistically essential and exclusive to SASs. 
 
3.1.3 Goals of this research 
The AFPL domain is a unique C-terminal extension which is critical to the functionality of NANAS.   
The aim of this chapter was to investigate the role of the AFPL domain through the construction and 
analysis of an NmeNANAS truncation from which the AFPL domain has been completely excised. As 
discussed in Chapter 2 of this thesis, the AFPL domain contributes a critical arginine residue into the 
catalytic site which is involved in steering ManNAc into a reactive position. Substrate-binding 
analyses also indicate that PEP liganding pre-organises the active site for ManNAc binding in 
NmeNANAS (Chapter 2). The work outlined in this chapter aims to further investigate the 
mechanism of ManNAc binding in NmeNANAS through molecular dynamics and site-directed 
mutagenesis. 
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3.2 Cloning, expression and purification of  
NmeG272Term 
 
3.2.1 Cloning of NmeG272Term 
To assess the role of the AFPL domain, a truncated variant of NmeNANAS was generated which 
lacked the C-terminal AFPL domain (NmeG272Term). The truncation was made at residue Gly272 
prior to the linker region (Figure 3.2).  
 
 
 
 
 
 
Figure 3.2 NmeNANAS monomer indicating position of Gly272. Catalytic domain is in purple, linker 
domain in orange and AFPL domain in blue. ManNAc is coloured green, PEP pink and Mn2+ yellow. 
NmeNANAS PDB coordinates 1XUZ (112).  
The NmeNANAS wild-type pDEST-17 vector described in Chapter 2 was used as a template to 
generate the NmeG272Term construct. The NmeG272Term construct was created by inserting a stop 
codon into the NmeNANAS template sequence subsequent to the encoding of residue Gly272. Once 
synthesised, the NmeG272Term gene was cloned into vector pDONR 221. DNA sequence encoding 
an N-terminal TEV protease cleavage site was incorporated during the construction of the 
NmeG272Term gene. The NmeG272Term gene was sub-cloned into the expression vector pDEST-17 
which encodes an N-terminal His-tag. The methods used for PCR amplification are outlined in 
Section 8.3.2, and primer sequences are displayed in Table 8.7. 
 
 
Gly272 
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3.2.2 Expression and purification 
The vector pDEST-17 (NmeG272Term) was transformed into three different expression cell lines 
to optimise the yield of soluble protein. Vector pDEST-17 (NmeG272Term) was transformed into E. 
coli BL21 (DE3) Star cells, E. coli Rosetta™ 2 (DE3) cells and Chaperone 3 cells. In order to compare 
induced against non-induced samples, two cultures of each cell line were grown overnight in LB, 
with one induced by IPTG and the other not. The best yield of soluble protein was attained using 
Chaperone 3 cells as analysed by SDS PAGE. NmeG272Term was thus expressed and purified from 
this cell line. NmeG272Term was expressed and purified using a similar method to that used for 
NmeNANAS wild-type as outlined in Section 8.4. Purified NmeG272Term was concentrated, flash-
frozen and stored at -80 °C. Samples of purified enzyme were analysed by SDS PAGE (Figure 3.3). 
 
 
 
 
 
 
 
 
 
Figure 3.3 SDS-PAGE gel of purified NmeNANAS wild-type and NmeG272Term. Lane M contains marker 
with molecular weights defined. Lane 1 contains purified NmeNANAS wild-type and Lane 2 contains 
purified NmeG272Term. 
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3.3 Kinetic analysis of NmeG272Term 
 
3.3.1 Attempted kinetic characterisation of G272Term 
To determine the kinetic parameters of NmeG272Term, the consumption of PEP was monitored 
using the assay described in Section 8.5.1. NmeG272Term was assayed with PEP and ManNAc at 
several different pH levels and temperatures. No kinetic activity could be observed for 
NmeG272Term with PEP (up to 400 µM) and ManNAc (up to 500 mM) even at high protein 
concentrations of approximately 1 mg/mL. Lack of activity equates to a kcat of enzyme less than 
0.004 s-1.   
 
3.4 Binding studies of NmeG272Term 
 
3.4.1 Isothermal titration calorimetry 
In order to probe the causes for the loss of activity of NmeG272Term, binding studies were 
undertaken using ITC. NmeG272Term ligand binding was investigated with respect to metal, PEP 
and rManNAc using the methods described for NmeNANAS wild-type (Section 8.5.4). ITC data from 
NmeG272Term was compared to the previously determined dissociation constants (Kd) for 
NmeNANAS wild-type outlined in Chapter 2 (Table 3.1) (114). The raw experimental binding curves 
and one-site model fitted ITC data for Mn2+ and PEP with NmeG272Term are displayed in Figure 3.4. 
 
 NmeNANAS (114) NmeG272Term 
Kd Mn
2+ (µM) 10.6 ± 0.5 5.3 ± 0.1 
Kd PEP (µM) 219 ± 11 320 ± 20 
Kd rManNAc (µM) 201 ± 16 - 
 
Table 3.1 ITC derived binding constants for wild-type NmeNANAS and NmeG272Term. Values with – 
indicate binding was not observed. 
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Figure 3.4 Enthalpy changes measured by isothermal titration calorimetry. (A) Mn2+ (5 mM) titrated into 
metal-free NmeG272Term (65 µM). (B) PEP (50 mM) titrated into NmeG272Term (40 µM) in the presence 
of Mn2+ (1 mM).  
 
To determine the Kd value for metal ion with NmeG272Term, Mn
2+ was titrated into metal-free 
enzyme. Mn2+ was chosen to investigate metal binding, as it has been previously established as the 
most activating metal for wild-type NmeNANAS (5, 104).  Some differences between the Mn2+ and 
PEP affinities of NmeNANAS wild-type and NmeG272Term were noted.  The affinity of 
NmeG272Term for Mn2+ was determined to be two-fold higher (Table 3.1).  In contrast, although PEP 
still bound to the truncated enzyme, a decrease in the affinity of PEP for the inactive enzyme variant 
was apparent.  
The most striking result of these studies was the change in the affinity of the truncated protein 
for the reduced form of ManNAc (rManNAc).  As discussed in Chapter 2, this substrate analogue 
binds to the wild-type enzyme only in the presence of PEP (114), which is consistent with the 
proposed order of binding where PEP binds first to form the ManNAc binding site (114).  For the 
truncated variant, no enthalpy of binding was observable for either ManNAc or rManNAc titrations 
performed either in the presence or absence of PEP and Mn2+. These results indicate that loss of the 
AFPL domain has completely disabled the ability of NmeG272Term to bind ManNAc. 
A A B 
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3.4.2 Thermal stability 
DSF was used to assess the effect of substrate binding on the thermal stability of NmeNANAS 
wild-type and NmeG272Term. The method used for DSF analysis is outlined in Section 8.5.3. 
Enzymes used for DSF were treated with 10 mM EDTA prior to SEC to ensure removal of trace 
metals. The melting points determined for each sample were plotted graphically and are compared 
in Figure 3.5 as well as Table3.2. 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.5 Bar graph of thermal melting points for NmeNANAS wild-type (red) and NmeG272Term (blue) 
in the presence of ligand as determined by DSF. EDTA, Mn2+ and PEP were each used at a concentration of 
1 mM and ManNAc/rManNAc at 10 mM. ManNAc/rManNAc was used at 1 mM when in combination with 
PEP.  
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Table 3.2 Thermal melting points for NmeNANAS wild-type and NmeG272Term in the presence of ligand 
as determined by DSF. EDTA, Mn2+ and PEP were each used at a concentration of 1 mM and 
ManNAc/rManNAc at 10 mM. ManNAc/rManNAc was used at 1 mM when in combination with PEP.  
 
Apoenzyme NmeNANAS wild-type melted at 42.7 ± 0.2 °C, whilst apoenzyme NmeG272Term 
melted at 36.5 ± 0.5 °C. The lower thermal stability observed for NmeG272Term compared with 
wild-type enzyme is likely caused by the loss of the linker and AFPL domain. As mentioned earlier, 
wild-type NmeNANAS is a domain swapped homodimer, and the linker and AFPL domains make 
several contacts between the two monomer units (Section 3.1.2). The loss of these interactions may 
result in destabilisation of the enzyme’s quaternary structure and possibly exposes more of the 
NmeG272Term barrel surface. This lower thermal stability of NmeG272Term when compared to 
wild-type NmeNANAS is a likely cause of the decreased melting temperature observed for the 
truncated enzyme.  
Depicted in Figure 3.5 and Table 3.2, the addition of 1 mM EDTA to apoenzyme did not influence 
the thermal stability of either NmeNANAS wild-type or NmeG272Term. The absence of an effect 
caused by EDTA is likely due to the successful removal of trace metal ions during purification. The 
addition of 1 mM Mn2+ increased the melting points of both wild-type NmeNANAS and 
NmeG272Term by approximately 6 °C, to 48.9 ± 0.3 °C and 42.6 ± 0.5 °C respectively.   
 
 
 
Addition NmeNANAS Wild-type (°C) NmeG272Term (°C) 
Nothing 42.7 ± 0.2 36.5 ± 0.5 
EDTA 43.6 ± 0.3 36.0 ± 0.5 
Mn2+ 48.9 ± 0.3 42.6 ± 0.5 
Mn2+ + PEP 56.2 ± 0.7 42.8 ± 0.2 
Mn2+ + ManNAc 49.0 ± 0.4 41.6 ± 0.2 
Mn2+ + PEP + ManNAc 48.7 ± 0.2 43.2 ± 0.2 
Mn2+ + rManNAc 50.4 ± 0.3 41.6 ± 0.3 
Mn2+ + PEP + rManNAc 56.4 ± 0.2 43.2 ± 0.2 
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A significant thermal shift was observed for NmeNANAS wild-type in the presence of Mn2+ and 
PEP. The melting point of NmeNANAS with Mn2+ and PEP was approximately 13 °C higher than 
apoenzyme, with a melting temperature of 56.2 ± 0.7 °C. Interestingly this thermal shift was not 
observed for NmeG272Term which had a similar melting temperature to when only Mn2+ was 
present. NmeG272Term is capable of binding PEP (Section 3.4.1), however the thermal stability 
afforded by binding is not observed through DSF. For both NmeNANAS wild-type and 
NmeG272Term, the addition of 10 mM ManNAc or rManNAc in combination with 1 mM Mn2+ did 
not have any additional influence to that observed for only Mn2+. 
The melting temperature of wild-type NmeNANAS in the presence of Mn2+, PEP and ManNAc was 
similar to that observed for NmeNANAS in the presence of Mn2+. This is likely a result of PEP and 
ManNAc reacting to form NANA. Since equimolar PEP and ManNAc concentrations were used, the 
substrates are completely utilised and converted to product which is subsequently released by the 
enzyme. If this is true, only Mn2+ would remain bound to NmeNANAS, thus the melting temperature 
for the enzyme is similar to that observed when only Mn2+ is added. The similar melting 
temperatures for enzyme in the presence of Mn2+ and NANA when compared with the melting 
temperature for enzyme and only Mn2+ also indicates that NmeNANAS is not stabilised by the 
product of its reaction.  
Likewise, the melting temperature for NmeG272Term in the presence of Mn2+, PEP and ManNAc 
was similar to that observed for NmeG272Term in the presence of Mn2+. Unlike the wild-type 
enzyme, NmeG272Term is unable to convert PEP and ManNAc to NANA (Section 3.3.1). The results 
from DSF thereby indicate that NmeG272Term is not stabilised by the presence of either substrate 
and the only stabilisation afforded is likely attributed to the presence of Mn2+.  
Displayed in Figure 3.5 and Table 3.2, the melting temperature for wild-type NmeNANAS in the 
presence of Mn2+, PEP and rManNAc is similar to that observed for NmeNANAS in the presence of 
Mn2+ and PEP. As discussed in Chapter 2, NmeNANAS is able to bind Mn2+, PEP and rManNAc. 
rManNAc is an unreactive analogue of ManNAc, and it is therefore likely that rManNAc, PEP and 
Mn2+ are each bound within the NmeNANAS active site. The presence of rManNAc does not appear 
to contribute any additional thermal stability over what is already afforded by PEP and Mn2+. 
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As discussed in Section 3.4.1, NmeG272Term is unable to bind rManNAc. The melting 
temperature for NmeG272Term in the presence of Mn2+, PEP and rManNAc is similar to that 
observed for NmeG272Term in the presence of Mn2+ (Figure 3.5). Similar to wild-type NmeNANAS, 
the presence of rManNAc does not confer additional thermal stability to NmeG272Term, even 
though the wild-type enzyme is known to bind rManNAc (Chapter 2). 
 
 The data obtained from DSF reveals that there is a significant thermal shift between the melting 
points of ligand-free and metal and PEP bound NmeNANAS wild-type which is not observed for 
NmeG272Term. This result indicates that PEP binding has a major effect on the thermal stability of 
NmeNANAS wild-type and that loss of the AFPL domain in NmeG272Term removes this property 
even though the NmeNANAS truncation appears to bind PEP relatively efficiently.   
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3.5 Structural analysis of NmeG272Term 
 
3.5.1 Circular dichroism 
CD was used to assess and compare the secondary structure of NmeG272Term with NmeNANAS 
(Figure 3.6). The K2D3 server (142) was used to estimate the secondary structure composition from 
CD spectra. Shown in Table 3.3, estimated secondary structure is compared to values derived from 
the crystal structure of NmeNANAS wild-type (PDB code: 1XUZ). 
 
 
 
 
 
 
Figure 3.6 CD spectra for NmeNANAS wild-type (red) and NmeG272Term (blue). 
 
As previously mentioned in Section 3.3, the activity of NmeG272Term could not be detected. It 
was therefore neccessary to determine that NmeG272Term was folded in solution using CD (Figure 
3.6). Depicted in Table 3.2, the secondary structure composition calculated from the CD data of 
NmeG272Term gives comparable levels of α-helix and β-sheet to that estimated for an AFPL domain 
truncation derived from the crystal structure of NmeNANAS 1XUZ.  
 
 
 
 
82 
 
 
 
 
 
 
 
Table 3.3 Predictions of secondary structure composition for NmeNANAS and NmeG272Term calculated 
from CD data using K2D3 server (142). Secondary structure composition of NmeNANAS structure and 
NmeG272Term model calculated from crystallographic coordinates 1XUZ. 
 
3.5.2 Mass spectrometry 
The molecular mass of His6-tagged NmeG272Term was analysed using mass spectrometry. A 
theoretical mass of 33,607 Da was calculated for NmeG272Term from the peptide sequence using 
ProtParam (141). The experimental mass determined by mass spectrometry was 33,608 Da which 
was almost identical to the aforementioned calculated mass.  
 
3.5.3 Analytical size exclusion chromatography 
Analytical SEC was used to determine whether the removal of the linker region and AFPL domain 
from NmeNANAS had affected the quaternary structure of NmeG272Term. The methods used for 
analytical SEC are outlined in Section 8.5.6. A calibration curve was generated using protein 
standards of known molecular weight. The elution volume (Ve) of protein standards relative to the 
column void volume (V0) was plotted against the log of the protein standards molecular mass. A 
linear fit of the analytical SEC calibration data was determined to have an R2 value of 0.987. 
Displayed in Figure 3.7, the calibration curve was used to extrapolate the molecular masses of 
NmeNANAS wild-type and NmeG272Term.  
 
 
 
 
 NmeNANAS   NmeNANAS 
(structure) 
G272Term  G272Term 
(model) 
α-helix 59.9 % 50.3 % 67.6 % 73.2 % 
β-sheet 12.3 % 15.5 %   21.8 %  18.0 % 
other 27.8 % 34.2 % 10.6 %    8.8 % 
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Figure 3.7 Analytical size exclusion chromatograms measured at 280 nm absorbance. (A) 
Chromatography traces of NmeNANAS wild-type at 130 µM in red, 52 µM in black and 26 µM in blue. (B) 
Chromatography traces of NmeNANAS G272Term at 167 µM in red, 67 µM in black and 33 µM in blue. 
Monomer peak indicated as 1 and Dimer peak indicated as 2. (C) Analytical SEC calibration curve. Protein 
standards are marked in grey, NmeNANAS wild-type in red, NmeNANAS G272Term peak 1 (first elution) 
in blue and peak 2 (second elution) in purple. A line of best fit is plotted in black.  (D) Table of estimated 
and theoretical masses for NmeNANAS and NmeNANAS G272Term. 
A B 
C 
 
 NmeNANAS  NmeG272Term (1) NmeG272Term (2) 
Ve/V0 1.74 1.82 1.96 
Estimated mass (kDa) 81 61 34 
Theoretical mass of dimer (kDa) 77 60 30 
 
D
1 2 
   167 µM G272Term 
   67 µM G272Term 
   33 µM G272Term 
 
   130 µM Wild-type 
   52 µM Wild-type 
   26 µM Wild-type 
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As shown in Figure 3.7, wild-type NmeNANAS eluted with a single peak for all protein 
concentrations, consistent with the dimeric form of the enzyme. The estimated weight for dimeric 
NmeNANAS wild-type was 81 kDa with a calculated weight of 77 kDa.  
In contrast two peaks were observed for NmeG272Term, with the higher retention time peak 
increasing in relative intensity as the protein concentration was decreased (Figure 3.7). These two 
peaks have the expected retention times of a dimeric and monomeric form of the NmeG272Term 
protein. The estimated weight for NmeG272Term peak 1 was 61 kDa with a calculated weight of 60 
kDa for dimeric protein. Estimated weight for NmeG272Term peak 2 was 34 kDa with a calculated 
weight of 30 kDa for monomeric protein.  
The results from analytical SEC indicate that wild-type NmeNANAS is a dimer at the 
concentrations tested. Furthermore, quaternary stability is decreased in the AFPL domain truncation 
resulting in a concentration dependent, monomer-dimer equilibrium. This reveals that the AFPL 
domain plays an important role in stabilising the quaternary structure of NmeNANAS.  
   
3.5.4 Analytical Ultracentrifugation 
Analytical ultracentrifugation (AUC) was also used to assess the quaternary structures of wild-
type NmeNANAS and NmeG272Term. To determine the stability of their quaternary states, 
sedimentation velocity experiments were caried out at varied protein concentrations. To determine 
whether the quaternary states of wild-type NmeNANAS and NmeG272Term were concentration 
dependent, samples were run at 0.5 mg/mL, 1.0 mg/mL and 2.0 mg/mL. Displayed in Figure 3.8 and 
3.9, data was fitted to a continuous size-distribution (cs) model using the program SEDFIT (150, 151). 
Weight average molecular masses were calculated using weight average sedimentation coefficients 
and f/f0 values from cs fits.  
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Figure 3.8 Analytical ultra centrifugation fits measured at 280 nm absorbance. (A) NmeNANAS wild-type 
at 0.5 mg/mL, residual data (top), and fit of model to data from SEDFIT (bottom). (B) NmeNANAS wild-
type at 1.0 mg/mL, residual data (top), and fit of model to data from SEDFIT (bottom). (C) NmeNANAS 
wild-type at 2.0 mg/mL, residual data (top), and fit of model to data from SEDFIT (bottom). (D) 
Normalised c(s) profiles for NmeNANAS wild-type at 0.5 mg/mL (red), 1.0 mg/mL (black) and 2.0 mg/mL 
(purple). 
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Figure 3.9 Analytical ultra centrifugation fits measured at 280 nm absorbance. (A) NmeG272Term at 0.5 
mg/mL, residual data (top), and fit of model to data from SEDFIT (bottom). (B) NmeG272Term at 1.0 
mg/mL, residual data (top), and fit of model to data from SEDFIT (bottom). (C) NmeG272Term at 2.0 
mg/mL, residual data (top), and fit of model to data from SEDFIT (bottom). (D) Normalised c(s) profiles 
for NmeG272Term at 0.5 mg/mL (red), 1.0 mg/mL (black) and 2.0 mg/mL (purple). 
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Wild-type NmeNANAS was determined to be a single species at each of the tested concentrations 
(Figure 3.8). The estimated molecular weight from AUC for NmeNANAS wild-type was 68 kDa, which 
is approximately that of dimeric NmeNANAS. In contrast, NmeG272Term was present as two species 
(Figure 3.9). One peak corresponded to an estimated molecular weight of 31 kDa (close to the 30 
kDa molecular weight calculated for monomer NmeG272Term) and a second peak to 51 kDa (close 
to the 60 kDa molecular weight calculated for dimer NmeG272Term). The equilibrium between 
these two species was demonstrated by the change in relative proportions of these two species with 
different protein concentrations; the ratio of monomer peak intensity to dimer peak intensity 
increased as the concentration of enzyme was decreased.   
The results obtained from AUC correlate with analytical SEC data for NmeNANAS wild-type and 
NmeG272Term (Section 3.5.3). Whilst NmeNANAS is a dimer at each of the concentrations analysed 
by AUC and analytical SEC, both techniques reveal a schizophrenic quaternary state in 
NmeG272Term. In addition, the observations of a destabilised quaternary structure correlate with 
the decreased thermal stability observed in NmeG272Term when compared with NmeNANAS wild-
type (Section 3.4.2). Each of the aforementioned analyses indicates that the AFPL domain plays an 
important role in quaternary structure stabilisation of NmeNANAS. 
 
3.5.5 Attempted crystallisation 
Several attempts at crystallising NmeG272Term were made. NmeG272Term was screened using 
conditions modified from those previously described for crystallising wild-type NmeNANAS (112). 
Protein crystallisation conditions were also screened using commercially available Morpheus, PACT 
and JCSG screens. Protein was concentrated to 5 mg/mL, 10 mg/mL and 15 mg/mL and screened in 
the absence and presence of ligands. Screens were incubated at 5 °C and 20 °C for several months, 
but none of the conditions that were screened yielded crystals of diffraction quality. Crystallisation 
of NmeG272Term is likely to have been problematic due to the unstable quaternary state of the 
protein (Sections 3.5.3 and 3.5.4). Low protein concentrations at which NmeG272Term would be 
predominantly monomeric resulted in rapid precipitation of protein, and thus screening for 
crystallisation conditions at these concentrations were not feasible.    
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3.5.6 Surface interactions of NmeNANAS wild-type and 
NmeG272Term 
As outlined in Sections 3.5.3 and 3.5.4, the NmeNANAS AFPL domain truncation NmeG272Term 
has a concentration dependent quaternary state which is not observed for the wild-type enzyme. 
The AFPL domain is therefore involved in stabilising the dimeric form of NmeNANAS. In order to 
assess the differences in intermolecular interactions between the dimeric form of wild-type 
NmeNANAS and NmeG272Term, their structures were investigated using PISA (152). The crystal 
structure coordinates 1XUZ were used to assess wild-type NmeNANAS (112). Since a crystal 
structure of NmeG272Term could not be obtained, an AFPL domain truncation of the NmeNANAS 
1XUZ structure was used to approximate the structure of NmeG272Term for PISA analysis.  
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.10 Intermolecular interactions of dimeric NmeNANAS wild-type (A) and NmeG272Term (B) as 
determined by PISA (152).  Chain A of NmeNANAS wild-type and NmeG272Term are coloured cyan and 
Chain B in dark blue. Chain A surface interactions are in green and Chain B surface interactions are in red. 
NmeNANAS structure and NmeG272Term model were derived from crystallographic coordinates 1XUZ 
(112).  
A 
B 
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Depicted in Figure 3.10, a significant percentage of the intermolecular contacts present in 
NmeNANAS are lost in NmeG272Term. As calculated by PISA (152), 31.8 % of the barrel surface is 
involved in intermolecular contact for NmeNANAS wild-type whereas in comparison, only 7.1 % of 
the barrel surface for NmeG272Term would make contact in its dimeric form. Thus 77.6 % of the 
intermolecular contact between the monomers in NmeNANAS wild-type is contributed by the AFPL 
and linker domain. The number of interfacing atoms (iNat), was calculated from PISA to be 395 in 
NmeNANAS wild-type and only 86 in NmeG272Term. This significant loss of interdomain interaction 
is likely to be the causative factor for instability observed with dimeric NmeG272Term (Sections 
3.5.3 and 3.5.4). 
Additionally, the solvation free energy gain yielded upon interface formation (ΔiG), was 
determined to be -44.0 kcal/mol for wild-type NmeNANAS and -15.1 kcal/mol for NmeG272Term. A 
negative ΔiG value indicates hydrophobic interface contact or positive protein affinity but does not 
include the effects of satisfied hydrogen bonds and salt bridges across the interface (152). The values 
derived from PISA thus indicate that the dimerisation of wild-type NmeNANAS is more energetically 
favourable than that for NmeG272Term. 
  
3.5.7 Small-angle X-ray scattering 
Small angle X-ray scattering (SAXS) profiles were determined to assess the solution structures of 
NmeNANAS wild-type and NmeG272Term and to probe conformational changes of the proteins 
upon ligand binding. The SAXS profiles of NmeNANAS wild-type and NmeG272Term were 
determined using the methods outlined in Sections 8.5.8 and 8.5.9.  
Displayed in Figure 3.11, the scattering profile of wild-type NmeNANAS without ligand present is 
compared to the scattering profile of NmeNANAS in the presence of Mn2+ and PEP.  The 
experimental scattering obtained for NmeNANAS is also compared with CRYSOL (153) fits generated 
from the ligand bound NmeNANAS crystal structure 1XUZ (112). The structural parameters 
calculated for NmeNANAS via SAXS, are compiled in Table 3.4. 
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Figure 3.11 SAXS profiles of liganded and ligand-free wild-type NmeNANAS compared against theoretical 
CRYSOL scattering derived from crystallographic coordinates of NmeNANAS structure 1XUZ. In red is the 
experimental scattering profile for ligand-free NmeNANAS and in blue is the experimental scattering 
profile for NmeNANAS in the presence of 1 mM Mn2+ and 1 mM PEP. Theoretical scattering of NmeNANAS 
wild-type is depicted with a black line. SAXS data was collected using approximately 10 mg mL-1 protein 
in 30 mM triethanolamine-HCl buffer at pH 7.5. Samples were eluted by SEC (Superdex 200 5/150). 
 
 
 
 
 
 
 
Table 3.4 SAXS structural parameters determined for wild-type NmeNANAS in the presence of 1 mM 
Mn2+ and 1 mM PEP. SAXS data obtained at a wavelength of 1.0332 Å.  
 
 
 
 
 NmeNANAS  
I0 (cm
-1) 0.082 ± 0.001 
Rg (Å) 33.0 ± 0.5 
Dmax (Å) 116 
Porod volume (Å3) 121,724 
Estimated mass (kDa) 85 
Theoretical mass of dimer (kDa) 77 
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As shown in Figure 3.11, there is a discernible difference between the experimental scattering 
profiles determined for NmeNANAS wild-type in the presence and absence of Mn2+ and PEP. When 
compared to theoretical scattering generated from an NmeNANAS crystal structure (PDB code 
1XUZ), it was observed that the experimental profile of liganded NmeNANAS wild-type protein fits 
significantly better than that for ligand-free enzyme (Chi values of 2.0 and 6.1 respectively). This 
result indicates that binding of Mn2+ and PEP is associated with a change in the average 
conformation of NmeNANAS. It can also be inferred that the solution structure of ligand-free 
NmeNANAS is different to the crystal structure, and that the crystal structure more closely 
resembles the Mn2+ and PEP bound solution conformation. 
The structure parameters displayed in Table 3.4 correlate with a dimeric quaternary state for wild-
type NmeNANAS. The molecular mass of NmeNANAS was calculated from SAXS data using SAXS 
MoW (154). The molecular mass of NmeNANAS estimated from SAXS was 85 kDa and is similar to 
that expected for dimeric enzyme (Table 3.4). The results from SAXS concur with the crystal 
structures of NmeNANAS (112, 113) and the results obtained from both analytical SEC (Section 3.5.3) 
as well as AUC (Section 3.5.4). 
Unlike wild-type NmeNANAS, no obvious change was noted for the experimental profiles of 
NmeG272Term in the presence and absence of Mn2+ and PEP (Figure 3.12). In addition, both 
experimental scattering profiles for liganded and ligand-free NmeG272Term fit well to theoretical 
scattering generated from the truncated NmeNANAS crystal structure 1XUZ (Chi values of 0.52 and 
0.66 respectively). These results indicate that the ability of PEP binding to induce a conformational 
change akin to what is observed for NmeNANAS wild-type is lost in NmeG272Term, and correlates 
with the observations made from DSF in Section 3.4.2, where NmeG272Term is not thermally 
stabilised by the addition of PEP. 
The structure parameters obtained for NmeG272Term correlate with a dimeric quaternary state 
(Table 3.5). The molecular mass of NmeG272Term estimated from SAXS MoW (154) was 61 kDa and 
is similar to that expected for dimeric protein. The calculation of a dimeric molecular weight for 
NmeG272Term using SAXS data is likely due to the concentration of protein used for analysis. The 
solution structure of NmeG272Term was investigated by SAXS at approximately 10 mg/mL; a 
concentration at which the enzyme is most likely to be dimeric, given the results attained from 
analytical SEC and AUC (Sections 3.5.3 and 3.5.4). 
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Figure 3.12 Small-angle X-ray scattering (SAXS) profiles of liganded and ligand-free NmeG272Term 
compared against theoretical CRYSOL scattering derived from modified crystallographic coordinates of 
NmeNANAS structure 1XUZ. In red is the experimental scattering profile for ligand-free NmeG272Term 
and in blue is the experimental scattering profile for NmeG272Term in the presence of 1 mM Mn2+ and 1 
mM PEP. Theoretical scattering of NmeG272Term is depicted with a black line. SAXS data was collected 
using approximately 10 mg mL-1 protein in 30 mM triethanolamine-HCl buffer at pH 7.5. Samples were 
eluted by SEC (Superdex 200 5/150). 
 
 
 
 
 
 
 
Table 3.5 Small-angle X-ray scattering (SAXS) structural parameters determined for NmeG272Term in 
the presence of 1 mM Mn2+ and 1 mM PEP. SAXS data obtained at a wavelength of 1.0332 Å.  
 
 
 
 
 NmeG272Term  
I0 (cm
-1) 0.157 ± 0.001 
Rg (Å) 26.7 ± 0.3 
Dmax (Å) 89 
Porod volume (Å3) 97,478 
Estimated mass (kDa) 61 
Theoretical mass of dimer (kDa) 60 
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3.6 Molecular dynamics 
  
In order to examine the difference in dynamic motions of wild-type NmeNANAS caused by PEP 
binding in the active site and the dynamic role of the AFPL domain, molecular dynamics (MD) 
simulations (270 ns) were conducted for NmeNANAS with and without PEP present. MD simulations 
as well as the following analyses were carried out by Dr Wanting Jiao. 
The simulations of NmeNANAS with and without PEP both equilibrated after 100 ns. The average 
structures from both simulations were generated using MD trajectories from the equilibrated time 
period (100 – 270 ns). The MD simulations for NmeNANAS with or without PEP bound both started 
with the “closed” conformation of the active site, based on the crystal structure that contains both 
PEP and rManNAc in the active site (PDB 1XUZ). During the MD simulation for ligand-free 
NmeNANAS, the active site loops that contain ManNAc binding residues (Gln55 to Asn89) and the 
AFPL domain linker (residues Ala270 to Ile279) in both monomers were found to open up, (Figure 
3.13A and Figure 3.13B). As a result, the critical Arg314 residue in both monomers has shifted 
outwards, by 4.2 Å and 2.2 Å relative to its starting positions in chain A and chain B respectively.  
In the MD simulation with PEP bound in the active site, the two monomers exhibit slightly 
different behaviours. In chain A (Figure 3.13C), the linker region showed similar outwards motion as 
in the ligand-free system, and results in an outward shift of 2.2 Å of residue Arg314 relative to the 
starting position. In chain B (Figure 3.13D), interestingly, the main AFPL domain (residues 291 to 349) 
moved towards the main barrel, in contrast to what is observed in the calculations for chain A and 
the ligand-free system. This movement of the AFPL domain did not result in Arg314 being pulled 
away from the active site as for chain A; the distance shifted by Arg314 was only 0.6 Å relative to the 
starting position in chain B.  Therefore, it appears that PEP binding restricts the movement of the 
AFPL domain and its linker, so that the position of the catalytically critical Arg314 residue is held 
closer to the active site (0.6 Å and 2.2 Å in PEP bound NmeNANAS compared to 2.2 Å and 4.2 Å in 
the ligand-free NmeNANAS relative to their starting positions).  
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Figure 3.13 Conformations of the ManNAc loop and the AFPL domain superimposed between A) chain A 
of average structure from MD simulation of ligand-free NmeNANAS (yellow) and crystal structure 
(purple); B) chain B of average structure from MD simulation of ligand-free NmeNANAS (yellow) and 
crystal structure (purple); C) chain A of average structure from MD simulation for PEP bound NmeNANAS 
(green) and crystal structure (purple); D) chain B of average structure from MD simulation for PEP bound 
NmeNANAS (green) and crystal structure (purple). Residue Arg314 is displayed with sticks 
representation. Figure created by Dr Wanting Jiao. 
 
The chain average RMSF values for PEP bound and ligand-free NmeNANAS were calculated in 
order to investigate any change in flexibility of the enzyme associated with PEP binding (Figure 
3.14C). The difference in RMSF values indicate that the flexibility of the ManNAc binding, β2-α2 loop 
and AFPL domain regions are reduced significantly upon PEP binding (Figure 3.14D). 
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Figure 3.14 (A) Chain average residue RMSF values during MD simulations for PEP bound and ligand-
free NANAS. (B) Difference in chain average RMSF values between PEP bound and ligand-free 
NmeNANAS. Figure created by Dr Wanting Jiao. 
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The interactions between the AFPL domain (residues Gly272 to Glu349) and the main barrel 
excluding the ManNAc binding loop (Gln55 to Asn89) during the equilibrated time period in MD 
simulations were examined.  In the PEP bound system, analyses identified four interactions between 
the main barrel and the AFPL domain, Arg114-Asp296, Arg194-Glu282, Asn184-Thr285 and Arg314-
Glu134, with high occupancy (Figure 3.15, table of data from hydrogen bond analysis is in Table 3.6). 
Interestingly, these four interactions are distributed across the structure of the AFPL domain, so that 
the domain is well anchored to the main barrel. The interaction between Arg194 and Asp282 is 
particularly interesting because Arg194 belongs to the PEP binding loop, and any changes in this loop 
caused by PEP binding may be communicated through to the AFPL domain through this key 
interaction. There is a network of hydrogen bonds formed around this region, involving the 
backbone of Asn184 and side-chains of Asp282 and Thr285 (Figure 3.15). In the crystal structure 
NmeNANAS 1XUZ, the side-chain of Asn184 forms a hydrogen bond with the phosphate group of PEP 
(Figure 3.1B).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.15 Key hydrogen bonding interactions between main barrel and the AFPL domain observed 
from MD simulations. Figure created by Dr Wanting Jiao. 
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Table 3.6 Key hydrogen bonds and their occupancy between the main barrel and the AFPL domain from 
both monomers. Table created by Dr Wanting Jiao. 
 
The same hydrogen bond analysis was conducted for the ligand-free NmeNANAS system, which 
identified similar hydrogen bonds with high occupancy to those found in the PEP bound system 
(Table 3.7). The most significant difference in occupancy occurs for the interaction between Arg314 
and Glu134, the occupancy of which increases by more than 40% upon PEP binding. This change in 
occupancy suggests that PEP binding in the active site indeed affects how Arg314 interact with the 
surrounding residues and how this residue is held in the active site. 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3.7 Hydrogen bonds occupancies in ligand-free and PEP bound NmeNANAS during MD simulations. 
Table created by Dr Wanting Jiao. 
 
Chain B barrel & Chain A AFPL domain Chain A barrel & Chain B AFPL domain 
donor acceptor occupancy donor acceptor occupancy 
Arg314-Side Glu134-Side 71.07% Arg314-Side Glu134-Side 52.78% 
Arg114-Side Asp296-Side 68.93% Arg114-Side Asp296-Side 88.04% 
Asn184-Main Glu282-Side 40.96% Asn184-Main Glu282-Side 38.70% 
Arg194-Side Glu282-Side 31.96% Arg194-Side Glu282-Side 85.26% 
Thr285-Side Asn184-Main 31.26% Thr285-Side Asn184-Main 44.37% 
Asn184-Side Glu282-Side 12.85% Asn184-Side Glu282-Side 3.52% 
 
 
 PEP bound Ligand-free 
Donor Acceptor Occupancy Donor Acceptor Occupancy 
Chain A barrel  
& Chain B  
AFPL domain 
Arg114-Side Asp296-Side 88.04% Arg114-Side Asp296-Side 83.81% 
Arg194-Side Glu282-Side 85.26% Arg194-Side Glu282-Side 85.48% 
Arg314-Side Glu134-Side 52.78% Arg314-Side Glu134-Side 0.37% 
Chain B barrel  
& Chain A  
AFPL domain 
Arg114-Side Asp296-Side 68.93% Arg114-Side Asp296-Side 76.22% 
Arg194-Side Glu282-Side 31.96% Arg194-Side Glu282-Side 1.33% 
Arg314-Side Glu134-Side 71.07% Arg314-Side Glu134-Side 28.63% 
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3.7 Cloning, expression and purification of 
NmeNANAS hydrogen bond network 
variants 
 
3.7.1 Site-directed Mutagenesis  
In order to investigate the role of the AFPL domain, several point mutations of NmeNANAS were 
generated using residues identified from the MD simulations of wild-type apoenzyme and enzyme 
bound to Mn2+ and PEP (Section 3.6). Residues Thr285, Glu282 and Glu134 were each substituted to 
Ala to completely remove side-chain hydrogen bonding capability. Residue Thr282 was also mutated 
to Phe to remove hydrogen bonding functionality but also preserve a similar steric presence. The 
final variant was a double mutation of Thr285 and Glu282 to alanine to investigate if their combined 
loss of functionality would affect catalysis.   
The NmeNANAS wild-type pDEST-17 vector described in Chapter 2 was used as a template to 
generate the NmeNANAS hydrogen bond network variants. The methods used for PCR amplification 
of the variant genes are outlined in Section 8.3.2, and primer sequences used for site-directed 
mutagenesis are displayed in Table 8.7. 
 
3.7.2 Expression and purification 
The pDEST-17 vectors bearing the variant genes were transformed into Chaperone 3 cells to 
optimise the yield of soluble protein. NmeE134A, NmeE282A, NmeT285A, NmeT285F, and 
NmeE282A/T285A were each expressed and purified using a similar method to that outlined for 
NmeNANAS wild-type in Section 8.4. Purified enzymes were concentrated, flash-frozen and stored at 
-80 °C. Samples of purified enzyme were analysed by SDS PAGE (Figure 3.16). 
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 M         1        2         3        4         5        6 
160 kDa 
 
110 kDa 
 
80 kDa 
 
60 kDa 
 
50 kDa 
 
40 kDa 
 
 
30 kDa 
 
20 kDa 
 
 
 
 
 
  
 
 
 
 
 
 
Figure 3.16 SDS-PAGE gel of purified NmeNANAS wild-type and hydrogen bond network variants. Lane 
M contains marker with molecular weights defined. Lane 1 contains purified NmeNANAS wild-type, Lane 
2 NmeE134A, Lane 3 NmeE282A, Lane 4 NmeT285A, Lane 5 NmeT285F and Lane 6 NmeE282A/T285A.  
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3.8 Physical characterisation of NmeNANAS 
hydrogen bond network variants 
 
3.8.1 Circular dichroism 
CD was used to assess and compare the secondary structure of the hydrogen bond network 
variants with wild-type NmeNANAS (Figure 3.17).  
 
 
 
 
 
 
 
 
 
Figure 3.17 CD spectra for NmeNANAS wild-type (red), NmeE134A (orange), NmeE282A (yellow), 
NmeT285A (green), NmeT285F (blue) and NmeE282A/T285A (purple).   
 
Displayed in Figure 3.17 the CD profiles for each of the NmeNANAS hydrogen bond network 
variants are almost identical to the profile for NmeNANAS wild-type. Furthermore, the secondary 
structure ratios determined from the variant CD data using the K2D3 server (142), were nearly 
identical to the values obtained for wild-type NmeNANAS. The results from CD thereby indicate that 
the secondary structure of the variants is unlikely to have been significantly affected by any of the 
mutations made.    
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3.8.2 Mass spectrometry 
The masses of each of the NmeNANAS hydrogen bond network variants were analysed using 
mass spectrometry (Table 3.8). Each of the experimental masses obtained were almost identical to 
those calculated from the respective peptide sequences using ProtParam (141).  
 
3.8.3 Thermal stability 
DSF was used to assess the melting temperatures of the NmeNANAS hydrogen bond network 
variants. The method used for DSF analysis is outlined in Section 8.5.3. Displayed in Table 3.8, the 
melting points for apoenzyme NmeE134A, NmeE282A, NmeT285A, NmeT285F, and 
NmeE282A/T285A were approximately 43 °C, similar to that determined for wild-type NmeNANAS 
(Section 3.4.2). The results from DSF indicate that the thermal stability of the variant proteins have 
not been significantly altered through mutagenesis.  
 
 
Table 3.8 Mass spectrometry measurements and melting temperatures of His6-tagged NmeE134A, Nme-
E282A, NmeT285A, NmeT285F and NmeE282A/T285A. 
 
 
 
 
 NmeNANAS 
wild-type 
NmeE134A NmeE282A NmeT285A NmeT285F NmeE282A/ 
T285A  
Experimental 
mass (Da) 
41,977  41,919 41919   41,947 42023   41,889 
Theoretical  
mass (Da) 
41,977 41,918 41,917 41,947 42,023 41,888 
Melting 
Temperature  (°C) 
42.7 ± 0.2 43.0 ± 0.5 42.9 ± 0.2 43.4 ± 0.4 43.3 ± 0.2 42.2 ± 0.2 
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3.9 Kinetic characterisation of NmeNANAS 
hydrogen bond network variants 
 
3.9.1 Michaelis-Menten kinetics 
To determine the kinetic parameters of the NmeNANAS hydrogen bond network variants, the 
consumption of PEP was monitored using the assay described in Section 8.5.1.  Cuvettes containing 
50 mM BTP (pH 8), 1 mM MnCl2, PEP (varied) and ManNAc (varied) were incubated for 10 min at 25 
°C. The enzymatic reaction was initiated by the addition of purified enzyme. Michaelis-Menten 
steady-state approximations were utilised to determine kinetic parameters (Figure 3.18). Kinetic 
parameters were compared to the values ascertained for NmeNANAS wild-type (Table 3.9).  
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Figure 3.18 Michaelis-Menten curves for NmeNANAS hydrogen bond network variants with ManNAc and 
PEP. (A) NmeE134A PEP Km curve, (B) NmeE134A ManNAc Km curve, (C) NmeE282A PEP Km curve, (D) 
NmeE282A ManNAc Km curve, (E) NmeT285A PEP Km curve, (F) NmeT285A ManNAc Km curve, (G) 
NmeT285F PEP Km curve, (H) NmeT285F ManNAc Km curve, (I) NmeE282A/T285A PEP Km curve and (J) 
NmeE282A/T285A ManNAc Km curve. Data points are shown in black and a line of best fit in red. A double 
reciprocal plot is displayed as an inset for each graph. Assays were carried out in 50 mM BTP at pH 7.5 
with 1 mM MnCl2, PEP (varied) and ManNAc (varied) at 25 °C. Reaction was initiated by the addition of 5 
µL of purified enzyme at a stock concentration of 2.5 – 3.5 mg/mL. Michaelis-Menten steady-state 
approximations were utilised to determine kinetic parameters with nonlinear fitting in GraFit (Erathicus 
Software). To determine apparent Km (PEP), ManNAc concentration was held at 30 mM, and the 
concentration of PEP varied. To determine apparent Km (ManNAc), PEP was kept constant at 1 mM, and 
ManNAc concentration was varied.  
H 
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 Wild-type  G272Term  T285A  T285F
 
E282A  E282A/T285A
 
E134A
 
kcat (s
-1
) 3.1 ± 0.1 - 2.8 ± 0.1 3.0 ± 0.1 0.082 ± 0.003 0.085 ± 0.002 0.3 ± 0.01 
Km PEP (µM) 28 ± 3 - 24 ± 2 27 ± 2 24 ± 1 26 ± 2 27 ± 2 
Km ManNAc (mM) 2.9 ± 0.2 - 3.1 ± 0.3 2.8 ± 0.3 20.1 ± 1.6 21.0 ± 1.9 13 ± 1 
kcat/Km  ManNAc (s
-1
/M) 1068 ± 108 - 900 ± 120 1071 ± 150 4.7 ± 0.5 4.4 ± 0.5 23 ± 3 
 
 
 
 
 
 
 
Table 3.9 Kinetic parameters for wild-type NmeNANAS, NmeG272Term, NmeE134A, NmeE282A, Nme-
T285A, NmeT285F and NmeE282A/T285A. Values with - indicates kcat of enzyme is less than 0.004 s-1.  
  
Depicted in Table 3.9, each of the variants retain similar Km (PEP) values to that observed in wild-
type NmeNANAS, indicating that the PEP binding site has not been affected by mutation. Variants 
NmeT285A and NmeT285F demonstrated very similar kinetic parameters to the wild-type enzyme 
(Table 3.9). This indicates that the mutation of Thr285 has no effect upon the catalytic function of 
NmeNANAS.  
In contrast, both NmeE282A and the double variant NmeE282A/T285A exhibited an 
approximately 230-fold reduction in kcat/Km (ManNAc) compared to wild-type enzyme. This results 
from an approximately 35-fold reduction in kcat and 7-fold increase in the Km (ManNAc) for both 
NmeE282A and NmeE282A/T285A. The similar kinetic values for NmeE282A and NmeE282A/T285A 
correlate with the observation that Thr285 is not essential to the catalytic function of NmeNANAS as 
no additional kinetic penalty is afforded through the double mutation when compared with 
NmeE282A (Table 3.9). 
Variant NmeE134A has a somewhat less drastic affect on catalysis when compared with 
NmeE282A. NmeE134A has an approximately 45-fold reduction in kcat/Km (ManNAc) when compared 
to wild-type enzyme, arising from an approximately 10-fold reduction in kcat and 4-fold increase in Km 
(ManNAc).  
Glu282, Glu134 and Thr285 are each fully conserved in NANAS enzymes; however, T285 is not 
conserved in other members of the SAS family such as LegSs and PseSs. It is thereby likely that 
Glu282 and Glu134 are involved in the ManNAc site pre-organisation and hydrogen bond relay 
whereas Thr285 is not.  
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3.10 Summary of results 
An AFPL domain truncation of NmeNANAS was successfully amplified and cloned into a His-tag 
expression vector, and subsequently expressed and purified by IMAC and SEC. NmeG272Term was 
found to be soluble but inactive using the continuous assay previously described for wild-type 
NmeNANAS in Chapter 2.  
Binding studies using ITC identified that the Mn2+ and PEP binding sites of NmeG272Term were 
intact however the protein was unable to bind rManNAc. The loss of rManNAc binding indicates that 
the AFPL domain plays an important role in this process for wild-type NmeNANAS. In addition, the 
thermal stabilities of NmeNANAS wild-type and NmeG272Term were assessed in the presence of 
various substrate combinations. The results from DSF revealed a significant thermal stabilisation of 
wild-type enzyme in the presence of PEP which was absent in NmeG272Term. 
Unlike wild-type NmeNANAS which is a tight dimer, NmeG272Term was proven to have a 
concentration dependent, monomer-dimer equilibrium using analytical SEC and AUC. The results 
from analytical SEC and AUC thus strongly imply that the AFPL domain plays an important role in 
stabilising the quaternary structure of wild-type NmeNANAS.  
Several attempts to crystallise NmeG272Term were made however no diffraction quality crystals 
were obtained. The solution structures of wild-type NmeNANAS and NmeG272Term were assessed 
in the absence and presence of Mn2+ and PEP using SAXS. Wild-type NmeNANAS was observed to 
undergo conformational changes in the presence of Mn2+ and PEP whereas NmeG272Term was not. 
These results strongly imply that the AFPL domain is repositioned upon binding of PEP and correlates 
with the premise that PEP liganding pre-organises the ManNAc binding site (Chapter 2). 
Molecular dynamics simulations of wild-type NmeNANAS with and without PEP were able to 
identify a hydrogen bonding relay, linking the AFPL domain and catalytic domains. Key residues 
involved in the hydrogen bond network were mutated and variant enzymes were generated and 
kinetically analysed. The conserved residues Glu134 and Glu282 were identified to play a key role in 
the function of the hydrogen bonding relay, as loss of their functionality was observed to 
significantly detriment catalytic function. 
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The results from this chapter identify that the AFPL domain of NmeNANAS is bifunctional, playing 
both catalytic and structural roles. The AFPL domain is linked to the catalytic domain via a hydrogen 
bonding network and is crucial to the mechanism by which the ManNAc binding site is pre-organised 
by PEP. The AFPL domain is also involved in maintaining a stable quaternary state in wild-type 
NmeNANAS. 
 
3.10 Discussion 
The work in Chapter 3 details an investigation into the role of the AFPL domain of NmeNANAS 
This was achieved through the generation of an AFPL domain truncation NmeNANAS variant.  
NmeG272Term was found to be soluble. ITC binding studies with NmeG272Term were able to 
determine that the truncated variant could still bind Mn2+ and PEP, but that the ability to bind 
rManNAc had been lost. The AFPL domain is therefore critical to ManNAc binding in NmeNANAS.  
DSF analysis revealed a significant thermal stabilisation of wild-type NmeNANAS in the presence 
of PEP. Additionally, SAXS data revealed that wild-type NmeNANAS undergoes a conformational 
change when PEP is bound. Neither thermal stabilisation nor conformational change were observed 
with NmeG272Term in the presence of PEP, implying that the mechanism by which PEP pre-
organised the ManNAc binding site in wild-type NmeNANAS had been lost in NmeG272Term.  A 
hydrogen bonding relay linking the AFPL domain and catalytic domain was identified through MD 
simulations of wild-type NmeNANAS. Residues Glu134 and Glu282 were identified though kinetic 
characterisation of variant enzymes, to play a key role in the function of the aforementioned 
hydrogen bonding relay. 
Analytical SEC and AUC revealed that the AFPL domain plays a vital structural role, as loss of the 
AFPL domain in NmeG272Term resulted in a schizophrenic quaternary structure. The results 
described in Chapter 3 thus identified a bifunctional role of the NmeNANAS AFPL domain, which is 
involved in both the pre-organisation of the ManNAc binding site via a hydrogen bonding relay, as 
well as stabilisation of the enzyme’s dimeric state. 
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Chapter 4 
Evolutionary relationships within the 
bacterial sialic acid synthase family 
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4.1 Background 
 
4.1.1 Bacterial sialic acid synthases 
NANAS is the most extensively researched member of the SAS family (5). The crystal structure of 
NANAS from N. meningitidis is the only wild-type SAS structure currently elucidated (112, 113).  PseS 
and LegS are also members of the SAS family (64, 68, 89, 135, 138). Shown in Figure 4.1, LegS 
catalyses an aldol-like condensation reaction between PEP and 2,4-diacetamido-2,4,6-
trideoxymannose to form Leg and PseS reacts PEP with 2,4-diacetamido-2,4,6-trideoxyaltrose to 
form Pse. 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1 Enzymatic reactions catalysed by N-acetylneuraminic acid synthase (NANAS), legionaminic 
acid synthase (LegS) and pseudaminic acid synthase (PseS). 
 
Leg has the same absolute configuration at each of its stereocentres as N-acetylneuraminic acid 
(NANA) (Figure 4.1).  The structure of Leg differs from NANA at position C-7 where Leg has a second 
N-acetyl group and C-9 where NANA has a hydroxyl group but Leg does not. Pse is a diastereoisomer 
of Leg with inverted stereochemistry at positions C-5, C-7 and C-8.   Both PseS and LegS have been 
studied previously to a much lesser extent than NANAS and thus very little is currently known of the 
evolutionary relationships between these enzymes.  
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4.1.2 Goals of this research 
This research aims to further develop the understanding of the structural and functional 
relationships within the family of SAS enzymes. The first step in this investigation required the 
analysis of available bacterial SAS sequences in an effort to uncover evolutionary relationships. 
Three different SAS genes are found in C. jejuni (64). The enzyme encoded by Cj1141 has been 
characterised as a NANAS (90), Cj1327 as a LegS (68) and Cj1317 as a PseS (89). The existence of 
each of these genes in the same organism provides a useful model for investigating the evolutionary 
relationships between these members of the SAS family. The SAS enzyme from C. tepidum (a green 
sulphur bacterium first isolated from acidic sulphide hot springs in New Zealand (160)) was selected 
to investigate a member of the SAS family which naturally lacked and AFPL domain.  
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4. 2 Sequence and Phylogenetic Analysis of 
SASs  
 
4.2.1 Sialic acid synthase phylogenetics 
In order to determine the evolutionary relationships within the sialic synthase (SAS) family, an 
extensive sequence alignment of 410 known and potential SASs genes was constructed using 
ClustalW2 (155, 156). The methods used for sequence selection are outlined in Section 8.8.2. A 
phylogenetic tree was generated from the output of the ClustalW2 alignment using FigTree (157) 
(Figure 4.2). The sequence identity of SASs genes used in the alignment varied from 98.7 % to 21.1 
%.  
The SAS phylogenetic tree (Figure 4.2) identifies four major clades within the SAS family. These 
clades have been assigned in this thesis as NANAS, LegS, PseS and a fourth grouping of enzymes with 
unkown activity labelled as Type IV. The cluster termed as NANAS enzymes contains the sequences 
for NmeNANAS and CjeNANAS which  have both been previously reported to have NANAS activity 
(90, 112).  
The largest clade is labelled as the LegS subfamily. Within this cluster are both LpnLegS and 
CjeLegS which have both been previously reported to have LegS activity (68, 71, 135). Futhermore 
this grouping contains the SAS from Photobacterium profundum strain 3TCK which was identified to 
produce Leg but not NANA or Pse through high-performace liquid chromatography (HPLC) and mass 
spectroscopy (MS) experiments (134).  
Interestingly, the LegS clade also contains the SAS enzymes from both E. coli and Streptococcus 
agalacticae. Both of these enzymes have been shown to have NANAS activity (95, 105, 158) yet they 
are grouped within the LegS subfamily and not the NANAS subfamily. The SAS from S. agalacticae 
has 44.5 % and 52.5% sequence identity with LpnLegS and CjeLegS respectively and only 33.1% 
sequence identity with NmeNANAS. Similarly, the SAS synthase from E. coli has 41.5 % and 55.2 % 
sequence identity with LpnLegS and CjeLegS respectively and only 33.1 % sequence identity with 
NmeNANAS. Unfortunately, neither EcoSAS nor SagSAS have been tested for LegS activity. 
 
 
 
112 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Organism SAS activity 
1 Neisseria meningitidis NANAS (5, 103, 112) 
2 Campylobacter jejuni (Cj1141) NANAS (90) 
3 Escherichia coli NANAS (95, 158) 
4 Streptococcus agalacticae NANAS (105) 
5 Streptococcus suis NANAS 
6 Legionella pneumophila LegS (68) 
7 Campylobacter jejuni (Cj1327) LegS (135) 
8 Photobacterium profundum strain 3TCK LegS (134) 
9 Campylobacter jejuni (Cj1317) PseS (89, 138) 
10 Methanobrevibacter smithii PseS (134) 
11 Photobacterium profundum strain SS9 PseS (134) 
12 Helicobacter pylori PseS (63)  
13 Chlorobium tepidum - 
Figure 4.2 Phylogenetic tree of bacterial SAS. In red are NANASs, purple are LegSs, blue are PseSs and green 
are Type IV SASs. Numbers depict SASs which have been identified in the literature. Organism name and 
known activity is tabulated above. Activities marked with a - indicate that the reaction is currently unknown.  
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The grouping of enzymes observed as both NANAS and LegS within the same clade may indicate 
that members within this subfamily have the ability to synthesise either NANA or Leg. Further 
evidence for this is given by the minimal NANAS activity observed with CjeLegS (64). Although 
NANAS activity has not been directly investigated for LpnLegS, complementation studies in E. coli 
have shown that LpnNDP-sugar hydrolase/2-epimerase and LpnLegS restored the biosynthesis of 
capsular polysialic acid in the corresponding E. coli K1 gene knock-out mutants. This strongly 
suggests that the SAS from  L. pneumophila could synthesise either Leg (from 2,4-diacetamido-2,4, 6-
trideoxymannose) or NANA (from N-acetylmannosamine) (136).  
A third clade is denoted as the PseS subfamily. Within this grouping are both CjePseS which has 
been kinetically characterised as a PseS (89), and HpyPseS, which was used to elucidate the CMP-Pse 
pathway in H. pylori (63). Additionally, this grouping contains the SASs from P. profundum strain SS9 
and Methanobrevibacter smithii, which were both identified to produce Pse but not NANA or Leg 
through HPLC and MS (134). Unlike the LegS from C. jejuni, CjePseS was reported to lack NANAS 
activity (89).  
A fourth clade of SAS genes is identified in the bacterial SAS phylogram and is denoted as Type IV. 
Currently none of the enzymes from this particular subfamily have been tested for SAS activity in the 
literature. This grouping of unknown SAS enzymes has been previously noted in the literature (134). 
The phylogenetic analysis described by Lewis et al (2009), incorporates the mammalian SAS, NANA-
9-PS. The SAS phylogram published in Lewis et al (2009) indicates that NANA-9-PS is more closely 
related to the unknown SAS enzymes than to any of the previously identified NANAS, LegS or PseS 
enzymes. In addition, certain members grouped in Type IV, such as the SAS from Chlorobium 
tepidum, have been previously hypothesised to have NANA-9-PS activity (122).  
Lewis et al (2009) do not propose that the uncharacterised SAS orthologues are NANA-9-PSs. 
Instead they postulate that the origins of bacterial SAS enzymes did not arise through lateral gene 
transfer from the animal kingdom, but that NANA biosynthesis is a relic of an ancient pathway that 
was universally adopted by animals. This is evidenced by the distant sequence relationship observed 
between animal and ‘animal-like’ clades. Furthermore, the presence of archael sequences in each of 
the distinct SAS clades strongly supports the theory of paralogous gene duplication with divergence 
of enzymatic function occurring very early in cellular evolution (134). This is particularly interesting 
with respect to the AFPL domain and may suggest that the fold originated in the SAS family and was 
eventually commandeered and modified to resemble modern Type III anti-freeze proteins. 
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4.2.2 Sequence analysis of sialic acid synthases 
To elucidate the key differences between the bacterial SASs that determines substrate selectivity, 
the previously mentioned SAS sequence alignment was thoroughly analysed. An abbreviated 
sequence alignment using 60 SAS sequences (15 from each clade) is shown in Figure 4.3. Active site 
residues determined from the substrate bound NmeNANAS crystal structure (1XUZ) (112) were 
identified in the complete sequence alignment, and the conservation of these residues is displayed 
in Table 4.1.    
 
Catalytic Domain 
Linker AFPL domain 
Catalytic Domain β2-α2 loop 
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Catalytic Domain 
Catalytic Domain 
116 
 
 
Figure 4.3 Alignment of 60 SAS sequences displayed using Jalview (159). 15 sequences were selected 
from each of the four SAS clades. Residues highlighted in blue indicate conservation across the SAS family, 
with increasing intensity of blue indicating higher identity and absence of blue indicating lack of identity. 
The domain annotation is based on the NmeNANAS crystal structure (PDB code (1XUZ) (112)). 
Residue Domain Proximal 
ligand 
Contact to ligand Conserved in all 
bacterial SASs 
Conserved in all 
NANASs 
His215 Catalytic Mn
2+
 Dipolar Yes Yes 
His236 Catalytic Mn
2+
 Dipolar Yes Yes 
Lys053 Catalytic PEP H-bond Yes Yes 
Thr110 Catalytic PEP None Thr or Ser only Yes 
Lys129 Catalytic PEP H-bond Yes Yes 
Ser132 Catalytic PEP H-bond Yes Yes 
Ser154 Catalytic PEP H-bond Yes Yes 
Ser213 Catalytic PEP H-bond Yes Yes 
Asn184 Catalytic PEP H-bond No Yes 
Gln055 Catalytic rManNAc H-bond Yes Yes 
Asn074 Catalytic rManNAc H-bond No Yes 
Tyr186 Catalytic rManNAc H-bond Yes Yes 
Asp247 Catalytic rManNAc H-bond Yes Yes 
Phe288 Linker rManNAc None No Yes 
Arg314 AFPL rManNAc H-bond Except Type IV Yes 
 
Table 4.1 Conserved SAS residues. Residues are numbered according to the sequence from NmeNANAS. 
Ligand proximity and Hydrogen bonding contacts are determined with respect to the crystal structure of 
NmeNANAS bound with Mn2+, PEP and rManNAc (PDB code 1XUZ).  
 
Linker AFPL domain 
117 
 
The members of the SAS family have relatively high sequence identity (98.7 % to 21.1 %) and are 
likely to share a similar overall fold to what is observed in the NmeNANAS crystal structure (Figure 
4.4A). Observed in Figure 4.3, a notable difference between the various clades of the SAS family is 
that unlike NANAS, LegS and PseS enzymes, Type IV SASs do not contain peptide sequence 
pertaining to a C-terminal AFPL domain. 
 
 
 
 
 
 
 
 
 
 
Figure 4.4 (A) NmeNANAS dimer with one monomer coloured grey and the second coloured by domain. 
The catalytic domain is shown in purple, linker domain in orange and AFPL domain in blue. (B) Close up 
of active site. Residues contributed by the catalytic domain are in grey, linker in orange and AFPL domain 
in blue. ManNAc is coloured green, PEP pink, Mn2+ yellow and waters are shown in red. H-bonds are 
depicted with black dashes and dipolar bonds with red dashes (PDB code (1XUZ) (112)). 
A 
B 
Phe288 
Arg314 
His215 
His236 
Lys53 
Thr110 
Lys129 
Ser213 
Ser132 
Ser154 
Asn184 
Tyr186 
Asp247 
Asn74 
Gln55 
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Each of the SAS enzymes currently described in the literature has required a divalent metal ion 
for catalysis (5, 89). As shown in Figure 4.3 and Table 4.1, the metal binding residues NmeHis215 and 
NmeHis236 are both fully conserved in all members of the SAS family. The metal ion in the 
NmeNANAS crystal structure is shown to have octahedral geometry with NmeHis215, NmeHis236, a 
water molecule and O2P from PEP occupying the equatorial plane whilst a second water molecule 
and the carbonyl group of ManNAc occupy the axial positions (Figure 4.4B). NmeHis215 and NmeHis236 
are the only metal binding ligands that are contributed by the enzyme itself, and the full 
conservation of these residues within the SAS family strongly indicates that all SASs are metal-
dependent enzymes.   
The phosphate group of PEP forms hydrogen bonds with NmeSer132, NmeSer154 and NmeSer213 in 
the crystal structure of NmeNANAS. Each of these three serine residues is fully conserved within the 
SAS family. NmeAsn184 is also involved in PEP phosphate binding, however, it is only fully conserved 
in enzymes from the NANAS clade (Figure 4.3). In both PseS and Type IV SASs, this position 
correlates with a fully conserved serine, and in LegS a highly conserved threonine. Residues NmeLys53 
and NmeLys129 form favourable interactions with the PEP carboxylate group, and are both conserved 
in all SAS enzymes. The side-chain of NmeThr110 is proximal to the PEP carboxylate, but is not close 
enough to form a hydrogen bond in the NmeNANAS crystal structure. The positioning of NmeThr110 is 
consistent amongst available NmeNANAS structures (113). NmeThr110 is highly conserved as either a 
threonine or serine (Figure 4.3).  
In the NmeNANAS crystal structure several strong hydrogen bonding interactions with rManNAc 
are noted (112). Unlike the metal and PEP binding sites, the ManNAc binding site is composed of 
residues from both the catalytic domain and the AFPL domain (Figure 4.4B). The catalytic domain 
residues NmeAsp247, NmeGln55 and NmeTyr186 are each fully conserved in the SAS family and form 
hydrogen bonds with rManNAc. NmeAsn74 is also contributed by the catalytic domain but is only 
conserved in the NANAS clade. In the NmeNANAS crystal structure, NmeAsn74 interacts with the C-6 
hydroxyl of rManNAc. As shown in Figure 4.1, the substrates of both PseS and LegS do not contain a 
C-6 hydroxyl and thus conservation of NmeAsn74 would be unnecessary from an evolutionary 
perspective. 
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NmePhe288 and NmeArg314 are the only two catalytic residues contributed by the linker and AFPL 
domain (Table 4.1) and are thus not present in Type IV SASs. NmeArg314 interacts with the N-acetyl 
group at C-2 of ManNAc and is involved in steering the sugar substrate into a suitable reactive 
position (114). NmeArg314 is conserved in all NANAS, LegS and PseS enzymes. As shown in Figure 4.1, 
the N-acetyl group at position C-2 is present in the sugar substrates of NANAS, LegS and PseS 
enzymes. It is thus highly likely that the positioning role of NmeArg314 is maintained in these three 
SAS clades. Unlike NmeArg314, NmePhe288 does not directly interact with ManNAc but is in close 
proximity and forms part of the ManNAc binding pocket (Figure 4.4B). NmePhe288 is only conserved 
in members of the NANAS clade. 
There are two prominent regions where considerable sequence variation is observed within the 
entire SAS family but high conservation is observed within members of the same clade. These 
regions are likely indicative of residues, combination of residues or motifs that enable the SAS 
enzymes to differentiate between the required sugar substrates. The first of these regions is the β2-
α2 loop of the catalytic domain shown in Figure 4.5. In the crystal structure of NmeNANAS, the β2-
α2 loop closes over the ManNAc site and contributes the residue NmeAsn74, which forms a hydrogen 
bond with the C-6 hydroxyl of ManNAc. NmeAsn74 is fully conserved in all NANASs but is not present 
in any other SAS.  
 
 
 
 
 
 
 
   
Figure 4.5 View of catalytic site and β2-α2 loop. β2-α2 loop is coloured in red. ManNAc is coloured green, 
PEP pink and Mn2+ yellow. H-bonds are depicted with black dashes (PDB code (1XUZ) (112)). 
 
Phe288 
Asn74 
Asn74 
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As can be seen in Figure 4.6, the residues comprising the β2-α2 loop differ significantly within the 
entire SAS family but show remarkably high conservation within each clade. Furthermore, as 
depicted in Figure 4.6, there are several residues that are fully conserved within each of the four SAS 
clades. In the NANAS clade the residues surrounding NmeAsn74 are fully conserved, resulting in a Pro-
Gly-Asn motif. Similarly, in the LegS clade there is a cluster of conserved residues in the β2-α2 loop 
resulting in an Ala-X-Tyr-Gln motif, where the residue indicated by X is variable. In the PseS clade, 
there are five fully conserved residues within the β2-α2 loop region, a tyrosine, threonine, 
phenylalanine, tryptophan and a leucine. Unlike the NANAS and LegS clades, the conserved residues 
in the PseS β2-α2 loop are sparsely distributed. Lastly, in the Type IV SAS clade, there is a conserved 
Arg-X-Thr-Pro-Trp-Gly motif.  
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Figure 4.6 Alignment of SAS β2-α2 loop sequences displayed using Jalview (159). 15 sequences were 
selected from each of the four SAS clades. (A) 15 β2-α2 loop sequences from NANAS clade, (B) 15 β2-α2 
loop sequences from LegS clade, (C) 15 β2-α2 loop sequences from PseS clade and (D) 15 β2-α2 loop 
sequences from Type IV clade. Residues highlighted in blue indicate conservation across the SAS family, 
with increasing intensity of blue indicating higher identity and absence of blue indicating lack of identity. 
Residues fully conserved within clade are marked with a red dot. 
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B 
C 
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As depicted in Figure 4.6, the β2-α2 loops of both LegSs and PseSs are slightly longer than that of 
NANASs, which arises from the full SAS sequence alignment. The increased length may be to 
accommodate the slightly bulkier substrates of LegSs and PseSs which, as depicted in Figure 4.1, 
have an additional N-acetyl group when compared to ManNAc. The β2-α2 loop of Type IV SASs is 
also shorter than that of PseSs and LegSs and is a similar length to that for NANASs.  The length of 
the Type IV β2-α2 loop may be indicative that the as yet unknown sugar substrate of this clade is a 
relatively simple member of the sialic acid family.  
The second region of high intraclade conservation corresponds to the AFPL domain linker. The 
linker crosses over the catalytic site (Figure 4.7) and contributes a single phenylalanine residue into 
the active site of NmeNANAS. As aforementioned NmePhe288 is only conserved in the NANAS clade. 
As shown in Figure 4.8, the residues comprising the AFPL domain linker differ significantly within the 
entire SAS family but show remarkably high conservation within each clade. Within this region there 
are several residues that are fully conserved within each of the four SAS clades (Figure 4.8). In the 
NANAS clade there is a highly conserved motif of NmeAsp285-Phe-Ala-Phe-Ala289 which contains 
residue NmePhe288. In the LegS clade there is a highly conserved motif of Arg-Lys-Ser-Ile-Val-Ala and 
in the PseS clade a motif of Phe-Ala/Ser-Arg-Ser-Leu-Tyr in the corresponding locations.   
 
 
 
 
 
 
 
 
 
 
Figure 4.7 View of catalytic site and AFPL domain linker. AFPL domain linker is coloured in orange. 
ManNAc is coloured green, PEP pink and Mn2+ yellow. (PDB code (1XUZ) (112)). 
 
Phe288 
123 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.8 Alignment of SAS AFPL domain linker sequences displayed using Jalview (159). 15 sequences 
were selected from each of the four SAS clades. (A) 15 AFPL domain linker sequences from NANAS clade, 
(B) 15 AFPL domain linker sequences from LegS clade and (C) 15 AFPL domain linker sequences from 
PseS clade. Residues highlighted in blue indicate conservation across the SAS family, with increasing 
intensity of blue indicating higher identity and absence of blue indicating lack of identity. Residues fully 
conserved within clade are marked with a red dot. 
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4. 3 Cloning, expression and purification of  
C. jejuni SASs 
 
4.3.1 Cloning of C. jejuni SASs 
The genes encoding Cj1141 (NANAS), Cj1327 (LegS) and Cj1317 (PseS) from C. jejuni NCTC 11168 
were amplified from genomic DNA using the nested PCR method outlined in Section 8.3.2. Gene- 
specific nested primers were designed incorporating generic extensions for further rounds of nested 
PCR (Table 8.8). Following successful amplification as determined by agarose gel electrophoresis, the 
product from the first round of nested PCR was purified. Purified first round product was extended 
using generic gateway primers, which incorporated sequence encoding an N-terminal TEV protease 
cleavage site (Table 8.8).  
 
Successful amplification was determined by agarose gel electrophoresis and the product from the 
second round of nested PCR was also purified. Cloning and sub-cloning of the C. jejuni SAS genes 
were achieved through the use of the gateway system as outlined in Section 8.3. The linear product 
from second round nested-PCR was cloned into the donor vector pDONR-221. Ligated product was 
subsequently transformed into E. coli One Shot® TOP10 cells (Invitrogen) as outlined in Section 
8.3.10. Plasmids from transformants were purified and each of the three C. jejuni SAS genes were 
successfully sequence verified in the donor vector. The three C. jejuni SAS genes were sub-cloned 
into the destination vector pDEST-17, which encodes an N-terminal His-tag.  
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4.3.2 Expression and purification 
Each of the three C. jejuni SAS genes were transformed into three different expression cell lines 
to optimise the yield of soluble protein. The genes encoding CjeNANAS, CjeLegS and CjePseS were 
each transformed into E. coli BL21 (DE3) Star cells, E. coli Rosetta™ 2 (DE3) cells and E.coli Bl21 (DE3) 
pBB540/pBB542 (Chaperone 3) cells. In order to compare induced against non-induced samples, two 
cultures of each cell line were grown overnight in LB, with one induced by IPTG and the other not. 
The best yield of soluble protein was attained using Chaperone 3 cells as analysed by SDS PAGE. 
CjeNANAS, CjeLegS and CjePseS were thus expressed and purified from this cell line.  
 
Each of the C. jejuni SASs were expressed and purified using a similar method to that used for 
NmeNANAS wild-type as outlined in Section 8.4. Cell pellets were resuspended in buffer and lysed 
via sonication. The resulting lysate was clarified by centrifugation to separate out the cell debris. 
Soluble protein was filtered and run through an IMAC column to purify the His-tagged protein. After 
the first round of IMAC purification, protein was desalted and treated with TEV protease to remove 
the His-tag and then run through a second IMAC column to separate the tag and TEV protease from 
the target protein. SEC was used as a final, polishing step and fractions were subsequently pooled, 
concentrated, flash-frozen and stored at -80 °C. Samples of purified enzyme were analysed by SDS 
PAGE (Figure 4.9). 
 
 
 
 
 
 
 
 
 
 
M          1           2           3 
160 kDa 
110 kDa 
80 kDa 
 
60 kDa 
 
50 kDa 
 
40 kDa 
 
 
30 kDa 
 
20 kDa 
 
Figure 4.9 SDS-PAGE gel of purified C. jejuni SAS enzymes. Lane M contains marker with molecular 
weights defined. Lane 1 contains CjeNANAS (Cj1141), lane 2 CjePseS (Cj1317) and lane 3 CjeLegS 
(Cj1327). 
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4.4 Kinetic analysis of C. jejuni SASs 
 
4.4.1 Michaelis-Menten kinetics 
To determine the kinetic parameters of the C. jejuni SAS enzymes with respect to NANA 
synthesis, the consumption of PEP was monitored using the assay described in Section 8.5.1.  LegS 
and PseS activity were not tested for any of the C. jejuni SAS enzymes as the substrates for  Leg and 
Pse biosynthesis (2,4-diacetamido-2,4,6-trideoxymannose and 2,4-diacetamido-2,4,6-trideoxaltrose 
respectively) were not commercially available and their chemical synthesis is complex (161).  
Cuvettes containing 50 mM BTP (pH 8), 1 mM MnCl2, PEP (varied) and ManNAc (varied) were 
incubated for 10 min at 25 °C. The enzymatic reaction was initiated by the addition of purified 
enzyme. Michaelis-Menten steady-state approximations were utilised to determine kinetic 
parameters (Figure 4.10). Kinetic parameters were compared to the values ascertained for wild-type 
NmeNANAS (Table 4.2).  
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Figure 4.10 Michaelis-Menten curves for CjeNANAS and CjeLegS with ManNAc and PEP. (A) CjeNANAS 
PEP Km curve, (B) CjeNANAS ManNAc Km curve, (C) CjeLegS PEP Km curve and (D) CjeLegS ManNAc Km 
curve. Data points are shown in black and a line of best fit in red. A double reciprocal plot is displayed as 
an inset for each graph.  
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Table 4.2 Kinetic parameters for CjeNANAS, CjeLegS and CjePseS compared with NmeNANAS. Values with 
- indicates kcat of enzyme is less than 0.004 s-1.  
 
CjeNANAS was determined to have relatively similar kinetic parameters to NmeNANAS. The Km 
(PEP) for CjeNANAS was almost the same as that calculated for NmeNANAS (33 ± 1 µM and 28 ± 3 
µM  respectively) whilst the Km (ManNAc) for CjeNANAS was slightly larger than that for NmeNANAS 
(4.9 ± 0.2 mM and 2.9 ± 0.2 mM  respectively). The kcat for CjeNANAS was determined to be 
approximately half that for NmeNANAS at 1.7 ± 0.1 s-1 and 3.1 ± 0.1 s-1 respectively.  
The kinetic values determined for CjeNANAS differ to those previously published in the literature 
by Sundaram et al (90). The Km (PEP) and Km (ManNAc) values formerly reported for CjeNANAS were 
7.3 mM and 17.6 mM respectively with a kcat of 0.3 s
-1 (90). The differences in kinetic parameters 
attained may be attributed to several key experimental variations. The kinetic assay used in this 
study was a continuous assay which monitored the loss of PEP, whereas the assay used in the 
literature was a thiobarbituric acid stopped assay. Furthermore, Sundaram et al characterised 
CjeNANAS as an N-terminal His6-S-tag chimera as opposed to an un-tagged enzyme. The 
incorporation of the N-terminal solubility extension may account for the larger Km values and lower 
kcat as it is possible that the solubility tag could interfere with the enzyme’s ability to catalyse the 
NANAS reaction through preclusion of the active site. Therefore, the His6-S-tagged enzyme may not 
accurately portray in vivo kinetic parameters for CjeNANAS. 
Lastly, in this study CjeNANAS was assayed at 25 °C whereas the literature assay was done at 37 
°C. 25 °C was chosen to keep consistency between each of the wild-type enzymes assayed in this 
thesis as many of the enzymes were found to be unstable in the absence of ligand (described in 
Section 4.5.2). It is possible that the higher temperature used to assay CjeNANAS in the literature 
had a negative effect on the enzyme’s stability and thus the kinetic parameters as well. 
 NmeNANAS CjeNANAS  CjeLegS CjePseS 
kcat (s
-1) 3.1 ± 0.1 1.7 ± 0.1 0.05 ± 0.01 - 
Km PEP (µM) 28 ± 3 33 ± 1 15 ± 1 - 
Km ManNAc (mM) 2.9 ± 0.2 4.9 ± 0.2 256 ± 23 - 
kcat/Km  ManNAc (s
-1/M) 1068 ± 108 346 ± 35 0.21 ± 0.05 - 
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Minimal NANAS activity has been previously reported for CjeLegS, however, kinetic parameters 
were not quantified (64).  The Km (PEP) and Km (ManNAc) for CjeLegS were calculated to be 15 ± 1 
µM and 256 ± 23 mM respectively. The Km (PEP) for CjeLegS is approximately half that observed 
for either NmeNANAS of CjeNANAS. In comparison, the Km (ManNAc) for CjeLegS is over 50 times 
greater than that observed for CjeNANAS and over 80 times greater than that observed for 
NmeNANAS. As previously mentioned, 2,4-diacetamido-2,4,6-trideoxymannose is not readily 
available, thus no kinetic parameters have been published in the literature for a LegS with the 
natural sugar substrate for Leg biosynthesis. As no Km or kcat values are available for CjeLegS with 
respect to 2,4-diacetamido-2 4,6-trideoxymannose, it is not possible to directly compare the 
catalytic efficiency of the enzyme between NANAS and LegS activity.  However, it can be noted that 
CjeLegS is far less efficient than CjeNANAS at synthesising NANA.  
CjePseS was assayed for NANAS activity under the same physiological conditions previously used 
to determine PseS activity (89) as well as that described in Chapter 2 for NmeNANAS. The 
aforementioned single-step assay was used instead of the coupled assay described in the literature, 
and 2,4-diacetamido-2,4,6-trideoxyaltrose was substituted with ManNAc. Up to 35 µg of purified 
enzyme was used to initiate reaction (10 fold greater than that used to assay CjePseS in the 
literature), however, no NANAS activity was observed. It was previously observed that Co2+ was 
more activating than Mn2+, thus activity was also tested using Co2+. Activity was tested with ManNAc 
at each step of the purification process, however, no loss of PEP was detected at any stage. This 
correlates with previous studies which concluded that CjePseS is the only C. jejuni SAS without 
NANAS activity (64).   
 
4.4.2 Attempted alternative substrate analysis 
CjeNANAS has been previously kinetically characterised with several N-acetylmannosamines with 
modified acyl chains (90). The N-acetyl group of ManNAc was modified to a propionyl, butanoyl and 
pentanoyl and successfully reacted with PEP using CjeNANAS (90). Alternative sugar substrates have 
also been successfully observed with S. agalacticae NANAS (105). In order to probe the ability of the 
C. jejuni SASs to use alternative substrates, several ManNAc analogues were assayed (Table 4.3). 
However, no detectable activity could be measured for any of the three C. jejuni SASs with the 
ManNAc analogues depicted below, even in the presence of high enzyme concentrations 
(approximately 1 mg/mL) and high sugar concentration (up to 500 mM). 
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Name Structure Name Structure 
N-acetyl-D-
mannosamine 
 
D-glucose 
 
N-acetyl-D-
galactosamine 
 
2-deoxy-D-glucose 
 
N-acetyl-D-
glucosamine 
 
D-mannosamine 
 
D-mannose 
 N-acetyl-D-
mannosamine-6-
phosphate 
 
 
Table 4.3 Structures of ManNAc analogues assayed with CjeNANAS, CjePseS and CjeLegS. 
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4.5 Binding studies of C. jejuni SASs 
 
4.5.1 Isothermal titration calorimetry 
Binding constants for Mn2+ and PEP were determined for each of the three C. jejuni SASs using the 
methods described in Section 8.5.4. ITC results from CjeNANAS, CjePseS and CjeLegS were compared 
to previously determined dissociation constants (Kd) for NmeNANAS wild-type (Table 4.4) (114). Raw 
experimental and one-site model fitted ITC data is displayed in Figure 4.11. 
 
 NmeNANAS 
(114) 
CjeNANAS CjePseS CjeLegS 
Kd Mn
2+ (µM) 10.6 ± 0.5 3.9 ± 0.1 4.0 ± 0.2 13 ± 1 
Kd PEP (µM) 219 ± 11 320 ± 10 347 ± 9 356 ± 14 
 
Table 4.4 ITC derived binding constants for wild-type NmeNANAS, CjeNANAS, CjePseS and CjeLegS. 
 
To determine the Kd value for metal with each of the C. jejuni SASs, Mn
2+ was titrated into metal-
free enzyme. The Mn2+ affinities of CjeNANAS and CjePseS were determined to be approximately 
two-fold greater than that for NmeNANAS and three-fold greater than for CjeLegS. As depicted in 
Figure 4.11, the binding of Mn2+ is an exothermic event in each of the three C. jejuni enzymes and 
thus an enthalpically favourable process.  
 The Kd (PEP) values of CjeNANAS, CjePseS and CjeLegS were determined to be very similar at 320 ± 
10 µM, 347 ± 9 µM and 356 ± 14 µM respectively. The PEP affinities for each of the three C. jejuni 
SASs were slightly lower than that observed for NmeNANAS wild-type. As shown in Figure 4.11, the 
binding of PEP is an endothermic event in each of the three C. jejuni enzymes. This correlates with 
previous observations for PEP binding with wild-type NmeNANAS that was determined to be an 
entropically favourable event.  
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A B 
C D 
E F 
Figure 4.11 Enthalpy changes measured by isothermal titration calorimetry. (A) Mn2+ (5 mM) titrated 
into metal-free CjeNANAS (65 µM). (B) PEP (50 mM) titrated into CjeNANAS (40 µM) in the presence of 
Mn2+ (1 mM). (C) Mn2+ (5 mM) titrated into metal-free CjePseS (65 µM). (D) PEP (50 mM) titrated into 
CjePseS (40 µM) in the presence of Mn2+ (1 mM). (E) Mn2+ (5 mM) titrated into metal-free CjeLegS (65 µM). 
(F) PEP (50 mM) titrated into CjeLegS (40 µM) in the presence of Mn2+ (1 mM). 
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4.5.2 Thermal stability 
The effects of Mn2+, PEP and ManNAc/rManNAc on the thermal stability of the three C. 
jejuni SASs were assessed by DSF using the method outlined in Section 8.5.3. Enzymes used for DSF 
were treated with 10 mM EDTA prior to SEC to ensure removal of trace metals. The melting points 
determined for each sample were plotted and compared with data obtained for NmeNANAS wild-
type (Figure 4.12 and Table 4.5). 
Figure 4.12 Bar graph of thermal melting points for NmeNANAS (red), CjeNANAS (orange), CjePseS (blue) 
and CjeLegS (purple) in the presence of ligand as determined by DSF. EDTA, Mn2+ and PEP were each used 
at a concentration of 1 mM and ManNAc/rManNAc at 10 mM. ManNAc/rManNAc was used at 1 mM when 
in combination with PEP.  
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Table 4.5 Thermal melting points for NmeNANAS, CjeNANAS, CjePseS and CjeLegS in the presence and 
absence of ligand as determined by DSF. EDTA, Mn2+ and PEP were each used at a concentration of 1 mM 
and ManNAc/rManNAc at 10 mM. ManNAc/rManNAc was used at 1 mM when in combination with PEP.  
 
Apoenzyme CjeNANAS, CjePseS and CjeLegS melted at 51.2 ± 0.5 °C, 43.0 ± 0.3 °C and 45.8 ± 0.3 
°C respectively. Shown in Figure 4.12, CjeNANAS was found to have slightly higher thermal stability 
than CjePseS, CjeLegS and NmeNANAS under each of the conditions tested. As shown in Figure 4.12, 
the addition of 1 mM EDTA to apoenzyme did not influence the thermal stability of CjeNANAS, 
CjePseS or CjeLegS. The absence of an effect caused by EDTA is likely due to the successful removal 
of trace metal ions during purification. The addition of 1 mM Mn2+ increased the melting points of 
CjeNANAS, CjePseS and CjeLegS by approximately 6 °C, 11 °C and 5 °C respectively. This increased 
thermal stability in the presence of Mn2+ is also observed in NmeNANAS.  
The largest thermal shift observed for each of the three C. jejuni enzymes was in the presence of 
both Mn2+ and PEP. The combined addition of 1 mM Mn2+ and 1 mM PEP to CjeNANAS, CjePseS and 
CjeLegS increased the melting point of apoenzyme by approximately 12 °C, 17.5 °C and 12 °C 
respectively. The observation that Mn2+ and PEP are so significantly stabilising has been previously 
noted for NmeNANAS (Chapter 3). For each of the C. jejuni SASs, the addition of 10 mM ManNAc or 
rManNAc in combination with 1 mM Mn2+ did not have any additional effect to that observed for 
only Mn2+.  
 
 
 
 
 
Addition NmeNANAS (°C) CjeNANAS (°C) CjePseS (°C) CjeLegS (°C) 
Nothing 42.7 ± 0.2 51.2 ± 0.5 43.0 ± 0.3 45.8 ± 0.3 
EDTA 43.6 ± 0.3 51.2 ± 0.5 42.8 ± 0.4 46.0 ± 0.2 
Mn2+ 48.9 ± 0.3 56.9 ± 0.5 53.7 ± 0.4 50.9 ± 0.2 
Mn2+ + PEP 56.2 ± 0.7 63.2 ± 0.2 60.5 ± 0.2 58.3 ± 0.5 
Mn2+ + ManNAc 49.0 ± 0.4 57.2 ± 0.2 53.7 ± 0.2 52.0 ± 0.2 
Mn2+ + PEP + ManNAc 48.7 ± 0.2 57.1 ± 0.2 59.6 ± 0.2 53.1 ± 0.5 
Mn2+ + rManNAc 50.4 ± 0.3 57.4 ± 0.5 54.7 ± 0.9 51.1 ± 0.3 
Mn2+ + PEP + rManNAc 56.4 ± 0.2 63.2 ± 0.2 59.3 ± 0.2 57.5 ± 0.5 
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The melting temperatures for both CjeNANAS and CjeLegS in the presence of 1 mM Mn2+, 1 mM 
PEP and 1 mM ManNAc were similar to that observed for enzyme in the presence of Mn2+. As 
described in Section 4.4.2, both CjeNANAS and CjeLegS are able to synthesise NANA. Therefore, the 
melting temperatures observed for CjeNANAS and CjeLegS in the presence of Mn2+, PEP and ManNAc 
are likely caused by the presence of Mn2+ and NANA. It is unlikely that NANA would favourably bind 
to either CjeNANAS or CjeLegS given that it is the product of the reaction catalysed and would need 
to be removed from the active site for further reactions to progress. The resulting thermal stability 
observed for CjeNANAS and CjeLegS in the presence of Mn2+, PEP and ManNAc may consequentially 
be contributed solely by Mn2+, hence the similar melting temperatures observed when compared to 
enzyme in the presence of only Mn2+.  
 
Conversely, CjePseS in the presence of Mn2+, PEP and ManNAc has a similar melting temperature 
to CjePseS in the presence of Mn2+ and PEP. As described in Sections 4.3.1 and 4.4.1, CjePseS is able 
to bind PEP but does not catalyse the formation of NANAS. Given that the presence of ManNAc has 
little to no effect on the thermal stability of any of the SASs tested, it is likely that the thermal shift 
observed for CjePseS in the presence of Mn2+, PEP and ManNAc is caused by PEP still being present 
in the active site. In the presence of Mn2+, PEP and rManNAc, each of the three C. jejuni SASs have 
similar melting temperatures to enzyme in the presence of Mn2+ and PEP. This is likely caused by an 
inability to turn over rManNAc and the retained presence of PEP in the active site for each enzyme. 
 
PEP binding in wild-type NmeNANAS has been shown to trigger a hydrogen bonding network that 
rearranges the active site for ManNAc binding (Chapter 3). Given the similar observations for both 
ITC and DSF with respect to PEP between the C. jejuni SASs and NmeNANAS, it is highly likely that an 
analogous mechanism is employed by each of these enzymes. Furthermore, residue NmeGlu134, 
which was identified to be involved in the hydrogen bonding network is highly conserved in NANAS, 
LegS and PseS enzymes. 
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4.6 Structural analysis of C. jejuni SASs 
 
4.6.1 Circular dichroism 
CD was used to assess and compare the secondary structures of CjeNANAS, CjePseS and CjeLegS. 
CD spectra of the C. jejuni SASs are compared with NmeNANAS data in Figure 4.13. The K2D3 server 
(142) was used to estimate the secondary structure composition from CD spectra. Shown in Table 
4.6, estimated secondary structure is compared to values derived from the crystal structure of 
NmeNANAS (PDB code: 1XUZ) and computational models of each of the C. jejuni enzymes (models 
are described in Section 4.6.6). 
 
   
 
 
 
 
 
 
Figure 4.13 CD spectra for NmeNANAS (red), CjeNANAS (orange), CjePseS (blue) and CjeLegS (purple).  
 
 
 
 
 
 
 
 
 
 
Table 4.6 Predictions of secondary structure composition for NmeNANAS, CjeNANAS, CjePseS and 
CjeLegS calculated from CD data using K2D3 server (142). Secondary structure composition of 
NmeNANAS structure calculated from crystallographic coordinates 1XUZ. 
 
 NmeNANAS NmeNANAS 
(structure) 
CjeNANAS CjeNANAS 
(Model) 
CjePseS CjePseS 
(Model) 
CjeLegS 
 
CjeLegS 
(Model) 
α-helix 59.9 % 50.3 % 51.3 % 48.1 % 54.3 % 54.1 % 54.2 % 50.0 % 
β-sheet 12.3 % 15.5 % 13.6 % 16.5 % 13.3 % 15.2 % 13.3 % 16.4 % 
other 27.8 % 34.2 % 35.1 % 35.4 % 32.4 % 30.7 % 32.5 % 33.6 % 
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As depicted in Figure 4.13 and Table 4.6, each of the C. jejuni enzymes are folded in solution and 
have comparable secondary structure compositions. The secondary structure predictions from K2D3 
are similar to those calculated from the computational models of the C.jejuni enzymes. Furthermore, 
the secondary structure compositions of each of the three C. jejuni enzymes are relatively similar to 
NmeNANAS and indicates that these enzymes are all structurally analogous. 
 
4.6.2 Mass spectrometry 
The masses of each of the C. jejuni SASs were analysed using MS (Table 4.7). Each of the 
experimental masses obtained were almost identical to those calculated from the respective peptide 
sequences using ProtParam (141).  
 
 
 
 
Table 4.7 Mass spectrometry measurements of His6-tagged CjeNANAS, CjePseS and CjeLegS. 
 
4.6.3 Analytical size exclusion chromatography 
The quaternary structure of CjeNANAS, CjePseS and CjeLegS was investigated using analytical SEC. 
The method used for analytical SEC is outlined in Section 8.5.6. A calibration curve was generated 
using protein standards of known molecular weight. The elution volume (Ve) of protein standards 
relative to the column void volume (V0) was plotted against the log of the protein standards 
molecular mass. A linear fit of the analytical SEC calibration data was determined to have an R2 value 
of 0.987. The calibration curve was used to extrapolate the molecular masses of each of the three C. 
jejuni SASs as shown in Figure 4.14. 
 
 
 
 
 CjeNANAS CjePseS CjeLegS 
Experimental mass (Da) 42,111 42,275 40,719 
Theoretical mass (Da) 42,111 42,276 40,720 
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Figure 4.14 (A) Normalised analytical SEC chromatograms for NmeNANAS (red), CjeNANAS (orange), 
CjePseS (blue) and CjeLegS (purple). (B) Analytical SEC calibration curve. Protein standards are marked in 
grey, NmeNANAS in red, CjeNANAS in orange, CjePseS in blue and CjeLegS in purple. A line of best fit is 
plotted in black. (C) Table of estimated and theoretical masses for NmeNANAS and C. jejuni SAS enzymes. 
 
As shown in Figure 4.14, each of the three C. jejuni enzymes elute as a single species at  molecular 
weights correpsonding to that calculated for dimeric protein. NmeNANAS has been previously 
identified as a dimer, and given the high sequence similarity of each of the C. jejuni SASs with 
NmeNANAS, it is unsurprising that they are dimeric as well. Shown in Figure 4.14A, NmeNANAS, 
CjeNANAS and CjePseS elute at almost identical volumes, whilst CjeLegS elutes slightly later. This 
corresponds with the molecular masses of NmeNANAS, CjeNANAS and CjePseS being very similar 
(approximately 77 kDa dimers) whilst the molecular mass of CjeLegS is slightly smaller 
(approximately 74 kDa dimer).  
 
 
 
 
 NmeNANAS  CjeNANAS CjePseS CjeLegS 
Ve/V0 1.74 1.75 1.74 1.77 
Estimated mass (kDa) 81 79 81 72 
Theoretical mass of dimer (kDa) 77 77 77 74 
A B 
C 
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4.6.4 Small-angle X-ray scattering 
SAXS profiles were determined to assess the solution structures of CjeNANAS, CjePseS and 
CjeLegS. The methods used to determine the SAXS profiles of these enzymes are outlined in Section 
8.5.8 and 8.5.9. The SAXS profiles of ligand-free C. jejuni SASs are displayed in Figure 4.15 and are 
overlaid with the ligand-free scattering profile of NmeNANAS. 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.15 SAXS profiles of ligand-free NmeNANAS (red), CjeNANAS (orange), CjePseS (blue) and 
CjeLegS (purple). Scattering data was collected using approximately 10 mg mL-1 protein in 30 mM 
triethanolamine-HCl buffer at pH 7.5. Samples were eluted by SEC (Superdex 200 5/150). 
As portrayed in Figure 4.15, each of the three C. jejuni SASs have remarkably similar SAXS profiles. 
Furthermore, the profiles are analogous to what is observed for ligand-free NmeNANAS. The 
structure parameters obtained from SAXS are also similar between each of the three C. jejuni 
enzymes (Table 4.8). The molecular masses of each of the C. jejuni SASs were calculated from SAXS 
data using SAXS MoW (154). The estimated masses for CjeNANAS, CjePseS and CjeLegS were 
calculated to be 88, 84 and 83 kDa respectively, which is comparable to the 85 kDa mass estimated 
for NmeNANAS. The masses of the C. jejuni SASs indicate that the enzymes are dimeric under the 
conditions used for SAXS, which correlates with the results obtained from analytical SEC outlined in 
Section 4.6.3.  
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Table 4.8 SAXS structural parameters determined for C. jejuni SASs compared with parameters for 
NmeNANAS. SAXS data obtained at a wavelength of 1.0332 Å.   
 
Theoretical scattering curves were generated from atomic coordinates of the C. jejuni SAS models 
described in Section 4.6.6 and compared with experimental scattering curves using CRYSOL (153) 
(Figure 4.16). Each of the C. jejuni SAS models were generated from the liganded NmeNANAS 1XUZ 
template, yet none of the theoretical plots generated from the C. jejuni SAS models fit well with the 
respective experimental scattering profiles. As displayed in Figure 4.16A-C, each of the fits appear to 
be good at S values below 0.12 Å-1 but subsequently deteriorate in quality. The Chi values for 
CjeNANAS, CjePseS and CjeLegS with their respective theoretical scattering profiles are 5.4, 5.4 and 
5.8 respectively.  
The poor fit between experimental SAXS profiles of ligand-free enzyme and theoretical scattering 
has been previously observed with NmeNANAS (Chapter 3). Although the ligand-free fit is poor, the 
experimental SAXS profile of NmeNANAS is altered in the presence of 1 mM Mn2+ and 1 mM PEP and 
the chi value of the fit is improved from 6.1 to 2.0. In Chapter 3, the conformational change 
observed with PEP-bound NmeNANAS has been attributed to PEP binding, reorganising the active 
site in preparation for ManNAc binding. As described in Section 4.5, the DSF and ITC profiles of each 
of the three C. jejuni enzymes with regards to PEP are very similar to what is observed with 
NmeNANAS. Given the similarities observed, it is highly likely that each of the C. jejuni SASs also 
undergoes a conformational change upon PEP binding and that the poor fits observed in Figure 
4.16A-C are due to the absence of ligand.  
Shown in Figure 4.16D, the theoretical scattering profiles from the models of CjeNANAS and 
CjePseS align well with the profile generated from the crystallographic coordinates of NmeNANAS 
(1XUZ).  The profile generated from the CjeLegS model also aligns well but is slightly different from 
the other three at higher S values.  
 NmeNANAS  CjeNANAS CjePseS CjeLegS 
I0 (cm
-1) 0.082 ± 0.001 0.079 ± 0.001 0.078 ± 0.001 0.078 ± 0.001 
Rg (Å) 33.0 ± 0.5 32.3 ± 0.1 31.7 ± 0.2 31.8 ± 0.2 
Dmax (Å) 116 113 111 111 
Porod volume (Å3) 121,724 122,906 115,453 112,927 
Estimated mass (kDa) 85 88 84 83 
Theoretical mass of dimer (kDa) 77 77 77 74 
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Figure 4.16 Comparisons of experimental and theoretical SAXS profiles using CRYSOL. (A) Comparison of 
SAXS profiles for ligand-free CjeNANAS (orange) with theoretical scattering generated from dimer model 
of CjeNANAS (black line). (B) Comparison of SAXS profiles for ligand-free CjePseS (blue) with theoretical 
scattering generated from dimer model of CjePseS (black line). (C) Comparison of SAXS profiles for 
ligand-free CjeLegS (purple) with theoretical scattering generated from dimer model of CjeLegS (black 
line). (D) Comparison of theoretical scattering profiles of NmeNANAS (red), CjeNANAS (orange), CjePseS 
(blue) and CjeLegS (purple). Theoretical scattering for NmeNANAS was generated from crystallographic 
coordinates 1XUZ. SAXS data was collected using approximately 10 mg mL-1 protein in 30 mM 
triethanolamine-HCl buffer at pH 7.5. Samples were eluted by SEC (Superdex 200 5/150). 
 
4.6.5 Attempted crystallisation 
Several attempts at crystallising the C. jejuni SASs were made. Each of the enzymes were 
screened using conditions modified from those previously described for crystallising NmeNANAS 
(112). Protein crystallisation conditions were also screened using commercially available Morpheus, 
PACT and JCSG screens. Protein was concentrated to 6 mg/mL and 15 mg/mL and screened in the 
absence and presence of ligands. Screens were incubated at 5 °C and 20 °C for several months, but 
none of the conditions that were screened yielded crystals of diffraction quality. 
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4.6.6 Modelling of C. jejuni SASs 
Given that crystallisation of the C. jejuni SASs was unsuccessful, modelling was used to elucidate 
the structures of CjeNANAS, CjePseS and CjeLegS. Models of CjeNANAS, CjeLegS and CjePseS were 
generated from the SWISS-MODEL server (162) using the methods outlined in Section 8.8.3. The 
crystal structure of NmeNANAS (PDB code 1XUZ) was used as a template for each of the C. jejuni 
enzymes. Displayed in Figures 4.17-4.19 are the results from modelling of CjeNANAS, CjePseS and 
CjeLegS. The C. jejuni SAS models were also aligned with the crystal structure of NmeNANAS for 
comparison.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.17 Modelling results of CjeNANAS generated using the SWISS-MODEL server.  (A) CjeNANAS 
dimer aligned to NmeNANAS dimer (PDB code 1XUZ). CjeNANAS is coloured orange and NmeNANAS is 
coloured grey. ManNAc and PEP from NmeNANAS 1XUZ are coloured green and Mn2+ yellow. (B) 
Comparison of model QMEAN score with non-redundant PISA assemblies. (C) Graphical representation of 
local model quality. Chain A in green and chain B in blue.  
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Figure 4.18 Modelling results of CjePseS generated using the SWISS-MODEL server.  (A) CjePseS dimer 
aligned to NmeNANAS dimer (PDB code 1XUZ). CjePseS is coloured blue and NmeNANAS is coloured grey. 
ManNAc and PEP from NmeNANAS 1XUZ are coloured green and Mn2+ yellow. (B) Comparison of model 
QMEAN score with non-redundant PISA assemblies. (C) Graphical representation of local model quality. 
Chain A in green and chain B in blue. 
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Figure 4.19 Modelling results of CjeLegS generated using the SWISS-MODEL server.  (A) CjeLegS dimer 
aligned to NmeNANAS dimer (PDB code 1XUZ). CjeLegS is coloured purple and NmeNANAS is coloured 
grey. ManNAc and PEP from NmeNANAS 1XUZ are coloured green and Mn2+ yellow. (B) Comparison of 
model QMEAN score with non-redundant PISA assemblies. (C) Graphical representation of local model 
quality. Chain A in green and chain B in blue. 
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As expected, the overall folds of the catalytic and AFPL domains are maintained among each of 
the three models with comparison to the template structure of NmeNANAS 1XUZ (Figures 4.17-
4.19). The root mean square deviation (RMSD) values for the models of CjeNANAS, CjePseS and 
CjeLegS aligned to the NmeNANAS crystal structure are 0.25 Å (642 atoms to 642 atoms), 0.60 Å (619 
atoms to 619 atoms) and 0.26 Å (530 atoms to 530 atoms)  respectively.  
The quality of the models were assessed using the quality model energy analysis (QMEAN) server 
in SWISS-MODEL (163). QMEAN is a composite scoring function utilising six different structural 
descriptors to assess the major geometrical aspects of a protein model. Models with QMEAN scores 
closest to 0 are deemed more reliable. The QMEAN scores determined for CjeNANAS, CjePseS and 
CjeLegS were -0.23, -0.90 and -0.66 respectively. Furthermore, as shown in Figures 4.17B, 4.18B and 
4.19B, the normalised QMEAN scores for each of the C. jejuni models are well within the expected 
range for proteins of their respective molecular weights. The reliability of a generated model is 
strongly influenced by the sequence similarity to the template structure. The sequence identity of 
CjeNANAS, CjePseS and CjeLegS with NmeNANAS is 58.6 %, 32.4 % and 34.1 % respectively. The best 
QMEAN score was observed for the CjeNANAS model which has the highest sequence identity to the 
template, and the worst QMEAN score was observed for the CjePseS model which has the lowest 
sequence identity to the template. 
Displayed in Figures 4.17C, 4.18C and 4.19C are plots of predicted C-α error against residue 
number for each of the three C. jejuni models. For each of the models, the C-α error is consistent 
between chains A and B, indicating that the quality of the model is not influenced by the quaternary 
state. Shown in Figure 4.17C, the C-α error for the CjeNANAS model is relatively consistent along the 
entire length of sequence when compared with the C-α error for the CjePseS and CjeLegS models in 
Figures 4.18C and 4.19C respectively. The consistently low C-α error observed for the CjeNANAS 
model is likely due to the high level of similarity observed between the CjeNANAS and template 
sequences.  
Conversely, in each of the local model quality plots for CjePseS and CjeLegS there is a large spike 
in C alpha error observed around residues 55-75, and a second, smaller fluctuation around residues 
270-290 (Figures 4.18C and 4.19C). These fluctuations correlate with the regions of low sequence 
identity observed between the SAS clades, as outlined in Section 4.2.2. Since the template used for 
modelling both CjePseS and CjeLegS was a NANAS, it is unlikely that the aforementioned regions 
would be modelled accurately. The first of these regions (residues 55-75) corresponds to the β2-α2 
loop, which was observed to have significant flexibility in the MD analysis for wild-type NmeNANAS 
(Chapter 2). 
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Displayed in Figures 4.20-4.22 are the model active sites of CjeNANAS, CjePseS and CjeLegS 
respectively. Each model is overlaid with the active site residues from the NmeNANAS 1XUZ 
structure to highlight the differences and similarities between the model and template. Depicted in 
Figure 4.20, the active site residues of CjeNANAS are completely conserved with the template 
NmeNANAS structure. Given the degree of conservation between these two enzymes, it can be 
assumed that the interactions between the substrates and active site are analogous. This correlates 
with the results attained via kinetic analysis, where catalytic parameters were determined to be 
similar between CjeNANAS and NmeNANAS (Section 4.4.1).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.20 Overlay of NmeNANAS (crystal structure) and CjeNANAS (model) active site residues. 
Residues from NmeNANAS are coloured grey and CjeNANAS orange. Ligands are included from the 
NmeNANAS structure with Mn2+ in yellow, PEP in pink, rManNAc in green and waters as red spheres. 
Polar contacts are depicted with black dashes and metal-ligand interactions with red dashes. 
Crystallographic coordinates for the NmeNANAS structure are 1XUZ (112). 
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The majority of the active site residues in the CjePseS model are conserved between NmeNANAS 
1XUZ (Figure 4.21). Each of the metal binding residues are retained, as are each of the PEP binding 
residues with the exception of NmeAsn184. NmeAsn184 is only conserved in the NANAS clade (Section 
4.2.2) and is replaced by CjeSer181 in CjePseS which is conserved within the PseS clade. The 
conserved sugar binding residues are similarly positioned however CjeArg309 is slightly askew relative 
to NmeArg314, possibly to accommodate residue CjeArg282. Notably NmePhe288 is replaced by 
CjeArg282 in CjePseS. CjeArg282 is poised above the sugar substrate and possibly interacts with the 
second N-acetyl group of the PseS substrate. NmePhe288 is fully conserved in the NANAS clade whilst 
CjeArg282 is fully conserved in the PseS clade. NmeAsn74 is replaced by CjeGly68 in CjePseS, though the 
positioning of this residue may not be accurate. CjeGly68 is contributed by the β2-α2 loop and, as 
shown in Figure 4.20B, is poorly modelled due to low sequence identity with the template. 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.21 Overlay of NmeNANAS (crystal structure) and CjePseS (model) active site residues. Residues 
from NmeNANAS are coloured grey and CjePseS blue. Ligands are included from the NmeNANAS structure 
with Mn2+ in yellow, PEP in pink, rManNAc in green and waters as red spheres. Polar contacts are 
depicted with black dashes and metal-ligand interactions with red dashes. Crystallographic coordinates 
for the NmeNANAS structure are 1XUZ (112). 
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Displayed in Figure 4.24, most of the active site residues are similarly placed between the CjeLegS 
model and NmeNANAS 1XUZ. Similar to CjePseS, each of the metal binding residues are retained, as 
are each of the PEP binding residues with the exception of NmeAsn184 which is replaced by CjeThr175. 
CjeThr175 is a highly conserved threonine in the LegS clade. All of the conserved sugar binding 
residues are similarly positioned in CjeLegS. NmePhe288 is replaced by CjeIle278 in CjeLegS, which is 
fully conserved in the LegS clade. None of the residues from the β2-α2 loop in CjeLegS were 
modelled within the active site, however, the positioning of this loop is unlikely to be very accurate 
given its low identity to the template sequence (Figure 4.21B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.22 Overlay of NmeNANAS (crystal structure) and CjeLegS (model) active site residues. Residues 
from NmeNANAS are coloured grey and CjeLegS purple. Ligands are included from the NmeNANAS 
structure with Mn2+ in yellow, PEP in pink, rManNAc in green and waters as red spheres. Polar contacts 
are depicted with black dashes and metal-ligand interactions with red dashes. Crystallographic 
coordinates for the NmeNANAS structure are 1XUZ (112). 
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4.6.7 Substrate docking in C. jejuni SAS models 
The active site residues of the CjeNANAS model are completely conserved with respect to the 
template NmeNANAS structure, and it can be subsequently assumed that the interactions between 
the sugar substrate and active site are almost identical (Section 4.6.6). Since the active site residues 
of the template are not fully conserved in either CjePseS or CjeLegS and the sugar substrates differ, 
docking studies were used to infer the interactions within the respective active sites. Docking 
experiments were carried out by Dr Wanting Jiao for the CjePseS model with Mn2+, PEP and 2,4-
diacetamido-2,4, 6-trideoxyaltrose as well as CjeLegS with Mn2+, PEP and 2, 4-diacetamido-2, 4, 6-
trideoxymannose.  
Unfortunately, docking of 2,4-diacetamido-2,4,6-trideoxyaltrose in CjePseS was unsuccessful. The 
PseS substrate did not dock in a suitable pose and several of the outcomes orientated the sugar 
molecule in a reversed conformation. Given that the enzyme has been confirmed to have PseS 
activity in the literature (89), the lack of a suitable reactive pose for the CjePseS model with its 
substrate is likely an indicator that the model is critically flawed. The source of this flaw is probably 
the positioning of the CjePseS β2-α2 loop which, as previously mentioned, has very low sequence 
identity to the NmeNANAS template. The lower sequence identity results in poor modelling of 
residues pertaining to that region, which in turn interferes with the docking of 2,4-diacetamido-
2,4,6-trideoxyaltrose. 
Conversely, 2,4-diacetamido-2,4,6-trideoxymannose was successfully docked into the active site 
of CjeLegS (Figure 4.23). The positioning of the metal and PEP binding residues are retained in the 
docking analysis of CjeLegS, as are their interactions. Both of the N-acetyl groups from the LegS 
substrate form interactions with CjeArg304. CjeArg304 is the congruent residue to NmeArg314 from 
NmeNANAS. NmeArg314 interacts with the N-acetyl functionality of ManNAc and is involved in 
steering the sugar into a reactive position with PEP (Chapter 2). Polar contacts are also formed 
between 2,4-diacetamido-2,4,6-trideoxymannose and CjeGlu39, CjeTyr178 and CjeAsp237 which are 
each conserved ManNAc binding residues identified in NmeNANAS 1XUZ. Interestingly, no 
interactions are observed between 2,4-diacetamido-2,4,6-trideoxymannose and the β2-α2 loop of 
CjeLegS, however, this may be due to incorrect positioning of the β2-α2 loop in the CjeLegS model.  
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Figure 4.23 Best pose attained from docking of Mn2+, PEP and 2, 4-diacetamido-2, 4, 6-trideoxymannose 
into the active site of the CjeLegS model. CjeLegS residues are shown in grey, with Mn2+ in yellow, PEP in 
pink and 2, 4-diacetamido-2, 4, 6-trideoxymannose in blue. Polar contacts are depicted with black dashes. 
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4.7 Cloning, expression and purification of  
C. tepidum SAS 
 
4.7.1 Cloning of C. tepidum SAS  
 The gene encoding CteSAS was codon optimised for expression in an E. coli cell line, synthesised 
and cloned into the vector pDONR221 by GeneArt®. DNA sequence encoding an N-terminal TEV 
protease cleavage site was incorporated during the construction of the CteSAS gene. The CteSAS 
gene was sub-cloned into the expression vector pDEST-17 which encodes an N-terminal His-tag. 
 
4.7.2 Expression and purification 
The vector pDEST-17 (CteSAS) was transformed into three different expression cell lines to 
optimise the yield of soluble protein. Vector pDEST-17 (CteSAS) was transformed into E. coli BL21 
(DE3) Star cells, E. coli Rosetta™ 2 (DE3) cells and Chaperone 3 cells. In order to compare induced 
against non-induced samples, two cultures of each cell line were grown overnight in LB, with one 
induced by IPTG and the other not. The best yield of soluble protein was attained using Chaperone 3 
cells as analysed by SDS PAGE. CteSAS was thus expressed and purified from this cell line.  
CteSAS was expressed and purified using a similar method to that used for NmeNANAS wild-type 
as outlined in Section 8.4. It was determined that CteSAS was unstable in 30 mM triethanolamine 
and in the absence of Mn2+ and PEP. The buffer used for SEC and storage of CteSAS was thus 
modified to 20 mM bis-tris propane, 150 mM NaCl, 100 µM Mn2+ and 0.5 mM PEP at pH 7.5. Purified 
CteSAS was concentrated, flash-frozen and stored at -80 °C. Samples of purified enzyme were 
analysed by SDS PAGE (Figure 4.24). 
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Figure 4.24 SDS-PAGE gel of purified CteSAS. Lane M contains marker with molecular weights defined. 
Lane 1 contains purified CteSAS. 
 
 
 
 
4.8 Kinetic analysis of C. tepidum SAS 
 
4.8.1 Attempted kinetic characterisation of C. tepidum SAS 
To determine the kinetic parameters of CteSAS, the consumption of PEP was monitored using the 
assay described in Section 8.5.1.  CteSAS was assayed with PEP and ManNAc at several different pH 
levels and temperatures as well as a variety of metal ions, however activity could not be observed. It 
has been previously proposed that CteSAS is closely related to the mammalian SAS enzyme NANA-9-
PS (122). It was hypothesised that CteSAS could thereby utilise N-acetylmannosamine-6-phosphate 
(ManNAc-6-P) as its sugar substrate. ManNAc-6-P was thus tested for activity with PEP and ManNAc-
6-P but no loss of PEP was observed. Lack of activity equates to a kcat for the enzyme less than 0.004 
s-1.   
As outlined in Section 4.2.2, CteSAS belongs to a distinct clade of SASs (Type IV) from which no 
enzyme has been currently characterised. In an attempt to determine the sugar substrate for Type IV 
SASs, a range of different sugar substrates were assayed with CteSAS. The ManNAc analogues 
outlined in Table 4.3 were each tested, however no detectable activity could be measured even in 
the presence of excess enzyme. Since neither substrate for Pse or Leg biosynthesis was available for 
testing, the ability of CteSAS to catalyse either of these reactions cannot be currently ruled out. 
 M          1          
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4.9 Physical analysis of C. tepidum SASs 
 
4.9.1 Circular dichroism 
CD was used to assess and compare the secondary structure of CteSAS with NmeNANAS (Figure 
4.25). The K2D3 server (142) was used to estimate the secondary structure composition from CD 
spectra. Shown in Table 4.9, estimated secondary structure is compared to values derived from the 
crystal structure of NmeNANAS (PDB code: 1XUZ). 
 
   
 
 
 
 
 
 
Figure 4.25 CD spectra for NmeNANAS (red) and CteSAS (green). 
 
 
 
 
 
 
Table 4.9 Predictions of secondary structure composition for NmeNANAS and CteSAS calculated from CD 
data using K2D3 server (142). Secondary structure composition of NmeNANAS structure calculated from 
crystallographic coordinates 1XUZ. 
 
 NmeNANAS   NmeNANAS 
(structure) 
CteSAS 
α-helix 59.9 % 50.3 % 57.5 % 
β-sheet 12.3 % 15.5 % 18.6 % 
other 27.8 % 34.2 % 23.9 % 
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As previously mentioned in Section 4.8, the activity of CteSAS could not be validated. It was 
therefore neccessary to determine that CteSAS was folded in solution using CD (Figure 4.25).  As 
depicted in Table 4.9, CteSAS has comparable levels of α-helix and β-sheet to NmeNANAS which is 
unexpected given that CteSAS lacks an AFPL domain. However, as portrayed in Figure 4.25, the CD 
profile of CteSAS is slightly different to that for NmeNANAS, which may be more indicative of 
structural differences between these two enzymes. 
 
4.9.2 Mass spectrometry 
The molecular mass of His6-tagged CteSAS was analysed using M. A theoretical mass of 34,112 Da 
was calculated for CteSAS from the peptide sequence using ProtParam (141). The experimental mass 
determined by mass spectrometry was 34,111 Da which was almost identical to the aforementioned 
calculated mass.  
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4.9.3 Thermal stability 
The effects of Mn2+, PEP and ManNAc/rManNAc on the thermal stability of CteSAS were assessed 
by DSF using the method outlined in Section 8.5.3. CteSAS was treated with 10 mM EDTA prior to 
SEC to ensure removal of trace metals. The melting points determined for each sample were plotted 
graphically and compared with data obtained for NmeNANAS wild-type (Figure 4.26 and Table 4.10). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.26 Bar graph of thermal melting points for NmeNANAS (red), and CteSAS (green) in the 
presence of ligand as determined by DSF. EDTA, Mn2+ and PEP were each used at a concentration of 1 mM 
and ManNAc/rManNAc at 10 mM. ManNAc/rManNAc was used at 1 mM when in combination with PEP.  
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Table 4.10 Thermal melting points for NmeNANAS and CteSAS in the presence and absence of ligand as 
determined by DSF. EDTA, Mn2+ and PEP were each used at a concentration of 1 mM and 
ManNAc/rManNAc at 10 mM. ManNAc/rManNAc was used at 1 mM when in combination with PEP.  
 
Apoenzyme CteSAS was determined to unfold at 28.1 ± 1 °C (Figure 4.26 and Table 4.10), and is 
far less stable than apo-NmeNANAS, which melts at 42.7 ± 0.2 °C. The addition of 1 mM EDTA to 
apo-CteSAS did not influence the thermal stability of the enzyme which likely indicates the successful 
removal of trace metal ions during purification. The addition of 1 mM Mn2+ increased the melting 
point of CteSAS, by 4 °C, similar to what is observed with NmeNANAS. An enormous thermal shift is 
observed for CteSAS in the presence of both Mn2+ and PEP. The combined addition of 1 mM Mn2+ 
and 1 mM PEP to CteSAS increased the melting point of apoenzyme by approximately 30 °C. The 
combined stabilisation of Mn2+ and PEP results in a melting point of 58.2 ± 0.7 °C for CteSAS, and is 
slightly higher than that for NmeNANAS which melts at 56.2 ± 0.7 °C under the same conditions. It 
can be concluded that CteSAS is extremely unstable in the absence of Mn2+ and PEP.  
CteSAS in the presence of Mn2+ and ManNAc/rManNAc has a similar melting temperature to 
CteSAS in the presence of Mn2+. This trend is observed in each of the SAS wild-type enzymes 
reported in this thesis.  CteSAS in the presence of Mn2+, PEP and ManNAc/rManNAc has a similar 
melting temperature to CteSAS in the presence of Mn2+ and PEP. As mentioned in Section 4.8, 
CteSAS does not catalyse the condensation reaction between PEP and ManNAc. It is likely that the 
thermal shift observed for CteSAS in the presence of Mn2+, PEP and ManNAc/rManNAc is caused by 
un-reacted PEP still present in the active site. This is analogous to the trend observed in CjePseS 
(outlined in Section 4.4.2) which also does not catalyse NANA formation.   
 
Addition NmeNANAS (°C) CteSAS (°C) 
Nothing 42.7 ± 0.2 28.1 ± 1 
EDTA 43.6 ± 0.3 28.2 ± 1 
Mn2+ 48.9 ± 0.3 32.3 ± 0.2 
Mn2+ + PEP 56.2 ± 0.7 58.2 ± 0.7 
Mn2+ + ManNAc 49.0 ± 0.4 32.3 ± 0.3 
Mn2+ + PEP + ManNAc 48.7 ± 0.2 57.8 ± 0.2 
Mn2+ + rManNAc 50.4 ± 0.3 31.6 ± 0.2 
Mn2+ + PEP + rManNAc 56.4 ± 0.2 57. 7 ± 0.2 
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As previously mentioned, PEP binding in NmeNANAS pre-organises the binding site of ManNAc 
(Chapter 2). The mechanism by which this occurs involves a hydrogen bonding network which links 
the catalytic and AFPL domains. Interestingly, a significant thermal shift is observed in CteSAS in the 
presence of PEP indicating a major structural change associated with PEP binding. The thermal shift 
upon PEP binding is observed in each of the wild-type SASs investigated in this thesis. However, 
CteSAS does not have an AFPL domain nor does it contain the H-bond network residues conserved in 
each of the AFPL domain bearing SAS clades. It is possible that a congruent method for sugar binding 
site pre-organisation is employed by CteSAS. Unfortunately due to the instability of CteSAS without 
PEP over long periods, ITC experiments could not be used to accurately investigate PEP binding.  
 
 
4.9.4 Analytical size exclusion 
The quaternary state of CteSAS was investigated via analytical SEC using the method outlined in 
Section 8.5.6. A calibration curve was generated using protein standards of known molecular weight. 
The elution volume (Ve) of protein standards relative to the column void volume (V0) was plotted 
against the log of the protein standards molecular mass. A linear fit of the analytical SEC calibration 
data was determined to have an R2 value of 0.987. The calibration curve was used to extrapolate the 
molecular masses of CteSAS as shown in Figure 4.27. 
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Figure 4.27 (A) Normalised analytical SEC chromatograms for NmeNANAS (red) and CteSAS (green). (B) 
Analytical SEC calibration curve. Protein standards are marked in grey, NmeNANAS in red and CteSAS in 
green. A line of best fit is plotted in black. (C) Table of estimated and theoretical masses for NmeNANAS 
and CteSAS. 
 
 
As shown in Figure 4.27 , CteSAS elutes as a single species at  a molecular weight of 61 kDa. The 
molecular weight of CteSAS determined from analytical SEC is almost identical to the theoretical 
mass for dimeric CteSAS. Each of the wild-type SASs examined in this thesis are also dimeric. 
Interestingly, CteSAS elutes as a dimer even though it lacks an AFPL domain. As mentioned in 
Chapter 3, the AFPL domain was shown to be necessary in  stabilising the dimer of NmeNANAS. The 
NmeNANAS AFPL domain truncation NmeG272Term was shown to have a concentration dependent 
monomer-dimer equilibrium through results from both analytical SEC and AUC. 
 
 
 
 
 NmeNANAS  CteSAS 
Ve/V0 1.74 1.82 
Estimated mass (kDa) 81 61 
Theoretical mass of dimer (kDa) 77 62 
A B 
C 
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4.9.5 Analytical ultracentrifugation 
As discussed in Chapter 3, the AFPL domain plays an important role in stabilising the dimeric state 
of NmeNANAS. CteSAS does not bear an AFPL domain and thus in order to elucidate its quaternary 
state, CteSAS was examined through sedimentation velocity experiments. The method used for 
anlaysis is outlined in Section 8.5.7. To determine if the quaternary state of CteSAS was 
concentration dependent, samples were run at 0.1 mg/mL, 0.5 mg/mL and 1.0 mg/mL. Displayed  in 
Figure 4.28, data was fitted to a continuous size-distribution (cs) model using the program SEDFIT 
(150, 151). Weight average molecular masses were calculated using weight average sedimentation 
coefficients and f/f0 values from cs fits. 
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Figure 4.28 Analytical ultra centrifuge fits measured at 280 nm absorbance.  (A) CteSAS at 0.1 mg/mL, 
residual data (top), and fit of model to data from SEDFIT (bottom). (B) CteSAS at 0.5 mg/mL, residual data 
(top), and fit of model to data from SEDFIT (bottom). (C) CteSAS at 1.0 mg/mL, residual data (top), and fit 
of model to data from SEDFIT (bottom). (D) Normalised c(s) profiles for enzyme at 0.1 mg/mL (red), 0.5 
mg/mL (black) and 1.0 mg/mL (purple). 
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Wild-type CteSAS was determined to be a single species at each of the tested concentrations 
(Figure 4.28).  The estimated molecular weight from AUC for CteSAS wild-type was 57 kDa, which is 
closest to the molecular weight of dimeric CteSAS. The results from AUC thereby correlate with 
those obtained from analytical SEC detailed in Section 4.9.5. As revealed by sedimentation velocity, 
CteSAS forms a very strong dimer and does not show any inclination of a schizophrenic quaternary 
state even at 0.1 mg/mL.  
Although the AFPL domain provides quaternary stabilisation in NmeNANAS, no such interaction 
appears necessary in maintaining the dimeric state of CteSAS. Although the enzymes lack sequence 
for an AFPL domain, it should be noted that CteSAS and other members of the Type IV SAS clade 
contain a short C-terminal extension (Figure 4.3). This extension may aid the quaternary stabilisation 
of CteSAS, however, further analysis would be required to confirm this. 
 
4.9.6 Attempted crystallisation 
Several attempts at crystallising CteSAS were made. CteSAS was screened using conditions 
modified from those previously described for crystallising NmeNANAS (112). Protein crystallisation 
conditions were also screened using commercially available Morpheus, PACT and JCSG screens. 
Protein was concentrated to 6 mg/mL and 15 mg/mL and screened in the absence and presence of 
ligands. Screens were incubated at 5 °C and 20 °C for several months, but none of the conditions 
that were screened yielded crystals of diffraction quality. Modelling of CteSAS was also attempted; 
however the sequence identity between CteSAS and the NmeNANAS template was only 25.4 % 
which is well below the 30 % threshold for accurate modelling (162).  
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4.9.7 Small-angle X-ray scattering 
SAXS was used to assess the solution structure of CteSAS. CteSAS was analysed in the absence and 
presence of 1 mM Mn2+ and 1 mM PEP (Figure 4.29). SAXS profiles of CteSAS were determined using 
the methods outlined in Sections 8.5.8 and 8.5.9. 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.29 SAXS profiles of ligand-free CteSAS (green) and CteSAS in the presence of 1 mM Mn2+ and 1 
mM PEP (blue). Scattering data was collected using approximately 10 mg mL-1 protein in 50 mM BTP at 
pH 7.5. Samples were eluted by SEC (Superdex 200 5/150). 
 
 
Table 4.11 SAXS structural parameters determined for CteSAS. SAXS data obtained at a wavelength of 
1.0332 Å.   
 CteSAS (Ligand-free) CteSAS (PEP bound) 
I0 (cm
-1) 0.033 ± 0.001 0.032 ± 0.001 
Rg (Å) 30.1 ± 0.4 30.2 ± 0.3 
Dmax (Å) 103 105 
Porod volume (Å3) 110,161 110,671 
Estimated mass (kDa) 68 69 
Theoretical mass of dimer (kDa) 62 62 
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The structure parameters obtained from SAXS are very similar between liganded and ligand-free 
CteSAS (Table 4.11). The molecular masses of liganded and ligand-free CteSAS were calculated from 
SAXS data using SAXS MoW (154), and were estimated to be 69 kDa and 68 kDa respectively.  The 
experimental masses were similar to the theoretical molecular mass calculated for dimeric CteSAS 
(Table 4.11). The results from SAXS indicate that CteSAS is dimeric which acquiesces with data 
obtained from both analytical SEC and AUC.  
Shown in Figure 4.29, the SAXS profile of CteSAS is not altered in the presence or absence of 
ligand.  As described in Chapter 3, wild-type NmeNANAS undergoes a conformational change in the 
presence of Mn2+ and PEP that is detectable by SAXS. The AFPL domain of NmeNANAS is involved in 
a hydrogen bonding network where PEP binding pre-organises the binding site of ManNAc. Due to 
the involvement of the AFPL domain in this process, a conformational change is not observed for 
NmeG272Term in the presence of ligand. It is likely that CteSAS does not undergo a conformational 
change upon PEP binding due to the absence of an AFPL domain. Interestingly, a significant thermal 
stabilisation of CteSAS is observed in the presence of PEP, as detailed in Section 4.9.3. Unfortunately, 
if there is a physical change in the structure of CteSAS induced by PEP binding it cannot be observed 
via SAXS.   
As mentioned in Section 4.9.6, neither a crystal structure nor model of CteSAS could be obtained. 
The experimental scattering of CteSAS was thus fitted to theoretical scattering generated from an 
AFPL domain truncation of the NmeNANAS crystal structure 1XUZ (112). The truncated NmeNANAS 
structure was also used to generate a CRYSOL fit for NmeG272Term as outlined in Chapter 3. Shown 
in Figure 4.30A, the experimental SAXS profile of liganded CteSAS fits well with the CRYSOL 
generated profile for the NmeG272Term model and has a Chi value of 0.68. In comparison, the 
experimental SAXS profile of liganded NmeG272Term fits slightly better, with a Chi value of 0.52 
(Figure 4.30B). The results from CRYSOL indicate that CteSAS adopts a dimer of (β/α)8 barrels which 
correlates with the results from analytical SEC, AUC and sequence homology of CteSAS to other 
members of the SAS family.   
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Figure 4.30 Comparisons of experimental and theoretical SAXS profiles using CRYSOL. (A) Comparison of 
SAXS profiles for CteSAS in the presence of Mn2+ and PEP (green) with theoretical scattering generated 
from dimer model of NmeG272Term (black line). (B) Comparison of SAXS profiles for NmeG272Term in 
the presence of Mn2+ and PEP (red) with theoretical scattering generated from dimer model of 
NmeG272Term (black line). Theoretical scattering for NmeG272Term was generated from 
crystallographic coordinates 1XUZ. CteSAS SAXS data was collected using approximately 10 mg mL-1 
protein in 50 mM BTP at pH 7.5. NmeG272Term SAXS data was collected using approximately 10 mg mL-1 
protein in 30 mM triethanolamine-HCl buffer at pH 7.5. Samples were eluted by SEC (Superdex 200 
5/150). 
A 
B 
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4.10 Summary of results 
 
The three SAS paralogues from C. jejuni were successfully amplified from genomic DNA and 
cloned into His-tag expression vectors. CjeNANAS, CjePseS and CjeLegS were each expressed and 
purified by metal affinity and size exclusion chromatography. NANAS activity was confirmed for 
CjeNANAS and comparable kinetic parameters to wild-type NmeNANAS were obtained. Low levels of 
NANAS activity were also observed with CjeLegS, however, no activity was yielded with CjePseS. 
Activity with ManNAc analogues was not observed with any of the three C. jejuni SASs. 
The thermal stabilities of CjeNANAS, CjePseS and CjeLegS were analysed in the presence of 
various ligand combinations. Similar to the observations made with wild-type NmeNANAS, a 
significant thermal shift was noted upon the addition of PEP for each of the three C. jejuni SASs. The 
ITC profiles of CjeNANAS, CjePseS and CjeLegS with Mn2+ and PEP were also analogous to 
NmeNANAS wild-type. As outlined in Chapter 3, PEP liganding pre-organises the ManNAc binding 
site via a hydrogen bonding network. Given the similarity in experimental observations for PEP 
binding it is highly likely that the binding mechanism of PEP in NmeNANAS is conserved in each of 
the C. jejuni SASs. 
The molecular masses of CjeNANAS, CjePseS and CjeLegS were successfully ascertained using 
mass spectroscopy and each of the enzymes were determined to be folded in solution using CD. 
Each of the three C. jejuni paralogues was confirmed to be dimeric by SAXS and analytical SEC. 
Although extensive attempts to crystallise the enzymes were made, no diffraction quality crystals for 
CjeNANAS, CjePseS or CjeLegS were obtained. 
In an attempt to glean the active site interactions of the C. jejuni SASs, models of each of the 
enzymes were generated using the SWISS-MODEL server. The structures were determined to have 
good overall homology to the template structure from NmeNANAS, with only small regions of the 
model lacking good sequence identity. Docking of the PseS substrate into the active site of the 
CjePseS was unsuccessful, likely due to incorrect positioning of residues from the β2-α2 loop. In 
comparison, 2,4-diacetamido-2,4,6-trideoxymannose was successfully docked into the active site of 
CjeLegS, revealing several key interactions with active site residues. 
The putative SAS from C. tepidum was successfully expressed and purified by metal affinity and 
size exclusion chromatography. Unfortunately no catalytic activity for CteSAS was afforded with 
either ManNAc or any of the ManNAc analogues available. CteSAS was confirmed to be folded in 
solution using CD and the molecular mass was obtained using mass spectroscopy.  
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The thermal stability of CteSAS was analysed using DSF. Similar to each of the wild-type enzymes 
analysed in this thesis, PEP was observed to have a significant stabilising effect upon CteSAS. 
Furthermore, CteSAS was noted to be relatively unstable in the absence of PEP when compared with 
the other wild-type enzymes examined.  
CteSAS was proven to be dimeric though SAXS, analytical SEC and AUC, even though the enzyme 
lacks an AFPL domain. As discussed in Chapter 3, the AFPL domain plays an important role in 
stabilising the quaternary structure of wild-type NmeNANAS. Several attempts to crystallise CteSAS 
were made, however, no diffraction quality crystals were obtained. Modelling of the CteSAS 
structure was not possible due to low sequence identity to currently available template structures. 
 
4.11 Discussion 
 
The aim of the work outlined in Chapter 4 was to uncover the evolutionary relationships within 
the bacterial SAS family. The first step in the analysis was a sequence alignment of known and 
potential bacterial SAS sequences. A dendogram generated from the sequence alignment identified 
four distinct clades within the SAS family. These were denoted NANAS, LegS, PseS and Type IV SASs, 
the latter of which had unknown catalytic activity. The sequence alignment of bacterial SASs also 
identified regions of high sequence identity that were specific to each clade; including a region 
corresponding to the β2-α2 loop of NmeNANAS. Given that the majority of active site residues are 
otherwise conserved, the residues from this loop are likely involved in distinguishing between the 
different sugar substrates of NANAS, LegS, PseS and Type IV SASs.  
Further investigation of the evolutionary relationships was undertaken by cloning, expressing and 
purifying a selected member from each clade. The NANAS, LegS and PseS from C. jejuni were 
selected for analysis as was the putative Type IV SAS from C. tepidum. NANAS activity was observed 
in CjeNANAS with comparable catalytic efficiency to wild-type NmeNANAS. Low levels of NANAS 
activity was also observed in CjeLegS, however, no NANAS activity was detected in either CjePseS or 
CteSAS. Several ManNAc analogues were assayed with each of the four SAS homologues, however, 
no activity was detected with any of the compounds tested.  
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DSF revealed that CjeNANAS, CjePseS, CjeLegS and CteSAS were each thermally stabilised in the 
presence of PEP, with ITC and SAXS analysis confirming that each C. jejuni enzyme had a similar 
profile to NmeNANAS when in the presence of PEP.  The mechanism by which PEP pre-organises the 
sugar substrate binding site in NmeNANAS is potentially conserved in CjeNANAS, CjePseS and 
CjeLegS. Interestingly, CteSAS was stabilised by PEP even though it naturally lacks an AFPL domain. 
Conversely, the NmeNANAS truncation - NmeG272Term, was not stabilised by PEP which may 
indicate that CteSAS employs a different rearrangement mechanism upon PEP binding when 
compared with AFPL domain bearing SASs. Each of the three C. jejuni SASs as well as CteSAS were 
confirmed to be dimeric.  Models generated of each of the C. jejuni SASs identified key structural 
differences and similarities, and successful docking of the LegS substrate into the active site of 
CjeLegS revealed several potential active site interactions that may be involved in substrate binding.  
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Chapter 5 
Characterisation of Streptococcus suis 
sialic acid synthase  
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5.1 Background 
 
5.1.1 S. agalactiae NANAS 
The SAS from Streptococcus agalactiae has been previously characterised as an NANAS (105). S. 
agalactiae NANAS (SagNANAS) is the only bacterial SAS which has shown the propensity to utilise 
alternative sugar substrates. SagNANAS was determined to be most active with ManNAc, however 
trace levels of activity were observed using both GlcNAc and GalNAc as alternative substrates along 
with PEP (Table 5.1). SagNANAS catalytic activity was characterised in these studies using a 
thiobarbituric acid stopped assay (105). 
 
Name Structure Relative Activity (%) 
N-acetyl-D-mannosamine 
 
100 
N-acetyl-D-galactosamine 
 
15 
N-acetyl-D-glucosamine 
 
5 
 
Table 5.1 Alternative sugar substrates utilised by S. agalactiae NANAS. Percentage relative activity of 
substrates is calculated with respect to activity with ManNAc (105). 
 
The melting point of SagNANAS was determined to be around 37 °C (105). Maximal activity was 
observed at a pH of 7.0, however activity was observed between pH 5.0 and 10.0. The metal 
dependency of SagNANAS was also analysed. Complete inhibition of the SagNANAS enzyme was 
observed after treatment with EDTA, indicating an essential role of metal ions in catalysis. Maximal 
activity was observed in the presence of Co2+, with Mn2+ being the second strongest activating metal 
ion. Both Cu2+ and Zn2+ were observed to have dramatic inhibitory affects upon SagNANAS. 
SagNANAS was also inhibited by phenylglyoxal suggesting that one or more arginine residues were 
essential to the catalytic function of the enzyme (105).  
170 
 
5.1.2 Streptococcus suis  
Using the online BLAST server (164), the SAS from Streptococcus suis was identified as the 
enzyme with the greatest sequence similarity to SagNANAS, sharing 81% identity. S. suis is a Gram-
positive anaerobe and is primarily responsible for bacterial meningitis in pigs (165). Although the 
exact pathogenetic mechanism of S. suis is currently unknown, the bacterium has been linked to 
several syndromes in swine including arthritis, pneumonia, septicaemia, endocarditis, polyserositis, 
abortions and abscesses (166, 167). S. suis infection was estimated to be a 300 million dollar 
economic loss to the swine industry in the United States alone (167). S. suis infection is zoonotic 
(165), and can cause meningitis in humans resulting in permanent hearing loss, septicaemia, 
endocarditis and death (168-171). Deaths caused by S. suis infection occur primarily in abattoir 
workers and butchers handling infected pork (168, 169). Immunoprophylaxis of S. suis infection is 
currently unavailable and thus control of the disease is dependent upon antimicrobials such as 
penicillin (172).  
 
5.1.3 Phylogeny of S. suis SAS 
Described in Section 4.2.2, an extensive sequence alignment of 410 known and potential SAS 
genes was constructed using ClustalW2 (155, 156). Depicted in Figure 5.1 is a phylogram derived 
from the SAS sequence alignment. The SAS phylogenetic tree identifies four major clades within the 
SAS family. These clades have been assigned in this thesis as NANAS, LegS, PseS and a fourth 
grouping of enzymes with unknown activity labelled as Type IV.  
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Figure 5.1 Phylogenetic tree of bacterial SASs. In red are NANAS, purple are LegSs, blue are PseSs and 
Type IV SASs. Numbers depict SASs which have been identified in the literature. Organism name and 
known activity is tabulated above.  
 Organism SAS activity 
1 Neisseria meningitidis NANAS (5, 103, 112) 
2 Campylobacter jejuni (Cj1141) NANAS (90) 
3 Escherichia coli NANAS (95, 158) 
4 Streptococcus agalactiae NANAS (105) 
5 Streptococcus suis NANAS 
6 Legionella pneumophila LegS (68) 
7 Campylobacter jejuni (Cj1327) LegS (135) 
8 Photobacterium profundum strain 3TCK LegS (134) 
Type IV 
NANAS 
LegS 
PseS 
1 
2 
3 
4
0 
5 
6
6 
7 
8 
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As aforementioned, the SAS from S. agalactiae has been characterised as a NANAS (105). 
However, as shown In the SAS phylogram, it is grouped in the LegS clade (Figure 5.1). SagNANAS and 
SsuSAS share 51 % and 48 % sequence identity with CjeLegS respectively. In comparison, SagNANAS 
and SsuSAS share only 35 % and 34 % identity with NmeNANAS respectively. Interestingly, the SAS 
from E. coli has also been previously characterised as a NANAS (95, 158) yet is located in the LegS 
clade. Like SagNANAS, EcoNANAS shares higher identity with CjeLegS (54 %) than with NmeNANAS 
(34 %).  
As mentioned in Chapter 4, CjeLegS is capable of NANAS activity although it is significantly 
diminished when compared with CjeNANAS. It is possible that LegSs are capable of NANAS activity 
resulting in the mislabelling of the SASs from S. agalactiae and E. coli as NANASs. Furthermore, the 
sugar substrate for Leg synthesis (2,4-diacetamido-2,4,6-trideoxymannose) is both structurally and 
stereochemically similar to ManNAc (Figure 5.2). Unfortunately the activity of these enzymes with 
the substrate for Leg biosynthesis has not currently been tested.  
 
Figure 5.2 Enzymatic reactions catalysed by NANAS and LegS. 
 
5.1.4 Sequence analysis of SsuSAS 
Displayed in Figure 5.3 is a sequence alignment of SsuSAS, SagNANAS, EcoNANAS and 
NmeNANAS with identified LegSs from C. jejuni and L. pneumophila. Figure 5.3 clearly illustrates the 
similarity of SsuSAS, SagNANAS and EcoNANAS to CjeLegS and LpnLegS. It can also be observed that 
SsuSAS, SagNANAS, EcoNANAS, CjeLegS and LpnLegS have regions which are significantly different to 
the NmeNANAS sequence, specifically the sequence pertaining to the β2-α2 loop which was implied 
in Chapter 4 to play a role in substrate recognition.  
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Figure 5.3 Sequence alignment of SsuSAS, SagNANAS, EcoNANAS, CjeLegS, LpnLegS and NmeNANAS 
displayed using Jalview (159). Residues highlighted in blue indicate conservation. Conserved active site 
residues from NmeNANAS are marked with dots; metal binding residues in green, PEP binding residues in 
blue and ManNAc binding residues in red. Lines indicate sequence pertaining to NmeNANAS domains; 
catalytic barrel in red, β2-α2 loop in blue, linker in black and AFPL domain in green. The residue and 
domain annotation is based on the NmeNANAS crystal structure (PDB code (1XUZ) (112)). 
Catalytic Domain 
β2-α2 loop 
Linker 
AFPL domain 
NmeArg314 
NmePhe288
8 
NmeAsn74 
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All of the key active site residues identified in the NmeNANAS crystal structure are conserved in 
each of the aligned sequences with the exception of NmeAsn74 and NmePhe288 (Figures 5.3 and 
5.4). As explained in Chapter 4, NmeAsn74 and NmePhe288 are only conserved in the NANAS clade. 
Interestingly, the sequences in the regions corresponding to NmeAsn74 and NmePhe288 are similar 
between each of the enzymes aligned with the exception of NmeNANAS, further indicating that each 
of these enzymes are both similar to one another and distinct from NmeNANAS.  
  
 
 
 
 
 
 
 
 
Figure 5.4 Close up of NmeNANAS active site. Residues contributed by the catalytic domain are shown in 
grey and residues from linker and AFPL domain in red. ManNAc is coloured green, PEP pink, Mn2+ yellow 
and waters are shown in red. H-bonds are depicted with black dashes and dipolar bonds with red dashes 
(PDB code (1XUZ) (112)). 
 
5.1.5 Goals of this research 
As previously mentioned, SagNANAS is the only known bacterial SAS with the ability to utilise 
alternative sugar substrates (105). Activity with alternative sugar substrates was not observed in any 
of the SASs from C. jejuni nor the Type IV SAS from C. tepidum (Chapter 4). The SAS from S. suis was 
identified to have the greatest sequence similarity to SagNANAS. SsuSAS was thus expressed, 
purified and characterised in an effort to determine whether substrate promiscuity was unique to 
SagNANAS or could be observed in other SASs.  
Phe288 
Arg314 
His215 
His236 
Lys53 
Thr110 
Lys129 
Ser213 
Ser132 
Ser154 
Asn184 
Tyr186 
Asp247 
Asn74 
Gln55 
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5.2 Cloning, expression and purification of 
SsuSAS 
 
5.2.1 Cloning of SsuSAS 
 The gene encoding SsuSAS was codon optimised for expression in an E. coli cell line, synthesised 
and cloned into the vector pDONR 221 by GeneArt®. DNA sequence encoding an N-terminal TEV 
protease cleavage site was incorporated during the construction of the SsuSAS gene. The SsuSAS 
gene was sub-cloned into the expression vector pDEST-17 which encodes an N-terminal His-tag. 
5.2.2 Expression and purification of SsuSAS 
The vector pDEST-17 (SsuSAS) was transformed into three different expression cell lines to 
optimise the yield of soluble protein. Vector pDEST-17 (SsuSAS) was transformed into E. coli BL21 
(DE3) Star cells, E. coli Rosetta™ 2 (DE3) cells and Chaperone 3 cells. In order to compare induced 
against non-induced samples, two cultures of each cell line were grown overnight in LB, with one 
induced by IPTG and the other not. The best yield of soluble protein was attained using Chaperone 3 
cells as analysed by SDS PAGE. SsuSAS was thus expressed and purified from this cell line. SsuSAS 
was expressed and purified using a similar method to that used for NmeNANAS wild-type as outlined 
in Section 8.4. Purified SsuSAS was concentrated, flash-frozen and stored at -80 °C. Samples of 
purified enzyme were analysed by SDS PAGE (Figure 5.5). 
 
 
 
 
 
 
 
 
 M        1        
160 kDa 
 
110 kDa  
80 kDa 
 
60 kDa 
 
50 kDa 
 
40 kDa 
 
 
30 kDa 
 
20 kDa 
 
Figure 5.5 SDS-PAGE gel of purified S. suis SAS enzymes. Lane M contains marker with molecular weights 
defined. Lane 1 contains purified SsuSAS. 
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5.3 Kinetic analysis of SsuSAS 
 
 
5.3.1 Michaelis-Menten kinetics of SsuSAS 
To determine the kinetic parameters of SsuSAS, the consumption of PEP was monitored using the 
assay described in Section 8.5.1. Cuvettes containing 50 mM BTP (pH 7.5), 1 mM MnCl2, PEP (varied) 
and ManNAc (varied) were incubated for 10 min at 25 °C. The enzymatic reaction was initiated by 
the addition of purified enzyme. Michaelis-Menten steady-state approximations were utilized to 
determine kinetic parameters (Figure 5.6). Kinetic parameters were compared to the values 
ascertained for NmeNANAS wild-type (Table 5.2).  
 
 
 
 
 
 
 
 
 
 
 
  
Figure 5.6 Michaelis-Menten curves for SsuSAS with ManNAc and PEP. (A) SsuSAS PEP Km curve and (B) 
SsuSAS ManNAc Km curve. Data points are shown in black and a line of best fit in red. A double reciprocal 
plot is displayed as an inset for each graph.  
 
 
 
 
 
 
 
 
Table 5.2 Kinetic parameters for SsuSAS compared with NmeNANAS. 
 NmeNANAS SsuSAS  
kcat (s
-1) 3.1 ± 0.1 0.6 ± 0.02 
Km PEP (µM) 28 ± 3 24 ± 2 
Km ManNAc (mM) 2.9 ± 0.2 4.2 ± 0.1 
kcat/Km ManNAc (s
-1/M) 1068 ± 108 142 ± 8 
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Displayed in Table 5.2, the kcat for SsuSAS was determined to be 1/5 that for wild-type NmeNANAS 
under the same conditions. The Km (ManNAc) for SsuSAS was determined to be slightly greater than 
that determined for wild-type NmeNANAS at 4.2 ± 0.1 mM and 2.9 ± 0.2 mM respectively. The Km 
(PEP) value for SsuSAS was very similar to that determined for NmeNANAS at 24 ± 2 µM and 28 ± 3 
µM respectively. Unfortunately, kcat and Km parameters for SagNANAS were not reported by Suryanti 
et al (105) and thereby a comparison to the values obtained for SsuSAS could not be made.  
  
5.3.2 pH dependence of activity 
In order to determine the optimal pH for activity of SsuSAS, changes in reaction rate were 
examined using the kinetic assay described in Section 8.5.1 at a variety of different pH values. The 
buffers used were varied over different pH ranges; acetate was used from pH 4 - 5.5, 2-(N-
morpholino) ethanesulfonic acid (MES) was used from pH 5.5 – 6.5 and bis-tris propane was used 
from pH 6.5 – 8.5. Substrates were confirmed to be at saturating levels for each pH analysed. The 
reaction rate determined at each pH was repeated in triplicate and the average rate plotted 
graphically (Figure 5.7). 
 
 
 
 
 
 
 
 
 
 
Figure 5.7 pH dependence of SsuSAS activity. Data taken in triplicate and plotted as an average rate 
(A.min-1). Assays performed at 25 °C with 1mM Mn2+, 50 mM ManNAc and 0.2 mM PEP. 
 
178 
 
Shown in Figure 5.7, the activity of SsuSAS increased steadily from pH 4 to 7 and gradually 
dropped away between pH 7.5 to 8.5. Due to the rapid oxidation of Mn2+, data beyond pH 8.5 could 
not be accurately measured. The different buffers used did not appear to have a major affect on the 
activity of SsuSAS. From this experiment it was determined that pH 7 is optimal for SsuSAS activity.  
 
5.3.3 Temperature dependence of activity 
In order to determine the optimal temperature for activity of SsuSAS, changes in reaction rate 
were examined using the kinetic assay described in Section 8.5.1 at a variety of different 
temperatures. Buffers used for each data point were made by standardising to pH 7 while 
equilibrated at the appropriate temperature. Substrates were confirmed to be at saturating levels 
for each temperature analysed. The reaction rate determined at each temperature was repeated in 
triplicate and the average rate was plotted graphically (Figure 5.8).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.8 Temperature dependence of SsuSAS activity. Data taken in triplicate and plotted as an average 
rate (A.min-1). Assays performed at pH 7 with 1mM Mn2+, 50 mM ManNAc and 0.2 mM PEP. 
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As displayed in Figure 5.8, the activity of SsuSAS, increased steadily from 15 °C to 40 °C and then 
dropped rapidly to 50 °C where no activity was observed. From this experiment it was determined 
that a temperature of around 40 °C is optimal for SsuSAS activity. Given that the host organism for 
this enzyme, S. suis is a pathogen of pigs, the enzyme is likely to operate around 37 °C in vivo. The 
complete loss of activity observed at 50 °C is likely due to denaturation of the enzyme. Although 40 
°C was determined to be the optimal temperature for SsuSAS, the enzyme was characterised at 25 °C 
for comparison of kinetic parameters with NmeNANAS. 
 
5.3.4 Metal dependence of activity 
The metal dependence of SsuSAS activity was examined using the kinetic assay described in 
Section 8.5.1 and substituting MnCl2 with a variety of different metal chlorides. Enzyme was 
equilibrated with metal and the reaction was initiated by the addition of ManNAc. To remove 
residual activity, metal was also substituted with 1 mM and 10 mM EDTA. 
The kinetic effect of different metal ions was analysed using holoenzyme and apoenzyme SsuSAS. 
Holoenzyme has had access to metal ions from the expression cell line and IMAC chromatography. 
Apoenzyme was prepared through an additional purification step where enzyme was incubated with 
10 mM EDTA for 2 hours at 4 °C after IMAC, to sequester undesired metal ions. EDTA was then 
separated from the enzyme using SEC. Buffers used for subsequent steps of apoenzyme purification 
were treated with Chelex® 100 resin (Sigma-Aldrich), and all glassware used was washed with 
concentrated nitric acid. Each kinetic measurement was determined in triplicate. The percentage 
relative activity compared to holoenzyme with no metal added was calculated and plotted 
graphically (Figure 5.9).  
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Figure 5.9 Metal dependence of SsuSAS activity. Relative activity was calculated by comparison to 
holoenzyme with no metal added. Holoenzyme data is shown in blue and apoenzyme data is shown in red. 
Data was taken in triplicate and averaged prior to calculation of percentage change. Assays performed at 
25 °C and pH 7 with 50 mM ManNAc, 0.2 mM PEP. Metals used at 1 mM.  
 
As shown in Figure 5.9, SsuSAS was most strongly activated by Co2+ followed by Mn2+ for both 
holoenzyme and apoenzyme. This trend has also been observed previously in SagNANAS (105), 
however, for both CjeNANAS and NmeNANAS, Mn2+ was determined as the most strongly activating 
metal ion followed by Co2+(90, 104). Although Co2+ was found to be the most activating metal of 
SsuSAS, the enzyme was characterised with Mn2+ for comparison of kinetic parameters with 
NmeNANAS. Furthermore, the kinetic analysis described in the previous analysis of SagNANAS was 
determined for holoenzyme without the addition of metal (105).  
Interestingly, both SsuSAS and SagNANAS (105) are activated by Mg2+, as are both CjeNANAS and 
NmeNANAS (90, 104). The activation of these enzymes by Mg2+ indicates that the metal ion plays an 
important role in substrate binding/phosphate recognition (173). As depicted in Figure 5.4, the 
phosphate group of PEP acts as one of the ligands to the Mn2+ ion in the crystal structure of 
NmeNANAS 1XUZ (112). Given the similarity of inner and outer shell complexation for Mn2+ and 
Mg2+, it is likely that Mg2+ coordinates in a similar fashion depicted for Mn2+.  
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SsuSAS was also determined to be strongly inhibited by both Zn2+ and Cd2+ and to a lesser 
extent inhibited by Fe2+, Ca2+, and then Li+ (Figure 5.9). Both Ni2+ and Ru2+ showed no effect on 
enzyme activity whilst Cu2+ and Ba2+ increased the activity of holoenzyme but showed no effect on 
apoenzyme.  
Addition of 1 mM and 10 mM EDTA abolished activity of holoenzyme and apoenzyme 
revealing the importance of a divalent metal ion for enzyme activity. Displayed in Figure 5.9, both 
holoenzyme and to a lesser extent apoenzyme had residual NANAS activity. It is likely that this was 
caused by the enzyme adventitiously scavenging metal ions during the purification process. The 
addition of EDTA prior to SEC for purification of apoenzyme diminished residual activity to 25% that 
observed for holoenzyme, suggesting that some metal ion was still present in ‘apoenzyme’ SsuSAS.  
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5.3.5 Attempted alternative substrate analysis 
As aforementioned, sugar substrate promiscuity has been previously observed with the SAS from 
S. agalacticae (105). Activity of SagNANAS with GlucNAc and GalNAc was described as being 15 % 
and 5 % respectively of the activity measured for enzyme with ManNAc. SsuSAS was calculated to 
have 81 % sequence identity with SagNANAS and was thus tested for substrate promiscuity with a 
range of ManNAc analogues (Table 5.3). Unfortunately, no detectable activity could be measured 
with any of the ManNAc analogues depicted below, even in the presence of 10-fold excess enzyme. 
Substrates were analysed at 25 °C and 40 °C and at pH 7 and 8 with either 1 mM Mn2+, Mg2+ or Co2+ 
however no activity could be observed. Lack of activity equates to a kcat of less than 0.005 s
-1.  
 
Name Structure Name Structure 
N-acetyl-D-
mannosamine 
 
D-glucose 
 
N-acetyl-D-
galactosamine 
 
2-deoxy-D-glucose 
 
N-acetyl-D-
glucosamine 
 
D-mannosamine 
 
D-mannose 
 N-acetyl-D-
mannosamine-6-
phosphate 
    
 
Table 5.3 Structures of ManNAc and ManNAc analogues assayed with SsuSAS. 
 
 
 
 
183 
 
5.4 Binding studies of SsuSAS 
 
5.4.1 Isothermal titration calorimetry 
Binding constants for Mn2+ and PEP were determined for the SsuSAS using the methods described 
for NmeNANAS wild-type (Section 8.5.4). ITC results attained for SsuSAS are compared to previously 
determined dissociation constants (Kd) for NmeNANAS wild-type in Table 5.4 (114). The raw 
experimental binding curves and one-site model fitted ITC data for Mn2+ and PEP with SsuSAS are 
displayed in Figure 5.10. 
 
 NmeNANAS (114) SsuSAS 
Kd Mn
2+ (µM) 10.6 ± 0.5 3.4 ± 0.2 
Kd PEP (µM) 219 ± 11 312 ± 9 
 
Table 5.4 ITC derived binding constants for wild-type NmeNANAS and wild-type SsuSAS. 
 
To determine the Kd value for metal with SsuSAS, Mn
2+ was titrated into metal-free enzyme. The 
Mn2+ affinity of SsuSAS was determined to be approximately 3-fold higher than that previously 
determined for NmeNANAS (Table 5.4). As depicted in Figure 5.10A, the binding of Mn2+ is an 
exothermic event in SsuSAS and is thus an enthalpically favourable process. This is also observed for 
binding of Mn2+ with NmeNANAS wild-type (Chapter 2). 
  
Depicted in Table 5.4, the PEP affinity for SsuSAS is slightly lower than that observed for 
NmeNANAS wild-type but is not significantly different. As shown in Figure 5.10B, the binding of PEP 
is an endothermic event in SsuSAS. This correlates with previous observations for PEP binding with 
wild-type NmeNANAS, which was determined to be an entropically favourable event (Chapters 2 and 
3). These results indicate that the SsuSAS Mn2+ and PEP binding sites behave similarly to the 
corresponding sites in NmeNANAS. This is unsurprising given that each of the residues involved with 
metal and PEP binding are fully conserved in both species (Section 5.1.4).  
 
 
A 
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Figure 5.10 Enthalpy changes measured by isothermal titration calorimetry. (A) Mn2+ (5 mM) titrated 
into metal-free SsuSAS (65 µM). (B) PEP (50 mM) titrated into SsuSAS (40 µM) in the presence of Mn2+ (1 
mM). 
 
 
 
 
 
 
 
 
 
A B 
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5.4.2 Thermal stability with metals 
The effect of metal ions on the thermal stability of apoenzyme SsuSAS was assessed by DSF. Melt 
temperatures of SsuSAS were determined in the presence of a variety of different metal ions using 
the method outlined in Section 8.5.3. Samples were run in triplicate with 1 mM metal chloride. 
Controls were run with either no additive or 10 mM EDTA. The melting points determined for each 
sample are plotted in Figure 5.11 and compiled in Table 5.5. 
 
 
 
 
 
 
 
 
 
Figure 5.11 Bar graph of thermal melting points for SsuSAS (red) in the presence of metal as determined 
by DSF. Metal chloride salts were added at a concentration of 1 mM and EDTA at 10 mM. 
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Table 5.5 Thermal melting points for SsuSAS in the presence of metal as determined by DSF. Metal 
chloride salts were added at a concentration of 1 mM and EDTA at 10 mM. – indicates protein 
denaturation upon addition of metal.  
 
Apoenzyme SsuSAS was determined to melt at 34.0 ± 0.3 °C (Figure 5.11). Apo-SsuSAS is far less 
stable than apo-NmeNANAS which melts at 47.0 ± 0.2 °C (Chapter 2). The addition of 1 mM Mn2+ 
increased the melting point of SsuSAS, by approximately 5 °C, similar to what is observed with 
NmeNANAS. As shown in Figure 5.11, Co2+, Ni2+ and Mn2+ each increased the melting temperature of 
SsuSAS. While both Co2+ and Mn2+ activate SsuSAS, Ni2+ was shown to have little effect on activity 
(Figure 5.9). Of the metals analysed, SsuSAS was most thermally stabilised by Co2+ and Mn2+ which 
produced similar melting temperatures of 41.3 ± 0.5 °C and 39.2 ± 0.1 °C respectively. Described in 
Section 5.3.4 both Co2+ and Mn2+ were also the most activating of the metals analysed with SsuSAS. 
 
 
 
 
 
Addition SsuSAS (°C) 
Nothing  34.0 ± 0.3 
Mg2+ 34.9 ± 0.3 
Ca2+ 33.8 ± 0.5 
Mn2+  39.2 ± 0.1 
Fe2+  31.7 ± 0.3 
Co2+  41.3 ± 0.5 
Ni2+  40.0 ± 0.2 
Cu2+  34.1 ± 0.2 
Zn2+  - 
Ru2+  33.8 ± 0.2 
Cd2+  - 
Ba2+  34.2 ± 0.5 
Li+  34.1 ± 0.5 
EDTA (10 mM) 34.1 ± 0.2 
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Mg2+, Ca2+, Cu2+, Ru2+, Ba2+, Li+, and 10 mM EDTA had little to no effect on the melting point of 
SsuSAS, whereas Fe2+, which was shown to inhibit SsuSAS (Figure 5.9), lowered the melting point of 
apo-SsuSAS to 31.7 ± 0.3 °C. The observation that EDTA did not influence the thermal stability of the 
enzyme likely indicates the successful removal of trace metal ions during purification. Interestingly, 
both Zn2+ and Cd2+, which were shown to inhibit SsuSAS activity completely (Figure 5.9), showed high 
fluorescence of SYPRO orange dye from the onset of the temperature melt experiment, indicating 
that the enzyme had been unfolded upon addition of the metal. It is likely that the loss of activity 
observed with 1 mM Zn2+ and Cd2+ was caused by denaturation of the protein.  
 
5.4.3 Thermal stability with substrates and analogues 
The effect of natural substrates and ManNAc analogues on the thermal stability of apoenzyme 
SsuSAS was assessed by DSF using the method outlined in Section 8.5.3. Combinations of metal, PEP 
and ManNAc/ManNAc analogue were used for analysis. The effects of the substrates and analogues 
upon the thermal stability of SsuSAS were analysed in combination with either Mn2+ or Co2+. The 
melting points determined for each sample are displayed in Figure 5.12 and Table 5.6.  
  
 
 
 
 
 
 
 
 
Figure 5.12 Bar graph of thermal melting points for SsuSAS (red) in the presence of ligands as 
determined by DSF. Metal chloride salts were added at 1 mM, PEP at 1 mM and ManNAc/ManNAc 
Analogues at 10 mM with metal and at 1 mM when added in combination with PEP and metal.  
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Table 5.6 Thermal melting points for SsuSAS in the presence of ligands as determined by DSF. Metal 
chloride salts were added at 1 mM, PEP at 1 mM and ManNAc/ManNAc Analogues at 10 mM with metal 
and at 1 mM when added in combination with PEP and metal.  
 
The thermal melt profile of SsuSAS is very similar to that observed for NmeNANAS (Chapter 2). 
Similar to NmeNANAS, an enormous thermal shift is observed for SsuSAS in the presence of both 
Mn2+ and PEP. The combined addition of 1 mM Mn2+ and 1 mM PEP to SsuSAS increased the melting 
point of apoenzyme from 34.0 ± 0.3 °C to 49.1 ± 0.3 °C. The observation of such a dramatic 
temperature change induced by the presence of both Mn2+ and PEP, likely indicates a significant 
conformational change that stabilises the enzyme.  
 
 
Addition SsuSAS (°C) 
Nothing 34.0 ± 0.3 
Mn2+ 39.2 ± 0.1 
PEP + Mn2+ 49.1 ± 0.3 
ManNAc + Mn2+ 38.9 ± 0.2 
PEP + ManNAc + Mn2+ 41.0 ± 0.2 
rManNAc + Mn2+ 38.0 ± 0.5 
PEP + rManNAc + Mn2+ 50.1 ± 0.2 
Co2+ 41.3 ± 0.5 
PEP + Co2+ 49.2 ± 0.6 
ManNAc + Co2+ 40.1 ± 0.5 
PEP + ManNAc + Co2+ 40.5 ± 0.2 
rManNAc + Co2+ 40.1 ± 0.2 
PEP + rManNAc + Co2+ 49.0 ± 0.5 
PEP + GalNAc + Mn2+ 52.3 ± 0.2 
PEP + GlucNAc + Mn2+ 51.4 ± 0.4 
PEP + Mannose + Mn2+ 50.1 ± 0.5 
PEP + Glucose + Mn2+ 49.8 ± 0.2 
PEP + 2-Deoxy-glucose + Mn2+ 50.0 ± 0.5 
PEP + Mannosamine + Mn2+ 49.2 ± 0.1 
PEP + ManNAc-6-P + Mn2+ 45.4 ± 0.3 
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As depicted in Figure 5.12 and Table 5.6, SsuSAS in the presence of Mn2+ and ManNAc/rManNAc 
mirrors the melting temperature of SsuSAS in the presence of Mn2+. This trend is observed with each 
of the wild-type SASs examined in this thesis. As commented in Chapters 2 and 3, NmeNANAS is 
unable to bind ManNAc without PEP binding first. Given the high conservation of active site residues 
between NmeNANAS and SsuSAS (described in Section 5.1.4), it is likely that a similar mechanism is 
employed by SsuSAS. 
When in combination with Mn2+, PEP and ManNAc, the melting temperature of SsuSAS is very 
similar to that observed for SsuSAS with just Mn2+. SsuSAS is able to catalyse the formation of NANA 
from PEP and ManNAc (Section 5.3). Since the aforementioned ligands are in equimolar proportions, 
SsuSAS will likely be in the presence of Mn2+ and NANA. It is unlikely that SsuSAS binds to or is 
stabilised by NANA to ensure favourable product release. Furthermore, no product inhibition was 
observed in kinetic analysis of SsuSAS with ManNAc.  
The melting temperature of SsuSAS in the presence of Mn2+, PEP and rManNAc is very similar to 
that of SsuSAS in the presence of Mn2+ and PEP (Figure 5.12 and Table 5.6). Since the aldehyde 
component of rManNAc is removed, SsuSAS can no longer utilise rManNAc as a substrate. The 
thermal shift observed is thus likely caused by unreacted PEP still present in the active site. This is 
also observed for NmeNANAS under the same conditions.  
The thermal melting profile of SsuSAS was primarily analysed using Mn2+ in order to compare DSF 
results with each of the wild-type enzymes mentioned in this thesis. Since Co2+ was determined to 
be the most activating metal for SsuSAS (Section 5.3.4) and most thermally stabilising (Section 5.4.2), 
DSF of SsuSAS with substrates was also carried out in the presence of Co2+. As observed in Figure 
5.12, the thermal melt profile of SsuSAS and substrates is comparable in the presence of either 
metal. 
As outlined in Section 5.3.5, none of the ManNAc analogues assayed with SsuSAS showed any 
activity including both GalNAc and GlucNAc which had been previously indicated as alternative 
substrates of SagNANAS (105). No loss of PEP was observed for the ManNAc analogues assayed with 
SsuSAS even with the addition of 10-fold excess enzyme, indicating that SsuSAS was unable to 
catalyse the aldol condensation between PEP and the alternative sugar compounds. 
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Shown in Figure 5.12, combinations of PEP and Mn2+ with ManNAc analogues did not significantly 
affect the thermal stability of SsuSAS when compared to the melting point of SsuSAS with only PEP 
and Mn2+ (49.1 ± 0.3 °C). Both GalNAc and GlucNAc did increase the melting temperate of SsuSAS 
with metal and PEP from 49.1 ± 0.3 °C to 52.3 ± 0.2 °C and 51.4 ± 0.4 °C respectively. This may 
indicate that although the enzyme is unable to react with either GalNAc or GlucNAc, these 
compounds are still able to bind to the enzyme. Interestingly, ManNAc-6-P (the natural substrate of 
the SAS from H. sapiens) lowered the melting temperature to 45.4 ± 0.3 °C when in combination 
with PEP and Mn2+.  
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5.5 Physical characterisation of SsuSAS 
 
5.5.1 Circular dichroism 
CD was used to assess and compare the secondary structure of SsuSAS with NmeNANAS (Figure 
5.13). The K2D3 server (142) was used to estimate the secondary structure composition from CD 
spectra. Shown in Table 5.7, estimated secondary structure is compared to values derived from the 
crystal structure of NmeNANAS (PDB code: 1XUZ) and the crystal structure of SsuSAS outlined in 
Section 5.6. 
 
 
 
 
 
 
 
 
Figure 5.13 CD spectra for NmeNANAS (red) and SsuSAS (purple). 
 
 
 
 
 
 
Table 5.7 Predictions of secondary structure composition for NmeNANAS and SsuSAS calculated from CD 
data using K2D3 server (142). Secondary structure composition of NmeNANAS structure calculated from 
crystallographic coordinates 1XUZ and secondary structure composition of SsuSAS structure calculated 
from crystal structure outlined in Section 5.6. 
 NmeNANAS  NmeNANAS 
(structure) 
SsuSAS SsuSAS 
(structure) 
α-helix 59.9 % 50.3 % 57.9 % 40.1 % 
β-sheet 12.3 % 15.5 % 16.7 % 17.2 % 
other 27.8 % 34.2 % 25.4 % 42.7 % 
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As depicted in Figure 5.13, SsuSAS is properly folded in solution and has a similar CD profile to 
NmeNANAS. Shown in Table 5.7, the levels of α-helix and β-sheet for the CD profiles of NmeNANAS 
and SsuSAS are comparable to the secondary strucutre ratios calculated from NmeNANAS crystal 
structure 1XUZ. Interestingly, the predicted secondary structure ratios calculated from the SsuSAS 
crystal structure are fairly different to those derived from both the CD profile of SsuSAS and the 
secondary structure ratio calculated from NmeNANAS 1XUZ. This is likely due to the secondary 
strucuture in the SsuSAS crystal strucutre being less defined when compared with NmeNANAS 1XUZ.  
 
5.5.2 Mass spectrometry  
The molecular mass of His6-tagged SsuSAS was analysed using MS. A theoretical mass of 41,160 
Da was calculated for SsuSAS from the peptide sequence using ProtParam (141). The experimental 
mass determined by MS was 41,159 Da which was almost identical to the aforementioned calculated 
mass.  
 
5.5.3 Analytical size exclusion 
The quaternary state of SsuSAS was investigated via analytical SEC using the method outlined in 
Section 8.5.6. A calibration curve was generated using protein standards of known molecular weight. 
The elution volume (Ve) of protein standards relative to the column void volume (V0) was plotted 
against the log of the protein standards molecular mass. A linear fit of the analytical SEC calibration 
data was determined to have an R2 value of 0.987. The calibration curve was used to extrapolate the 
molecular mass of each of SsuSAS as shown in Figure 5.14.  
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Figure 5.14 (A) Normalised analytical SEC chromatograms for NmeNANAS (red) and SsuSAS (purple). (B) 
Analytical SEC calibration curve. Protein standards are marked in grey, NmeNANAS in red and SsuSAS in 
purple. A line of best fit is plotted in black. (C) Table of estimated and theoretical masses for NmeNANAS 
and SsuSAS. 
 
Depicted in Figure 5.14A, SsuSAS elutes as a single species. The molecular weight of SsuSAS 
derived from the standard curve corresponds to 75 kDa (Figure 5.14B). The molecular weight of 
SsuSAS determined from analytical SEC is almost identical to the theoretical mass for dimeric SsuSAS. 
The observation that SsuSAS is dimeric correlates with the results obtained from analytical SEC for 
each of the wild-type SASs examined in this thesis.  
 
 
 
 
 
 NmeNANAS  SsuSAS 
Ve/V0 1.74 1.77 
Estimated mass (kDa) 81 75 
Theoretical mass of dimer (kDa) 77 75 
A B 
C 
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5.6 Structure of SsuSAS 
 
5.6.1 Crystallisation 
Purified SsuSAS was crystallised using a condition obtained from a Morpheus™ crystallisation 
screen (Molecular Dimensions). Monoclinic crystals of apo-SsuSAS were formed using the hanging 
drop crystallisation technique in the presence of 0.09 M NaNO3/Na2HPO4/NH4)2SO4, 0.1 M 
Imidazole/MES and 37.5% racemic MPD/PEG 1000/PEG 03350 at pH 6.5 (Figure 5.15). Data sets 
were collected at the Australian Synchrotron using the MX2 beamline.  
 
 
 
 
 
 
 
 
 
Figure 5.15 Image of rod shaped SsuSAS crystals viewed through a Leica light microscope. 
 
5.6.2 Crystal structure of SsuSAS 
A crystal structure of SsuSAS was successfully solved to a resolution of 2.30 Å. The structure of 
SsuSAS was solved via molecular replacement using a model generated from the wild-type 
NmeNANAS crystal structure 1XUZ (112), which had the linker, AFPL domain, ligands and non-
conserved side-chains removed. The AFPL domains and linker domains for both monomers of SsuSAS 
were manually built during refinement. The methods for molecular replacement and refinement of 
the SsuSAS structure are outlined in Section 8.5.12. Due to anisotropy in the diffraction data, the 
resolution cut-off for the SsuSAS structure was made at 2.30 Å. The final refinement statistics for the 
structure of SsuSAS are given in Table 5.8 (SsuSAS structure currently not deposited).  
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 SsuSAS 
A. Data collection  
Crystal system; space group P1211 
Unit cell parameters (Å) 
a, b, c, α, β, γ 
82.03, 58.19, 90.49, 
90.00, 108.04, 90.00 
Resolution range (outer shell) 
(Å) 
48.20-2.30 (2.38-2.30) 
Measurements 137,121 
Unique reflections 36,417 
Redundancy 3.4 
Completeness (outer shell) (%) 99.4 (99.7) 
I/σ(outer shell) (I) 6.7 (2.6) 
Rmerge (outer shell) 0.128 (0.502) 
Wilson B-value (Å
2
) 13.824 
  
B. Refinement  
Resolution (Å) 2.30 
Rcryst 0.1924 
Rfree 0.2545 
Chain length 337 
Observed number of residues 674 
Water molecules 231 
Other 4 
Mean B (Å
2
)  
 Protein 13.8 
 Water 26.4 
 Other 44.3 
r.m.s.d. from target values  
 Bond lengths (Å) 0.0165 
 Bond angles (°) 1.8965 
 Dihedral angles (°) 0.1048 
Ramachandran  
 Most favored (%) 97.3 
 Allowed (%) 2.7 
 Generously allowed (%) 0 
 Disallowed (%) 0 
 
Table 5.8 Crystal parameters, data collection and refinement statistics for crystal structure of SsuSAS. 
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Displayed in Figure 5.16, the SsuSAS crystal structure is a domain swapped homodimer similar to 
the previously determined structures of wild-type NmeNANAS (112, 113). Each monomer of SsuSAS 
comprises an N-terminal (β/α)8 barrel catalytic domain with a short linker sequence to a C-terminal 
AFPL domain. The dimeric form of SsuSAS is unsurprising, given the aforementioned results obtained 
from analytical SEC, SAXS and AUC as well as the comparable sequence homology to NmeNANAS. 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.16 Crystal structure of SsuSAS domain-swapped homodimer. Chain A is coloured by domain and 
Chain B is in grey. The Chain A catalytic domain is in red, linker domain in green and AFPL domain in 
purple.  
 
Although holistically similar, a comparison of the SsuSAS crystal structure with previously 
obtained structures of NmeNANAS reveals several key differences. Firstly, the unit cell dimensions 
differ between SsuSAS and NmeNANAS, as do the space groups which are P1211 and P21212 
respectively. For the structures of NmeNANAS, the dimeric enzyme is generated through symmetry, 
whereas for the structure of SsuSAS the full dimer is observed within the unit cell. 
Conformational differences between the crystal structures of SsuSAS and NmeNANAS are 
highlighted through structural alignments. RMSD values for alignments between the SsuSAS crystal 
structure and NmeNANAS 1XUZ are compiled in Table 5.9. 
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Alignment RMSD (Atoms in alignment) 
SsuSAS dimer to NmeNANAS dimer 1.961 Å (524 to 524 atoms) 
SsuSAS chain A to SsuSAS chain B 0.146 Å (317 to 317 atoms) 
SsuSAS chain A to NmeNANAS monomer 1.704 Å (254 to 254 atoms) 
SsuSAS chain B to NmeNANAS monomer 1.698 Å (254 to 254 atoms) 
SsuSAS chain A catalytic domain to SsuSAS chain B catalytic domain 0.130 Å (236 to 236 atoms) 
SsuSAS chain A catalytic domain to NmeNANAS catalytic domain 1.126 Å (215 to 215 atoms) 
SsuSAS chain B catalytic domain to NmeNANAS catalytic domain 1.104 Å (215 to 215 atoms) 
SsuSAS chain A AFPL domain to SsuSAS chain B AFPL domain 0.124 Å (55 to 55 atoms) 
SsuSAS chain A AFPL domain to NmeNANAS monomer AFPL domain 1.658 Å (31 to 31 atoms) 
SsuSAS chain B AFPL domain to NmeNANAS monomer AFPL domain 1.168 Å (31 to 31 atoms) 
 
Table 5.9 RMSD values for structural alignments between the crystal structures of SsuSAS and 
NmeNANAS. The crystallographic coordinates for the NmeNANAS structure are 1XUZ (112).  
 
Dimer and monomer structural alignments of the SsuSAS crystal structure with NmeNANAS 1XUZ 
are displayed in Figure 5.17. The RMSD between the dimer of SsuSAS and dimer of 1XUZ was 
calculated to be 1.961 Å. Denoted in Table 5.9, Chains A and B of the SsuSAS structure are 
conformationally similar and have an RMSD value of 0.146 Å. Depicted in Figure 5.18B, SsuSAS Chain 
A and Chain B, have RMSD values of 1.704 Å and 1.698 Å respectively, when aligned to the monomer 
of NmeNANAS 1XUZ.  
In Figure 5.17, dimer and monomer alignments for the substrate-free structure of SsuSAS with 
the substrate-bound structure of NmeNANAS (1XUZ) reveal that the AFPL domains of SsuSAS are 
positioned closer to the catalytic domains. This degree of domain movement has been observed in 
MD simulations of the NmeNANAS wild-type structure (Chapter 3).  
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Figure 5.17 SsuSAS and NmeNANAS structural alignments. (A) Alignment of SsuSAS and NmeNANAS 
dimers. (B) Alignment of SsuSAS and NmeNANAS monomers. NmeNANAS is coloured grey, Chain A of the 
SsuSAS structure is in red and Chain B is in blue. The crystallographic coordinates for the NmeNANAS 
structure are 1XUZ (112). The structural differences are highlighted with yellow boxes. 
 
As discussed in Chapter 3, a conformational change in NmeNANAS is observed upon liganding of 
PEP which pre-organises the ManNAc binding site. Evidence obtained from SAXS, ITC and DSF with 
PEP indicate that a similar mechanism is employed by SsuSAS. It is possible that the observed 
changes in positioning of the AFPL domains in the SsuSAS structure have resulted from the absence 
of ligand. Unfortunately, a structural comparison of liganded and ligand-free SsuSAS could not be 
made, as a liganded crystal structure of SsuSAS was not obtained despite extensive crystallisation 
trials. Ligand soaking, co-crystallisation and crystal seeding of SsuSAS were attempted with several 
conditions, however, crystals of appropriate diffraction quality were not afforded.  
A 
B 
199 
 
The conformation of the core N-terminal (β/α)8 barrel is mostly retained in both SsuSAS and 
NmeNANAS (Table 5.9), however, there are two key structural differences observed. Displayed in 
Figure 5.18A, an N-terminal β hairpin loop comprising approximately 20 amino acids is observed in 
the NmeNANAS structure which is not present in SsuSAS. The sequence of this loop is not conserved, 
as its composition and length varies within the SAS family. As depicted by sequence alignment with 
NmeNANAS (Figure 5.18B), this region is completely missing from the SsuSAS sequence.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.18 SsuSAS and NmeNANAS catalytic domain alignments. (A) Structural alignment of SsuSAS and 
NmeNANAS catalytic domains. NmeNANAS is coloured grey, Chain A of the SsuSAS structure is in red and 
Chain B is in blue. The NmeNANAS β-hairpin loop is highlighted in yellow. The crystallographic 
coordinates for the NmeNANAS structure are 1XUZ (112). (B) Sequence alignment of N-terminal residues 
from SsuSAS and NmeNANAS. Conserved residues are highlighted in blue, missing residues are depicted 
with dashes.  
 
 
 
 
A 
B 
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The second difference between the catalytic domains of SsuSAS and NmeNANAS is the β2-α2 
loop. The β2-α2 loop closes over the catalytic site and contributes residue NmeAsn74 in the 
NmeNANAS structure 1XUZ, which forms a hydrogen-bond to the C-6 hydroxyl of ManNAc (Figure 
5.19A). Shown in Figure 5.19B, this residue is not conserved in SsuSAS. Instead the SsuSAS β2-α2 
loop has a similar sequence to members of the LegS clade of SASs (Figure 5.3). Displayed in Figure 
5.19A, the SsuSAS β2-α2 loop forms an α-helix and thus differs in secondary structure composition 
when compared with the corresponding region from NmeNANAS 1XUZ.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.19 SsuSAS and NmeNANAS β2-α2 loops. (A) Position of β2-α2 loops from a structural alignment 
of SsuSAS and NmeNANAS catalytic domains. NmeNANAS is coloured grey, Chain A of the SsuSAS structure 
is in red and Chain B is in blue. Ligands are included from the NmeNANAS structure with Mn2+ in yellow, 
PEP in pink and rManNAc in green. H-bonds are depicted with black dashes. Crystallographic coordinates 
for the NmeNANAS structure are 1XUZ (112). (B) Sequence alignment of β2-α2 loops from SsuSAS and 
NmeNANAS. Conserved residues are highlighted in blue, missing residues are depicted with dashes. 
NmeAsn74 is marked with a red circle. (B) Sequence alignment of β2-α2 loops from SsuSAS and CjeLegS. 
Conserved residues are highlighted in blue. 
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A sequence alignment of the β2-α2 loop from SsuSAS and NmeNANAS (Figure 5.19B) reveals that 
there is significant sequence variation between the two enzymes at this position. Notably, the 
SsuSAS β2-α2 loop is extended by 4 amino acid residues. Multiple sequence alignments of bacterial 
SAS enzymes have indicated that this loop is likely to have a major influence on substrate selectivity 
(Chapter 4). Displayed in Figure 5.20C, the β2-α2 loop from SsuSAS is of identical length and has far 
greater sequence identity to the β2-α2 loop from the LegS of C. jejuni (50 %) than to the β2-α2 loop 
from NmeNANAS (22 %). This observation concurs with the phylogenetic analyses detailed in 
Sections 5.1.3 and 5.1.4 which also indicate that SsuSAS is a member of the LegS clade. 
In addition, the β2-α2 loop has been identified in MD simulations of NmeNANAS as a region of 
significant flexibility when in a ligand-free state (Chapter 3). As previously mentioned, the structure 
of SsuSAS was attained without substrate present. The combined absence of ligand and flexibility of 
the β2-α2 loop may indicate that the crystallised conformation of this region in the SsuSAS structure 
may not be observed when Mn2+, PEP and ManNAc are bound. 
Similar to NmeNANAS, the N-terminal sequence of SsuSAS has an analogous fold to Type III 
antifreeze proteins. The RMSD values for alignments of the NmeNANAS AFPL domain with Chain A 
and Chain B AFPL domains from SsuSAS are 1.658 Å and 1.168 Å respectively. Illustrated in Figure 
5.20, the AFPL domain of SsuSAS retains most of the secondary structural elements observed in 
NmeNANAS 1XUZ, but is slightly less structured in some regions. The C-terminus of the AFPL domain 
is extended in SsuSAS and does not share the partial helix that is formed by the last five residues in 
the NmeNANAS structure. Instead, the last few C-terminal residues of the SsuSAS structure trail 
away in the opposite direction to that of the NmeNANAS structure (Figure 5.20).  
NmeArg314 is an active site residue, contributed by the opposing monomer in NmeNANAS which is 
shown to interact with the N-acetyl group of rManNAc in the 1XUZ structure (Figure 5.20). Discussed 
in Chapter 2, NmeArg314 is an essential catalytic residue and is responsible for steering ManNAc into 
a reactive position. NmeArg314 and the corresponding residue in SsuSAS (SsuArg301) are in very similar 
positions relative to the AFPL domains of their respective structures (Figure 5.20). 
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Figure 5.20 Structural alignments of NmeNANAS and SsuSAS AFPL domains. NmeNANAS is coloured 
grey, Chain A of the SsuSAS structure is in red and Chain B is in blue. rManNAc (green) is included from 
the NmeNANAS structure. H-bonds are depicted with black dashes. Crystallographic coordinates for the 
NmeNANAS structure are 1XUZ (112). 
 
As aforementioned, SsuSAS was crystallised without Mn2+, PEP or rManNAc bound, however, a 
phosphate ion and glycerol molecule were observed in both chains. Displayed in Figure 5.21, the 
phosphate ion makes polar contacts with SsuLys115, SsuSer118, SsuSer140 and SsuSer200 of SsuSAS. The 
corresponding residues in the NmeNANAS structure 1XUZ form similar contacts with the phosphate 
moiety of PEP (Figure 5.22). The glycerol molecule observed in the active site of SsuSAS forms 
interactions with SsuGlu55, SsuArg301 and two water molecules. The most probable source of the 
phosphate ion is from Na2HPO4 which, as mentioned in Section 5.6.1, was a component in the 
crystallisation conditions for SsuSAS. A glycerol mixture was used as a cryoprotectant for SsuSAS 
crystals which is likely to have entered the active site, an occurrence which is well documented in 
the literature (174-176). 
 
 
 
 
 
 
 
Figure 5.21 Ligand interactions observed in the SsuSAS crystal structure. Chain A of SsuSAS (red) is 
aligned with Chain B (blue). Bound glycerol from Chain A is in green and from Chain B in pink. Polar 
contacts to ligands in Chain A are depicted with black dashes and in Chain B with red dashes. Waters are 
displayed as red spheres.  
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Figure 5.22 Overlay of NmeNANAS and SsuSAS active site residues. Residues from NmeNANAS structure 
are coloured grey and Chain A of SsuSAS in red. Ligands are included from the NmeNANAS structure with 
Mn2+ in yellow, PEP in pink, rManNAc in green and waters as red spheres. Glycerol is included from Chain 
A of the SsuSAS structure in orange. Polar contacts are depicted with black dashes and metal-ligand 
interactions with red dashes. Crystallographic coordinates for the NmeNANAS structure are 1XUZ (112). 
 
 The positioning of the SsuSAS active site residues is analogous to what is observed in the crystal 
structure of NmeNANAS 1XUZ (Figure 5.22). The residues involved with metal coordination 
(SsuHis202/NmeHis215 and SsuHis223/NmeHis236) are located similarly in both 1XUZ and the structure 
of SsuSAS even though SsuSAS was not solved with metal bound. As previously mentioned in Section 
5.1.4, the majority of active site residues are conserved between both species, however, there are 
some notable differences.  
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With the exception of NmeAsn184, each of the residues which form contacts to PEP in the 1XUZ 
structure are conserved and similarly positioned in the SsuSAS structure. As previously mentioned, a 
phosphate ion is observed in each SsuSAS active site. Shown in Figure 5.22, the phosphate moiety 
from Chain A of the SsuSAS structure overlays well with the phosphate group of the PEP molecule in 
1XUZ, which likely accounts for the similar positioning of the surrounding residues. No electron 
density was observed for a metal ion in the metal binding site of the SsuSAS structure in either chain.  
Depicted in Figure 5.22, NmeAsn184 forms a polar contact to the phosphate of PEP. In the SsuSAS 
structure, NmeAsn174 is replaced by SsuThr171, which is not in a suitable position to interact with PEP. 
The shorter side-chain of threonine compared to asparagine may indicate that the contact observed 
in the NmeNANAS structure is not possible in SsuSAS. This difference may account for the somewhat 
decreased binding affinity for PEP in SsuSAS compared to NmeNANAS noted in Section 5.4.1. In 
addition, NmeAsn184 is fully conserved in all members of the NANAS clade, whereas SsuThr171 is a 
conserved threonine or serine in the LegS clade. 
As mentioned in Section 5.1.4, each of the sugar binding residues in NmeNANAS are conserved in 
SsuSAS with the exception of NmeAsn74 and NmePhe288. NmeAsn74 is contributed by the β2-α2 loop in 
NmeNANAS which, as discussed in Chapter 4, is a region which varies in sequence between each 
clade of the SAS family. Whilst NmeAsn74 is not conserved in SsuSAS, a bulky tyrosine (SsuTyr54) 
protrudes into the active site from a similar position (Figure 5.22). SsuTyr54 is conserved within the 
LegS clade whilst NmeAsn74 is only conserved within the NANAS clade. Similarly, NmePhe288 which is 
conserved in the NANAS clade, is replaced by SsuVal275, which is conserved in the LegS clade 
(Chapter 4).  
Furthermore, the conserved ManNAc binding residues are slightly adjusted in the SsuSAS 
structure when compared with their counterparts in 1XUZ. Depicted in Figure 5.22, SsuGlu37, 
SsuAsp234 and SsuArg301 have shifted by 0.8 Å, 2.2 Å and 1.3 Å respectively from the corresponding 
residues in the NmeNANAS structure. The differences in positioning of the aforementioned residues 
are fairly minor and a similar degree of movement is observed in un-liganded dynamics of the 
NmeNANAS structure (Chapter 3). The alternative posturing of the SsuSAS ManNAc binding residues 
may be caused by the absence of ManNAc and PEP in the active site. Furthermore, the position of 
SsuArg301 is likely influenced by the movement of the AFPL domain which, as depicted in Figure 
5.17A, has moved closer to the catalytic domains in the SsuSAS structure when compared to 1XUZ. 
Alternatively, the position of SsuArg301 may be influenced by the presence of the bound glycerol 
molecule depicted in Figure 5.21. 
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5.6.3 Small-angle X-ray scattering 
SAXS was used to assess the solution structure of SsuSAS. SsuSAS was analysed in the presence of 
1 mM Mn2+ and 1 mM PEP (Figure 5.23). The SAXS profile of SsuSAS was determined using the 
methods outlined in Sections 8.5.8 and 8.5.9. Displayed in Figure 5.23A, the scattering profile of 
SsuSAS in the presence of Mn2+ and PEP is compared to the scattering profile of NmeNANAS under 
the same conditions. The experimental scattering obtained for SsuSAS is also compared with CRYSOL 
(153) fits generated from the ligand bound NmeNANAS crystal structure 1XUZ (112) and the ligand-
free crystal structure of SsuSAS outlined in Section 5.6.2. The structural parameters calculated for 
SsuSAS via SAXS, are compiled in Table 5.10 and compared against values determined for liganded 
NmeNANAS. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 5.10 SAXS structural parameters determined for SsuSAS in the presence of 1 mM Mn2+ and 1 mM 
PEP, compared with structural parameters for NmeNANAS determined under the same conditions. SAXS 
data obtained at a wavelength of 1.0332 Å.  
 
 
 
 
 
 
 
 NmeNANAS  SsuSAS 
I0 (cm
-1) 0.082 ± 0.001 0.075 ± 0.001 
Rg (Å) 33.0 ± 0.5 31.9 ± 0.3 
Dmax (Å) 116 113 
Porod volume (Å3) 121,724 115,631 
Estimated mass (kDa) 85 81 
Theoretical mass of dimer (kDa) 77 75 
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Figure 5.23 SAXS profile of SsuSAS in the presence of 1 mM Mn2+ and 1 mM PEP. (A) Comparison of SAXS 
data for SsuSAS (black triangles) with NmeNANAS wild-type (red circles). (B) CRYSOL fits of liganded 
SsuSAS SAXS data with theoretical scattering of NmeNANAS wild-type generated from crystallographic 
coordinates 1XUZ (red line) and theoretical scattering generated from the SsuSAS crystal structure 
detailed in Section 5.6 (blue line). SAXS data was collected using approximately 10 mg mL-1 protein in 30 
mM triethanolamine-HCl buffer at pH 7.5. Samples were eluted by SEC (Superdex 200 5/150). 
A 
B 
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The structure parameters obtained for SsuSAS via SAXS are similar to those determined for 
liganded NmeNANAS (Table 5.10). Depicted in Figure 5.23A, the scattering profile of SsuSAS is also 
similar to that observed for liganded NmeNANAS, indicating that the two enzymes have similar 
structures in solution. The molecular mass of SsuSAS was calculated from SAXS data using SAXS 
MoW (154), and was estimated as 81 kDa, which is similar to that expected for dimeric enzyme 
(Table 5.10). The quaternary state of SsuSAS determined from SAXS correlates with the results 
obtained from analytical SEC of SsuSAS, which also indicates that SsuSAS exists as a dimer in solution 
(Section 5.5.3).  
Displayed in Figure 5.23B, the SAXS data obtained for SsuSAS fits moderately well to the CRYSOL 
profile generated from the liganded NmeNANAS crystal structure 1XUZ and has a Chi value of 2.05. 
However, the fit to the CRYSOL profile generated from the ligand-free SsuSAS crystal structure is 
significantly lower and has a Chi value of 6.06. The theoretical scattering profile generated from the 
SsuSAS crystal structure is quite different to the profile for the NmeNANAS structure and is likely 
caused by the differences in conformation between the two crystal structures (as can be observed in 
Figure 5.17A). The conformational differences between the NmeNANAS and SsuSAS structures are 
discussed in detail in Section 5.6.2.  
Described in Chapter 3, wild-type NmeNANAS undergoes a conformational change in the 
presence of Mn2+ and PEP that is detectable by SAXS, and is linked to a H-bonding network that 
involves the rearrangement of the ManNAc binding site upon ligation of PEP. The SsuSAS crystal 
structure does not have ligands bound and is possibly in a conformation which does not accurately 
reflect the state of the enzyme when Mn2+ and PEP are present. Given that the experimental 
scattering obtained for SsuSAS was obtained in the presence of Mn2+ and PEP, it is unsurprising that 
the data fits better to the theoretical scattering of ligand bound NmeNANAS than to that of the 
ligand free SsuSAS CRYSOL. 
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Figure 5.24 SAXS profile of SsuSAS in the presence of 1 mM Mn2+ and 1 mM PEP compared with liganded 
and ligand-free scattering for NmeNANAS wild-type. SAXS data for liganded SsuSAS is in black, liganded 
NmeNANAS wild-type in red and ligand-free NmeNANAS wild-type in green. 
Displayed in Figure 5.24, the experimental scattering determined for SsuSAS in the presence of 
Mn2+ and PEP is analogous to that obtained for liganded NmeNANAS and not ligand-free 
NmeNANAS. This likely indicates that a conformational change occurs upon binding of PEP to SsuSAS, 
similar to what is observed for NmeNANAS (Chapter 3). The conformational change observed in the 
presence of Mn2+ and PEP would also explain the increased thermal stability observed for SsuSAS 
with Mn2+ and PEP described in Section 5.4.3.  
The results obtained from SAXS and DSF as well as the PEP ITC profile for SsuSAS, correlate with 
the observations for NmeNANAS outlined in Chapter 3 and indicate that the mechanism for pre-
organisation of the NmeNANAS ManNAc binding site is retained in SsuSAS. Described in Chapter 3, 
residues NmeGlu134 and NmeGlu282 were identified to play a key role in the hydrogen bonding 
network involved with ManNAc pre-organisation. Depicted in the sequence alignment between 
NmeNANAS and SsuSAS in Figure 5.3, both NmeGlu134 and NmeGlu282 are conserved in SsuSAS. The 
conservation of these residues is further confirmation that the ManNAc pre-organisation mechanism 
is retained in SsuSAS. 
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5.6.4 Analytical ultracentrifugation 
Both analytical SEC (Section 5.5.3) and SAXS (Section 5.6.3) indicated that SsuSAS exists as a 
dimeric protein. However, both of these techniques were run at high protein concentrations (2 - 10 
mg/mL) and may not accurately portray the quaternary state at lower concentrations of SsuSAS. 
Analytical ultracentrifugation (AUC) allows monitoring of quaternary structure at much lower 
protein concentrations than either SAXS or analytical SEC. AUC was thus used to determine if the 
quaternary state of SsuSAS was concentration dependent by running samples at 0.1 mg/mL, 0.5 
mg/mL and 1.0 mg/mL. Displayed in Figure 5.25, data was fitted to a continuous size-distribution (cs) 
model using the program SEDFIT (150, 151). Weight average molecular masses were calculated using 
weight average sedimentation coefficients and f/f0 values from cs fits. The method used for anlaysis 
is outlined in Section 8.5.7. 
As displayed in Figure 5.25D, SsuSAS eluted as a single species at each of the concentrations 
tested via AUC. The sedimentation coefficient peak corresponds to a molecular weight of 78 kDa 
which is very similar to that calculated for dimeric SsuSAS (75 kDa). The results from AUC indicate 
that SsuSAS is a stable dimer even at low concentrations and agrees with the results ascertained 
using analytical SEC and SAXS. Similar stability of dimeric protein is observed with wild-type 
NmeNANAS (Chapter 3). 
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Figure 5.25 Analytical ultra centrifuge fits measured at 280 nm absorbance. (A) SsuSAS at 0.1 mg/mL, 
residual data (top), and fit of model to data from SEDFIT (bottom). (B) SsuSAS at 0.5 mg/mL, residual data 
(top), and fit of model to data from SEDFIT (bottom). (C) SsuSAS at 1.0 mg/mL, residual data (top), and fit 
of model to data from SEDFIT (bottom). (D) Normalised c(s) profiles for SsuSAS at 0.1 mg/mL (red), 0.5 
mg/mL (black) and 1.0 mg/mL (purple). 
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5.6.5 Substrate docking  
Since a structure of SsuSAS could not be elucidated with substrates bound, docking of Mn2+, PEP 
and ManNAc was attempted by Dr Wanting Jiao in order to determine the interactions within the 
SsuSAS active site. Displayed in Figure 5.26 is the best pose afforded from docking experiments with 
ManNAc. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.26 Best pose attained from docking of Mn2+, PEP and ManNAc into the active site of SsuSAS. 
SsuSAS residues are shown in grey, with Mn2+ in yellow, PEP in pink and ManNAc in green. Polar contacts 
are depicted with black dashes. 
 
Displayed in Figure 5.26, the docked PEP molecule forms similar contacts in SsuSAS to 
NmeNANAS 1XUZ. Interestingly, the best pose obtained from docking of ManNAc was not a suitable 
reactive orientation. The docked ManNAc bound deep into the active site pocket, forming contacts 
with residues contributed from the β2-α2 loop of SsuSAS such as SsuTyr54, SsuGlu55 and SsuThr69. 
SsuTyr54, SsuGlu55 are each fully conserved within the LegS clade, however, SsuThr69 is not (Figure 
5.3).  
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The most significant difference in the positioning of the docked ManNAc in SsuSAS compared to 
rManNAc in NmeNANAS 1XUZ, is the loss of the interaction between SsuArg301 and the N-acetyl 
group of ManNAc. As outlined in Chapter 2, NmeArg314 plays an important role in the positioning of 
ManNAc for reaction with PEP. Displayed in Figure 5.26, SsuArg301 is 4.5 Å away from the N-acetyl 
group of ManNAc and is thus not within hydrogen bonding distance. Although the docking analysis 
of ManNAc did not provide a reactive pose for the sugar substrate, SsuSAS was successfully 
characterised with NANAS activity (Section 5.3.1).  
The unexpected binding pose for ManNAc is likely caused by the template structure used for 
docking. As discussed in Section 5.6.2 the SsuSAS structure is in a different conformation to 
NmeNANAS which is probably due to the absence of PEP. In particular, the SsuSAS AFPL domains are 
re-orientated and consequently the position of SsuArg301 is slightly adjusted. 
As discussed in Section 5.1.4, SsuSAS bears remarkable sequence similarity to members of the 
LegS clade of SAS enzymes. Unfortunately, the sugar substrate for Leg biosynthesis (2,4-
diacetamido-2,4,6-trideoxymannose) is not commercially available and its synthesis is not trivial. 
Due to the unavailability of 2,4-diacetamido-2,4,6-trideoxymannose, SsuSAS could not be tested for 
LegS activity. However, to determine if SsuSAS could possibly bind 2,4-diacetamido-2,4,6-
trideoxymannose, the LegS substrate was docked with Mn2+ and PEP into the active site of the 
SsuSAS crystal structure (Figure 5.27).  
Contrary to ManNAc, 2,4-diacetamido-2,4,6-trideoxymannose docks in a suitable reactive 
position in the active site of SsuSAS (Figure 5.27). Both of the N-acetyl groups from the LegS 
substrate form interactions with SsuArg301 which, as aforementioned, is likely involved in steering 
the sugar substrate into a reactive stance. Polar contacts are also formed between SsuGlu37, 
SsuTyr173 and SsuAsp234 which are each conserved ManNAc binding residues identified in 
NmeNANAS 1XUZ. Unlike the docking of ManNAc, no interactions are observed between 2,4-
diacetamido-2,4,6-trideoxymannose and the β2-α2 loop of SsuSAS. 
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Figure 5.27 Best pose attained from docking of Mn2+, PEP and 2,4-diacetamido-2,4,6-trideoxymannose 
into the active site of SsuSAS. SsuSAS residues are shown in grey, with Mn2+ in yellow, PEP in pink and 2,4-
diacetamido-2,4,6-trideoxymannose in blue. Polar contacts are depicted with black dashes. 
 
The results from docking suggest that SsuSAS is capable of binding 2,4-diacetamido-2,4,6-
trideoxymannose in a more favourable reactive orientation than ManNAc. Consequently, the 
docking results strongly suggest that SsuSAS is capable of LegS activity. Additionally, the results from 
docking of 2,4-diacetamido-2,4,6-trideoxymannose in SsuSAS produce almost identical interactions 
to those obtained for docking of the same compound with CjeLegS in Section 4.6.7. This correlates 
with the genealogical analysis outlined in Sections 5.1.3 and 5.1.4, indicating that SsuSAS is a LegS. 
However, it should be noted that the results from substrate docking may be influenced by the 
starting positions of the active site residues in the SsuSAS structure. Thus further experimental 
evidence would be required to validate LegS activity, i.e. kinetically assaying SsuSAS with 2,4-
diacetamido-2,4,6-trideoxymannose.  
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5.7 Summary of results 
 
The SAS from S. suis was successfully expressed and purified by metal affinity and size exclusion 
chromatography. NANAS activity was confirmed by assaying SsuSAS with PEP and ManNAc. SsuSAS 
was revealed to have comparable kinetic parameters to those previously determined for wild-type 
NmeNANAS in Chapter 2. An optimal pH of 7 and optimal temperature of 40 °C was determined for 
NANAS activity. 
The effects of metal ions upon the activity of SsuSAS were analysed, with maximal activity 
observed for Co2+ followed by Mn2+. Several metal ions were discovered to inhibit activity including 
Ca+, Fe2+, Zn2+ and Cd2+. Activity of SsuSAS could be abolished upon the addition of EDTA confirming 
metal dependence of catalysis. Although sugar substrate promiscuity was observed in the literature 
for the closely related enzyme SagSAS (105), no activity could be ascertained for SsuSAS with the 
same compounds.  
The thermal stability of SsuSAS was analysed in the presence of various metal ions. Similar to the 
trends observed with metal activation, Co2+ was found to be the most stabilising metal ion followed 
by Mn2+. DSF of SsuSAS with combinations of PEP, ManNAc and rManNAc revealed a similar thermal 
melting profile to that of wild-type NmeNANAS, where a significant thermal shift was observed upon 
the addition of PEP. 
ITC profiles of SsuSAS with Mn2+ and PEP were also similar to NmeNANAS wild-type. Furthermore, 
results obtained from SAXS indicate that SsuSAS is capable of undergoing a similar conformational 
change to that observed for wild-type NmeNANAS in the presence of PEP and Mn2+. Outlined in 
Chapter 3, PEP binding pre-organises the ManNAc binding site via a hydrogen bonding network 
which links the catalytic and AFPL domains. The H-bond network residues NmeGlu134 and 
NmeGlu282 are both conserved in SsuSAS, indicating that a similar mechanism is possible. 
The molecular mass of SsuSAS was successfully ascertained using MS and the protein was 
determined to be folded in solution using CD. SsuSAS was confirmed to be dimeric by SAXS, 
analytical SEC and AUC.  
SsuSAS was successfully crystallised and a structure with phosphate and glycerol bound was 
elucidated. SsuSAS was determined to be a domain swapped homodimer with each monomer unit 
comprised of a (β/α)8 barrel catalytic domain with a short linker sequence to a C-terminal AFPL 
domain, similar to the previously refined structures of NmeNANAS (112, 113).  
215 
 
Slight structural differences were observed between SsuSAS and NmeNANAS. The AFPL domains 
in the SsuSAS structure were positioned closer to the catalytic domains when compared to the 
NmeNANAS structure. As a result, SsuArg301 which is contributed by the AFPL domain of the 
opposing monomer was repositioned in the active site of SsuSAS when compared with the 
congruent residue in NmeNANAS 1XUZ. 
Since a crystal structure of SsuSAS could not be obtained with substrates bound, molecular 
docking was used to determine possible catalytic site interactions. Docking of ManNAc into the 
active site of SsuSAS did not afford a reactive pose, however, docking of the LegS substrate 2,4-
diacetamido-2,4,6-trideoxymannose did. The docking results obtained for SsuSAS with 2,4-
diacetamido-2,4,6-trideoxymannose imply that the substrate for Leg biosynthesis can be reacted 
with PEP. Furthermore, SsuSAS shares high sequence identity to members of the LegS clade of SASs, 
indicating the enzyme is likely to have LegS activity.  
 
5.8 Discussion 
 
The initial aim of Chapter 5 was to uncover substrate promiscuity in the SAS family. The SAS from 
S. suis was selected for investigation due to its high sequence similarity to the SAS from S. 
agalactiae, which was previously observed to utilise a variety of ManNAc analogues (105). Whilst the 
SAS from S. suis was determined to have NANAS activity, no detectable activity was observed with 
any of the ManNAc analogues tested. The optimal pH, temperature and metal ion for activity of 
SsuSAS were also identified. The DSF, ITC and SAXS profiles of SsuSAS in the presence of PEP were 
similar to those observed for wild-type NmeNANAS. Furthermore, the residues involved in the 
hydrogen bonding network of NmeNANAS are conserved in SsuSAS. Given the aforementioned 
observations, it is highly likely that the NmeNANAS mechanism of ManNAc binding-site pre-
organisation is also conserved in SsuSAS.  
A crystal structure of SsuSAS was elucidated to a resolution of 2.3 Å. SsuSAS was determined to 
be a domain swapped homodimer with a similar overall architecture to that previously observed for 
wild-type NmeNANAS (112, 113). Although it was observed to have NANAS activity, SsuSAS was 
positioned in the LegS clade of the phylogram described in Chapter 4. Inspection of the SsuSAS 
sequence revealed that the region pertaining to the β2-α2 loop was indeed more closely related to 
members of the LegS clade than NANAS clade.  
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Molecular modelling was used to predict the possible interactions of both ManNAc and 2,4-
diacetamido-2,4,6-trideoxymannose in the active site of the SsuSAS crystal structure. The docking 
results obtained for SsuSAS with 2,4-diacetamido-2,4,6-trideoxymannose strongly implied that that 
the substrate for Leg biosynthesis could be reacted with PEP. Furthermore, the binding poses 
attained for 2,4-diacetamido-2,4,6-trideoxymannose in the SsuSAS crystal structure were 
comparable to those observed for ManNAc. 
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Chapter 6 
Generation and characterisation of 
Homo sapiens and Neisseria 
meningitidis AFPL domain chimeras 
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6.1 Background 
 
6.1.1 Mammalian and bacterial NANA biosynthesis 
The sialic acid, NANA is commonly integrated as a terminal residue on mammalian cell surface 
glycoconjugates (177). NANA plays a significant role in both cellular recognition and cell adhesion 
processes in mammals (2, 178). NANA is also produced by neuroinvasive bacteria such as Neisseria 
meningitidis, the primary causative agent of bacterial meningitis (179) and by C. jejuni, the primary 
causative agent of food-borne gastroenteritis (88). These select pathogenic organisms incorporate 
NANA in their cell surface, mimicking the surface of a mammalian cell. This cellular mimicry enables 
the bacteria to evade the host’s immune response (180). 
 
 
 
 
 
 
 
 
 
Figure 6.1 The biosynthetic pathways of CMP-NANA in bacteria and mammals. The reaction pathway in 
bacteria is boxed in red and the pathway in mammals is boxed in blue. In bacteria, ManNAc is directly 
converted to NANA by NANA synthase whereas NANA is produced via phosphorylated intermediates in 
the mammalian pathway.   
 
 
 
 
 
 
 
 
Bacterial Pathway Mammalian Pathway 
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The biosynthesis of NANA in bacteria and mammals differs slightly (Figure 6.1) (5), though both 
pathways involve the formation of ManNAc from UDP-GlcNAc. This reaction is catalysed by UDP-
GlcNAc 2-epimerase, which hydrolyses the glycosidic-UDP linkage of UDP-GlcNAc and inverts the 
stereochemistry at C2. In the bacterial pathway, the subsequent reaction is the aldol-like 
condensation of PEP and ManNAc to form NANA which is catalysed by NANAS (112).  
In the mammalian pathway, ManNAc is first phosphorylated at C-6 by ManNAc kinase to form 
ManNAc-6-P. ManNac-6-P is then reacted with PEP by NANA-9-PS to form NANA-9-P (103). Finally, 
NANA-9-P is dephosphorylated by NANA-9-P phosphatase to produce NANA. In both bacteria and 
mammals, NANA is activated by CMP-NANA synthetase which utilises cytosine triphosphate (CTP) 
and NANA to produce CMP-NANA. CMP-NANA is subsequently incorporated into cell surface 
glycoconjugates (181). 
 
6.1.2 Goals of this research 
As described in Chapters 2 and 3 of this thesis, the AFPL domain plays an important role in the 
binding and positioning of ManNAc. The AFPL domain is linked with the pre-organisation of the 
ManNAc binding site via a hydrogen bonding network and provides an essential arginine residue that 
helps steer ManNAc into a reactive position. The AFPL domain sequence in HsaNANA-9-PS is 
significantly different to that from NmeNANAS and does not contain the aforementioned critical 
arginine.  
The aim of the work done in this chapter was to determine whether the function of the 
HsaNANA-9-PS and NmeNANAS AFPL domains were similar and could be interchanged. This was to 
be done by generating and characterising two chimeric proteins. Shown in Figure 6.2, the first 
chimera was designed to comprise of the N. meningitidis catalytic domain joined to the H. sapiens 
linker and AFPL domain (Nme/Hsa chimera) and the second chimera was designed to comprise of 
the H. sapiens catalytic domain joined to the N. meningitidis linker and AFPL domain (Hsa/Nme 
chimera). 
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Figure 6.2 Schematic depicting NANA/NANA-9-PS chimera constructs. The NmeNANAS catalytic domain 
is depicted in red, NmeNANAS AFPL- domain in green, HsaNANA-9-PS catalytic domain in blue and 
HsaNANA-9-PS AFPL domain in green. The Nme/Hsa chimera is comprised of the NmeNANAS catalytic 
domain and HsaNANA-9-PS linker and AFPL domain. The Hsa/Nme chimera is comprised of the 
HsaNANA-9-PS catalytic domain and NmeNANAS linker and AFPL domain. 
 
 
 
 
 
NmeNANAS HsaNANA-9-PS 
Nme/Hsa 
chimera 
Hsa/Nme 
chimera 
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6.2 Sequence and Structural Comparison of 
NmeNANAS and HsaNANA-9-PS 
 
6.2.1 Sequence alignment of NmeNANAS and HsaNANA-9-PS 
In order to determine the relationship between NmeNANAS and HsaNANA-9-PS, a sequence 
alignment was generated using ClustalW2 (155, 156). The sequence identity between NmeNANAS 
and HsaNANA-9-PS was determined to be 27.9 %. The catalytic domains of NmeNANAS and 
HsaNANA-9-PS share 29.8 % identity, whilst the AFPL domains have a lower identity of 25.9 %. As 
shown in Figure 6.3, the β2-α2 loop of HsaNANA-9-PS is slightly longer than that of NmeNANAS. 
Furthermore, HsaNANA-9-PS contains an additional eight C-terminal residues when compared to the 
sequence for NmeNANAS.  
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Figure 6.3 Sequence alignment of NmeNANAS and HsaNANA-9-PS displayed using Jalview (159). 
Residues highlighted in blue indicate conservation across the SAS family. Conserved active site residues 
from NmeNANAS are marked with dots; metal binding residues in green, PEP binding residues in blue and 
ManNAc binding residues in red. Lines indicate sequence pertaining to NmeNANAS domains; catalytic 
barrel in red, β2-α2 loop in blue, linker in black and AFPL domain in green. The residue and domain 
annotation is based on the NmeNANAS crystal structure (PDB code (1XUZ) (112)). 
β2-α2 loop 
Catalytic Domain 
Linker AFPL domain 
NmeArg314 
NmeGly272 
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As depicted in Figure 6.3, several of the key catalytic site residues are conserved between both 
NmeNANAS and HsaNANA-9-PS. The NmeNANAS metal binding residues His215 and His236 are both 
conserved in HsaNANA-9-PS. The NmeNANAS PEP binding residues Lys53, Lys129, Ser132, Ser154 
and Ser213 are each conserved in HsaNANA-9-PS. Thr110 is substituted by a serine residue in 
HsaNANA-9-PS, however as detailed in Section 4.2.2, this position is conserved as either threonine 
or serine in all bacterial SASs. Asn184 is not conserved in HsaNANA-9-PS either, but this residue is 
only conserved in the bacterial NANAS clade (Chapter 4).  
The ManNAc binding residues Gln55, Tyr186 and Asp247 are each conserved in HsaNANA-9-PS, 
however Asn74, Phe288 and Arg314 are not. The observation that Asn74 is not conserved in 
HsaNANA-9-PS is unsurprising given that Asn74 is contributed by the β2-α2 loop. As discussed in 
Section 4.2.2, the β2-α2 loop varies significantly between different SAS clades and is likely involved 
in sugar substrate recognition. Shown in Figure 6.4, Asn74 interacts with the C6 hydroxyl of ManNAc 
in NmeNANAS. As aforementioned, HsaNANA-9-PS utilises ManNAc-6-P and not ManNAc. The β2-α2 
loop of HsaNANA-9-PS would therefore be proximal to the C6 phosphate of ManNAc-6-P. Shown in 
Figure 6.5, the β2-α2 loop of HsaNANA-9-PS contains far more positive residues than the 
corresponding sequence in NmeNANAS. This correlates with the electrostatic requirements for 
interacting with the negatively charged phosphate moiety.   
 
 
 
 
 
 
 
 
Figure 6.4 Close up of NmeNANAS active site. Residues contributed by the catalytic domain are shown in 
grey and residues from linker and AFPL domain in red. ManNAc is coloured green, PEP pink, Mn2+ yellow 
and waters are shown in red. H-bonds are depicted with black dashes and dipolar bonds with red dashes 
(PDB code (1XUZ) (112)). 
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Figure 6.5 Sequence alignment of NmeNANAS and HsaNANA-9-PS β2-α2 loop displayed using Jalview 
(159). Residues highlighted in red indicate positively charged side-chains at neutral pH.  
 
It is also unsurprising that Phe288 is not conserved in HsaNANA-9-PS, as it is only conserved in 
members of the bacterial NANAS family and does not directly interact with ManNAc in the 
NmeNANAS structure (Figure 6.4). Surprisingly, the AFPL domain residue Arg314 is not conserved in 
HsaNANA-9-PS. Arg314 interacts with the N-acetyl group of ManNAc and has been previously 
identified as an essential component for catalysis in NmeNANAS (114). As outlined in Chapter 2, 
Arg314 steers ManNAc into a reactive position with PEP. As indicated in Figure 6.3, Arg314 is 
replaced by a valine in HsaNANA-9-PS, which is fully conserved in mammalian SASs.  It should be 
noted that less than 30 mammalian SAS sequences are currently available for comparison. 
 
6.2.2 Structure of H. sapiens NANA-9-PS 
Currently there is no complete crystal structure of HsaNANA-9-PS available however the 
structure of the HsaNANA-9-PS AFPL domain has been elucidated by NMR (115). Displayed in Figure 
6.6, the AFPL domain of HsaNANA-9-PS shows high structural similarity to the AFPL domain of 
NmeNANAS (RMSD = 0.40 Å).  
 
 
 
 
 
 
Figure 6.6 Alignment of NmeNANAS AFPL domain (grey) with HsaNANA-9-PS AFPL domain (green). N-
terminal residues are coloured blue and C-terminal residues are coloured red. NmeNANAS AFPL domain 
structure generated from crystallographic coordinates 1XUZ (112) and HsaNANA-9-PS AFPL domain from 
coordinates 1WVO (115). 
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To determine a more complete representation of the HsaNANA-9-PS structure, a molecular 
model was generated by Dr Wanting Jiao. The ligand bound NmeNANAS crystal structure (PDB code 
1XUZ) was used as a template for the HsaNANA-9-PS model (Figure 6.7). ManNAc-6-P was docked 
into the active site of the HsaNANA-9-PS model to ascertain the key interactions between the 
enzyme and substrates. The best ligand pose determined through docking is displayed in Figure 6.7B.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.7 (A) HsaNANA-9-PS dimer aligned to NmeNANAS dimer. Both chains of NmeNANAS are shown 
in black, chain A of HsaNANA-9-PS is in red and chain B is in green. (B) Close up of HsaNANA-9-PS active 
site with substrates docked. Residues contributed by the catalytic domain are shown in grey and residues 
from linker and AFPL domain in red. ManNAc-6-P is coloured blue, PEP pink, Mn2+ yellow. H-bonds are 
depicted with black dashes (PDB code (1XUZ) (112)). 
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As expected, the model of the HsaNANA-9-PS dimer aligns well with the crystal structure of 
NmeNANAS and has an RMSD = 0.1 Å (Figure 6.3A). The overall fold of each HsaNANA-9-PS 
monomer is maintained, with the catalytic barrel, linker and AFPL domains each structurally similar 
to the template fold.  
The docking of ManNAc-6-P, PEP and Mn2+ into the active site of the HsaNANA-9-PS model 
revealed several potential interactions between the enzyme and substrates. As mentioned in Section 
6.2.1, the majority of the residues involved with substrate binding in NmeNANAS are conserved in 
the sequence of HsaNANA-9-PS. Depicted in Figure 6.7B, the interactions of these conserved 
residues are shown to be maintained as well.   
Interestingly, the HsaNANA-9-PS docking experiment reveals several additional potential ligand 
interactions that were not identified through sequence comparison. Whilst the HsaNANA-9-PS β2-α2 
loop is rich in arginine and lysine (Figure 6.5), the only residue from the loop that is identified to 
hydrogen bond to the phosphate group of ManNAc-6-P is Thr79. It is possible, however, that while 
the identified arginine and lysine residues do not directly interact with the phosphate of ManNAc-6-
P, they provide a positively charged environment that aids in substrate recognition. The docking 
results also predict the involvement of Lys290 in phosphate recognition. Lys290 is the only amino 
acid revealed by docking which is contributed by the opposite monomer and directly interacts with 
substrate.  
It is notable that the N-acetyl group of ManNAc-6-P does not appear to interact with any amino 
acid side-chains. The interaction between the N-acetyl group of ManNAc and NmeArg314 in 
NmeNANAS was shown to be essential to catalysis, and positions ManNAc for reaction with PEP 
(Chapter 2). It is possible that this interaction is not necessary in HsaNANA-9-PS or that a similar 
mechanism remains as yet unidentified.  Furthermore, the lack of a congruent residue to 
NmeArg314 in HsaNANA-9-PS is particularly interesting given that HsaNANA-9-PS is able to catalyse 
the formation of 2-keto-3-deoxy-D-glycero-D-galacto-nonulosonic acid 9-phosphate (KDN-9-P) from 
PEP and mannose 6-phosphate (Man-6-P) (182). The ability of HsaNANA-9-PS to catalyse KDN-9-P 
formation further indicates that the steering mechanism of NmeArg314 is not required in HsaNANA-
9-PS. Conversely, NmeNANAS is unable to catalyse a reaction between Mannose and PEP, further 
implicating the necessity of the interaction between the N-acetyl group of ManNAc and NmeArg314 
in NmeNANAS.  
 
 
227 
 
6.3 Cloning, expression and purification 
 
6.3.1 Cloning, expression and purification of HsaNANA-9-PS 
The HsaNANA-9-PS construct was codon optimised for expression in E. coli, synthesised and 
cloned into pDONR221 by GeneArt®. Sub-cloning into pDEST17, expression and purification 
optimisation of HsaNANA-9-PS was carried out by Thomas Cotton as outlined in Section 8.10.2  
 
6.3.2 Cloning of Nme/Hsa chimeras 
Two chimeric constructs were generated from the genes encoding NmeNANAS and HsaNANA-9-
PS using a multi-step PCR protocol that is outlined in Figure 6.8. The sequence encoding the linker 
and AFPL domain of NmeNANAS was stitched to the sequence encoding the HsaNANA-9-PS catalytic 
domain to generate the Hsa/Nme chimera. The linker and AFPL domain of HsaNANA-9-PS was 
stitched to the sequence encoding the NmeNANAS catalytic domain to generate the Nme/Hsa 
chimera. The template used for amplification of the NmeNANAS sequence was the pDEST17-
NmeNANAS construct outlined in Chapter 2.  
The position chosen for interchanging the domains was residue NmeGly272, which is conserved 
in HsaNANA-9PS as residue HsaG274. This position is located prior to the linker sequence as 
indicated in Figure 6.2. The template used for amplification of the HsaNANA-9-PS sequence was a 
pDEST17-HsaNANA-9PS construct, sub-cloned from a sequence that was synthesised and codon 
optimised for expression in an E. coli system by GeneArt®. The methods used for PCR are outlined in 
Section 8.3.2, and primer sequences are displayed in Table 8.9.  
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Enzyme 1 catalytic domain sequence 
Enzyme 1 AFPL domain sequence 
Enzyme 2 catalytic domain sequence 
Enzyme 2 AFPL domain sequence 
Generic gateway cloning sequence  
Polymerase 
Direction of amplification 
A 
B 
C 
D 
Figure 6.8 Assembly of NANA/NANA-9-PS chimera 
constructs. (A) Round 1: Amplification of AFPL 
domain from enzyme 1. (B) Round 2: Amplification of 
catalytic domain from enzyme 2. (C) Round 3: Fusion 
of amplification products from rounds 1 & 2. (D) 
Round 4: Extension of round 3 product using generic 
nested primers. 
 
Fwd gene primer 
Fwd gene primer 
Rev gene primer 
Rev gene primer 
Rev bridge primer 
Fwd bridge primer 
Fwd generic primer Rev generic primer 
5’ 3’ 
5’ 3’ 
5’ 3’ 
5’ 3’ 
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The first two steps of chimera generation involved the amplification of the catalytic domain and 
linker/AFPL domain from each donor sequence. Shown in Figure 6.8A, the linker/AFPL domain was 
amplified from the first enzyme’s sequence using a gene specific reverse primer and forward 
bridging primer. The bridging primer comprised of sequence specific to the 5’ terminus of the first 
enzyme’s linker/AFPL domain and sequence specific to the 3’ terminus of the second enzyme’s 
catalytic domain. The resulting product was a linear construct of the first enzyme’s linker/AFPL 
domain sequence with a 5’ extension corresponding to sequence from the 3’ terminus of the second 
enzyme’s catalytic domain.  
The amplification of the second enzyme’s catalytic domain sequence is outlined in Figure 6.8B. 
The catalytic domain was amplified from the second enzyme’s sequence using a gene specific 
forward primer and reverse bridging primer. The bridging primer consisted of sequence specific to 
the 5’ terminus of the first enzyme’s linker/AFPL domain and sequence specific to the 3’ terminus of 
the second enzyme’s catalytic domain. The resulting product was a linear construct of the second 
enzyme’s catalytic domain sequence with a 3’ extension corresponding to sequence from the 5’ 
terminus of the second enzyme’s linker/AFPL domain.  
The third round of amplification involved stitching the linker/AFPL domain of the first enzyme to 
the catalytic domain of the second enzyme using overlap extension PCR (Figure 6.8C). The amplified 
products from rounds 1 and 2 were used as templates. Primers used for round 3 were the gene 
specific reverse primer from round 1 and the gene specific forward primer from round 2. The 
aforementioned gene specific nested primers were designed incorporating generic extensions for 
further rounds of nested PCR (Table 8.9). The product from the third round was the complete linear 
construct of the chimera with 5’ and 3’ extensions for nested PCR.   
Following amplification of the linear chimera construct in round 3, the purified product was 
extended using generic gateway primers which incorporated sequence encoding an N-terminal TEV 
protease cleavage site (Figure 6.8D). Successful amplification at each stage was determined by 
agarose gel electrophoresis. Cloning and sub-cloning of the chimera constructs was achieved 
through the use of the gateway system as outlined in Section 8.3. The linear product from round 4 
was cloned into the donor vector pDONR-221. Ligated product was subsequently transformed into E. 
coli One Shot® TOP10 cells (Invitrogen) as outlined in Section 8.3.10. Plasmids from transformants 
were purified and each of the chimera genes were successfully sequence verified in the donor 
vector. The chimera genes were sub-cloned into the destination vector pDEST-17, which encodes an 
N-terminal His-tag.  
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6.3.3 Expression and purification 
The pDEST-17-Nme/Hsa chimera and pDEST-17-Hsa/Nme chimera were both transformed into 
three different expression cell lines to optimise the yield of soluble protein. The expression vectors 
were transformed into E. coli BL21 (DE3) Star cells, E. coli Rosetta™ 2 (DE3) cells and E. coli Bl21 
(DE3) pBB540/pBB542 (Chaperone 3) cells. In order to compare induced against non-induced 
samples, two cultures of each cell line were grown overnight in LB, with one induced by IPTG and the 
other not. The results from the expression tests for the Nme/Hsa chimera and Hsa/Nme chimera 
were analysed by SDS-PAGE. The best yield of soluble protein for the Nme/Hsa chimera was attained 
using Chaperone 3 cells. Unfortunately, while the Hsa/Nme chimera did over-express with IPTG 
induction, there was no soluble protein observed in any of the expression systems used. In an effort 
to solubilise the Hsa/Nme chimera, the construct was sub-cloned into pDEST-15 which bears a GST 
solubility fusion tag and the expression test was repeated. Unfortunately, no soluble protein was 
afforded for the Hsa/Nme chimera.   
The Nme/Hsa chimera was expressed and purified using a similar method to that used for 
NmeNANAS wild-type as outlined in Section 8.4. Samples of purified enzyme were analysed by SDS 
PAGE (Figure 6.9). 
 
 
 
 
 
 
 
 
 
Figure 6.9 SDS-PAGE gel of purified Nme/Hsa chimera. Lane M contains marker with molecular weights 
defined. Lane 1 contains purified Nme/Hsa chimera. 
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6.4 Kinetic analysis of Nme/Hsa chimera 
 
6.4.1 Attempted kinetic characterisation of Nme/Hsa 
chimeras 
To determine the kinetic parameters of the Nme/Hsa chimera, the consumption of PEP was 
monitored using the assay described in Section 8.5.1. Nme/Hsa chimera was assayed with PEP and 
ManNAc/ManNAc-6-P at several different pH levels and temperatures as well as in the presence of a 
variety of metal ions. No kinetic activity could be observed for the Nme/Hsa chimera with either 
ManNAc of ManNAc-6-P even at high protein concentrations of approximately 1 mg/mL. Lack of 
activity equates to a kcat less than 0.004 s
-1.   
 
6.5 Binding studies of Nme/Hsa chimera 
 
6.5.1 Isothermal titration calorimetry 
Binding constants for Mn2+ and PEP were determined for the Nme/Hsa chimera using the methods 
described for NmeNANAS wild-type (Section 8.5.4). ITC results attained for the Nme/Hsa chimera are 
compared to previously determined dissociation constants (Kd) for NmeNANAS wild-type in Table 6.1 
(114). NmeNANAS wild-type was used for comparison as the residues for Mn2+ and PEP binding are 
contributed solely by the catalytic domain and the Nme/Hsa chimera contains the NmeNANAS 
catalytic barrel. The raw experimental binding curve and one-site model fitted ITC data for Mn2+ and 
PEP with the Nme/Hsa chimera are displayed in Figure 6.10. 
 
 NmeNANAS (114) Nme/Hsa Chimera 
Kd Mn
2+ (µM) 10.6 ± 0.5 11.7 ± 0.4 
Kd PEP (µM) 219 ± 11 374 ± 28 
 
Table 6.1 ITC derived binding constants for wild-type NmeNANAS and the Nme/Hsa chimera. 
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To determine the Kd value for metal with the Nme/Hsa chimera, Mn
2+ was titrated into metal-free 
enzyme. The Mn2+ affinity of the Nme/Hsa chimera was determined to be very similar to that 
measured for wild-type NmeNANAS. As depicted in Figure 6.10A, the binding of Mn2+ is an 
exothermic event in the Nme/Hsa chimera and is thus an enthalpically favourable process.  
  
Shown in Table 6.1, the PEP affinity for the Nme/Hsa chimera is slightly lower than that observed 
for NmeNANAS wild-type. As shown in Figure 6.10B, the binding of PEP is an endothermic event in 
the Nme/Hsa chimera. This correlates with previous observations for PEP binding with wild-type 
NmeNANAS which was determined to be an entropically favourable event. The results from ITC 
indicate that the Nme/Hsa chimera behaves in a similar manner to that observed for NmeNANAS 
wild-type with respect to PEP and Mn2+ binding even though the chimera is not active (Section 6.4). 
These results indicate that the Mn2+ and PEP binding sites are still intact in the Nme/Hsa chimera.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.10 Enthalpy changes measured by ITC. (A) Mn2+ (5 mM) titrated into metal-free Nme/Hsa 
chimera (65 µM). (B) PEP (50 mM) titrated into Nme/Hsa chimera (40 µM) in the presence of Mn2+ (1 
mM). 
 
A B 
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6.5.2 Thermal stability 
The effects of Mn2+, PEP and ManNAc/rManNAc/ManNAc-6-P on the thermal stability of the 
Nme/Hsa chimera were assessed by DSF. The protocol used for DSF is outlined in Section 8.5.3. 
Protein used for DSF was treated with 10 mM EDTA prior to SEC to ensure removal of trace metals. 
The melting points determined for each sample were plotted graphically and compared to data 
obtained for NmeNANAS and HsaNANA-9-PS wild-type enzymes (Figure 6.11 and Table 6.2).  
 
 
 
 
 
 
 
 
 
 
Figure 6.11 Bar graph of thermal melting points for NmeNANAS wild-type (red), HsaNANA-9-PS wild-
type (blue) and Nme/Hsa chimera (purple) in the presence of ligand as determined by DSF. EDTA, Mn2+ 
and PEP were each used at a concentration of 1 mM and ManNAc/rManNAc/ManNAc-6-P at 10 mM. 
ManNAc/rManNAc/ManNAc-6-P was used at 1 mM when in combination with PEP.  
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Table 6.2 Thermal melting points for NmeNANAS wild-type, HsaNANA-9-PS wild-type and Nme/Hsa 
chimera in the presence of ligand as determined by DSF. EDTA, Mn2+ and PEP were each used at a 
concentration of 1 mM and ManNAc/rManNAc/ManNAc-6-P at 10 mM. ManNAc/rManNAc/ManNAc-6-P 
was used at 1 mM when in combination with PEP. 
 
Apoenzyme Nme/Hsa chimera was found to melt at 43.6 °C (Figure 6.11 and Table 6.2). The 
melting point of the apo-Nme/Hsa chimera is very similar to that for both NmeNANAS and 
HsaNANA-9-PS wild-type enzymes which melt at 42.7 ± 0.2°C and 43.0 ± 0.3°C respectively. The 
addition of 1 mM EDTA to apo- Nme/Hsa chimera did not influence the thermal stability of the 
enzyme which likely indicates the successful removal of trace metal ions during purification. The 
addition of 1 mM Mn2+ increased the melting point of Nme/Hsa chimera, by approximately 4 °C. 
Shown in Figure 6.11 and Table 6.2, Mn2+ stabilises both NmeNANAS and HsaNANA-9-PS wild-type 
enzymes also. 
As discussed in Chapter 3, metal bound NmeNANAS is significantly stabilised upon the addition of 
PEP. Shown in Figure 6.11 and Table 6.2, HsaNANA-9-PS is similarly stabilised by PEP. Interestingly, 
the Nme/Hsa chimera is not thermally stabilised in the presence of PEP. This is surprising given that 
the Nme/Hsa chimera is shown to bind both metal and PEP in a similar fashion to NmeNANAS wild-
type as discussed in Section 6.5.1. Furthermore, the Nme/Hsa chimera is not thermally stabilised by 
any of the combinations of PEP with ManNAc, rManNAc or ManNAc-6-P.   
 
 
 
 
Addition NmeNANAS (°C) HsaNANAS (°C) Nme/Hsa Chimera (°C) 
Nothing 42.7 ± 0.2 43.0 ± 0.3 43.6 ± 0.3 
EDTA 43.6 ± 0.3 43.2 ± 0.4 42.0 ± 0.2 
Mn2+ 48.9 ± 0.3 46.0 ± 0.4 47.6 ± 0.2 
Mn2+ + PEP 56.2 ± 0.7 52.4 ± 0.2 48.2 ± 0.4 
Mn2+ + ManNAc 49.0 ± 0.4 45.8 ± 0.5 47.6 ± 0.2 
Mn2+ + PEP + ManNAc 48.7 ± 0.2 53.4 ± 0.2 47.8 ± 0.5 
Mn2+ + rManNAc 50.4 ± 0.3 46.3 ± 0.9 47.8 ± 0.3 
Mn2+ + PEP + rManNAc 56.4 ± 0.2 52.9 ± 0.2 47.6 ± 0.5 
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6.6 Structural analysis of Nme/Hsa chimera 
 
6.6.1 Circular dichroism 
CD was used to assess and compare the secondary structure of Nme/Hsa chimera with 
NmeNANAS and HsaNANA-9-PS wild-types (Figure 6.12). The K2D3 server (142) was used to estimate 
the secondary structure composition from CD spectra. Shown in Table 6.3, estimated secondary 
structure is compared to values derived from the crystal structure of NmeNANAS (PDB code: 1XUZ) 
and HsaNANA-9-PS model. 
 
 
 
 
 
 
 
 
Figure 6.12 CD spectra for NmeNANAS (red), HsaNANA-9-PS (blue) and Nme/Hsa chimera (purple). 
 
 
Table 6.3 Predictions of secondary structure composition for NmeNANAS, HsaNANA-9-PS and Nme/Hsa 
chimera calculated from CD data using K2D3 server (142). Theoretical secondary structure composition 
of NmeNANAS and HsaNANA-9-PS calculated from crystallographic coordinates 1XUZ and HsaNANA-9-PS 
model respectively.  
 NmeNANAS   NmeNANAS 
(structure) 
HsaNANA-9-PS   HsaNANA-9-PS   
(model) 
Nme/Hsa 
Chimera 
α-helix 59.9 % 50.3 % 54.3 % 50.1 % 54.9 % 
β-sheet 12.3 % 15.5 % 15.2 % 15.8 % 13.8 % 
other 27.8 % 34.2 % 30.5 % 34.1 % 31.3 % 
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Since kinetic activity of the Nme/Hsa chimera could not be detected (Section 6.4), CD was used to 
ascertain whether the fusion protein was folded in solution. As depicted in Figure 6.12 and Table 6.3, 
the Nme/Hsa chimera is folded in solution and has comparable levels of α-helix and β-sheet to both 
NmeNANAS and HsaNANA-9-PS. Depicted in Figure 6.12, the CD profile of the Nme/Hsa chimera is 
slightly different to that of NmeNANAS and HsaNANA-9-PS. 
 
6.6.2 Mass spectrometry 
The molecular mass of His6-tagged Nme/Hsa chimera was analysed using MS. A theoretical mass 
of 42,930 Da was calculated for the Nme/Hsa chimera from its peptide sequence using ProtParam 
(141). The experimental mass of the Nme/Hsa chimera as determined by MS was 42,926 Da which 
differs by only 0.01 % from the aforementioned calculated mass.  
 
6.6.3 Analytical size exclusion chromatography 
The quaternary state of the Nme/Hsa chimera was investigated via analytical SEC using the 
method outlined in Section 8.5.6. A calibration curve was generated using protein standards of 
known molecular weight. The elution volume (Ve) of protein standards relative to the column void 
volume (V0) was plotted against the log of the protein standards molecular mass. A linear fit of the 
analytical SEC calibration data was determined to have an R2 value of 0.987. The calibration curve 
was subsequently used to extrapolate the molecular masses of each of the Nme/Hsa chimera as 
shown in Figure 6.13. 
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Figure 6.13 (A) Normalised analytical SEC chromatograms for NmeNANAS (red), HsaNANA-9-PS (blue) 
and Nme/Hsa chimera (purple). (B) Analytical SEC calibration curve. Protein standards are marked in 
grey, NmeNANAS in red, HsaNANA-9-PS in blue and Nme/Hsa chimera in purple. A line of best fit is 
plotted in black. (C) Table of estimated and theoretical masses for NmeNANAS and HsaNANA-9-PS and the 
Nme/Hsa chimera.  
 
As shown in Figure 6.13, the Nme/Hsa chimera elutes as a single species at a molecular weight 
corresponding to 83 kDa. The molecular weight of Nme/Hsa chimera determined from analytical SEC 
is thus similar to the theoretical mass for dimeric Nme/Hsa chimera. Displayed in Figure 6.13C, both 
NmeNANAS and HsaNANA-9-PS elute as dimeric enzymes also. The results from analytical SEC 
indicate that the Nme/Hsa chimera is a dimer in solution. 
 
 
 
 
 
 
 
 NmeNANAS  HsaNANA-9-PS Nme/Hsa Chimera 
Ve/V0 1.74 1.73 1.74 
Estimated mass (kDa) 81 85 83 
Theoretical mass of dimer (kDa) 77 81 79 
A B 
C 
238 
 
6.6.4 Attempted crystallisation 
Several attempts at crystallising the Nme/Hsa chimera were made. The Nme/Hsa chimera was 
screened using conditions modified from those previously described for crystallising wild-type 
NmeNANAS (112). Protein crystallisation conditions were also screened using commercially available 
Morpheus, PACT and JCSG screens. Protein was concentrated to 6 mg/mL and 15 mg/mL and 
screened in the absence and presence of ligands. Screens were incubated at 5 °C and 20 °C for 
several months, but none of the conditions that were screened yielded crystals of diffraction quality. 
 
6.6.5 Small-angle X-ray scattering 
Given the lack of success in crystallising the Nme/Hsa chimera, SAXS was used to assess the 
chimera’s solution structure. The Nme/Hsa chimera was analysed in the presence of 1 mM Mn2+ and 
1 mM PEP. The SAXS profile of the Nme/Hsa chimera was determined using the methods outlined in 
Sections 8.5.8 and 8.5.9. Displayed in Figure 6.14A, the scattering profile of the Nme/Hsa chimera is 
compared to the profiles of NmeNANAS and HsaNANA-9-PS in the presence of ligand. Since a crystal 
structure of the Nme/Hsa chimera could not be obtained, the experimental scattering of the 
Nme/Hsa chimera was fitted to CRYSOL (153) plots generated from the NmeNANAS crystal structure 
1XUZ (112) and the HsaNANA-9-PS homology model (Figure 6.14B). 
 
 
Table 6.4 SAXS structural parameters determined for Nme/Hsa chimera compared with parameters for 
NmeNANAS and HsaNANA-9-PS. SAXS data obtained at a wavelength of 1.0332 Å.   
 
 
 NmeNANAS  HsaNANA-9-PS Nme/Hsa Chimera 
I0 (cm
-1) 0.082 ± 0.001 0.079 ± 0.001 0.076 ± 0.001 
Rg (Å) 33.0 ± 0.5 35.1 ± 0.8 33.6 ± 0.1 
Dmax (Å) 116 123 118 
Porod volume (Å3) 121,724 125,364 123,358 
Estimated mass (kDa) 85 88 86 
Theoretical mass of dimer (kDa) 77 81 79 
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Figure 6.14 SAXS profile of Nme/Hsa chimera in the presence of 1 mM Mn2+ and 1 mM PEP. (A) 
Comparison of SAXS data for Nme/Hsa chimera (purple) with NmeNANAS wild-type (red) and HsaNANA-
9-PS wild-type (blue). (B) CRYSOL fits of Nme/Hsa chimera SAXS data with theoretical scattering of 
NmeNANAS wild-type generated from crystallographic coordinates 1XUZ (red line) and theoretical 
scattering generated from the HsaNANA-9-PS wild-type homology model (blue line). SAXS data was 
collected using approximately 10 mg mL-1 protein in 30 mM triethanolamine-HCl buffer at pH 7.5. 
Samples were eluted by SEC (Superdex 200 5/150). 
A 
B 
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The Nme/Hsa chimera structure parameters obtained from SAXS are comparable to those 
obtained for both NmeNANAS and HsaNANA-9-PS wild-types (Table 6.4). As depicted in Figure 
6.14A, the scattering profile of the Nme/Hsa chimera is also similar to those attained for NmeNANAS 
and HsaNANA-9-PS. The molecular mass of liganded Nme/Hsa chimera was calculated from SAXS 
data using SAXS MoW (154), and was estimated to be 86 kDa, which is similar to that expected for 
dimeric protein (Table 6.4). The results from SAXS comply with data obtained from analytical SEC 
which also indicate that the Nme/Hsa chimera is dimeric (Section 6.6.3).   
Shown in Figure 6.14B, the SAXS data obtained for the Nme/Hsa chimera fits well to the 
theoretical scattering profile generated from the liganded NmeNANAS crystal structure (Chi value of 
1.56). The fit to the theoretical scattering profile of the HsaNANA-9-PS model is also good with a Chi 
value of 1.58. The similar theoretical scattering profiles generated for NmeNANAS and HsaNANA-9-
PS are likely caused by their high structural similarity. This similarity is forced by the method of 
model construction where the NmeNANAS structure was used as a template for the HsaNANA-9-PS 
model (Section 6.2.2). The overall structure of the HsaNANA-9-PS model is thus very comparable to 
that of the NmeNANAS crystal structure and the resulting theoretical scattering profiles are almost 
identical.  
Described in Chapter 3, wild-type NmeNANAS undergoes a conformational change in the 
presence of Mn2+ and PEP that is detectable by SAXS. The conformational change in NmeNANAS is 
linked to a hydrogen bonding network that involves the rearrangement of the ManNAc binding site 
upon liganding of PEP. Shown in Figure 6.15, the SAXS profile of the Nme/Hsa chimera resembles the 
profile of liganded and not ligand-free NmeNANAS. This may indicate that the conformational 
change induced by PEP binding is still possible in the Nme/Hsa chimera.  
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Figure 6.15 SAXS profile of Nme/Hsa chimera in the presence of 1 mM Mn2+ and 1 mM PEP compared 
with liganded and ligand-free scattering for NmeNANAS wild-type. SAXS data for liganded Nme/Hsa 
chimera is in purple, liganded NmeNANAS wild-type in red and ligand-free NmeNANAS wild-type in 
green. 
 
Residue NmeGlu282 was identified to play an important role in the hydrogen bonding network of 
NmeNANAS (Chapter 3). Shown in Figure 6.2, NmeGlu282 is conserved as HsaGlu284. MD 
simulations outlined in Chapter 3 revealed that NmeGlu282 forms a hydrogen bond with NmeArg194 
of the opposing monomer. In the Nme/Hsa chimera, residues Gly272 onwards are contributed by 
the HsaNANA-9-PS sequence. An alignment of the HsaNANA-9-PS model with NmeNANAS crystal 
structure 1XUZ (112) is depicted in Figure 6.16, where it can be observed that residue HsaGlu284 
would still be in a suitable position to interact with NmeArg194 in the Nme/Hsa chimera.  
The NmeGlu282-NmeArg194 is the only interaction from the hydrogen bonding network 
identified in Chapter 3 that is retained in the Nme/Hsa chimera. Interestingly, the NmeGlu282-
NmeArg194 interaction is not retained in the Hsa/Nme chimera since NmeArg194 is not conserved in 
HsaNANA-9-PS. NmeArg194 is instead replaced by HsaAsn196 (Figure 6.2) which may not have a 
long enough side-chain to hydrogen bond with NmeGlu282. The abolition of the entire hydrogen 
bonding network in the Hsa/Nme chimera may be the cause of its insolubility. It is also possible that 
insolubility of the Hsa/Nme chimera is caused by repulsive electrostatic interactions not present in 
the Nme/Hsa chimera, or an inability to bury hydrophobic surfaces resulting in dimer instability. 
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Figure 6.16 Alignment of NmeNANAS crystal structure (catalytic domain in grey) with HsaNANA-9-PS 
model (linker and AFPL domain in green) showing the possible H-bond interaction (black dashes) 
between NmeArg194 and HsaGlu284 in the Nme/Hsa chimera.  
 
6.6.6 Analytical Ultracentrifugation 
To determine the stability of the Nme/Hsa chimera quaternary state, sedimentation velocity 
experiments were caried out at varied protein concentrations. To determine if the quaternary state 
of the Nme/Hsa chimera was concentration dependent, samples were run at 0.1 mg/mL, 0.5 mg/mL 
and 1.0 mg/mL. Displayed in Figure 6.17, data was fitted to a continuous size-distribution (cs) model 
using the program SEDFIT (150, 151). Weight average molecular masses were calculated using 
weight average sedimentation coefficients and f/f0 values from cs fits.  
 
 
 
 
 
 
NmeArg194 
HsaGlu284 
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Figure 6.17 Analytical ultra centrifuge fits measured at 280 nm absorbance. (A) Nme/Hsa chimera at 0.1 
mg/mL, residual data (top), and fit of model to data from SEDFIT (bottom). (B) Nme/Hsa chimera at 0.5 
mg/mL, residual data (top), and fit of model to data from SEDFIT (bottom). (C) Nme/Hsa chimera at 1.0 
mg/mL, residual data (top), and fit of model to data from SEDFIT (bottom). (D) Normalised c(s) profiles 
for Nme/Hsa chimera at 0.1 mg/mL (red), 0.5 mg/mL (black) and 1.0 mg/mL (purple). 
 
 
 
C D 
A B 
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Displayed in Figure 6.17, the Nme/Hsa chimera was revealed to exist as two species at the 
concentrations used for AUC. In Figure 6.17D, there is a peak corresponding to an estimated 
molecular weight of 38 kDa (close to that calculated for monomer Nme/Hsa chimera) and a second 
peak to 81 kDa (close to that calculated for dimer Nme/Hsa chimera). A concentration dependent 
equilibrium is observed between these two species where the first peak is increasingly prominent at 
lower protein concentrations and the second peak is increasingly prominent at higher protein 
concentrations. The results from AUC suggest that at lower concentrations the Nme/Hsa chimera 
favours a monomeric quaternary state whereas at higher concentrations a dimeric state is favoured. 
Both NmeNANAS and HsaNANA-9-PS are confirmed to be stable dimers indicating that the 
interactions that stabilise their respective quaternary states have been disrupted in the Nme/Hsa 
chimera. Furthermore, the cs profiles displayed in Figure 6.17D reveal that there is minor protein 
aggregation present at higher sedimentation coefficient values.  
Described in Sections 6.5.3 and 6.5.5, the results from both analytical SEC and SAXS imply that 
the Nme/Hsa chimera exists as a dimer. However, the protein concentrations used for both 
analytical SEC and SAXS were much greater than those used for AUC. As revealed by AUC, the 
Nme/Hsa chimera is primarily dimeric at 1 mg/mL. Consequentially, experiments done above this 
concentration would suggest that the chimera is dimeric.  
Similarly, the results from ITC were obtained at protein concentrations where the chimera is 
likely to have been dimeric whereas for DSF the chimera is likely to have been monomeric. Outlined 
in Chapter 3, the conformational change of NmeNANAS imposed by PEP binding relies on the 
hydrogen bonding network that links the AFPL domain to the catalytic domain. The hydrogen 
bonding network is dependent on a dimeric quaternary state as the key interactions are contributed 
between opposing chains. Without the domain crossed homodimeric structure, the hydrogen 
bonding network is defunct. The ability of the Nme/Hsa chimera to undergo conformational change 
in the presence of PEP, could thus be observed by SAXS, where the Nme/Hsa chimera is dimeric. 
Conversely, the thermal stabilisation of the protein which is associated with PEP binding, could not 
be observed by DSF, where the Nme/Hsa chimera is monomeric. 
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6.7 Summary of results 
 
The Hsa/Nme and Nme/Hsa chimeras were each successfully cloned from the genes encoding 
NmeNANAS and HsaNANA-9-PS. The Nme/Hsa chimera was solubly expressed however soluble 
expression of the Hsa/Nme chimera could not be coerced even with the fusion of an N-terminal GST-
tag. The Nme/Hsa chimera was successfully purified by metal affinity and size exclusion 
chromatography. Unfortunately, no activity could be observed with either ManNAc or ManNAc-6-P 
even at high enzyme concentrations.   
Although the Nme/Hsa chimera was inactive, the protein was still able to bind both Mn2+ and PEP 
with dissociation constants comparable to that of wild-type NmeNANAS. The Nme/Hsa chimera did 
not share a similar thermal melting profile with either wild-type NmeNANAS or HsaNANA-9-PS. As 
determined by DSF, apo-Nme/Hsa chimera melted at a similar temperature to both apo-NmeNANAS 
and apo-HsaNANA-9-PS and was similarly stabilised by Mn2+. Unlike the parent enzymes however, 
the Nme/Hsa chimera was not significantly stabilised in the presence of both PEP and Mn2+. 
Results obtained from SAXS indicate that the Nme/Hsa chimera is capable of undergoing a similar 
conformational change to that observed for wild-type NmeNANAS and HsaNANA-9-PS in the 
presence of PEP and Mn2+. Outlined in Chapter 3, a hydrogen bonding network links the catalytic and 
AFPL domains which are reorganised by PEP liganding to bind ManNAc. Only the NmeGlu282-
NmeArg194 interaction from the hydrogen bonding network is retained in the Nme/Hsa chimera 
through the conservation of residue HsaGlu284.  
The molecular mass of the Nme/Hsa chimera was successfully ascertained using MS and the 
protein was determined to be folded in solution using CD. At high protein concentrations (above 1 
mg/mL), the Nme/Hsa chimera was revealed to be a dimer by SAXS, Analytical SEC and AUC. AUC 
also uncovered a concentration dependent quaternary state of the Nme/Hsa chimera at protein 
concentrations below approximately 1 mg/mL.  
The results from AUC imply that under the conditions used for SAXS and ITC, the Nme/Hsa 
chimera was dimeric and for DSF the Nme/Hsa chimera was monomeric. This correlates with 
observations that PEP did not stabilise the Nme/Hsa chimera in DSF but had similar ITC and SAXS 
profiles to wild-type NmeNANAS with PEP.  
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6.8 Discussion 
 
The work described in Chapter 6 sought to interconvert the catalytic functions of a bacterial 
NANAS with a mammalian NANA-9-PS. This was to be achieved by interchanging the AFPL domains 
of NmeNANAS and HsaNANA-9-PS to create two chimeric proteins; one with an NmeNANAS catalytic 
domain joined to a HsaNANA-9-PS linker and AFPL domain (Nme/Hsa chimera), and one with a 
HsaNANA-9-PS catalytic domain joined to an NmeNANAS linker and AFPL domain (Hsa/Nme 
chimera).  
The Hsa/Nme and Nme/Hsa chimeras were both successfully cloned, however, only the Nme/Hsa 
chimera was solubly expressed. Unfortunately, neither NANAS nor NANA-9-PS activity was observed 
with the Nme/Hsa chimera. Though inactive, DSF and ITC indicated that the Nme/Hsa chimera was 
able to bind both Mn2+ and PEP. Unlike NmeNANAS and HsaNANA-9-PS, the chimeric protein was 
not thermally stabilised in the presence of PEP. SAXS analysis indicates that the Nme/Hsa chimera 
retains the ManNAc binding-site pre-organisation mechanism of NmeNANAS, however, these results 
conflict with the lack of thermal stabilisation observed via DSF. 
AUC revealed that at high protein concentrations (like those used for ITC and SAXS), the Nme/Hsa 
chimera was dimeric, whilst at low protein concentrations (like those used for DSF), the Nme/Hsa 
chimera was monomeric. The concentration dependent quaternary state of the Nme/Hsa chimera is 
the likely cause for the variable PEP binding capability observed, as the protein would need to be 
dimeric for the hydrogen bonding relay to function.  
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Chapter 7 
Discussion  
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7.1 Chapter outline 
 
This chapter summarises and interprets the key findings made in this thesis. The role of the AFPL 
domain is discussed in detail, as are the evolutionary relationships of the SAS family. Potential, 
future analyses which continue the research outlined in this thesis are also discussed.  The work 
described in this thesis builds upon previous studies of the SASs (5, 112, 113); enzymes which are 
responsible for the biosynthesis of sialic acids.  Sialic acids are involved in many important biological 
processes, such as cell signalling, cell motility and evasion of host immune systems. The investigation 
of the enzymes responsible for sialic acid synthesis provides valuable insight into their numerous 
roles.  
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7.2 Role of the AFPL domain 
 
7.2.1 Contribution of a specific catalytic residue 
(β/α)8 Barrel extensions serve many roles in nature (183-186). They have been observed to have 
functional roles such as aiding in catalysis or regulation (183, 185) and have also been shown to 
provide structural support (184). The AFPL domain of the SAS family is a unique (β/α)8 barrel 
decoration (112). Described in Chapters 4 and 5 of this thesis, sequence pertaining to the AFPL 
domain is observed in both mammalian and bacterial SASs, with the only exception being members 
of the bacterial Type IV SAS clade. The crystal structure of NmeNANAS revealed that the AFPL 
domain contributes a single arginine residue into the active site of the opposing monomer (Figure 
7.1). Residue NmeArg314 contributes hydrogen bonding interactions with the N-acetyl functionality of 
rManNAc and hence ManNAc. NmeArg314 is completely conserved in bacterial SASs which contain an 
AFPL domain. The high conservation of this arginine residue implicates its importance in bacterial 
SASs.  
 
 
 
 
 
 
 
 
 
Figure 7.1 Close up of NmeNANAS active site. Residues contributed by the catalytic domain are in grey, 
linker in orange and AFPL domain in blue. ManNAc is coloured green, PEP pink, Mn2+ yellow and waters 
are shown in red. H-bonds are depicted with black dashes and dipolar bonds with red dashes. NmeNANAS 
PDB coordinates (1XUZ) (112). 
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From the crystal structure of NmeNANAS, the role of NmeArg314 appears to be in the binding of 
ManNAc, however, the results obtained in Chapter 2 of this thesis indicate that the guanidinium 
functionality of NmeArg314 is vital in steering ManNAc into a reactive position with PEP. Whilst 
removal of the functionality of NmeArg314 abolishes activity, it does not remove the ability of the 
enzyme to bind ManNAc, implying that there may be other, more vital interactions involved in 
binding of the NANAS sugar substrate.   
As previously mentioned, NmeArg314 is fully conserved in bacterial SASs which bear AFPL domains. 
The structure of SsuSAS, detailed in Chapter 5, similarly positions the congruent catalytic Arg residue 
(SsuArg301), into the active site of the opposing monomer. The conservation of the NmeArg314 residue 
in LegSs and PseSs is not surprising given that the sugar substrate of each clade contains an N-acetyl 
functional group at position C-2 (Figure 7.2). The C-2 N-acetyl group of the Pse sugar substrate, 2,4-
diacetamido-2,4,6-trideoxyaltrose, has inverted stereochemistry when compared with the sugar 
substrates of NANAS and LegS. It is unknown if or how the difference in substrate stereochemistry 
would affect the role of the catalytic Arg in PseSs, however, the full conservation of NmeArg314 in the 
PseS clade implies that the residue plays an important role. It is highly likely that the role of the 
conserved Arg residue in NANASs, LegSs and PseSs is similar to that observed for NmeNANAS, and 
that the charged guanidinium group steers each of these substrates into a reactive position.  
 
 
 
 
 
Figure 7.2 The sugar substrates of (A) NANAS, (B) LegS and (C) PseS. 
 
The lack of an AFPL domain and thus a corresponding residue to NmeArg314 in Type IV SASs, poses 
an interesting question as to how the enzymes of this clade position their aldehyde substrate for 
reaction. Given that the aldehyde substrate of CteSAS could not be determined, it is not possible to 
make any precise inferences into this query. The absence of the AFPL domain and catalytic Arg in 
Type IV SASs may give some insight into the identity of the sugar substrate for this clade. It is 
possible that the catalytic Arg is not required in Type IV SASs because the aldehyde substrate of the 
Type IV clade does not have an N-acetyl functionality at position C-2. The simplest 6 carbon ManNAc 
derivative with this parameter – mannose, was assayed with CteSAS with no observable activity. 
Further investigation is required to uncover the substrate and mechanism of this enzyme. 
A B C 
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Although mammalian NANA-9-PSs also bear AFPL domains (115), NmeArg314 is absent from the 
somewhat limited, available sequences of mammalian SASs. Instead, a fully conserved Val residue is 
present in each of the known mammalian SAS sequences. The absence of a congruent residue to 
NmeArg314 in mammalian SASs is particularly interesting given that the substrate of NANA-9-PS is 
ManNAc-6-P - which, like the substrates of the bacterial NANASs, LegSs and PseSs, contains an N-
acetyl functionality at position C-2.  
The absence of a catalytic Arg in the mammalian SAS family may indicate that a different 
mechanism is employed to position ManNAc-6-P for reaction with PEP. Further evidence that the 
interaction between a catalytic Arg and the N-acetyl group of ManNAc-6-P is not required in 
mammalian SASs, is given by the ability of HsaNANA-9-PS to catalyse KDN-9-P synthesis by 
condensing mannose-6-phosphate with PEP (182). Conversely, none of the wild-type bacterial 
enzymes described in this thesis or in previous studies are reported to be capable of synthesising 
KDN from PEP and mannose, further implicating the necessity of the catalytic Arg interaction in 
NANAS, LegS and PseS enzymes. Of note, only the NANA-9-PSs of H. sapiens and D. melanogaster 
have been observed to exhibit KDN-9-PS activity (30, 182). Conversely, the NANA-9-PS of Mus 
musculus was shown to be unable to produce KDN-9-P (187). 
Given the absence of the AFPL domain catalytic Arg in NANA-9-PSs, the residues which interact 
with the phosphate group of ManNAc-6-P may play a key role in both sugar substrate binding and 
reactive positioning. The Km (ManNAc-6-P) for NANA-9-PS enzymes is significantly lower than that 
observed for the Km (ManNAc) for NANAS enzymes (103, 182). It is possible that the role of the 
catalytic Arg is superseded by the residues which interact with the phosphate functionality of 
ManNAc-6-P in NANA-9PSs. Further experimental evidence would be required to compare the sugar 
substrate binding efficiencies of bacterial and mammalian SASs, such as ITC experiments using 
rManNAc and reduced ManNAc-6-P as well as site directed mutagenesis of key residues. 
 
 
 
 
 
252 
 
7.2.2 Pre-organisation of ManNAc binding site via a hydrogen 
bonding network 
Not only does the AFPL domain donate a key active site residue in NmeNANAS, but it also plays 
an essential role in controlling ManNAc binding. The NmeNANAS AFPL domain truncation, 
NmeG272Term, was inactive and unable to bind ManNAc. Conversely, the truncation could still bind 
PEP, implying that the residues contributing to PEP binding are provided by the catalytic domain 
alone. Given that ManNAc binding is lost in NmeG272Term, but not in NmeR314A, the AFPL domain 
must be essential to binding ManNAc. As NmeArg314 is non-essential to ManNAc binding, the AFPL 
domain likely contributes more than just a single essential residue into the active site.  
The results obtained in Chapter 2 of this thesis reveal that NmeNANAS requires PEP to be bound 
before the enzyme can bind ManNAc, indicating that PEP liganding initiates a rearrangement event, 
pre-organising the ManNAc binding site. Interestingly, ITC results also reveal that PEP binding is 
entropically favourable – counter to the expected observation of an enthalpically favourable 
rearrangement. The entropically favoured rearrangement of an enzyme is not without precedent, 
with other examples of enthalpically unfavourable binding events previously reported (188, 189).  
The largely favourable entropy in these examples is contributed by a hydrophobic effect where 
either water molecules are freed or hydrophobic surfaces are buried. Bezerra, G. A et al (188) 
describe an exceptionally large domain motion upon ligand binding in human dipeptidyl peptidase 
III, which is entropy driven. Dipeptidyl peptidase III releases water molecules from the substrate 
binding cleft of the enzyme upon substrate binding, a process which acts as a major thermodynamic 
driving force. The binding of PEP in NmeNANAS is accompanied by an observable conformational 
change as well as a significant thermal stabilisation of the enzyme. Given the structural analyses of 
the quaternary interfaces in the AFPL domain truncation and wild-type NmeNANAS enzyme, it is 
entirely plausible that the conformational change of NmeNANAS induced by PEP liganding involves a 
similar process which is driven by hydrophobic surface burial.  
The absence of PEP induced conformational change and thermal stabilisation in NmeG272Term 
implicates the AFPL domains involvement in ManNAc binding site pre-organisation. Furthermore, 
MD simulations of PEP-bound wild-type NmeNANAS revealed that the flexibility of the ManNAc 
binding (β2-α2) loop and AFPL domain were restricted, enabling the catalytically critical NmeArg314 
residue to be held closer to the active site when compared to ligand-free wild-type. This observation 
further validates that conformational change upon PEP binding constructs the ManNAc binding 
pocket of NmeNANAS. 
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MD simulations and site directed mutagenesis analyses identified a hydrogen bond relay which 
links PEP binding to rearrangement of the AFPL domain. Residues NmeGlu282 and NmeGlu134 are each 
fully conserved in bacterial NANAS, LegS and PseS. The conservation of the hydrogen bonding 
network in bacterial SASs which bear AFPL domains, implies that the mechanism elucidated for 
ManNAc binding site pre-organisation in NmeNANAS is common to all members of the NANAS, LegS 
and PseS clades. Furthermore, CjeNANAS, CjeLegS, CjePseS and SsuSAS each undergo a similar 
conformational change and display a similar thermal shift in the presence of PEP when compared 
with wild-type NmeNANAS. 
Discussed in Chapter 4, PEP binding did not appear to confer a significant conformational change 
in CteSAS, which complies with the absence of an AFPL domain. Interestingly, even though CteSAS 
does not contain an AFPL domain, PEP was observed to provide a significant amount of thermal 
stability to the enzyme. The lack of an AFPL domain in CteSAS may indicate that members of the 
bacterial Type IV SAS clade have a unique mechanism for sugar substrate, binding site pre-
organisation. Unfortunately, due to the unidentified sugar substrate and instability of CteSAS, ITC 
experiments were problematic and it could not be determined as to whether or not PEP binding was 
required for the subsequent binding of a sugar substrate. 
Whilst mammalian SASs do not lack an AFPL domain, the identified residues of the bacterial 
hydrogen bonding network are not conserved in NANA-9-PSs. Similar to each of the AFPL domain-
bearing, bacterial SASs investigated in this thesis, HsaNANA-9-PS was observed to undergo a 
conformational change and thermal shift in the presence of PEP. Given both the aforementioned 
observations and the presence of an AFPL domain in mammalian SASs, it is plausible that a similar 
network of residues is involved in a ManNAc-6-P binding site pre-organisation mechanism in the 
mammalian SAS family. Further investigation would be required to ascertain the exact residues 
involved, such as site-directed mutagenesis as well as molecular dynamics simulations of HsaNANA-
9-PS. 
The existence of a similar PEP binding mechanism to NmeNANAS in HsaNANA-9-PS is evidenced 
by the conformational change of the Nme/Hsa chimera in the presence of PEP. Since the catalytic 
domain is contributed by NmeNANAS and the linker and AFPL domain is contributed by HsaNANA-9-
PS, the typical interactions involved in either wild-type hydrogen bonding networks are not possible 
in the Nme/Hsa chimera. As a conformational change can still be induced by PEP binding, it is 
possible that the interactions between the NmeNANAS catalytic domain and HsaNANA-9-PS linker 
and AFPL domain are similar enough to that of either wild-type species, so as to substitute for their 
normal hydrogen bonding relay interactions. 
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7.2.3 Stabilisation of quaternary structure 
Lastly, the AFPL domain plays an important role in stabilising the quaternary state of NmeNANAS. 
The removal of the AFPL domain from NmeNANAS resulted in destabilisation of the protein’s 
quaternary structure. The AFPL domain of NmeNANAS covers a hydrophobic cleft in the catalytic 
domain which is exposed in NmeG272Term. It is likely that the exposure of this hydrophobic core 
contributes to the protein’s instability and eventual aggregation. Furthermore, the significant loss of 
intermolecular surface area contact in NmeG272Term when compared with wild-type NmeNANAS is 
responsible for destabilising the quaternary state of the truncated protein, which would in turn 
expose additional hydrophobic surfaces of NmeG272Term. The instability of NmeG272Term 
correlates with observations made of a previous truncation of the HsaNANA-9-PS enzyme. The 
truncation of HsaNANA-9-PS generated by Hao, J. et al (103), was also inactive and was noted to 
aggregate after a few hours. This indicates that the AFPL domain in HsaNANA-9-PS plays an 
analogous role to that of the AFPL domain in NmeNANAS. 
Similar to NmeG272Term, the Nme/Hsa chimera has a schizophrenic quaternary structure. Whilst 
the chimera is still able to retain some characteristics of the parent wild-type enzymes (such as 
conformational change induced by PEP binding), the Nme/Hsa chimera is not able to catalyse NANAS 
or NANA-9-PS reactions; even at concentrations where the chimera is predominantly dimeric. This is 
likely due to the incompatibility of the interfaces between the linker/AFPL domain and catalytic 
domain of the chimera. At high concentrations, the monomer-dimer equilibrium favours dimeric 
Nme/Hsa chimera, which may be able to overcome the energy barrier of the incompatibilities 
between the two interfaces. However, it is likely that the interfaces are too dissimilar to be able to 
complete a fully functional enzyme. The alternate, Hsa/Nme chimera is insoluble, which likely 
indicates that even fewer of the interactions are compatible between the Hsa catalytic domain and 
Nme linker/AFPL domain than between the Nme catalytic domain and Hsa linker/AFPL domain. 
A previous chimera combining the linker and catalytic domain of H. sapiens NANA-9-PS with the 
AFPL domain of M. musculus NANA-9-PS (Hsa/Mmu chimera) was purified as a GST-fusion complex, 
and was determined to have both NANA-9-PS as well as KDN-9-PS activity (187). Whilst the 
Hsa/Mmu chimera had solubility issues it still retained activity, unlike the Nme/Hsa chimera. This is 
likely due to a much higher compatibility between the interfaces of the Hsa/Mmu chimera when 
compared with the Nme/Hsa chimera.  
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The two parent enzymes of the Hsa/Mmu chimera are more closely related with both source 
organisms being mammalian, whilst the source organisms of the Nme/Hsa chimera are more 
genetically distant. The N. meningitidis SAS shares only 28.5 % sequence identity with the H. sapiens 
SAS whilst the M. musculus SAS shares 94.7 % identity. The subunit interfaces in the Hsa/Mmu 
chimera would thus have a far greater chance of retaining interface contacts than that of the 
Nme/Hsa chimera. 
As previously noted, members of the Type IV SASs naturally lack an AFPL domain. The results 
outlined in Chapter 4 of this thesis reveal that CteSAS is a tight dimer even though the interdomain 
interactions are limited when compared with AFPL domain bearing SASs. It is likely that the 
interactions between the catalytic domains of the Type IV SASs have evolved to be much stronger 
than those of AFPL domain bearing SASs in order maintain a dimeric quaternary state. A crystal 
structure of CteSAS would prove invaluable in determining the interactions of the dimer interface. 
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7.3 Evolutionary relationships of the sialic 
acid synthase family 
 
7.3.1 The bacterial SAS family 
Early investigation into the evolution of the SASs proposed that the enzymes were closely related 
to the PEP aldolase family (122).  It was hypothesised that the SASs, DAH7PSs and KDO8PSs were 
descended from an ancestral PEP aldolase, as each of the previously mentioned enzymes perform 
very similar reaction chemistries. Furthermore, each of these PEP aldolases comprises a core (β/α)8 
barrel catalytic domain. More recent investigations have dismissed this proposal, indicating that 
although the C-O bond cleavage mechanism is shared between these enzymes, it is only the 
DAH7PSs and KDO8PSs that are closely related (113, 134). The aforementioned investigations state 
that SASs appear to have a far more distant relationship to DAH7PSs and KDO8PSs, with the 
sequence identity of SASs to DAH7PSs and KDO8PSs being less than 10 % (113). Furthermore, the 
SASs have a distinct active site architecture as well as a unique barrel decoration that is not present 
in any DAH7PS or KDO8PS enzyme.  
The work in this thesis reveals that the bacterial SAS family can be subdivided into four distinct 
clades: NANASs, LegSs, PseSs and Type IV SASs. As previously mentioned, NANAS, LegS and PseS 
bear AFPL domains and behave very similarly with regards to their PEP binding mechanisms. Whilst 
the AFPL domain is involved in the positioning of the sugar substrate in these enzymes it is likely that 
the residues provided by the β2-α2 loop provide substrate selectivity.  
The Type IV SASs are unique in that they naturally lack AFPL domains. Originally, the Type IV SASs 
were proposed to be more closely related to the mammalian, NANA-9-PS enzymes and it was 
speculated that they synthesised NANA-9-P from PEP and ManNAc-6-P (122). The work in this thesis 
proved that this was not the case for CteSAS, thus the true function of the Type IV SASs remains 
elusive.  
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An interesting observation made from the SAS phylogram described in Chapter 4, is the unusual 
placement of several SASs with known NANAS activity in the LegS clade. Both the SAS from E .coli 
and S. agalacticae have been previously observed to synthesise NANA (95, 105, 158). Furthermore, 
SsuSAS (Chapter 5) has NANAS activity, yet is also placed in the LegS clade of the SAS family. SsuSAS, 
SagSAS and EcoSAS have high sequence identity to characterised LegSs such as LpnLegS and CjeLegS. 
Unfortunately, LegS activity has not been tested for in SsuSAS, SagSAS or EcoSAS.  
It is quite likely that LegSs are capable of catalysing both NANA and Leg biosynthesis. Described in 
both Chapter 4 of this thesis and a previous study (64), CjeLegS is observed to have minimal NANAS 
activity. In addition, complementation studies have indicated that LpnLegS could restore the 
biosynthesis of NANA in an E. coli gene knockout mutant, suggesting that the SAS from  L. 
pneumophila could synthesise either Leg or NANA (136). In addition, modelling of SsuSAS indicates 
that the enzyme’s active site is better suited to accommodate 2,4-diacetamido-2,4,6-
trideoxymannose than ManNAc.  
The ability of LegSs to catalyse the biosynthesis of both NANA and Leg, may provide insight into 
the ancestry of the SAS family. It is possible that NANAS enzymes such as those from N. meningitidis 
and C. jejuni evolved from LegSs which are capable of catalysing both NANAS and LegS reactions. The 
evolutionary pressure to mask pathogenic organisms such as N. meningitidis and C. jejuni from host 
immune responses may have driven the development of NANAS specific enzymes. This hypothesis 
would need to be further examined, as LegS and PseS activity have not been examined for either 
NmeNANAS or CjeNANAS.  
Similarly, it is possible that the PseS clade evolved from an ancestral LegS, as PseSs are more 
closely related to LegSs than NANASs or Type IV SASs. The substrate of LegS is quite similar to that of 
PseS, but whether or not LegSs can catalyse the formation of Pse, or PseSs the formation of Leg, is 
currently unknown. Described in Chapter 4, CjePseS cannot catalyse the formation of NANA. Both 
Leg and Pse are involved in the motility of prokaryotes, which is arguably a more fundamental and 
less niche evolutionary driving force than host immune evasion. It is thus possible that the enzymes 
required for the synthesis of Leg and Pse may have evolved before those involved in NANA 
biosynthesis.  
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The evolution of Type IV SASs is particularly interesting, as the proteins of the Type IV clade are 
distinct from the other members of the SAS family. The absence of the AFPL domain from the Type 
IV SASs may indicate that the decoration was lost due to its lack of necessity to the Type IV catalytic 
mechanism, or that Type IV SASs resemble an ancestral enzyme, prior to the acquisition of the AFPL 
domain in SAS evolution. The latter theory is supported by the previous findings of Lewis, A. L. et al 
(134) who identify several archael sequences in the Type IV clade and similarly suggest that the 
members of the Type IV clade are of a more ancient origin than the LegS, PseS and NANAS enzymes. 
The preceding arguments for the evolution of the bacterial SASs ignore the possibility of 
paralogous gene transfer between mammalian and bacterial SASs. Due to the similarity of NANA 
biosynthesis in both bacteria and mammals, it was once believed that the genes for bacterial 
NANASs had been acquired from the mammalian paralogue through horizontal gene transfer or vice 
versa (122). This is exceedingly unlikely given the wide distribution of bacterial and mammalian SASs, 
as well as the presence of several archael sequences in each of the SAS clades from the phylogram 
described in Lewis, A. L. et al (134). The presence of archael sequences in each of the SAS clades 
indicates their divergence occurred long ago.  Furthermore, there is a significant lack of sequence 
similarity between NANA and NANA-9-PS enzymes. Bacterial NANASs are far more closely related to 
other bacterial SASs than to mammalian NANA-9-PSs. As previously mentioned, NANA-9-P 
biosynthesis involves phosphorylated metabolites and an additional enzyme to phosphorylate and 
dephosphorylate ManNAc. Conversely, none of the bacterial sialic acids are known to utilise similar 
routes for biosynthesis.  
Lewis, A. L. et al (134) propose an alternative theory for the evolution of both bacterial and 
mammalian SASs, stating that present day SASs, which initially appeared to have an animal heritage, 
are more likely to be the present-day counterparts of an ancient pathway that was universally 
adopted by deuterostome animals.  Lewis, A. L. et al also suggest that SAS biosynthesis in animals 
did not arise by lateral gene transfer, but was instead inherited in the traditional sense, 
accompanied by multiple gene losses along other eukaryotic lineages.  
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7.3.2 Evolution of the antifreeze protein fold 
The theory of SAS evolution proposed by Lewis, A. L. et al  (134) is particularly interesting with 
respect to the evolution of the antifreeze protein fold which is present in both bacterial and 
mammalian SASs as well as Type III antifreeze proteins (115, 117). Based upon this theory, it is likely 
that the antifreeze protein fold originated in the SAS family and was eventually commandeered and 
modified to resemble modern, Type III antifreeze proteins.  
This correlates with the propositions of Baardsnes, J. et al (117) who observed that not only is the 
SAS AFPL domain related to Type III fish antifreeze proteins, but that many other types of antifreeze 
proteins have been evolutionarily repurposed.  Type II antifreeze proteins have been thought to 
have evolved from lectins, plant antifreeze proteins have been thought to have evolved from 
enzymes involved in polysaccharide hydrolysis, and carrot antifreeze proteins are evolutionarily 
related to a polygalacturonase inhibitor (117). Several modern antifreeze proteins are thus modified 
from proteins involved in sugar binding, which correlates with the theory that Type III antifreeze 
proteins may have been similarly adapted from the SAS AFPL domain. Baardsnes, J. et al also 
speculated that the hydroxyl groups of sugars and polysaccharides resemble the oxygen atoms on 
certain ice planes, and predicted that the AFPL domain of the SAS family was involved in sugar 
binding, prior to the elucidation of the NmeNANAS structure 1XUZ, and long before the findings 
reported in this thesis. 
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7.4 Future work 
 
7.4.1 Drug Design 
As previously mentioned, NANAS is essential to the pathogenesis of N. meningitidis, H. influenza, 
E. coli K1 and C. jejuni. Given the essential role of the catalytic Arg residue in bacterial SASs and its 
absence in the mammalian NANA-9-PS enzyme, inhibitors could be designed to take advantage of 
this difference by binding and removing access to the Arg guanidinium functionality. A previous 
analysis of SagSAS revealed that activity could be inhibited with the addition of phenylglyoxal, a 
compound which covalently modifies accessible arginine residues (105). Inhibitors could also be 
derived from PEP analogues, as has been previously described for both DAH7PS and KDO8PS 
enzymes (190, 191), and engineered to be specific to bacterial SASs.  Currently, the only inhibitor 
designed for NmeNANAS is the tetrahedral intermediate mimic described by Liu, F. et al (113).  
 
7.4.2 Crystallisation 
Currently, the structures of NmeNANAS and SsuSAS are the only complete SAS crystal structures 
known, and only the AFPL domain of HsaNANA-9-PS has been elucidated. The determination of 
additional SAS structures will be essential to uncovering evolutionary differences and identifying the 
residues involved in substrate selectivity between these enzymes. While it is yet to be determined 
whether or not SsuSAS is a LegS, there is no structure of a PseS, Type IV SAS or NANA-9-PS currently 
available. The work in this thesis has extensively trialled a range of crystallisation conditions for 
several enzymes, however, further work may still be done in this area. In particular, the thermal 
stability of SASs in the presence of Mn2+ and PEP may provide assistance in crystallisation. Although 
the enzymes described in this thesis were trialled with ligand present, conditions could still be 
optimised to provide diffraction quality crystals.  
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7.4.3 Evolution of the SAS family 
The work in this thesis outlines a preliminary investigation into the evolutionary history of the 
SAS family. Further analyses are required to probe the relationships within the SAS family and 
determine the ancestry of each clade. The work outlined in this thesis proposes that LegSs may be 
capable of catalysing both NANAS and LegS reactions. Several bacterial SASs, identified as LegSs in 
this thesis, have been denoted as NANASs in online databases, however, their ability to synthesise 
Leg has never been determined. Similarly, whether or not NANASs can catalyse LegS or PseS 
reactions and whether PseSs can catalyse LegS reactions or vice versa, has never been fully 
investigated. The absence of information in this regard is likely a result of the sugar substrates for 
LegSs (2,4-diacetamido-2,4,6-trideoxymannose) and PseSs (2,4-diacetamido-2,4,6-trideoxaltrose) 
not being commercially available and requiring several steps to be chemically synthesised (161). The 
work outlined in Chapter 5 of this thesis strongly indicates that SsuSAS is capable of LegS activity, 
however, kinetic analysis with 2,4-diacetamido-2,4,6-trideoxymannose would solidify these claims. 
The most direct method to determine whether or not different members of the SAS family are 
able to synthesise a variety of reactions, is through kinetic characterisation. However, this could also 
be proven through gene complementation studies. The restoration of a NANA biosynthetic pathway 
in a gene knockout mutant has been previously examined with LpnLegS (136), and similar 
experiments with other SASs could be used to the same effect. The determination of substrate 
plasticity in the SAS family would provide valuable insight into the evolution of the different clades. 
 
7.4.4 Can SAS activity be interconverted? 
Another interesting avenue in investigating the evolutionary relationships of the SAS family, is to 
determine which specific residues define the members of each clade and control substrate selection. 
Outlined in Chapter 4 of this thesis, there are two specific areas where the peptide sequence varies 
between clades; the first is a section on the AFPL domain linker and the second is the β2-α2 loop. 
Both regions provide residues proximal to the sugar binding site and are likely involved in sugar 
substrate recognition. Residues identified from the models and substrate docking experiments of 
CjeNANAS, CjeLegS and CjePseS in Chapter 4 may provide a basis for site-directed mutagenesis 
experiments to interconvert the activities of these enzymes. Similarly, chimeric enzymes could be 
generated which interchange the AFPL domain linker regions or β2-α2 loops.  
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The work outlining the H. sapiens and N. meningitidis chimeras in Chapter 6 identifies issues 
involved with interchanging the AFPL domains of different SASs. The compatibility of interdomain 
contacts needs to be examined thoroughly when constructing SAS AFPL domain chimeras. It is 
possible that the stability of SAS chimeras could be improved through site directed mutagenesis 
along the dimer interface, in an effort to strengthen interdomain interactions. 
The lack of NANAS activity in CteSAS is likely a result of the absence of an AFPL domain. It may be 
possible to confer NANAS, LegS, PseS or NANA-9-PS activity by incorporating an AFPL domain from a 
member of a selected SAS clade. As aforementioned, the naturally truncated form of CteSAS may be 
indicative of an ancestral SAS enzyme, and the ability of CteSAS to incorporate an AFPL domain may 
provide some insight into the evolution of the unique antifreeze protein fold.  
 
7.4.5 What is the reaction catalysed by Type IV SASs? 
As previously mentioned, the sugar substrate of the Type IV SAS clade has yet to be determined.  
Further kinetic analysis of alternative sugars with CteSAS or another Type IV SAS would be needed to 
identify the compound that is reacted with PEP. ITC could be used to determine whether particular 
sugar molecules are able to bind to CteSAS and provide a profile to narrow down possible targets. 
The crystallisation of a Type IV SAS would provide invaluable insight into the catalytic site and sugar 
binding pocket. Molecular modelling could then be used to investigate or probe the sugar binding 
site, and elucidate structural features pertaining to the substrate molecule. Another method would 
be to determine which sialic acid compounds are present in a selected organism which expresses a 
Type IV SAS, using NMR and mass spectroscopy. By identifying the sialic acids which are present in 
the organism, the identity of the sugar substrate that is reacted with PEP could be retrosynthetically 
determined. 
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7.5 Concluding remarks 
Sialic acids are almost ubiquitous in nature and are involved in a wide variety of intercellular 
processes. Sialic acids play a key role in the pathogenesis of neuroinvasive pathogens and as such, 
bacterial SASs such as NANAS are exemplary drug targets. Little is currently understood about the 
evolution of SASs which are widespread; present in both bacteria and mammalian species. The work 
outlined in this thesis has afforded considerable insight into the catalytic mechanism of NmeNANAS, 
and the role of the structurally unique, AFPL domain. Understanding the mechanism of SAS enzymes 
provides a valuable model for drug design against pathogenic organisms such as N. meningitidis and 
C. jejuni. Furthermore, a second SAS crystal structure has been elucidated, and an investigation into 
the evolutionary relationships of the SAS family has uncovered four distinct SAS clades and identified 
structural variances, which may control substrate selectivity.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
264 
 
Chapter 8 
Materials and Methods 
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8.1 Figures and alignments 
 
8.1.1 Protein structure figures 
Figures of protein structures were created using PyMOL (version 1.5, Schrödinger LLC) (192). 
 
8.1.2 Multiple sequence alignments 
Multiple sequence alignments were generated using Tcoffee (193) or ClustalW (155) and 
formatted for display using Jalview (159). 
 
8.1.3 Generation of phylograms 
ClustalW alignments were used to generate a distance matrix using the default settings. The 
distance matrix was subsequently entered into Figtree (157) to generate the phylograms displayed.  
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8.2 Reagent preparation 
  
8.2.1 Water 
All water used in these experiments was from a Millipore Milli-Q system. This water is referred to 
as Milli-Q water. Water used for PCR and crystallisation experiments was autoclaved prior to use. 
 
8.2.2 pH Measurements 
pH measurements were made using a Denver Instruments UB-10 Ultra-Basic pH meter, with a 
standard probe. Solutions were acidified by addition of 1 M or 10 M HCl and alkalised by addition of 
either 1 M or 10 M NaOH. When chloride ions were to be avoided (for circular dichroism 
experiments) H2SO4 was used instead of HCl. Unless otherwise noted, buffers were pH adjusted at 
room temperature. 
 
8.2.3 Removal of metal ions from solutions 
Divalent metal ions were removed from buffers used for metal dependency experiments by 
treatment with Chelex® 100 resin (Bio-Rad). The resin was added to the buffer solution at a ratio 
approximately 5 g per 100 mL of buffer and then stirred for approximately 1 hour. Resin was 
subsequently filtered under vacuum (0.2 µm filter). The resin invariably caused the pH of the 
solution to increase, often necessitating adjustment to correct the pH of the Chelex treated solution. 
Glassware used during and after chelex treatment were washed with concentrated nitric acid.    
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8.2.4 Determination of substrate concentrations 
Concentrations of PEP and ManNAc solutions were determined using the 232 nm assay with 
NmeNANAS. Known volumes of a solution containing the substrate for which the concentration was 
to be measured were added to the assay cuvette while the second substrate was kept at excess 
concentration. To confirm the desired substrate was limiting, after the enzyme catalysed reaction 
was complete more was added to the assay. 
The observed change in absorbance was measured in duplicate as ΔArxn. A control sample lacking 
substrates was used to measure the change in absorbance upon enzyme addition (ΔAenz). The 
corrected final change in absorbance, calculated as ΔArxn - ΔAenz, was converted to the concentration 
of the limiting substrate by the Beer-Lambert law, using the extinction coefficient of PEP (2.8 x 103 
M-1 cm-1). 
 
8.2.5 Antibiotics 
Ampicillin was added to all growth media to a final concentration of 0.1 mg/mL. Stock solutions 
of ampicillin at 100 mg/mL dissolved in Milli-Q were created, filter sterilised and stored at -80 °C, 
and freeze-thawed a maximum of two times. The E. coli Rosetta™ 2 (DE3) expression cell line 
contains resistance for chloramphenicol and the chaperone 3 expression cell line contains resistance 
to chloramphenicol and spectinomycin. When these cell lines were used, appropriate antibiotics 
were added to all growth media in addition to ampicillin, to a final concentration of 25 µg/mL for 
chloramphenicol and 0.1 mg/mL for spectinomycin. Stock solutions of chloramphenicol were 
dissolved in ethanol at 25 mg/mL and spectinomycin stocks were dissolved in Milli-Q at 10 mg/mL. 
Antibiotics were filter sterilised and stored at -80 °C, and freeze-thawed a maximum of two times. 
 
8.2.6 Culture media 
Lysogeny-broth (LB) agar was prepared by dissolving LB (Lennox L) (20 g L−1) and agar (15 g L−1) 
base in Milli-Q water and sterilised by autoclaving. The LB-agar solution was then heated in a 
microwave oven until boiling, and left to cool in a 60 °C oven. The LB-agar solution was then further 
cooled to 50 °C before antibiotic(s) were added immediately prior to pouring into round petri dishes. 
LB media for plasmid extraction, pre-cultures and protein expression cultures were prepared by 
dissolving 20 g L−1 LB (Lennox L) base in Milli-Q water and sterilised by autoclaving. Antibiotic(s) were 
added immediately prior to use. 
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8.3 Cloning and transformation 
  
8.3.1 Primers  
Primers were designed by hand or by PrimerX (www.bioinformatics.org/primerx) and synthesised 
by GeneWorks or Invitrogen. Primers were stored at 300 mM in autoclaved TE-buffer (10mM Tris-
HCl, 0.1mM EDTA).  
 
8.3.2 PCR  
Polymerase chain reactions (PCR) were performed using a Veriti®96-well Thermal Cycler (Applied 
Biosystems) or an iCycler (Bio-Rad). PCR was performed using PfuUltra High-Fidelity DNA Polymerase 
(Agilent). A 50 µL mixture was created for each reaction using the combination outlined in Table 8.1. 
The amplification protocol used for PCR is outlined in Table 8.2. PCR products were purified using E-
Gel® CloneWell™ gels (Life Technologies).  
 
 
 
 
 
 
 
 
Table 8.1 PCR reaction mixture for PfuUltra High-Fidelity DNA Polymerase (Agilent). 
 
 
 
 
Component Amount per reaction 
Distilled water (dH2O) 40.6 µL 
PfuUltra Reaction buffer 5.0 µL 
dNTP mix (25 mM each dNTP) 
DNA template (100 ng/µL) 
Fwd primer (100 ng/µL) 
Rev primer (100 ng/µL) 
PfuUltra DNA Polymerase (2.5 U/µL) 
Total reaction volume 
0.4 µL 
1.0 µL 
1.0 µL 
1.0 µL 
1.0 µL 
50.0 µL 
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Table 8.2 PCR amplification protocol for PfuUltra High-Fidelity DNA Polymerase (Agilent). 
 
8.3.3 Genomic cloning  
The gene encoding NmeNANAS was amplified from N. meningitidis MC58 (serogroup B) genomic 
DNA (ATCC) whilst genes encoding CjeNANAS, CjeLegS and CjePseS were amplified from C. jejuni 
NCTC 11168 genomic DNA (ATCC).  
Cycling parameters and components used for the 50 µL reaction are outlined in Section 8.3.2, but 
with the introduction of a touchdown annealing stage, wherein the annealing temperature of the 
PCR cycle started at 70 °C and dropped 1 °C each cycle for twenty cycles. The annealing temperature 
for the remaining 10 cycles was 40 °C. Resulting PCR fragments were assessed for appropriate size by 
agarose gel electrophoresis and ligated into vector pDONR-221 as described in Section 8.3.5. 
 
8.3.4 Mutagenesis  
Mutagenesis was performed using either a Quikchange® Lightning Mutagenesis Kit (Stratagene), 
Quikchange® XL Mutagenesis Kit, or with PfuUltra High-Fidelity DNA Polymerase (Agilent). PCRs 
were performed as outlined in Section 8.3.2. Template DNA (which is methylated) was digested by 
treatment with the restriction enzyme DpnI (Life Technologies).  
 
 
 
 
Number of Cycles Temperature Duration 
1 x 95 °C 1 minute 
30 x 95  °C 
40-60  °C 
72  °C 
30 seconds 
30 seconds 
1 minute per kb 
1 x 72  °C 10 minutes 
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8.3.5 Agarose gel electrophoresis 
Agarose gel electrophoresis was performed using either pre-cast E-Gel® 1.2 % (w/v) agarose gels 
(Invitrogen) or self-poured 1 % agarose gels. E-Gel® agarose gels were used as per manufacturer's 
instructions. Samples were added directly to the gel, without loading dye. Gels were run on and 
monitored with an E-Gel R iBase™ Safe Imager™. 
Self-poured gels were made by heating 0.3 g agarose in 30 mL tris-acetate-EDTA (TAE) buffer until 
dissolved. The solution was cooled to approximately 50 °C before being supplemented with SYBR 
Safe® DNA stain and poured. For self-poured gels, samples were mixed with a 6 x sample loading 
dye. Electrophoresis was performed for 60 min at 80 V in TAE buffer using a Mini-Sub® Cell GT (Bio-
Rad). All gels were viewed and photographed under UV light with a Molecular Imager® Gel Doc™ XR 
(Bio-Rad). 
TAE buffer: 60mM Tris-HCl, 1mM EDTA, 20mM acetic acid 
Sample loading dye (6 x): 60mM Tris-HCl, 60mM EDTA, 0.2% (w/v) orange G, 0.05% (w/v) xylene 
cyanol ff, 60% (v/v) glycerol  
 
8.3.6 Cell lines 
The cell lines used for plasmid propagation were E. coli TOP10 cells (Invitrogen). For protein 
expression E.coli BL21 (DE3) cells, E. coli Rosetta™ 2 (DE3), or E. coli BL21 (DE3) cells containing the 
plasmids pBB528 and pBB541 for co-expression of the chaperonins GroEL and GroES were used. 
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8.3.7 Preparation of chemically competent cells 
Chemically competent cells were prepared by two similar methods. In the first protocol, cells 
were prepared using the method of Hanahan (194). An overnight culture of the cells to be made 
competent was grown in the presence of the appropriate antibiotic(s). The following day lysogeny 
broth (LB) medium with the appropriate antibiotic was inoculated with one hundredth the volume of 
the overnight culture. Cells were grown at 37 °C until reaching an OD600 of 0.3 AU to 0.6 AU. The 
culture medium was then incubated on ice for 10 - 15 min, before being harvested by centrifugation 
for 15 min at 4 000 rpm and 4 °C, in a pre-chilled centrifuge and rotor. The pellet was then 
resuspended in 18 mL of RF1 solution and incubated on ice for 30 min. The cells were then harvested 
again by the same centrifugation method, and resuspended in 4 mL of RF2 solution. Suspended cells 
were then split into 50 µL to 100 µL aliquots, flash-frozen in liquid nitrogen and stored at -80 °C. 
 
RF1 solution: 100 mM RbCl2, 50 mM MnCl2, 30 mM KOAc, 10 mM CaCl2, pH 5.8 (adjusted using 
concentrated acetic acid). 
RF2 solution: 10 mM RbCl2, 10 mM MOPS, 75 mM CaCl2 · 6H2O, 15% (v/v) glycerol, pH 5.8 
(adjusted using NaOH). 
The RF1 and RF2 solutions were filter-sterilised (0.2 µm) rather than autoclaved to avoid 
formation of a Rb precipitate, and stored at 4 °C. 
In the second method to prepare competent cells, an overnight culture was grown including the 
appropriate antibiotic(s). The next morning, a 100mL culture was inoculated with 2mL of the 
overnight culture, and grown at 37 °C until OD600 reached 0.3 - 0.4 AU. At this point the cells were 
transferred to a sterile 50 mL centrifuge tube, and centrifuged at 4 000 rpm for 15 min at 4 °C to 
pellet the cells. The supernatant liquid was poured off and the pellet gently resuspended on ice in 50 
mL of freshly-made sterile 100 mM CaCl2. The resuspended cells were left on ice for 30 min, after 
which they were again centrifuged, and the pellet gently resuspended in 10 mL of cold CaCl2 on ice. 
The cells were then finally incubated on ice for at least 2 h, before being gently mixed with pre-
chilled sterile 60% (v/v) glycerol to a final concentration of 15% (v/v). The cells were then split into 
50 µL to 100 µL aliquots, snap-frozen in liquid nitrogen, and stored at - 80°C. 
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8.3.8 BP clonase reaction 
A BP reaction was used to transfer linear PCR product into the donor vector pDONR221 for 
subsequent use of the Gateway cloning system (Life Technologies). BP Clonase (Invitrogen) was used 
according to the manufacturer’s instructions, and the reaction product was transformed into TOP 10 
cells for plasmid proliferation using the method outlined in Section 8.3.10. The cells were grown on 
agar plates containing 50 µg/mL kanomycin and the plasmids extracted for sequence verification 
followed by subcloning into expression vectors using the LR reaction outlined in Section 8.3.9. 
 
8.3.9 LR clonase reaction 
An LR reaction was used to subclone the target gene into a selected destination vector via 
pDONR221. Destination vectors used were pDEST15 which contains an N-terminal GST-tag 
sequence, pDEST17 which contains an N-terminal His-tag sequence and pDEST566 which contains an 
N-terminal MBP-tag sequence. LR Clonase (Invitrogen) was used according to the manufacturer’s 
instructions, and the reaction product was transformed into TOP 10 cells for plasmid proliferation 
using the method outlined in Section 8.3.10. The cells were grown on agar plates containing 100 
µg/mL ampicillin and the plasmids extracted for subsequent transformation into expression cell lines 
for purification.  
 
8.3.10 Transformation 
Chemically competent cells (100 µL to 200 µL aliquots) were thawed on ice before addition of 2 
μL of either PCR product or purified plasmid. The mixture was left on ice for 30 min then placed in a 
42 °C water bath for 30 s to 45 s before being placed on ice again for 2 min. Cells were then 
outgrown for 1 hr at 37 °C while shaking after addition of  250 µL super optimal broth (SOC) or LB 
medium. A portion (50 µL to 200 µL) of the transformed cells was spread directly onto an LB-agar 
plate containing the appropriate antibiotic(s) and left to grow on the inverted medium overnight at 
37 °C. 
SOC medium: 2% (w/v) tryptone, 0.5% (w/v) yeast extract, 10 mM NaCl, 2.5 mM KCl, 10 mM 
MgSO4, 20 mM glucose. Filter sterilised in aliquots. 
 
273 
 
8.3.11 Plasmid extraction and purification 
Plasmids were extracted using a High Pure Plasmid Isolation Kit (Roche). Small cultures (5 mL) of 
plasmid-containing cells were grown overnight with the appropriate antibiotic(s). The cultures were 
harvested the following morning and plasmids extracted and purified as per the kit instructions. The 
concentration of purified plasmid was measured by absorption at 260 nm using an appropriately 
blanked Nanodrop ND-1000 spectrophotometer. 
 
8.3.12 Colony PCR 
After transformation of E. coli TOP10 cells with pDONR221plasmids, promising candidates for 
sequencing were identifed with colony PCR. This procedure used the forward gene specific DNA 
sequencing primer and reverse T7 sequencing primer (Table 8.3) to confirm that the subcloned gene 
had been inserted into the vector in the correct orientation. This was confirmed by the amplification 
of an appropriately sized DNA fragment from the colony PCR. 
PCR reactions were set up using Taq DNA Polymerase (Invitrogen) and following the 
manufacturer's instructions for reaction components and cycling parameters. Template DNA was 
provided as a toothpick scraping of an E. coli TOP10 colony from an agar plate of suitably-
transformed cells. 
 
 
 
 
 
Table 8.3 T7 primer sequences. 
 
 
 
 
 
 
 
Oligonucleotide Sequence (5' - 3') 
T7 Fwd TAATACGACTCACTATAGGG 
T7  Rev  GCTAGTTATTGCTCAGCGG  
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8.3.13 DNA sequencing 
DNA sequencing was used to verify amplified gene sequences after subcloning into pDONR221. 
Sequencing was performed by Canterbury Sequencing on an ABI3100 Genetic Analyzer (Applied 
Systems Inc.) using a procedure based on Sanger chain termination protocol. Typically, double-
stranded plasmid samples were prepared as 6 mL aliquots of 40 ng/mL plasmid per sequencing run. 
T7 Primers were used for sequencing at a concentration of 3.2 mM (Table 8.3). aliquots. 
 
8.3.14 Glycerol stocks 
In order to keep cells viable, all strains of E. coli cells containing plasmids were flash frozen and 
stored at -80 °C as glycerol stocks. Glycerol stocks were created by adding 400 µL of 50% (v/v) 
glycerol with 800 µL of an overnight culture in either a 1.6 mL eppendorf or screw-top tube. 
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8.4 Expression and purification 
  
8.4.1 IPTG-induced expression  
1L LB media cultures for protein expression were grown in 2 L baffled conical flasks in a shaking 
incubator at 170-180 rpm. Cultures were inoculated with an overnight culture 1/20 of the expression 
volume and grown at 37 °C until induction of protein expression. The OD600 of the cultures was 
monitored until reaching mid-logarithmic phase (OD600 of 0.4-0.8 AU), which generally took 2-4 
hours. At this point isopropyl β-D-1-thiogalactopyranoside (IPTG) was added to a final concentration 
of 0.5 mM. After induction, cultures were transferred to a 23 °C incubator shaking at 170-180 rpm 
and grown overnight. 
Cultures used for expression trials were grown using 50 mL of LB media in 300 mL conical flasks. 
 
8.4.2 Cell harvesting  
The method used to harvest cells from cultures used for protein expression varied depending on 
rotor and centrifuge availability. Typically, large cultures were harvested in 0.8 L or 1 L bottles at 14 
000 g for 30 min at 4 °C. The supernatant liquid was removed and pellets were then transferred to 
50 mL centrifuge tubes and stored at -80 °C. Alternatively, cultures were sometimes progressively 
harvested in 50 mL centrifuge tubes at 12 000 g for 10 min at 4 °C, or in 0.4 L buckets at 4 618 g for 
40 min at 4 °C before being transferred to 50 mL centrifuge tubes and stored at -80 °C. Small volume 
cultures (5 mL) were progressively harvested in 1.6 mL micro-centrifuge tubes at 17 000 g for 3 min. 
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8.4.3 Cell Lysis 
Cells were lysed by sonication using an Omni-Ruptor 4000 Ultrasonic Homogenizer (Omni 
International). Cell pellets were resuspended in chilled lysis buffer (typically 50 mL to 100 mL) on ice, 
and sonicated in a beaker surrounded by packed ice. Sonication was performed typically for 20 min 
at 40% pulsation and 70% power. Sample temperature was checked every 5 min to prevent over-
heating. Lysis buffer was varied from purification to purification and is addressed in Section 8.4.4. 
For small volumes such as with expression tests, Bugbuster® protein extraction reagent 
(Novagen) was used in place of sonication. Cell pellets were resuspended in a smaller volume of 
buffer (approximately 5 mL) containing Bugbuster® reagent. 5 µL of Benzonase nuclease® (Novagen) 
was added to break down DNA, and the solution shaken at 25 °C for 20-30 mins. 
After lysis, the soluble fraction was separated from the cell debris by centrifugation at 24,000 g 
for 30 min at 4 °C. Chromatography was performed as quickly as possible after lysis to reduce the 
effects of proteolysis.  
 
8.4.4 Chromatography 
All proteins were purified by a multi-step procedure outlined in Figure 8.1. The chromatography 
steps were performed on Bio-Rad Biologic DuoFlow and GE Healthcare ÄKTApurifier™ 10 machines. 
  
  
  
  
  
  
 
 
Figure 8.1 Purification procedure overview. 
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Before use, all buffers were filtered (0.2 μm) under vacuum. Protein samples were similarly 
filtered before being loaded on either a 50 mL or 200 mL Superloop™ (GE Healthcare). The eluate 
was fractionated in 2 mL fractions collected in 96-well plates. Elution from the columns was 
monitored principally at 280 nm, and depending on the machine being used, also at 260nm and 214 
nm. When the fractions corresponding to the target protein could not be deduced from the 
chromatogram, suspected fractions were analysed by sodium dodecyl sulfate polyacrylamide gel 
electrophoresis (SDS-PAGE) and/or for NANAS activity when possible. Fractions containing target 
protein were subsequently pooled and prepared for the next chromatographic step.  
Given the variety of proteins expressed and purified in this thesis, the same buffers could not 
always be used for purification. For the majority of wild-type and variant proteins the following 
buffers were used: 
Lysis buffer: 50 mM potassium phosphate (pH 7.5), 500 mM NaCl, 10 mM imidazole 
Talon equilibration: 50 mM potassium phosphate (pH 7.5), 500 mM NaCl, 10 mM imidazole 
Talon elution buffer: 50 mM potassium phosphate (pH 7.5), 500 mM NaCl, 200 mM imidazole 
Size exclusion buffer: 30 mM triethanolamine (pH 7.5) 
CteSAS was found to be unstable in the absence of PEP, thus 0.1 mM PEP was added to the buffer 
solutions for the purification of CteSAS. In addition, CteSAS was unstable in triethanolamine and was 
instead purified by SEC in 20 mM BTP and 150 mM NaCl at pH 7.5.  
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 8.4.5 Immobilised metal affinity chromatography   
Purification of all proteins described in this thesis involved two IMAC steps (Figure 8.1). The first 
of these separated the His-tagged protein from the soluble E. coli proteins, and the second 
separated untagged protein from the tag and TEV protease after cleavage. IMAC was performed 
using 5mL Talon® Superflow Metal Affinity resin packed in a Tricorn 10/50 column (GE Healthcare). 
The resin was equilibrated with five column volumes of equilibration buffer prior to injection of 
protein sample.  
Resin was washed with ten column volumes of equilibration buffer, before elution of bound 
protein with six column volumes of elution buffer. Following elution, the resin was washed with five 
column volumes of 2-(N-morpholino)ethanesulfonic acid (MES) buffer (pH 5.5), containing 200 mM 
NaCl, to remove bound imidazole before being stored in ethanol. The protein of interest was 
collected from either the eluted fraction (for the first IMAC step) or the washing step (for the second 
IMAC step) depending on the presence of the protein His-tag. The elution flow rate used for IMAC 
was 3 mL min−1 
 
8.4.6 Desalting 
Desalting was performed using a HiPrep 26/10 Desalting column pre-packed with Sephadex G-25 
Fine (GE Healthcare). Desalting chromatography was carried out at 4 °C in low imidazole buffer (50 
mM potassium phosphate at pH 7.5, 500 mM NaCl, 10 mM imidazole) to remove high imidazole 
concentrations subsequent to TEV protease treatment and also prior to the second IMAC run. The 
elution flow rate used for desalting was 2 - 5 mL min−1. 
 
8.4.7 TEV protease treatment 
Each of the proteins mentioned in this thesis contained cleavage sites for tobacco etch virus (TEV) 
protease, which was used to remove affinity tags. The cleavage sequence used was ENLYFQ/G, with 
TEV protease cleaving between the glutamine and glycine residues. To cleave the His-tag from the 
protein of interest, affinity-purified and desalted protein was incubated at 4 °C overnight with TEV 
protease. This reaction was performed in Talon equilibration buffer (Section 8.4.4) with the addition 
of 1 mM DTT and 0.5 mM EDTA. TEV protease was added at a ratio of 1:100 to the substrate protein 
(by mass, as determined by absorbance).  
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8.4.8 TEV protease purification 
Recombinant TEV protease was purified similarly to the purification protocol outlined in Section 
8.4.4. E. coli BL21(DE3) cells containing the plasmids pRIL (for rare codon production) and pRK793 
(encoding TEV protease) were grown in LB containing ampicillin and chloramphenicol. Protein over-
expression was induced with 0.5 mM IPTG and the cells grown overnight. Cells were harvested and 
lysed as outlined in Section 8.4.3, using the lysis buffer described below. Protein was then purified in 
a single IMAC step on a HisTrap HP column (GE Healthcare). IMAC procedures were identical to 
those used for Talon® resin (Section 8.4.5), using the buffers described below. Purified TEV protease 
was buffer exchanged into storage buffer, concentrated to 1 mg/mL and stored in 1 mL aliquots.  
 
TEV protease lysis/equilibration buffer:   50 mM potassium phosphate, pH 8.0, 500mM NaCl, 25 
mM imidazole  
TEV protease elution buffer: 50 mM potassium phosphate (pH 8.0), 500 mM NaCl, 250 mM, 500 
mM imidazole  
TEV protease storage buffer: 10% (v/v) glycerol, 25 mM potassium phosphate (pH 8.0), 200 mM 
NaCl, 10 mM DTT, 2 mM EDTA 
 
8.4.9 Size exclusion chromatography 
Pooled fractions containing target protein from the second IMAC run were pooled and loaded 
onto a HiLoad™ 26/60 Superdex™ 200 prep grade column (GE Healthcare). SEC chromatography was 
carried out at 4 °C in 30 mM triethanolamine buffer. The elution flow rate used for SEC purification 
was 0.5 - 1 mL min−1. 
 
8.4.10 SDS-PAGE electrophoresis  
Sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) was performed using 
pre-cast gels using NuPAGE® 10% Bis-Tris Gel 1.0mm × 12-well pre-cast gels (Invitrogen) in NuPAGE® 
MOPS SDS Running Buffer (Invitrogen). Electrophoresis was performed using a XCell SureLock™ 
Electrophoresis Cell (Invitrogen), at 200 V for 50 min. Samples were mixed with NuPAGE® LDS 
Sample Buffer (4×) and DTT, and  boiled before loading.  
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8.4.11 SDS-PAGE visualisation 
All SDS-PAGE gels were stained in square petri dishes by coomassie brilliant blue R-250, for at 
least 1 hour before being destained to remove excess dye.  
Stain: 0.1% (w/v) coomassie brilliant blue R-250, 10% (v/v) acetic acid and 40% (v/v) methanol 
Destain: 10% (v/v) acetic acid and 40% (v/v) methanol 
Molecular weight standards (Novex® Sharp Pre-Stained Protein Standards (Invitrogen)) were run 
as the sample in one lane of each gel. Photographs of gels were taken on a white light 
transilluminator in a Molecular Imager® Gel Doc™ XR (Bio-Rad). 
 
8.4.12 Protein concentration and buffer exchange 
Protein solutions were concentrated using 10 000 Da molecular weight cut-off (MWCO) devices 
(Vivaspin 2 (GE Healthcare), Vivaspin 500 and Vivaspin 20 (Sartorius Stedim Biotech) and Amicon® 
Ultra-4 (Millipore)). All filtration units were rinsed before use with Milli-Q water. Protein solutions 
were buffer exchanged by repeatedly concentrating in a MWCO device and diluting with desired 
buffer. 
 
8.4.13 Enzyme storage  
Purified protein was divided into aliquots in either 0.6 mL or 1.2 mL micro-centrifuge tubes in 0.1 
mL to 0.5 mL aliquots, flash-frozen in liquid nitrogen, and stored at -80 °C. All protein samples were 
rapidly thawed prior to use and kept on ice. Protein solutions were stored at 1.0 mg mL−1 to 15 mg 
mL−1. 
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8.4.14 Protein concentration determination  
Protein concentrations were measured by absorption at 280 nm by an appropriately blanked 
Nanodrop ND-1000 spectrophotometer, using 2 μL samples of purified protein solution. The 
concentration was calculated from the absorption using molar extinction coefficient values of 
purified enzyme (Table 8.4) Enzyme coefficient values were calculated from protein sequences using 
the ProtParam tool on the ExPASy Proteomics Server(195). 
  
 
 
 
 
 
 
 
 
Table 8.4 Extinction coefficients of enzymes calculated using ProtParam (195). * The NmeNANAS wild-
type extinction coefficient was used to determine the concentrations of NmeNANAS single and double 
point mutation variants as there was negligible difference in the calculated extinction coefficient values 
from ProtParam. 
 
 
 
 
 
 
 
 
Enzyme Extinction coefficient 
NmeNANAS wild-type* 22265 
NmeG272Term 9315 
CjeNANAS wild-type 26150 
CjeLegS wild-type 102510 
CjePseS wild-type 23045 
CteSAS wild-type 44265 
SsuSAS wild-type 21890 
Nme/Hsa chimera 16890 
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8.5 General characterisation procedures  
  
8.5.1 Standard kinetic assay  
The standard assay for SAS activity monitored the consumption of PEP by loss of absorbance at 
232 nm, based on the method of Schoner and Herrmann (196). All kinetic measurements were made 
using a Varian Cary 100 UV-visible spectrophotometer, stoppered 1 cm pathlength quartz cuvettes 
and a total assay volume of 1 mL. Standard assays were carried out at 25 °C and all assay solutions 
were equilibrated to temperature and baseline absorbance before initialisation. The enzymatic 
reaction was initiated by the addition of 5 µL of purified enzyme at a stock concentration of 2-3 
mg/mL. Standard reaction mixtures contained 50 mM BTP pH 7.5, a variable concentration of PEP, 
ManNAc, 1 mM MnCl2 and enzyme. 
Assay buffers were treated with Chelex® 100 resin (Bio-Rad) prior to use to remove metal ions, 
and Chelex-treated buffer solution was used to create concentrated stock solutions of PEP and 
ManNAc. Metal-ion solutions were created using either Chelex-treated buffer or Milli-Q water. 
Initial rates of reaction were measured as a least-squares fit of the initial rate data using Cary 
WinUV Kinetics Application (version 3.00, Varian). A unit of enzyme activity was defined as the loss 
of 1 μmol of PEP min-1 at 25 °C and could be calculated from the measured loss of absorbance (at 
232 nm) using Beer’s Law (ε = 2.8×103 M-1 cm-1 at 25 °C). The values of the kinetic parameters were 
determined by fitting data to the Michaelis-Menten equation  using the software GraFit 
5(197) (Erithacus Software Limited).  The concentration of one substrate was kept constant, while 
varying that of the other and vice versa.  To determine apparent Km (PEP), ManNAc concentration 
was held at 30 mM, and the concentration of PEP varied. To determine apparent Km (ManNAc), PEP 
was kept constant at 1 mM, and ManNAc concentration was varied.  
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8.5.2 Mass spectrometry  
The masses of purified proteins were measured by Bruker maXis 3G UHF-TOF tandem mass 
spectrometer. Proteins were either buffer exchanged into 5 mM ammonium bicarbonate, or were 
diluted from stored concentrations to 1 mg mL−1 with water. 
 
8.5.3 Differential scanning fluorimetry  
Melt temperatures of the proteins were determined both with and without the presence of 
different additives by differential scanning fluorimetry (DSF), using an iCycler iQ5 Multicolour Real-
Time PCR Detection System (Bio-Rad). The method used was based on that of Ericsson et al.(198) 
Triplicate protein samples were added with mixing to buffer (potentially containing additives) and 
SYPRO orange dye (Invitrogen) in a 96-well microplate (vide infra), which was then sealed. The melt 
proceeded in 0.2 °C increments from 20 - 95 °C, with a 20 s dwell time after each temperature rise. 
Measurements of the fluorescence were made at the end of each dwell time. 
For each sample (three replicates and blank) 100 μL of buffer (50 mM BTP pH 7.5) including any 
additive(s) was prepared, to which 5 μL of 250 x SYPRO orange dye was added (condition solution). 
In the blank well for the sample, 21 μL of the condition solution was added to 4 μL of water. Then, 16 
μL of protein (at 1 mg mL−1) was added to the remaining condition solution before 25 μL was 
dispensed into three replicate wells. Additives used in experiments were as follows: Metal (1 mM), 
PEP (1 mM) and ManNAc/rManNAc/ManNAc analogue (10 mM with metal, 1 mM with metal and 
PEP). 
 For analysis an Excel spreadsheet with custom VBA-scripted macro was created by Dr Timothy 
Allison to toggle and dynamically display melt and derivative curves for each sample. The melt 
temperatures were calculated as the temperature of maximum inflection of the melting curve after 
subtracting the reading of a blank well containing buffer and dye but lacking protein. 
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8.5.4 Circular dichroism  
Circular dichroism (CD) experiments were performed using a JASCO J-815 Spectropolarimeter. All 
CD spectra were recorded from 260 nm to 195 nm using a 0.5 nm data pitch, 1 s response, 1 nm 
bandwidth at 25 °C. A 3 mL protein solution at a concentration of 0.03 mg mL−1 in a 3 mL quartz 
cuvette with 1 cm path length was used for each measurement. The buffer for all experiments was 
20 mM sodium phosphate pH 8.0. Blank spectra were recorded of buffer alone for each experiment 
before addition of protein. Data were smoothed using the Savitzky-Golay algorithm of the Jasco 
Spectra Manager™ (version 1.5) with a convolution width of 15. 
 
8.5.5 Isothermal calorimetry  
The affinity of substrate and metal ions for enzyme was assessed by isothermal calorimetry (ITC) 
using a VP-ITC unit operating at 298 K (MicroCal; GE Healthcare). Prior to use, all solutions were 
filtered and degassed in a vacuum, and protein concentration was measured by UV absorption 
(ɛNmeNANAS = 22,270 M
-1 cm-1). The binding buffer was composed of 30 mM triethanolamine (pH 7.5). 
To determine Kd(Mn), 5 mM MnCl2 was titrated into 70 µM enzyme. To determine Kd (PEP), 50 mM PEP 
was titrated into 40 µM enzyme containing a background concentration of 1 mM MnCl2. To 
determine Kd (rManNAc), 10 mM rManNAc was titrated into 100 - 200 µM enzyme containing a 
background concentration of 1 mM MnCl2 and 1 mM PEP. Titrations were performed with fifty-five 
injections of ligand; one 2 µL injection followed by fifty-four 5 µL injections. Heats of dilution 
experiments were measured independently and subtracted from the integrated data before curve-
fitting in Origin 7.0 with the standard one-site model supplied by MicroCal. 
 
8.5.6 Synthesis of rManNAc 
Reduced ManNAc (rManNAc) was synthesised by Ryu Toyama using the method outlined in 
Gunawan et al (112). 0.21 g of ManNAc (1 mM) was dissolved in 10 mL of water and 0.08 g of 
sodium borohydride (2 mM) added to the solution. The mixture was subsequently stirred at room 
temperature for 2 hours. The resulting solution was neutralised using Dowex® 50WX8 hydrogen 
form, 100-200 mesh (Sigma-Aldrich). The solution was then filtered and lyophilised, producing a 
white solid. The product was subsequently refluxed in 50 mL of methanol for 30 min and 
concentrated under reduced pressure. The resultant oily film was re-dissolved in water and 
lyophilised to produce a white solid (0.15 – 0.16 g). Purity of rManNAc was determined through 1H 
NMR to be above 99 %. 
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8.5.7 Analytical gel filtration chromatography 
The multimeric states of enzyme were determined by gel filtration chromatography using a 
Superdex 200 10/300 GL column (GE Healthcare). Samples (500 μL, 1, 2 and 4 mg/mL) and standards 
(Sigma) were run in 50 mM bis-tris propane (pH 7.5) with 150 mM NaCl.  
 
8.5.8 Analytical ultracentrifugation 
Sedimentation velocity experiments were performed in a Beckman Coulter model XL-I analytical 
ultracentrifuge equipped with UV-visible scanning optics. Reference (400 µl; 30 mM triethanolamine, 
pH 7.5) and sample (380 µl) solutions were loaded into 12-mm double-sector cells with quartz 
windows, and the cells were then mounted in an An-50 Ti eight-hole rotor. Proteins were 
centrifuged at various rotor speeds at 20 °C, and radial absorbance data were collected at 
appropriate wavelengths in continuous mode every 8 min without averaging. Data were fitted to a 
continuous size-distribution (cs) model using the program SEDFIT (150, 151). The partial specific 
volume (-v) of the proteins, buffer density (0.9988 g·ml-1), and buffer viscosity (1.005 cp) were 
computed using the program SEDNTERP (199). Weight average molecular masses were calculated 
from weight average sedimentation coefficients and f/f0 values resulting from the fits using SEDFIT 
(150, 151). 
 
8.5.9 Small angle X-ray scattering data collection 
Measurements were performed at the Australian Synchrotron SAXS/WAXS beamline (where 
WAXS is wide angle X-ray scattering) equipped with a Pilatus detector (1 M, 170 X 170 mm, effective 
pixel size, 172 X 172 µm). The wavelength of the X-rays was 1.0332 Å. The sample detector distance 
was 1600 mm, which provided an s range of 0.0126 - 0.400Å-1 (where s is the magnitude of the 
scattering vector, which is related to the scattering angle (2ϴ) and the wavelength (λ) as follows: s = 
(4π/λ)sinϴ). Scattering data was collected from enzymes at approximately 10 mg ml-1  following 
elution from a size-exclusion chromatography column (Superdex 200 5/150), pre-equilibrated with 
30 mM Triethanolamine buffer at pH 7.5. As aforementioned CteNANAS was unstable in 
triethanolamine and was thus eluted with 20 mM BTP and 150 mM NaCl at pH 7.5. Liganded SAXS 
samples contained PEP (1 mM) and Mn2+ (1 mM) in buffer. Two dimensional intensity plots from the 
peak of the size-exclusion chromatography run were radially averaged, normalized to sample 
transmission and background-subtracted. 
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8.5.10 Small angle X-ray scattering data analysis 
Scattered intensity (I) was plotted versus s. Extrapolation of enzyme I(s) profiles to zero angle 
(I(0)) indicated a molecular mass consistent with the dimer molecular weights for each protein. All 
samples were devoid of an increase in intensity at low s (indicative of aggregation). Guinier plots 
were linear for s·Rg < 1.3. The data sets for structural analyses were recorded with approximately 
450 data points over the range 0.0135 ≤ s ≤ 0.4 Å-1. Indirect Fourier transform was performed using 
GNOM (200) to yield the function P(r), which gives both the relative probabilities of distances 
between scattering centers and the maximum dimension of the scattering particle Dmax. Theoretical 
scattering curves were generated from atomic coordinates and compared with experimental 
scattering curves using CRYSOL (153). 
To assess and compare the quality of the fits in CRYSOL, the χv
2 values for the fits were compared 
as outlined in Mills et al. (201). 
 
8.5.11 Crystallisation  
Crystals of variant NmeNANAS and SsuSAS were grown by hanging-drop vapour diffusion in 24-
well VDX plates (Hampton Research). Specific crystallisation protocols for NmeR314K and NmeR314A 
are outlined in Section 8.6.2 and for SsuSAS in Section 8.9.2. Unless otherwise stated, the 
crystallisation trays were left at 20 °C until immediately before data collection, with crystals being 
transferred briefly into a cryoprotectant composed of 20% (v/v) ethylene glycol in the respective 
reservoir solution. Crystals typically began to form overnight for both NmeNANAS and SsuSAS.  
Crystal screens were either completed by hand or using a Mosquito Crystal® (TTP Labtech) 
crystallisation robot on a 96-well sitting drop iQ plate (TTP Labtech). Proteins were screened at 
varied concentrations between 5 and 15 mg/mL using commercially available crystallisation screens. 
Protein crystallisation conditions were screened using Molecular Dimensions Morpheus, Midas, 
JCSG-plus, PACT premier, and ProPlex HT-96 screens. 
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8.5.12 X-ray data collection  
X-Ray diffraction data were collected at the Australian Synchrotron. Protein was transported 
frozen to Melbourne the day before collection.  Crystals were mounted on loops, flash-frozen in 
liquid nitrogen and placed in a sample storage cassette (Crystal Positioning Systems), which was 
stored in a dry shipper (Taylor-Wharton CX100) and transported as checked-in luggage. Data 
collection at the Australian Synchrotron used either the Macromolecular Crystallography (MX1) or 
Micro Crystallography (MX2) beamlines(202) and were processed using iMosflm and Scala (CCP4 
suite(203)). 
 
8.5.13 Structure determination and refinement 
Structures of NmeNANAS variant proteins  and SsuSAS were solved by molecular replacement, 
using the structure of wild-type NmeNANAS (PDB ID: 1XUZ) as a starting model (with all non-protein 
molecules removed) and performing ten rounds of rigid-body refinement using Refmac5.(204) The 
same set of reflections for calculation of Rfree was carried through. Further refinements were 
conducted with Refmac5,(204) and electron-density maps were analysed with Coot.(205) The 
validation tools of Coot and MolProbity(206) were used to check for, and correct, conformation 
infelicities. 
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8.6 Methods in Chapter 2  
  
8.6.1 Cloning  
The neuB gene from N. meningitidis serotype B strain MC58 was amplified from genomic DNA 
using PfuUltra DNA polymerase (Agilent) as described in Section 8.3.2. Gene specific nested primers 
(Table 8.5) were designed incorporating generic extensions (underlined) for further rounds of nested 
PCR. The product from first round PCR was extended using generic gateway primers (Table 8.5) 
which incorporated the attb sites (italicised) The linear product from second round nested-PCR was 
cloned into the donor vector pDONR-221 using BP clonase enzyme mix as outlined in Section 8.3.8. 
 
 
 
 
 
 
 
Table 8.5 First and second round nested primers used for amplification of N. meningitidis NANAS from 
genomic DNA. Start codons are in blue and stop codons are in red. Overlapping sequences for generic 
primer extension are underlined. TEV protease cleavage site is in bold and the attB1 (Fwd) and attb2 
(Rev) sites are italicised.   
 
Variants of NmeNANAS were generated by site-directed mutagenesis. The primers displayed in 
Table 8.6 were used to generate NmeR314K and NmeR314A, using the aforementioned pDEST-17-
NmeNANAS plasmid as a template.  
 
 
 
 
 
 
Table 8.6 Mutagenesis primers used for amplification of NmeR314K and NmeR314A from pDEST17-
NmeNANAS. Mutation sites are underlined. 
Oligonucleotide Sequence (5' - 3') 
NmeR314K Fwd GAGATAACCTATGGGTTAAAAAACCAGGCAATGGAGACTTCAG 
NmeR314K Rev 
 
CTGAAGTCTCCATTGCCTGGTTTTTTAACCCATAGGTTATCTC 
 
NmeR314A Fwd  GATAACCTATGGGTTAAAGCGCCAGGCAATGGAGACTTC 
NmeR314A Rev 
 
GAAGTCTCCATTGCCTGGCGCTTTAACCCATAGGTTATC 
 
 
 
Oligonucleotide Sequence (5' - 3') 
NmeNANAS WT Fwd GGCAGCGGCGGCATGCAAAACAACAACGA 
NmeNANAS WT Rev 
 
GAAAGCTGGGTGTTATTCAATATCAGT 
 
Generic Nested Fwd  GGGGACAAGTTTGTACAAAAAAGCAGGCTTCGAAAACCTGTATTTTCAGGGCAGCGGCGCG 
Generic Nested Rev GGGGACCACTTTGTACAAGAAAGCTGGGT 
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8.6.2 Crystallisation of NmeR314K and NmeR314A 
Purified R314K at a concentration of 12 mg/mL was crystallised in 1.9 M malate and 10 mM MnCl2 
at pH 6.2, and R314A at a concentration of 11.5 mg/mL was crystallised in 1.7 M malate and 10 mM 
MnCl2 at pH 6.2 using hanging drop vapor diffusion. Hanging drops were 2 µL in size combining 1 µL 
of protein with 1 µL of reservoir solution and the total volume of the reservoir solution was 500 µL. 
Data sets were collected at the Australian Synchrotron using the MX1 and MX2 beamlines.  
Orthorhombic crystals with a space group of P21212 were obtained of both mutants. The structures 
for both R314K and R314A were solved by molecular replacement using the structure of the wild-
type protein (1XUZ) (112). Measured intensities were converted into amplitudes by using TRUNCATE 
as part of Scalepack2mtz or dtrek2mtz (CCP4) (203). The structure was then solved by performing 
two rounds of rigid-body refinement (CCP4). Intensity-based refinement was carried out with 
REFMAC5 (CCP4) following each cycle of structure development from Coot. Water molecules were 
added automatically following the criterion that they had at least one hydrogen bonding partner to a 
protein atom and/or water molecule in the range 2.4–3.2 Å. Atomic coordinates and structure 
amplitudes have been deposited with the PDB under accession codes 4IPJ for R314K and 4IPI for 
R314A. 
  
8.6.3 Modelling of substrates in NmeR314K and NmeR314A  
Modelling studies were conducted by Dr Wanting Jiao, using software packages from Schrodinger 
Suite 2011. The structures of the substrate ManNAc were built in Maestro (19) and then prepared 
using LigPrep (20). Crystal structures of the wild-type (PDB code 1XUZ), were used as the wild-type 
enzyme for docking. Although the electron density map for the bound rManNAc in this crystal 
structure is not great, rManNAc would be removed prior to docking calculation, so that it does not 
affect the result of the modelling study. The wild-type crystal structure was then prepared using 
Protein Preparation Wizard in Schrodinger Suite 2011 (21).  Due to the malate molecules bound in 
the active site of R314A and R314K crystal structures, several active site residues adopted slightly 
different conformations to those observed in the wild-type crystal structure, e.g. the active site 
metal ions of R314A and R314K were shifted in position due to malate molecules coordinating to the 
metal ions; the residue Tyr186 also showed alternative conformations due to the flexibility of the 
active site residues in the absence of substrates PEP and ManNAc.  
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Since these residues all have interactions to the substrate bound in the active site, small changes 
in their positions may affect the outcome of a modelling study, and the differences seen in the 
modelling results for wild-type and the mutant systems may not reflect only the effect of mutation. 
Therefore, the enzyme structures of R314K and R314A mutants were made by in silico mutation of 
Arg314 in the prepared wild-type crystal structure (PDB code 1XUZ) to the corresponding Lys and 
Ala. All other residues in the wild-type structure including the substrate PEP in the active site were 
retained in the in-silico-generated mutant enzymes.  
The mutant enzymes from in silico mutagenesis showed little difference in side-chain and 
backbone positions at residue 314 compared to those in the corresponding crystal structures. For all 
three enzymes, the center of the receptor grid was defined as the centroid of the rManNAc molecule 
bound in the active site of Chain A; The docking of flexible ManNAc molecule into rigid enzyme 
receptors of wild-type, R314A and R314K enzymes was conducted in Glide (22, 207-209) with 
OPLS2005 force field and extra precision (XP) mode. The van der Waals radii of ligand atoms were 
not scaled. 90000 poses per ligand were kept for initial docking, and scoring window for keeping 
initial poses was 5000. The best 1000 poses per ligand were kept for energy minimization with a 
distance dependent dielectric constant of 2 and a maximum of 5000 conjugate gradient steps.  
Before any output poses were written out, the poses obtained in the docking calculation were 
clustered and duplicate poses were discarded if the RMS deviation is less than 0.5 Å and maximum 
atomic displacement is less than 1.3 Å. This clustering procedure ensures that the output poses were 
conformationally distinct, as a result different number of output poses was usually written out for 
different sets of calculations.  
In order to assess how closely the output poses from the modelling study resembles the 
crystallographically observed binding pose of the substrate analogue rManNAc, RMS deviations 
between poses from modelling study and the crystal structure were measured using the 
measurement tool in Maestro (19). The wild-type and mutant receptors used for the modelling 
study were first superimposed with the wild-type crystal structure, and then the RMS deviations 
between the modelled poses and the crystal structure of rManNAc were measured in place. Since 
there are no hydrogen atoms in the original crystal structure, hydrogen atoms in the modelled poses 
were not included for the calculation of RMS deviations. 
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8.7 Methods in Chapter 3  
  
8.7.1 Cloning  
Variants of NmeNANAS were generated by site-directed mutagenesis using PfuUltra DNA 
polymerase (Agilent) as described in Section 8.3.2. The truncation G272Term was made by inserting 
a stop codon. The following primers (Table 8.7) were used to generate mutants using the 
aforementioned pDEST17-NmeNANAS plasmid as a template. The double mutation E282A/T285A 
used pDEST17-NmeNANAS E282A as a template. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 8.7 Mutagenesis primers used for amplification of NmeG272Term, NmeT285A, NmeT285F, 
NmeE282A, NmeE282A/T285A and NmeE134A. Mutation sites are underlined. 
 
 
  
 
 
 
Oligonucleotide Sequence (5' - 3') 
NmeG272Term Fwd CTCATGCTTTAAAATTGGCACGCTAGGGCAAAAAAGACACGATTATCGC 
NmeG272Term Rev 
 
GCGATAATCGTGTCTTTTTTGCCCTAGCGTGCCAATTTTAAAGCATGAG 
 
NmeT285A Fwd  TCGCGGGAGAAAAGCCAGCTAAAGATTTCGCCTTT 
NmeT285A Rev 
 
AAAGGCGAAATCTTTAGCTGGCTTTTCTCCCGCGA 
 
Nme T285F Fwd ATTATCGCGGGAGAAAAGCCATTTAAAGATTTCGCCTTTGCATC 
Nme T285F Rev 
 
GATGCAAAGGCGAAATCTTTAAATGGCTTTTCTCCCGCGATAAT 
 
NmeE282A Fwd  GACACGATTATCGCGGGAGCAAAGCCAACTAAAGATTTC 
NmeE282A Rev 
 
GAAATCTTTAGTTGGCTTTGCTCCCGCGATAATCGTGTC 
 
NmeE282A/T285A Fwd CACGATTATCGCGGGAGCAAAGCCAGCTAAAGATTTCGCCTTT 
NmeE282A/T285A Rev 
 
AAAGGCGAAATCTTTAGCTGGCTTTGCTCCCGCGATAATCGTG 
 
NmeE134A Fwd GCATATAAAATCGGCTCTGGCGCATGTAATAACTACCCATTAATT 
NmeE134A Rev 
 
AATTAATGGGTAGTTATTACATGCGCCAGAGCCGATTTTATATGC 
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8.7.2 Molecular dynamics simulations 
Molecular dynamics simulations were conducted with (210) running on the BlueFern 
supercomputer at the University of Canterbury, New Zealand. Prior to molecular dynamics 
simulation, crystallographic water and ligands were deleted from the NmeNANAS crystal structure 
(PDB IXUZ). Each starting structure was solvated with explicit TIP3 water molecules in a box in (211), 
and ionized by adding Na+ and Cl- ions to balance the net charge of the water box. Ions were added 
with a minimum distance of 5 Å from the molecule and from each other. Topology and parameter 
files for PEP molecule was generated with SwissParam online server (http://swissparam.ch/) based 
on mol2 file obtained from ZINC database. Molecular dynamics simulations were conducted with the 
(212) all-hydrogen parameter file for proteins at constant temperature (322.15 K) and pressure (1 
atm). The cut-off distance for van der Waals interactions was set to 12 Å. In each simulation, the 
system was first minimized for 5000 steps followed by 270 ns of dynamics simulations conducted 
with 2 fs time steps. The trajectory was written out at 100 ps time intervals, and a total of 2700 
frames were obtained from each simulation. 
 
8.7.3 PISA 
Macromolecular interfaces were assessed using the online PDBePISA server 
(http://www.ebi.ac.uk/msd-srv/prot_int/cgi-bin/piserver) (152). Differences in surface area contacts 
for wild-type NmeNANAS and NmeG272Term were determined using the PDB coordinates 
NmeNANAS 1XUZ (112). PDB coordinates 1XUZ were modified to generate a model of 
NmeG272Term which lacked the AFPL and linker domains. PISA was used to calculate the 
interdomain surface area, number of interfacing atoms (iNat) as well as the solvation free energy gain 
yielded upon interface formation (ΔiG). 
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8.8 Methods in Chapter 4  
  
8.8.1 Cloning  
The genes encoding NANAS, LegS and PseS from C. jejuni NCTC 11168 were amplified from 
genomic DNA using PfuUltra DNA polymerase (Agilent) as described in Section 8.3.2. Gene specific 
nested primers (Table 8.8) were designed incorporating generic extensions (underlined) for further 
rounds of nested PCR. The product from first round PCR was extended using generic gateway 
primers (Table 8.8) which incorporated the attb sites (italicised) The linear product from second 
round nested-PCR was cloned into the donor vector pDONR-221 using BP clonase enzyme mix as 
outlined in Section 8.3.8. 
 
 
 
 
 
 
 
 
 
Table 8.8 First and second round nested primers used for amplification of C. jejuni SASs from genomic 
DNA. Start codons are in blue and stop codons are in red. Overlapping sequences for generic primer 
extension are underlined. TEV protease cleavage site is in bold and the attB1 (Fwd) and attb2 (Rev) sites 
are italicised.  
 
 
 
 
 
Oligonucleotide Sequence (5' - 3') 
CjeNANAS (Cj1141) Fwd GGCAGCGGCGCGATGCAAATAAAAATAGATA 
CjeNANAS (Cj1141) Rev 
 
GAAAGCTGGGTGTCATTCAAAATCATCCCATG 
 
CjeLegS (Cj1327) Fwd  GGCAGCGGCGCGATGAAAAAAACTTTAATCAT 
CjeLegS  (Cj1327) Rev 
 
GAAAGCTGGGTGTTACTCACGGATAAGCTCATCTTCT 
 
CjePseS (Cj1317) Fwd GGCAGCGGCGCGATGCAAATAGGAAATTTTAACACCG 
CjePseS  (Cj1317) Rev 
 
GAAAGCTGGGTGTCATTGGAAATCTCCTTGTTTTAAA 
 
Generic Nested Fwd  GGGGACAAGTTTGTACAAAAAAGCAGGCTTCGAAAACCTGTATTTTCAGGGCAGCGGCGCG 
Generic Nested Rev GGGGACCACTTTGTACAAGAAAGCTGGGT 
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8.8.2 Phylogram sequence selection 
The sequences of NANAS, LegS, PseS  and putative SASs were retrieved  from KEGG (213). In this 
database, several of the genes this thesis considers to be LegSs, PseSs or Type IV SASs were 
annotated as NANASs or putative NANASs.  
Very few sequences in KEGG were annotated as LegS or PseS and none were annotated as Type 
IV SASs as this notation is an invention of this thesis. In order to attain more LegS, PseS and Type IV 
sequences a protein BLAST (164) search was performed using CjeLegS, CjePseS and CteSAS as 
queries. From this BLAST search other putative LegS, PseS and Type IV SASs were selected for 
sequence alignment. Each of these sequences had at least 30 % sequence identity to the queried 
sequence. 
 
8.8.3 Modelling of CjeNANAS, CjeLegS and CjePseS 
 
Since crystal structures of CjeNANAS, CjeLegS and CjePseS could not be obtained, models were 
generated from the SWISS-MODEL server (http://swissmodel.expasy.org/) (162) using wild-type 
NmeNANAS PDB coordinates 1XUZ (112) as a template. The sequences of CjeNANAS, CjeLegS and 
CjePseS were retrieved from the KEGG (213) database and aligned with the sequence of NmeNANAS 
using ClustalW (155). The sequence identity of CjeNANAS, CjePseS and CjeLegS with NmeNANAS was 
determined to be 58.6 %, 32.4 % and 34.1 % respectively.  
Model quality was verified using online SWISS-MODEL assessment software. QMEAN composite 
scoring function was used to determine whether the models were correctly folded. QMEAN 
considers torsion angles, interaction potentials, solvation potential and the agreement of predicted 
secondary structure (from sequence) with calculated secondary structure. Models with QMEAN 
scores closest to 0 are deemed more reliable. The QMEAN scores determined for CjeNANAS, CjePseS 
and CjeLegS were -0.23, -0.90 and -0.66 respectively.  
 
8.8.4 Substrate docking of CjeNANAS, CjeLegS and CjePseS 
Induced fit docking of Mn2+, PEP and 2, 4-diacetamido-2, 4, 6-trideoxyaltrose into the model of 
CjePseS and induced fit docking of Mn2+, PEP and 2, 4-diacetamido-2, 4, 6-trideoxymannose into the 
model of CjeLegS were carried out by Dr Wanting Jiao. Induced fit docking was completed using 
Schrödinger Suite Software (Maestro, LigPrep, Epik, Glide) (207-209).  
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8.9 Methods in Chapter 5  
 
8.9.1 Crystallisation of SsuSAS 
Purified SsuSAS at a concentration of 6 mg/mL was crystallised using a condition obtained from a 
Morpheus™ crystallisation screen (Molecular Dimensions). Apoenzyme SsuSAS crystals were formed 
using the hanging drop crystallisation technique in the presence of 0.09 M 
NaNO3/Na2HPO4/NH4)2SO4, 0.1 M Imidazole/MES and 37.5% racemic MPD/PEG 1000/PEG 3350 at pH 
6.5. Hanging drops were 2 µL in size combining 1 µL of protein with 1 µL of reservoir solution and the 
total volume of the reservoir solution was 500 µL. Data sets were collected at the Australian 
Synchrotron using the MX1 and MX2 beamlines.  
 The structure of SsuSAS was solved by molecular replacement using the structure of the wild-type 
protein (1XUZ) (112). Measured intensities were converted into amplitudes by using TRUNCATE as 
part of Scalepack2mtz or dtrek2mtz (CCP4) (203). The structure was then solved by performing ten 
rounds of rigid-body refinement (CCP4). Intensity-based refinement was carried out with REFMAC5 
(CCP4) following each cycle of structure development from Coot. Water molecules were added 
automatically following the criterion that they had at least one hydrogen bonding partner to a 
protein atom and/or water molecule in the range 2.4–3.2 Å.   
 
8.9.2 Substrate docking in SsuSAS 
Induced fit docking analyses of Mn2+, PEP and ManNAc/2, 4-diacetamido-2, 4, 6-trideoxymannose 
into the active site of SsuSAS were carried out by Dr Wanting Jiao. Induced fit docking was 
completed using Schrödinger Suite Software (Maestro, LigPrep, Epik, Glide) (207-209).  
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8.10 Methods in Chapter 6 
  
8.10.1 Cloning  
The constructs for the Hsa/Nme chimera and Nme/Has chimera were generated from the genes 
encoding NmeNANAS and HsaNANA-9-PS using a multi-step PCR protocol that is outlined in Section 
6.3. The chimeric constructs were cloned using PfuUltra DNA polymerase (Agilent) as described in 
Section 8.3.2. The following primers (Table 8.9) were used to generate the Hsa/Nme chimera and 
Nme/Hsa chimera using pDEST17-NmeNANAS as well as a pDEST17-HsaNANA-9-PS as templates.  
 
 
 
 
 
 
Table 8.9 Primers used for generation of Nme/Hsa and Hsa/Nme chimeras. Start codons are in blue and 
stop codons are in red. Overlapping sequences for generic primer extension are underlined. Sequence 
corresponding to the NmeNANAS catalytic domain is highlighted in pink, NmeNANAS AFPL domain in 
green, HsaNANA-9-PS catalytic domain in blue and HsaNANA-9-PS AFPL domain in green.  
 
8.10.2 HsaNANA-9-PS cloning and purification 
The gene encoding HsaNANA-9-PS was codon optimised for expression in an E.coli cell line, 
synthesised and cloned into the vector pDONR 221 by GeneArt®. DNA sequence encoding an N-
terminal TEV protease cleavage site was incorporated during the construction of the HsaNANA-9-PS 
gene. The HsaNANA-9-PS gene was sub-cloned into the expression vector pDEST-17 which encodes 
an N-terminal His-tag by Thomas Cotton. Expression trials and purification of HsaNANA-9-PS were 
carried out Thomas cotton using the methods outlined in Section 8.4. 
Oligonucleotide Sequence (5' - 3') 
NmeNANAS catalytic domain Fwd GGCAGCGGCGCGATGCAAAACAACAACGAATTT 
HsaNANA-9-PS AFPL domain Rev 
  
GAAAGCTGGGTGTTAGCTTTTGATTTTTTTGCC  
 
Nme/Hsa Chimera bridge Fwd  GCTTTAAAATTGGCACGCGGCAGCCCGACCAAACAGCTGCTG 
Nme/Hsa Chimera bridge Rev 
  
CAGCAGCTGTTTGGTCGGGCTGCCGCGTGCCAATTTTAAAGC 
 
HsaNANA-9-PS catalytic domain Fwd GGCAGCGGCGCGATGCCGCTGGAACTGGAACTG 
NmeNANAS AFPL domain Rev 
  
GAAAGCTGGGTGTTATTCAATATCAGTTTTTTTG 
 
Hsa/Nme Chimera bridge Fwd  CTGGTTGAACGTGCCCTGGGTGGCAAAAAAGACACGATTATC 
Hsa/Nme Chimera bridge Rev  GATAATCGTGTCTTTTTTGCCACCCAGGGCACGTTCAACCAG 
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8.10.3 HsaNANA-9-PS modelling 
Homology modelling of HsaNANA-9-PS was completed by Dr Wanting Jiao. Since no full-length 
crystal structure of HsaNANA-9-PS is currently available, a homology model was generated based on 
the HsaNANA-9-PS amino acid sequence, using the crystal structure of NmeNANAS PDB code 1XUZ 
(112) as a template. Sequence alignment of HsaNANA-9-PS and NmeNANAS was generated using the 
ClustalW online server (155). The resulting alignment was used to generate the homology model, 
using Maestro 9.3.5 (Schrödinger Software). The model output was refined following alignment with 
the solved solution structure of HsaNANA-9-PS AFP domain (PDB code 1WVO).  
Induced fit docking of ManNAc-6-P into active site of the homology model of HsaNANA-9-PS was 
conducted for both monomers present in the dimer of the homology model, due to the difference in 
conformation of the predicted ManNAc binding loops in both monomers. Induced fit docking was 
completed using Schrödinger Suite Software (Maestro, LigPrep, Epik, Glide) (207-209).  
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